{"meta":{"query_hash":"6ac4a1fc57b1","filters":{"venue":"PharmacoEconomics"},"cohort_total":375,"direct_labels_cover":0,"predictions_cover":375,"exported":375,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/6ac4a1fc57b1","api":"https://metacan.xera.ac/api/v1/cohort?venue=PharmacoEconomics"},"results":[{"id":"W10179705","doi":"10.2165/00019053-199813060-00006","title":"Who should benefit and why?: Discourses on REDD+ benefit sharing","year":2012,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Housing, Finance, and Neoliberalism","field":"Economics, Econometrics and Finance","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CLARITY; Legitimacy; Business; Affect (linguistics); Public economics; Public relations; Political science; Economics; Psychology","score_opus":0.0637720317163588,"score_gpt":0.2940960229464842,"score_spread":0.23032399123012537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W10179705","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08508031,0.0064115673,0.028031044,0.5725017,0.0004924154,0.00012069442,0.00017379118,0.00004426304,0.30714414],"genre_scores_gemma":[0.9744038,0.0015378683,0.0042853425,0.012777057,0.0003538555,0.00010967735,0.000024785533,0.00003796936,0.006469625],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.9684825,0.026886994,0.00032236901,0.0011909509,0.0015466558,0.0015705146],"domain_scores_gemma":[0.93621856,0.05581402,0.002315665,0.0015749878,0.0019084042,0.0021683713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03520844,0.0006617031,0.0008743773,0.0009470621,0.00801163,0.011207632,0.0025433407,0.010116798,0.01397608],"category_scores_gemma":[0.052140553,0.00059718254,0.00076260266,0.001326201,0.031117328,0.017268185,0.010360933,0.0072804703,0.00063952414],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091176895,0.000037150643,0.0011865671,0.00008258737,0.000016767364,0.00026734336,0.011278876,0.0029844947,0.000052125022,0.96716,0.006693123,0.010149832],"study_design_scores_gemma":[0.000055612047,0.00004079621,0.00059412414,0.00027490672,0.000018196799,0.00015448498,0.012160476,0.0051642116,0.00007909057,0.9245709,0.05684905,0.00003814218],"about_ca_topic_score_codex":0.013486509,"about_ca_topic_score_gemma":0.008227382,"teacher_disagreement_score":0.03520844,"about_ca_system_score_codex":0.015837839,"about_ca_system_score_gemma":0.0076439856,"threshold_uncertainty_score":0.18620229},"labels":[],"label_agreement":null},{"id":"W1479842140","doi":"10.2165/00019053-200927010-00004","title":"Statin Therapy in Rheumatoid Arthritis","year":2009,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada; University of British Columbia; Centre for Advancing Health Outcomes; St. Paul's Hospital","funders":"","keywords":"Medicine; Rheumatoid arthritis; Statin; Quality-adjusted life year; Physical therapy; Randomized controlled trial; Internal medicine; Cost-effectiveness analysis; Combination therapy; Intensive care medicine; Cost effectiveness; Risk analysis (engineering)","score_opus":0.020837138331397227,"score_gpt":0.32319156734117654,"score_spread":0.3023544290097793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1479842140","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1089768,0.7879374,0.00037808798,0.060195655,0.002008215,0.0000611087,0.0010800575,0.000025442749,0.0393372],"genre_scores_gemma":[0.6567114,0.32122135,0.0007854406,0.010516759,0.004288998,0.00008360505,0.0006828733,0.000007902476,0.0057016737],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986467,0.00052349444,0.0002706713,0.000052625724,0.00039922397,0.00010737417],"domain_scores_gemma":[0.9986731,0.0005709632,0.0003610533,0.000041006097,0.00015523638,0.00019870796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010425955,0.00013241595,0.0005437756,0.00093978096,0.0003056967,0.0006487642,0.00017889214,0.0007541045,0.002793869],"category_scores_gemma":[0.0033911532,0.000095051575,0.00041596818,0.0017041408,0.00019193227,0.00022247681,0.00028408642,0.0006922685,0.00042071677],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007028602,0.000590168,0.118044466,0.0031739953,0.0012421664,0.0013027845,0.0002473115,0.00061708497,0.0019181021,0.00615772,0.04343574,0.81624174],"study_design_scores_gemma":[0.0026217327,0.0015888341,0.74024063,0.0038957282,0.0030717764,0.0037936002,0.00052550645,0.0015348161,0.0010342192,0.006690846,0.23494126,0.00006113204],"about_ca_topic_score_codex":0.008326718,"about_ca_topic_score_gemma":0.021325361,"teacher_disagreement_score":0.008326718,"about_ca_system_score_codex":0.0009286362,"about_ca_system_score_gemma":0.0020838086,"threshold_uncertainty_score":0.016556501},"labels":[],"label_agreement":null},{"id":"W1520835857","doi":"10.2165/11597660-000000000-00000","title":"Cost Effectiveness of Hepatitis C-Related Interventions Targeting Substance Users and Other High-Risk Groups","year":2012,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Institute for Work & Health; Toronto Baptist Seminary and Bible College","funders":"Canadian Institutes of Health Research","keywords":"Health economics; Quality of Life Research; Public health; Psychological intervention; Health administration; Medicine; Environmental health; Psychiatry; Nursing","score_opus":0.1327897595535637,"score_gpt":0.4346726858988664,"score_spread":0.30188292634530267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1520835857","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018514047,0.99744886,0.00007339325,0.00012903796,0.000061927436,0.00002403913,0.00006944533,0.0000033004337,0.00033862414],"genre_scores_gemma":[0.025605734,0.97346514,0.00044642558,0.00015648833,0.00006573533,0.000031704636,0.00009613771,0.000001871993,0.00013074417],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9991372,0.00032812782,0.00014542334,0.00007235892,0.00025752175,0.000059409274],"domain_scores_gemma":[0.99797755,0.001583016,0.00025846637,0.000020613252,0.00012498497,0.00003533094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016994292,0.0009998021,0.0038627288,0.0020309726,0.0001424612,0.0009196097,0.0011072916,0.0010041422,0.0040650456],"category_scores_gemma":[0.0045028194,0.00037059197,0.004099073,0.0025115174,0.00023896943,0.00067009503,0.00041905526,0.0010020621,0.00016102247],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029586884,0.00024272013,0.0014002989,0.29934037,0.023321453,0.00013607045,0.000055050674,0.0017597375,0.0005357663,0.001186638,0.004252816,0.6648104],"study_design_scores_gemma":[0.011483913,0.0065356814,0.061176904,0.37873474,0.34362692,0.0034391682,0.0008240224,0.004796164,0.0033885383,0.0075588212,0.17822959,0.00020562384],"about_ca_topic_score_codex":0.005042641,"about_ca_topic_score_gemma":0.008840918,"teacher_disagreement_score":0.005042641,"about_ca_system_score_codex":0.0014916038,"about_ca_system_score_gemma":0.0014701715,"threshold_uncertainty_score":0.013598919},"labels":[],"label_agreement":null},{"id":"W1545016258","doi":"10.1007/s40273-012-0007-4","title":"The Humanistic and Economic Burden of Systemic Lupus Erythematosus","year":2012,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"U.S. National Library of Medicine","keywords":"Medicine; Quality of life (healthcare); Health economics; Psychological intervention; MEDLINE; Intensive care medicine; Lupus nephritis; Public health; Disease; Gerontology; Family medicine; Pathology; Nursing","score_opus":0.06936924900146456,"score_gpt":0.3824387648429726,"score_spread":0.31306951584150805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1545016258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004010961,0.9992481,0.000016475873,0.00031580564,0.000094645875,0.0000013590612,0.000008407167,7.927061e-7,0.0002742786],"genre_scores_gemma":[0.00050818187,0.99906486,0.000042948668,0.00020015612,0.00011205374,0.0000016052119,0.000007378365,2.625607e-7,0.00006258376],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994454,0.00017350825,0.00008748581,0.000049089314,0.00020258027,0.000041983512],"domain_scores_gemma":[0.9981839,0.0012253654,0.0002739815,0.00002209187,0.000235005,0.000059522587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012663316,0.00075263914,0.0018476424,0.0031659007,0.0003011344,0.0012787544,0.0007201397,0.0012954657,0.004277262],"category_scores_gemma":[0.0029238267,0.0003036515,0.00083226745,0.005085149,0.00065084413,0.0011344363,0.000775087,0.0013855564,0.0004580537],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000957851,0.00004649847,0.00042291477,0.06428301,0.00053725066,0.00017682044,0.000062441955,0.00027173178,0.00023155061,0.0040688445,0.031395692,0.8984074],"study_design_scores_gemma":[0.000108669774,0.00009093452,0.0044065295,0.05752295,0.0014195369,0.0015085866,0.00023153496,0.00014703833,0.0001411331,0.0039129886,0.9304661,0.000043960397],"about_ca_topic_score_codex":0.0051715127,"about_ca_topic_score_gemma":0.013037143,"teacher_disagreement_score":0.0051715127,"about_ca_system_score_codex":0.001245422,"about_ca_system_score_gemma":0.0028427476,"threshold_uncertainty_score":0.01430887},"labels":[],"label_agreement":null},{"id":"W1547731140","doi":"10.2165/00019053-200624002-00006","title":"Disease Management Programmes in Germany","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Primary Care and Health Outcomes","field":"Health Professions","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Reimbursement; German; Medicine; Quality of Life Research; Incentive; Sick leave; Disease; Health economics; Public health; Family medicine; Physical therapy; Nursing; Economic growth; Economics; Health care; Internal medicine","score_opus":0.03409108430248398,"score_gpt":0.4351410120294341,"score_spread":0.40104992772695014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1547731140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9638711,0.0037266028,0.0003700971,0.0052113947,0.00018043115,0.00011162091,0.0016282535,0.000073742944,0.024826694],"genre_scores_gemma":[0.9864342,0.0015490034,0.0004241908,0.001077733,0.00005844484,0.000095171614,0.0010734741,0.000009150624,0.009278629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912065,0.00020805573,0.000051265288,0.000091485475,0.00006861349,0.00046004707],"domain_scores_gemma":[0.99923265,0.00009313959,0.000110233326,0.00003441367,0.000051473813,0.000478186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077081344,0.00023628243,0.00013993117,0.0011210734,0.00056472694,0.00074815704,0.0003984371,0.00062665896,0.005892004],"category_scores_gemma":[0.0012142047,0.00016714961,0.00022133028,0.0011300256,0.00034025332,0.00047453868,0.0013931865,0.00051224447,0.0005787114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001409797,0.0029955686,0.4930867,0.0010474753,0.00027060913,0.003293118,0.0054808566,0.0034639023,0.0058146585,0.026914017,0.034985792,0.42123744],"study_design_scores_gemma":[0.00020167614,0.0006420395,0.9274349,0.00034966358,0.000105005565,0.00069485075,0.0019549027,0.0012524012,0.0016102219,0.0007638316,0.064957194,0.00003336222],"about_ca_topic_score_codex":0.021630038,"about_ca_topic_score_gemma":0.02579558,"teacher_disagreement_score":0.021630038,"about_ca_system_score_codex":0.0028251237,"about_ca_system_score_gemma":0.004673775,"threshold_uncertainty_score":0.043008268},"labels":[],"label_agreement":null},{"id":"W1550647847","doi":"10.2165/11537550-000000000-00000","title":"Cost Effectiveness of Leukotriene Receptor Antagonists versus Inhaled Corticosteroids for Initial Asthma Controller Therapy","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Quality of Life Research; Asthma; Health economics; Medicine; Inhaled corticosteroids; Pharmacoeconomics; Public health; Intensive care medicine; Pharmacology; Internal medicine; Nursing","score_opus":0.05073648609986783,"score_gpt":0.3876800217527853,"score_spread":0.3369435356529175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1550647847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96892065,0.020253398,0.00052860385,0.0034531488,0.00031572176,0.00015769545,0.00095953967,0.00004358554,0.0053677512],"genre_scores_gemma":[0.99763596,0.0012854785,0.00019995355,0.00022454555,0.00006728656,0.000026556863,0.00021615144,0.000004373389,0.00033967767],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9984659,0.0008850638,0.000097846285,0.00010858851,0.00018174613,0.00026088508],"domain_scores_gemma":[0.99601436,0.0029000125,0.00042449232,0.00007622473,0.00013886859,0.00044608128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001723946,0.0007053091,0.0024833088,0.00088917464,0.00037209547,0.0015415414,0.0006551461,0.0018142883,0.008222018],"category_scores_gemma":[0.009143881,0.00038952846,0.003962944,0.00076321705,0.00043624497,0.0010655959,0.0006051533,0.0016127256,0.00022550857],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6153141,0.005393088,0.056955405,0.0020692763,0.0099556,0.0007734127,0.0001819669,0.0797695,0.0026295192,0.0035806727,0.005033379,0.21834409],"study_design_scores_gemma":[0.14953227,0.10097069,0.45920098,0.0014926252,0.04996943,0.0024945699,0.0018679998,0.217316,0.00376925,0.0077760625,0.005237963,0.00037225062],"about_ca_topic_score_codex":0.016724382,"about_ca_topic_score_gemma":0.010735183,"teacher_disagreement_score":0.016724382,"about_ca_system_score_codex":0.0043061906,"about_ca_system_score_gemma":0.0019268632,"threshold_uncertainty_score":0.033254087},"labels":[],"label_agreement":null},{"id":"W1592571893","doi":"10.2165/00019053-200927020-00004","title":"Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine","year":2009,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Centre for Disease Control; Centre for Advancing Health Outcomes; Université Laval; University of British Columbia","funders":"","keywords":"Medicine; Vaccination; Cost effectiveness; Cervical cancer; Human papillomavirus; Cost-effectiveness analysis; Health economics; Economic evaluation; Clinical trial; Quality of Life Research; Gynecology; Medical physics; Public health; Cancer; Immunology; Risk analysis (engineering); Pathology; Internal medicine","score_opus":0.08947033810605287,"score_gpt":0.48156241707605435,"score_spread":0.3920920789700015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1592571893","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002748349,0.99912196,0.00003691329,0.0001679678,0.000044807068,0.0000055019127,0.000028314873,0.0000014588005,0.00031820443],"genre_scores_gemma":[0.0056651523,0.99377865,0.00016028364,0.00019164095,0.00007466817,0.000009685692,0.000032983226,0.0000010221893,0.00008586364],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99868363,0.0005486822,0.00021331655,0.00009538287,0.00039996894,0.000058960715],"domain_scores_gemma":[0.99642307,0.0030013921,0.0003411107,0.000029775209,0.00017421416,0.000030369421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021717697,0.0007805921,0.0036109558,0.0021845005,0.000119391545,0.0009136003,0.00089422154,0.0011612108,0.0040480085],"category_scores_gemma":[0.006516254,0.00034939777,0.0021907517,0.0029689881,0.00035488402,0.0007565305,0.0003638113,0.0010406158,0.00027125157],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009310581,0.00008478549,0.0008708502,0.1528418,0.006389279,0.00019362908,0.000040593557,0.0013326532,0.0003457585,0.0021915347,0.010640033,0.8241379],"study_design_scores_gemma":[0.004085228,0.0023179525,0.034545816,0.31069627,0.10344697,0.005986607,0.00043754114,0.0027043482,0.0021630742,0.011802393,0.5216787,0.0001350652],"about_ca_topic_score_codex":0.0042538196,"about_ca_topic_score_gemma":0.006276293,"teacher_disagreement_score":0.0042538196,"about_ca_system_score_codex":0.0016713684,"about_ca_system_score_gemma":0.0017608133,"threshold_uncertainty_score":0.0135419965},"labels":[],"label_agreement":null},{"id":"W1592767674","doi":"10.2165/0019053-200826120-00005","title":"Management and Prevention of Diabetic Foot Ulcers and Infections","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Diabetic Foot Ulcer Assessment and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Health economics; Medicine; Diabetic foot; Quality of Life Research; Public health; Intensive care medicine; Diabetes mellitus; Health administration; Foot (prosody); Nursing","score_opus":0.037480069368571234,"score_gpt":0.36612063785218824,"score_spread":0.328640568483617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1592767674","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009771524,0.9992306,0.00007192178,0.00014818837,0.00007678686,0.0000057205443,0.000011954051,0.0000031796112,0.00035387688],"genre_scores_gemma":[0.000897571,0.99836,0.00026405923,0.00020342624,0.00011830933,0.0000071406153,0.00002060499,6.2974465e-7,0.00012824255],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995097,0.00010918973,0.00009886952,0.000059748698,0.00018610591,0.000036374247],"domain_scores_gemma":[0.9990702,0.00055452273,0.00018105353,0.000014449796,0.00014951218,0.000030384688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092675333,0.0009623772,0.0025464126,0.002866229,0.00021079944,0.0009250957,0.0010015258,0.0010776807,0.0030245087],"category_scores_gemma":[0.0018706272,0.0002935421,0.0009597958,0.0027113366,0.00034950557,0.000813831,0.00046283557,0.0014588076,0.00061771646],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000099996134,0.0001347055,0.0002877271,0.03173107,0.00038030956,0.00013216722,0.000032675205,0.00022143174,0.0003533384,0.00073344243,0.010889212,0.95500386],"study_design_scores_gemma":[0.00040226363,0.0006657789,0.00984263,0.06800894,0.0036106477,0.004035636,0.00024342092,0.00052543427,0.0008452362,0.0029990883,0.9087463,0.000074679876],"about_ca_topic_score_codex":0.0027264915,"about_ca_topic_score_gemma":0.004688789,"teacher_disagreement_score":0.0030245087,"about_ca_system_score_codex":0.0005184312,"about_ca_system_score_gemma":0.0010100703,"threshold_uncertainty_score":0.010118008},"labels":[],"label_agreement":null},{"id":"W1593327399","doi":"10.2165/00019053-200725120-00003","title":"NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors","year":2007,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Nova Scotia Health Authority","funders":"National Institutes of Health","keywords":"Health economics; Quality of Life Research; Nice; Health administration; Public health; Medicine; Cholinesterase; Pharmacoeconomics; Cost effectiveness; Intensive care medicine; Pharmacology; Risk analysis (engineering); Nursing; Computer science","score_opus":0.6032728442129532,"score_gpt":0.5930197540342943,"score_spread":0.010253090178658941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1593327399","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00053155725,0.99571097,0.0002395738,0.0012997254,0.00030400045,0.00009722278,0.00037289815,0.00001591441,0.0014281975],"genre_scores_gemma":[0.025967712,0.9670603,0.002226488,0.0022086895,0.00044453805,0.00036241522,0.00085575157,0.000023801476,0.0008503201],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99146616,0.0037104688,0.0013348614,0.0002786983,0.0030008343,0.00020898654],"domain_scores_gemma":[0.9878056,0.008132004,0.001960376,0.00014883572,0.001750436,0.00020277653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008437249,0.0012708488,0.0068520415,0.0035164608,0.00025534458,0.0016805113,0.0018128416,0.0019457614,0.005260852],"category_scores_gemma":[0.03072673,0.00057538226,0.005207673,0.0036617962,0.0005464897,0.0011232691,0.0008839508,0.0019378231,0.00051564723],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003530989,0.000092735885,0.00067280134,0.30946907,0.011928778,0.00021368322,0.00007845631,0.0024056484,0.00034402433,0.0031438963,0.058136027,0.6099839],"study_design_scores_gemma":[0.008503657,0.002371732,0.021093618,0.36884233,0.09637957,0.0022277222,0.00029198045,0.0030995922,0.0010433983,0.011527122,0.48445502,0.00016422303],"about_ca_topic_score_codex":0.009358537,"about_ca_topic_score_gemma":0.017631203,"teacher_disagreement_score":0.009358537,"about_ca_system_score_codex":0.0046071005,"about_ca_system_score_gemma":0.004287017,"threshold_uncertainty_score":0.04462093},"labels":[],"label_agreement":null},{"id":"W1751576414","doi":"10.2165/11536150-000000000-00000","title":"International Comparison of Comparative Effectiveness Research in Five Jurisdictions","year":2010,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"International Arbitration and Investment Law","field":"Business, Management and Accounting","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Dalhousie University","funders":"National Pharmaceutical Council; NHS Health Scotland","keywords":"Quality of Life Research; Health economics; Health administration; Comparative effectiveness research; Public health; Health services research; Health care management; Medicine; Political science; Environmental health; Health care; Nursing; Law","score_opus":0.19668410348605272,"score_gpt":0.48433326515327785,"score_spread":0.2876491616672251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1751576414","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005360056,0.98807496,0.0006047833,0.0005209349,0.00014876435,0.00025843785,0.00047880824,0.000008393935,0.0045448514],"genre_scores_gemma":[0.12845859,0.8633666,0.0048850477,0.0008563308,0.00028413069,0.0005731945,0.0010539867,0.000017864179,0.0005042185],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9504977,0.031794064,0.0069258665,0.0019907025,0.008030878,0.00076084805],"domain_scores_gemma":[0.8667641,0.10955433,0.009282673,0.002550545,0.011149985,0.00069841393],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.06357807,0.0008954104,0.0048052766,0.015523457,0.00048584028,0.0035594923,0.0021895876,0.0017797321,0.0047252085],"category_scores_gemma":[0.11807617,0.00049639895,0.003468328,0.01961144,0.001896699,0.0021788254,0.0018596859,0.0010660365,0.00024328989],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009092649,0.0004758495,0.01059407,0.20558831,0.031537484,0.0002261239,0.001031317,0.0011256689,0.00063854357,0.019425895,0.007940595,0.71232355],"study_design_scores_gemma":[0.007662444,0.0076640225,0.15648465,0.3041483,0.21361835,0.0017877702,0.0030103025,0.0011914723,0.004677505,0.015580663,0.2839558,0.00021870874],"about_ca_topic_score_codex":0.0052281325,"about_ca_topic_score_gemma":0.008914211,"teacher_disagreement_score":0.93642193,"about_ca_system_score_codex":0.005932897,"about_ca_system_score_gemma":0.007989646,"threshold_uncertainty_score":0.336237},"labels":[],"label_agreement":null},{"id":"W1761940517","doi":"10.2165/11531870-000000000-00000","title":"Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimerʼs Disease","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Donepezil; Medicine; Health economics; Disease; Clinical trial; Placebo; Economic evaluation; Randomized controlled trial; Cognition; Psychiatry; Gerontology; Public health; Dementia; Internal medicine; Alternative medicine","score_opus":0.42221274920245633,"score_gpt":0.5004944244712676,"score_spread":0.07828167526881125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1761940517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9458268,0.04314042,0.00081101566,0.0033405782,0.0003291175,0.00012435988,0.0011280399,0.00003779922,0.005261768],"genre_scores_gemma":[0.9976319,0.0019087387,0.00008758453,0.00007656997,0.000039052546,0.000010332097,0.00012454233,0.000001185932,0.000120078046],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99768496,0.0016759359,0.0001406427,0.00007873165,0.00024593898,0.00017367901],"domain_scores_gemma":[0.99582493,0.0032374696,0.0004199882,0.000081112994,0.00015037609,0.00028612505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021311387,0.0004839662,0.0014116633,0.00088150875,0.00018697232,0.00085542817,0.00042511028,0.00090056594,0.0015730889],"category_scores_gemma":[0.010368626,0.00020052597,0.0024358865,0.0006779404,0.00038711188,0.0006290444,0.00041437737,0.000968403,0.00006258731],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43926892,0.0052187503,0.10611058,0.0074972333,0.023164814,0.0013271825,0.0002564737,0.11989307,0.0023319407,0.009353258,0.0060839644,0.27949372],"study_design_scores_gemma":[0.070150346,0.07136457,0.5394303,0.0032845698,0.07033476,0.0023570482,0.001450374,0.21018748,0.0045622503,0.01792883,0.008606271,0.00034305296],"about_ca_topic_score_codex":0.012205304,"about_ca_topic_score_gemma":0.009533344,"teacher_disagreement_score":0.012205304,"about_ca_system_score_codex":0.0026957686,"about_ca_system_score_gemma":0.0012757126,"threshold_uncertainty_score":0.024268508},"labels":[],"label_agreement":null},{"id":"W185692532","doi":"10.2165/00019053-200018010-00006","title":"Using Economic Evaluations to Make Formulary Coverage Decisions","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Formulary; Checklist; Time horizon; Medicine; Health economics; Actuarial science; Discounting; Health administration; Economic evaluation; Cost–benefit analysis; Operations management; Public health; Family medicine; Business; Economics; Psychology; Political science; Finance; Nursing","score_opus":0.45840472527537623,"score_gpt":0.5295531540210864,"score_spread":0.07114842874571015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W185692532","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36350828,0.025689807,0.37234718,0.070529126,0.0017077624,0.0035034094,0.005488463,0.0010001613,0.15622585],"genre_scores_gemma":[0.89925945,0.004151252,0.09053109,0.0015811387,0.00048422077,0.00061654096,0.001234229,0.00008064383,0.0020614162],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.95833564,0.033187687,0.002002948,0.00074998057,0.005010109,0.00071372197],"domain_scores_gemma":[0.74949145,0.22783564,0.0072499616,0.0027540945,0.01098852,0.0016803843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.046465866,0.0013657068,0.0021305813,0.007563986,0.00065713713,0.0068395883,0.00092798425,0.0027440013,0.0058572697],"category_scores_gemma":[0.25625098,0.0006890226,0.0013945538,0.0037855385,0.0009389365,0.0054937666,0.0015257862,0.0036578507,0.0006226811],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034592026,0.002012191,0.08781454,0.0022871543,0.003591394,0.00078609167,0.00090264727,0.1880314,0.00079857366,0.10357423,0.056190442,0.55055207],"study_design_scores_gemma":[0.0013724335,0.0008678204,0.030680384,0.0017372348,0.0018224027,0.00028540386,0.0013265811,0.5967069,0.0022897432,0.33793947,0.024691433,0.00028013575],"about_ca_topic_score_codex":0.0056859665,"about_ca_topic_score_gemma":0.0069571184,"teacher_disagreement_score":0.046465866,"about_ca_system_score_codex":0.0034038546,"about_ca_system_score_gemma":0.004143557,"threshold_uncertainty_score":0.24573791},"labels":[],"label_agreement":null},{"id":"W1880829571","doi":"10.1007/s40273-015-0292-9","title":"A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; EuroQol Research Foundation; McMaster University","keywords":"Checklist; Reimbursement; Delphi method; Valuation (finance); Health care; Health administration; Health economics; Actuarial science; Psychological intervention; Delphi; EconLit; Benchmarking; Business; Medicine; Public health; MEDLINE; Computer science; Accounting; Psychology; Nursing; Marketing; Economics; Political science","score_opus":0.7950611671991774,"score_gpt":0.5695950477640246,"score_spread":0.22546611943515282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1880829571","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013956644,0.008486184,0.6029538,0.017297862,0.0031783762,0.2911123,0.03178558,0.00365806,0.027571104],"genre_scores_gemma":[0.017778173,0.0038541518,0.6727732,0.0030263793,0.0003286913,0.28976655,0.009928885,0.000414981,0.0021290148],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.62233555,0.24000214,0.10977156,0.002403288,0.02296315,0.0025242316],"domain_scores_gemma":[0.3866293,0.40625533,0.040671457,0.033224355,0.12904817,0.004171404],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.27920842,0.0029063453,0.002707537,0.012902999,0.0028164485,0.0049911705,0.0048423987,0.004627778,0.014996655],"category_scores_gemma":[0.47818282,0.002213812,0.0046666637,0.00921125,0.0030203203,0.0049632713,0.0073293676,0.0053854208,0.004622955],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012725267,0.0011041237,0.011101609,0.033997543,0.00065257656,0.001017281,0.010970045,0.004200566,0.0026921362,0.050686058,0.38682178,0.4954838],"study_design_scores_gemma":[0.0015641794,0.0014290083,0.017145839,0.03534119,0.000469412,0.0016172506,0.008874408,0.005723722,0.003937901,0.04971822,0.87348914,0.0006896907],"about_ca_topic_score_codex":0.002582562,"about_ca_topic_score_gemma":0.0050047035,"teacher_disagreement_score":0.7207916,"about_ca_system_score_codex":0.0069159255,"about_ca_system_score_gemma":0.030460658,"threshold_uncertainty_score":0.88886434},"labels":[],"label_agreement":null},{"id":"W1891390685","doi":"10.1007/s40273-015-0330-7","title":"Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Primary Care and Health Outcomes","field":"Health Professions","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Health Authority; University of Saskatchewan; University of Calgary","funders":"Agency for Healthcare Research and Quality","keywords":"Health economics; Health administration; Quality of Life Research; Big data; Health care; Healthcare delivery; Health informatics; Public health; Health services research; Data science; Business; Computer science; Medicine; Economics; Nursing; Economic growth; Data mining","score_opus":0.4067404254781069,"score_gpt":0.5568233110544322,"score_spread":0.15008288557632526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1891390685","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.064232334,0.0043287696,0.8374176,0.075069204,0.0013973925,0.00030868434,0.0020561027,0.001066901,0.014123008],"genre_scores_gemma":[0.729018,0.006434658,0.25577143,0.0039346847,0.00089596154,0.0005579644,0.0014099889,0.00033960515,0.0016377791],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98963165,0.0085238535,0.00038067534,0.0004579157,0.00076579314,0.00024010795],"domain_scores_gemma":[0.90038365,0.08816675,0.002972062,0.0044896407,0.0022127896,0.0017750885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017511705,0.00094991596,0.0016771667,0.0024907745,0.0006616365,0.006542754,0.0028136093,0.0027813602,0.0027200498],"category_scores_gemma":[0.07364362,0.000979193,0.0015490243,0.003052141,0.0026105002,0.007890648,0.0041264994,0.0055668694,0.00043437848],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017520977,0.0004025064,0.01752372,0.0005062118,0.00048615807,0.00013211776,0.0007606347,0.7363518,0.00023963944,0.18211666,0.0085068075,0.05279855],"study_design_scores_gemma":[0.00004581023,0.00003562808,0.0010866879,0.00018750194,0.000048511934,0.000032454744,0.00042937978,0.6269416,0.00013499681,0.36523208,0.005779403,0.000046002067],"about_ca_topic_score_codex":0.018429829,"about_ca_topic_score_gemma":0.020694517,"teacher_disagreement_score":0.018429829,"about_ca_system_score_codex":0.0038924797,"about_ca_system_score_gemma":0.0063623977,"threshold_uncertainty_score":0.09261191},"labels":[],"label_agreement":null},{"id":"W192050759","doi":"10.2165/00019053-200220001-00001","title":"New Solutions for Type 2 Diabetes Mellitus","year":2002,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Insulin resistance; Pioglitazone; Internal medicine; Endocrinology; Diabetes mellitus; Type 2 diabetes; Medicine; Insulin; Type 2 Diabetes Mellitus; Adipose tissue","score_opus":0.07626349876678085,"score_gpt":0.357591888788485,"score_spread":0.2813283900217042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W192050759","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017815184,0.9885563,0.00079603156,0.004828353,0.0022231329,0.000011409195,0.0000177949,0.000016580881,0.0033722064],"genre_scores_gemma":[0.0010832776,0.99104404,0.001152876,0.003057398,0.0013618916,0.000023706469,0.00003383618,0.0000040943746,0.002238779],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997273,0.00007319763,0.000024005809,0.000036905025,0.00010624,0.000032430333],"domain_scores_gemma":[0.99966514,0.00018448055,0.000035166413,0.000014939427,0.00006577857,0.00003449515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011809467,0.0012861718,0.0016725718,0.0016524099,0.0004968766,0.0012124383,0.0011474798,0.0019526343,0.0067464723],"category_scores_gemma":[0.0009753533,0.0002454205,0.0006197208,0.001397715,0.0009780094,0.0018061752,0.00092346565,0.0039111753,0.002282575],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018139106,0.00018358753,0.00016279821,0.004361526,0.000100629906,0.00062633463,0.00006346007,0.00043117264,0.001119472,0.022580938,0.06308227,0.9071064],"study_design_scores_gemma":[0.0000821345,0.000064765445,0.00028099146,0.0014477713,0.00005575819,0.000807604,0.000054919874,0.00007669567,0.00017299318,0.008443797,0.9885013,0.000011205539],"about_ca_topic_score_codex":0.0008468335,"about_ca_topic_score_gemma":0.0021075897,"teacher_disagreement_score":0.0067464723,"about_ca_system_score_codex":0.00084298203,"about_ca_system_score_gemma":0.00095729483,"threshold_uncertainty_score":0.02256918},"labels":[],"label_agreement":null},{"id":"W194666946","doi":"10.2165/11593030-000000000-00000","title":"Common Drug Review Recommendations","year":2012,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Programs for Assessment of Technology in Health Research Institute; McMaster University; Environment and Climate Change Canada","funders":"","keywords":"Formulary; Medicine; Univariate; Family medicine; Multivariate statistics; Statistics","score_opus":0.43995788830095434,"score_gpt":0.5232746190447435,"score_spread":0.08331673074378915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W194666946","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004929124,0.27561465,0.0026990806,0.4809444,0.048263542,0.00287073,0.013446323,0.0008467494,0.17482163],"genre_scores_gemma":[0.0077150227,0.29319417,0.016000977,0.48548752,0.038396623,0.004133485,0.01665748,0.000397581,0.13801712],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9721691,0.009742028,0.0050326874,0.0016210653,0.009779757,0.0016553948],"domain_scores_gemma":[0.9166638,0.019264668,0.010868995,0.00296347,0.043616507,0.0066224523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01896937,0.0017496838,0.0049419557,0.01506606,0.0018776496,0.008160011,0.0053914133,0.017419461,0.09305873],"category_scores_gemma":[0.096404724,0.0012222461,0.0055356477,0.010123333,0.0017914198,0.005751542,0.0036326388,0.008087458,0.049284205],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112241505,0.000047130663,0.00013167632,0.0033468392,0.000112639995,0.0000833286,0.000022556074,0.00007315553,0.000048954604,0.0018177709,0.9147077,0.07949596],"study_design_scores_gemma":[0.00033317084,0.00006921988,0.00097504124,0.012531819,0.00033166027,0.00015367767,0.00004298419,0.00008609494,0.00007728659,0.0035455723,0.9818204,0.00003303403],"about_ca_topic_score_codex":0.02034639,"about_ca_topic_score_gemma":0.052267704,"teacher_disagreement_score":0.09305873,"about_ca_system_score_codex":0.009184143,"about_ca_system_score_gemma":0.0256926,"threshold_uncertainty_score":0.3113125},"labels":[],"label_agreement":null},{"id":"W1947519512","doi":"10.1007/s40273-015-0332-5","title":"Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Health Canada; Novartis Pharmaceuticals Canada; GlaxoSmithKline","keywords":"Chlorambucil; Ofatumumab; Medicine; Fludarabine; Quality-adjusted life year; Cost effectiveness; Life expectancy; Actuarial science; Internal medicine; Chronic lymphocytic leukemia; Population; Chemotherapy; Leukemia; Environmental health; Economics","score_opus":0.07660397386840974,"score_gpt":0.35768279047389434,"score_spread":0.2810788166054846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1947519512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9587759,0.017074592,0.00016546815,0.010592699,0.00022155794,0.00026291696,0.0045997584,0.000032311546,0.008275007],"genre_scores_gemma":[0.9930276,0.0041394164,0.00020437174,0.000659827,0.000051125444,0.000031664687,0.0008342193,0.000006800019,0.0010448562],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99834335,0.00038083704,0.00010327171,0.00011612481,0.00040319268,0.0006531224],"domain_scores_gemma":[0.99542516,0.00082595553,0.0006250296,0.000045156386,0.0011862235,0.0018925297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009058444,0.00038349992,0.0009821975,0.0009217831,0.0012405632,0.0020614562,0.0014596699,0.0008956497,0.0034704548],"category_scores_gemma":[0.0072660306,0.0002910308,0.0015376989,0.0023479841,0.0007281181,0.00053338084,0.0007744284,0.0014371468,0.00009509454],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056138847,0.0028079282,0.59897393,0.0040841675,0.0055109346,0.0017803059,0.0010942465,0.050714828,0.0016594877,0.009816272,0.044740032,0.22267905],"study_design_scores_gemma":[0.015020811,0.0045364695,0.89890236,0.0019787431,0.007115874,0.0009840264,0.004473668,0.042177767,0.00092374755,0.0016285237,0.022009753,0.00024830614],"about_ca_topic_score_codex":0.9896103,"about_ca_topic_score_gemma":0.9936138,"teacher_disagreement_score":0.117654346,"about_ca_system_score_codex":0.117654346,"about_ca_system_score_gemma":0.110879384,"threshold_uncertainty_score":0.85364604},"labels":[],"label_agreement":null},{"id":"W1965598649","doi":"10.2165/11314010-000000000-00000","title":"Cost Effectiveness of Herpes Zoster Vaccine in Canada","year":2009,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Centre for Disease Control; Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Medicine; Shingles; Vaccination; Postherpetic neuralgia; Health economics; Incidence (geometry); Varicella zoster virus; Pharmacoeconomics; Vaccine efficacy; Health care; Cost effectiveness; Public health; Pediatrics; Demography; Emergency medicine; Intensive care medicine; Immunology; Virus; Alternative medicine","score_opus":0.026473600106542705,"score_gpt":0.3349733757912241,"score_spread":0.3084997756846814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965598649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9256205,0.022955067,0.00023055733,0.019199127,0.00033967095,0.00020229672,0.009774127,0.00004555852,0.021633225],"genre_scores_gemma":[0.98982084,0.005713085,0.00018288419,0.0008460586,0.00004679168,0.00002646684,0.0011436433,0.000007625227,0.0022125053],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9981711,0.00039638227,0.000098945515,0.00008801941,0.00060341565,0.00064214703],"domain_scores_gemma":[0.99653697,0.0007648225,0.00038640772,0.000042020012,0.0012640542,0.0010056673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008720235,0.0002991876,0.0006885785,0.001398308,0.0011254792,0.0017444312,0.0010428529,0.00085735973,0.0043117516],"category_scores_gemma":[0.0078585325,0.0002950235,0.0010224081,0.0033445724,0.0005666607,0.0005005665,0.00063474313,0.0010134431,0.00009590796],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010629983,0.0015431414,0.7184798,0.0016574276,0.0028346414,0.0010275868,0.00059326884,0.04533783,0.0007848959,0.011788359,0.04377869,0.16154437],"study_design_scores_gemma":[0.0022100657,0.00095820497,0.95213073,0.0005594426,0.0019849518,0.00040107264,0.0019966413,0.02580748,0.0004448658,0.0012820659,0.01213533,0.00008912627],"about_ca_topic_score_codex":0.9940864,"about_ca_topic_score_gemma":0.995398,"teacher_disagreement_score":0.093993165,"about_ca_system_score_codex":0.093993165,"about_ca_system_score_gemma":0.092232436,"threshold_uncertainty_score":0.6819713},"labels":[],"label_agreement":null},{"id":"W1966422135","doi":"10.2165/00019053-200220002-00003","title":"The Development and Use of Quality-of-Life Measures to Evaluate Health Outcomes in Japan","year":2002,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada); McMaster University","funders":"","keywords":"Health economics; Quality of life (healthcare); Quality-adjusted life year; EQ-5D; Quality of Life Research; Valuation (finance); Cost–utility analysis; Health administration; Measure (data warehouse); Health Utilities Index; Medicine; Health care; Actuarial science; Index (typography); Economic evaluation; Data collection; Quality (philosophy); Public health; Health related quality of life; Cost effectiveness; Business; Risk analysis (engineering); Economics; Economic growth; Computer science; Nursing; Statistics; Disease; Data mining; Finance","score_opus":0.7722328633379373,"score_gpt":0.5690684352575697,"score_spread":0.2031644280803676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966422135","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023910103,0.9964831,0.00030690027,0.00035071932,0.000051310493,0.00002017239,0.00006625756,0.0000021065825,0.00032844962],"genre_scores_gemma":[0.0199403,0.97793764,0.0015559947,0.00021644494,0.00008370551,0.00006562388,0.00011745079,0.0000024475694,0.00008034373],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996222,0.001325943,0.0011315484,0.00031240264,0.0009085343,0.00009953462],"domain_scores_gemma":[0.99372685,0.002848821,0.0015490175,0.00016156887,0.0016010489,0.0001126724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009685585,0.0008099623,0.0024452342,0.006518913,0.00031788618,0.0016792406,0.0008609113,0.00067071634,0.00037040352],"category_scores_gemma":[0.010007257,0.00044407567,0.0013894155,0.009803584,0.0007943534,0.0013721792,0.00075080217,0.000704604,0.00007504004],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024061311,0.00011502741,0.021762777,0.035974585,0.001303566,0.0001631304,0.00025060092,0.0008790965,0.00047567923,0.002382061,0.005451003,0.93100184],"study_design_scores_gemma":[0.00060372305,0.0013977949,0.45621312,0.0547124,0.021881614,0.0032522962,0.0014021073,0.0040497365,0.0036897617,0.0060300236,0.44641718,0.00035023413],"about_ca_topic_score_codex":0.015703827,"about_ca_topic_score_gemma":0.023844821,"teacher_disagreement_score":0.015703827,"about_ca_system_score_codex":0.0026572314,"about_ca_system_score_gemma":0.006230441,"threshold_uncertainty_score":0.05122292},"labels":[],"label_agreement":null},{"id":"W1967055941","doi":"10.2165/11535400-000000000-00000","title":"Comparative Effectiveness Research","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Government of Ontario; H2020 European Research Council; Eli Lilly and Company","keywords":"Comparative effectiveness research; Health technology; Context (archaeology); Pharmaceutical industry; Drug development; Business; Health care; Risk analysis (engineering); Management science; Medicine; Engineering; Economic growth; Economics; Drug; Pharmacology","score_opus":0.6774839488949597,"score_gpt":0.6109221430259052,"score_spread":0.06656180586905447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967055941","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012010074,0.65339786,0.046357855,0.015527374,0.011463852,0.0065511363,0.005768503,0.00021353163,0.24870983],"genre_scores_gemma":[0.56383896,0.29337776,0.076265804,0.016108364,0.00879639,0.01448939,0.004658483,0.00031445705,0.022150341],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.79660827,0.16643612,0.011426736,0.005013476,0.018816078,0.0016992937],"domain_scores_gemma":[0.72562116,0.23373134,0.009476748,0.014178006,0.01529663,0.001696131],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.08815719,0.0016736072,0.0042501353,0.013182584,0.00094362104,0.005119475,0.0023358902,0.0033265292,0.054129027],"category_scores_gemma":[0.275687,0.00065778656,0.0030830998,0.00896291,0.0026896964,0.0044207973,0.002226355,0.0022031623,0.0035004034],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006154892,0.0008688003,0.004195275,0.041698474,0.009780639,0.00013274522,0.0006481086,0.0020537223,0.0003057702,0.22414246,0.051362798,0.6586563],"study_design_scores_gemma":[0.009138961,0.0060080895,0.0142633915,0.08121732,0.020897115,0.0016358959,0.0023180242,0.004454005,0.0021323543,0.3602986,0.49745396,0.00018226274],"about_ca_topic_score_codex":0.002186057,"about_ca_topic_score_gemma":0.0017871003,"teacher_disagreement_score":0.9118428,"about_ca_system_score_codex":0.007728437,"about_ca_system_score_gemma":0.0063766935,"threshold_uncertainty_score":0.4662254},"labels":[],"label_agreement":null},{"id":"W1967313838","doi":"10.2165/00019053-200119100-00005","title":"Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); TransCanada (Canada); McMaster University","funders":"Merck Canada","keywords":"Rofecoxib; Medicine; Prostaglandin-Endoperoxide Synthase; Pharmacoeconomics; Osteoarthritis; Medical prescription; Internal medicine; Clinical trial; Cost effectiveness; Surgery; Intensive care medicine; Pharmacology; Cyclooxygenase; Alternative medicine","score_opus":0.02325721789784359,"score_gpt":0.3218060208392704,"score_spread":0.2985488029414268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967313838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93409383,0.03374496,0.013520566,0.002741533,0.0008028318,0.00141074,0.0049261646,0.00022009424,0.00853931],"genre_scores_gemma":[0.9931518,0.0025969318,0.002311093,0.00028318574,0.00012574982,0.00018453186,0.0008313594,0.000011226563,0.00050413865],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9961746,0.0028635424,0.00019817206,0.00018731462,0.0002773944,0.00029892544],"domain_scores_gemma":[0.9918977,0.0070211818,0.00033641618,0.0001318311,0.0002617949,0.00035111562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043701534,0.0018015072,0.0040509063,0.0018596168,0.0002764018,0.0017837249,0.0014042853,0.0018212792,0.00672141],"category_scores_gemma":[0.014686517,0.0009529963,0.006551088,0.001625864,0.000651137,0.001677601,0.0007541774,0.0019397535,0.00025382268],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51550114,0.002949402,0.026447423,0.006055558,0.043152165,0.0011333751,0.00012031567,0.27050307,0.0041125873,0.0043637995,0.0023454928,0.123315684],"study_design_scores_gemma":[0.13504015,0.07625493,0.093266964,0.0018713999,0.18377087,0.0027573658,0.0007555953,0.4810051,0.0062301196,0.012804932,0.0057902765,0.0004522325],"about_ca_topic_score_codex":0.010793626,"about_ca_topic_score_gemma":0.0064295703,"teacher_disagreement_score":0.010793626,"about_ca_system_score_codex":0.0039443276,"about_ca_system_score_gemma":0.002619189,"threshold_uncertainty_score":0.028618217},"labels":[],"label_agreement":null},{"id":"W1967566969","doi":"10.2165/11531480-000000000-00000","title":"Cost Effectiveness of High-Dose Intravenous Esomeprazole for Peptic Ulcer Bleeding","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Gastrointestinal Bleeding Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal General Hospital","funders":"AstraZeneca","keywords":"Esomeprazole; Medicine; Proton-pump inhibitor; Clinical trial; Intensive care medicine; Internal medicine; Emergency medicine","score_opus":0.03462260142695433,"score_gpt":0.3408558796709964,"score_spread":0.30623327824404206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967566969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817821,0.009662009,0.00060007966,0.002443485,0.000098281984,0.000056367648,0.00047723472,0.00003683013,0.004843654],"genre_scores_gemma":[0.9986841,0.0006527797,0.00018649724,0.0001356059,0.0000336993,0.000006600227,0.00012907031,0.0000016220059,0.00016996547],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990687,0.00065265974,0.00004706559,0.000044498975,0.000096858064,0.000090332374],"domain_scores_gemma":[0.99780995,0.0016333091,0.00021544285,0.000044150365,0.00007386014,0.00022337296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008242257,0.0002947266,0.0007704051,0.0004791127,0.00018946541,0.0006659317,0.00033287742,0.00092974986,0.003423106],"category_scores_gemma":[0.005681595,0.00018497443,0.0014716955,0.00047670328,0.00026714106,0.0005716011,0.00037196404,0.0008552167,0.000108883],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25217885,0.007497229,0.18026474,0.0018372084,0.007768765,0.0017555085,0.00015596015,0.09346559,0.0048889727,0.004852595,0.0070794304,0.43825522],"study_design_scores_gemma":[0.026438853,0.045667563,0.79898894,0.00046168355,0.009762924,0.0027290024,0.00069227314,0.10628347,0.0017196637,0.0032351317,0.0038864573,0.00013408161],"about_ca_topic_score_codex":0.006448481,"about_ca_topic_score_gemma":0.0060175234,"teacher_disagreement_score":0.006448481,"about_ca_system_score_codex":0.0018785686,"about_ca_system_score_gemma":0.0009041568,"threshold_uncertainty_score":0.013630092},"labels":[],"label_agreement":null},{"id":"W1969013485","doi":"10.2165/00019053-200826080-00001","title":"Waiting for Reimbursement of New Medicines in Canada","year":2008,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Institute","funders":"","keywords":"Reimbursement; Public health; Health economics; Public health insurance; Certification; Medicine; Family medicine; Quality of Life Research; Environmental health; Health insurance; Health administration; Business; Health care; Economic growth; Nursing; Political science","score_opus":0.11448916653243718,"score_gpt":0.31835818760973206,"score_spread":0.20386902107729488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969013485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5617758,0.01816912,0.0007291953,0.36679327,0.0015627339,0.00026739851,0.008142131,0.00017223696,0.042388074],"genre_scores_gemma":[0.94863796,0.004973413,0.0007565187,0.028882397,0.00056229666,0.00003515484,0.0013857115,0.00005056367,0.014716083],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927429,0.0003921935,0.00032561025,0.000383002,0.0022102667,0.003946068],"domain_scores_gemma":[0.9710769,0.004927282,0.0035529167,0.00026345675,0.008129393,0.012050104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037063002,0.00033992878,0.0010617833,0.001844963,0.006708034,0.0072580143,0.0025115088,0.005880982,0.007782336],"category_scores_gemma":[0.021054018,0.00076395704,0.0011482632,0.0044893394,0.0018717938,0.0014672364,0.0012675867,0.007000954,0.0002870675],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002032512,0.0007471046,0.4113028,0.0010649286,0.0006519249,0.0031996248,0.0036808443,0.01458921,0.0016451975,0.12531409,0.33151448,0.10425724],"study_design_scores_gemma":[0.0010308349,0.0003801289,0.7031431,0.0012471902,0.0009896463,0.0011074273,0.011313072,0.03660305,0.0017030234,0.016235806,0.22571194,0.0005347121],"about_ca_topic_score_codex":0.9972812,"about_ca_topic_score_gemma":0.99869305,"teacher_disagreement_score":0.7909701,"about_ca_system_score_codex":0.20902994,"about_ca_system_score_gemma":0.3169524,"threshold_uncertainty_score":0.9174132},"labels":[],"label_agreement":null},{"id":"W1970656907","doi":"10.2165/00019053-200220010-00006","title":"Economic Comparison of Leflunomide and Methotrexate in Patients with Rheumatoid Arthritis","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada; University of Ottawa; University Health Network","funders":"","keywords":"Medicine; Leflunomide; Rheumatoid arthritis; Placebo; Discontinuation; Physical therapy; Demography; Internal medicine; Alternative medicine","score_opus":0.019293109582837552,"score_gpt":0.3016139661087729,"score_spread":0.28232085652593536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970656907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9222731,0.056779534,0.0010495622,0.0067748097,0.0004062295,0.00057233125,0.0022857483,0.00003075602,0.009827839],"genre_scores_gemma":[0.99538934,0.0031498747,0.00029530708,0.0003561044,0.00008796559,0.00008449144,0.00029290255,0.0000032194064,0.00034076086],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9951748,0.0037683323,0.00030433733,0.00012107919,0.00036297282,0.00026847175],"domain_scores_gemma":[0.9925661,0.0054086368,0.0010581515,0.00014453432,0.00019491072,0.00062763214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034927642,0.0005176105,0.001791953,0.00083613617,0.0003233548,0.0011485744,0.00052755483,0.0013768498,0.0057705566],"category_scores_gemma":[0.01770646,0.0003239299,0.0026422772,0.00086882705,0.00046673574,0.00091016357,0.000645025,0.0015028587,0.00014432838],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8169965,0.0022255874,0.031257596,0.0034644238,0.0089575,0.0004955265,0.00012811035,0.014563798,0.0009227222,0.0028134007,0.00277376,0.1154011],"study_design_scores_gemma":[0.45553866,0.14595975,0.2779683,0.0028514708,0.036854353,0.0029322847,0.0016946478,0.050391596,0.0019767503,0.006051891,0.01744464,0.00033563355],"about_ca_topic_score_codex":0.007110571,"about_ca_topic_score_gemma":0.006787839,"teacher_disagreement_score":0.007110571,"about_ca_system_score_codex":0.0044899574,"about_ca_system_score_gemma":0.0020356819,"threshold_uncertainty_score":0.032577097},"labels":[],"label_agreement":null},{"id":"W1970936993","doi":"10.2165/00019053-200321090-00004","title":"Economic Evaluation of Norethisterone Acetate/Ethinylestradiol (FemHRT??) for Women with Menopausal Symptoms","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Menopause: Health Impacts and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Ottawa Hospital Research Institute","keywords":"Norethisterone; Medicine; Medroxyprogesterone acetate; Hormone replacement therapy (female-to-male); Norethisterone acetate; Cost effectiveness; Gynecology; Hormone therapy; Quality-adjusted life year; Obstetrics; Menopause; Internal medicine; Estrogen; Population; Breast cancer; Health services","score_opus":0.05937105870043457,"score_gpt":0.3790195173445483,"score_spread":0.31964845864411373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970936993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9044845,0.054408655,0.0028588665,0.009820665,0.000777513,0.0037004473,0.007929328,0.000115173425,0.015904812],"genre_scores_gemma":[0.99229515,0.004212038,0.0007623398,0.00054485165,0.000104058476,0.00034298436,0.0005851169,0.0000064331593,0.0011470774],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9957486,0.0034254834,0.00019939434,0.000120196804,0.00026499177,0.00024141055],"domain_scores_gemma":[0.99536926,0.0030380501,0.00072466314,0.00008559612,0.00016415636,0.0006183674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045649544,0.00080809824,0.0013727373,0.0009890321,0.00035081967,0.0009237209,0.0005952567,0.0018580819,0.011070135],"category_scores_gemma":[0.010449227,0.00039604478,0.0037573087,0.0006524595,0.0005691555,0.00070596614,0.00064722804,0.0016328418,0.00023178387],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85637337,0.0031233416,0.006879528,0.0034180265,0.005727516,0.0002573967,0.00006410795,0.01398837,0.00089103205,0.0015661309,0.0020828354,0.10562832],"study_design_scores_gemma":[0.6149717,0.19421695,0.07391394,0.0034397112,0.03987278,0.0009422346,0.00089877873,0.040443234,0.0025888074,0.0041548843,0.024337795,0.00021917524],"about_ca_topic_score_codex":0.008906988,"about_ca_topic_score_gemma":0.008880928,"teacher_disagreement_score":0.011070135,"about_ca_system_score_codex":0.003783523,"about_ca_system_score_gemma":0.0028875854,"threshold_uncertainty_score":0.03703326},"labels":[],"label_agreement":null},{"id":"W1971246182","doi":"10.2165/00019053-200321060-00005","title":"A Pharmacy-Based Health Promotion Programme in Hypertension","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); Hôpital du Saint-Sacrement; Université Laval","funders":"","keywords":"Pharmacy; Medicine; Pharmacist; Health economics; Psychological intervention; Health care; Family medicine; Health administration; Health promotion; Public health; Nursing; Environmental health","score_opus":0.26896895992880454,"score_gpt":0.4459164199547492,"score_spread":0.17694746002594464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971246182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895801,0.00040547433,0.000214732,0.0042100684,0.00022246552,0.0010266037,0.000101332145,0.00006310473,0.0041762125],"genre_scores_gemma":[0.99294734,0.0005342633,0.0013654074,0.0026540123,0.0005793502,0.0005630302,0.00013495209,0.000011000292,0.001210726],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9964353,0.0017319509,0.00023290892,0.00030307198,0.00046155922,0.0008351399],"domain_scores_gemma":[0.9875624,0.0016393733,0.00071871385,0.00031478246,0.00043331532,0.009331362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033277408,0.00054421765,0.00075477705,0.0015054395,0.004190621,0.0013446278,0.0012666978,0.0023427033,0.0040229135],"category_scores_gemma":[0.009423167,0.0006112721,0.0008158156,0.0010914089,0.00060703827,0.001650589,0.0029336363,0.0024512867,0.0004504682],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025322447,0.27410147,0.27681747,0.0008023976,0.00040468393,0.0025636386,0.0027903747,0.0013099218,0.0036176792,0.0005585949,0.0066290298,0.40508232],"study_design_scores_gemma":[0.01964119,0.060097706,0.90870583,0.00031196733,0.00048938085,0.00096901064,0.0019274743,0.0018070649,0.0011154946,0.00049083703,0.0043212776,0.00012283032],"about_ca_topic_score_codex":0.015437831,"about_ca_topic_score_gemma":0.031055624,"teacher_disagreement_score":0.015437831,"about_ca_system_score_codex":0.0025244013,"about_ca_system_score_gemma":0.00891445,"threshold_uncertainty_score":0.030695975},"labels":[],"label_agreement":null},{"id":"W1971890855","doi":"10.2165/00019053-200119090-00004","title":"Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia","funders":"National Institute of Neurological Disorders and Stroke; Heart and Stroke Foundation of Canada","keywords":"Medicine; Ischaemic stroke; Stroke (engine); Cohort; Tissue plasminogen activator; Thrombolysis; Quality-adjusted life year; Clinical trial; Internal medicine; Cost effectiveness; Emergency medicine; Physical therapy; Pediatrics; Ischemia; Myocardial infarction","score_opus":0.048404564636495694,"score_gpt":0.37625090538830464,"score_spread":0.32784634075180896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971890855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97572315,0.005845696,0.009027867,0.0018156028,0.00008247657,0.000315262,0.0021935254,0.00007036963,0.004926117],"genre_scores_gemma":[0.99748355,0.0004835367,0.001107212,0.00008833362,0.000025907204,0.00004281041,0.00041950986,0.000006177043,0.00034310194],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.996734,0.002612905,0.00008440249,0.00010299409,0.00025375708,0.00021197184],"domain_scores_gemma":[0.99025667,0.008520306,0.00038977753,0.00017269769,0.00038666293,0.00027393195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033375113,0.0011068332,0.001608056,0.0022150762,0.00029963406,0.0014556304,0.0010614839,0.0009323366,0.0037992676],"category_scores_gemma":[0.015971715,0.00047679985,0.0022762213,0.001980497,0.0005198323,0.0009315987,0.00062311505,0.00104329,0.00019518331],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055320077,0.0022552,0.09025451,0.0009335174,0.0058232667,0.0010624909,0.0001544443,0.73549736,0.002183903,0.011599623,0.004321836,0.09059376],"study_design_scores_gemma":[0.004084261,0.006698251,0.10459822,0.00015435462,0.0055863517,0.0010919488,0.00036467388,0.8676862,0.00097205705,0.006935126,0.0017112953,0.0001172728],"about_ca_topic_score_codex":0.016280707,"about_ca_topic_score_gemma":0.008292653,"teacher_disagreement_score":0.016280707,"about_ca_system_score_codex":0.004197085,"about_ca_system_score_gemma":0.0017503584,"threshold_uncertainty_score":0.03237188},"labels":[],"label_agreement":null},{"id":"W1972323838","doi":"10.2165/11584330-000000000-00000","title":"The Direct Medical Costs Associated with Suspected Heparin-Induced Thrombocytopenia","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Heparin-Induced Thrombocytopenia and Thrombosis","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"Bayer Fund; Sanofi","keywords":"Medicine; Emergency medicine; Indirect costs; Health economics; Health care; Adverse effect; Thrombosis; Public health; Surgery; Internal medicine; Pathology","score_opus":0.05595436473697466,"score_gpt":0.3136412365119274,"score_spread":0.2576868717749527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972323838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87984395,0.04618327,0.0016383152,0.018054932,0.00067023264,0.00016613795,0.004501566,0.00004111634,0.04890046],"genre_scores_gemma":[0.9906797,0.006261135,0.00061568944,0.00048698953,0.00047320267,0.00002022674,0.000779462,0.000003508417,0.0006801075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838305,0.0007175357,0.00023455388,0.000068998255,0.00042913324,0.00016663542],"domain_scores_gemma":[0.99192715,0.0044682864,0.0017444467,0.00015994003,0.0008838365,0.0008163299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007025891,0.00032401702,0.00042664888,0.0015448432,0.00038279954,0.0009312477,0.00030048253,0.0010629188,0.0058428934],"category_scores_gemma":[0.018294388,0.0002038145,0.0008360389,0.0013968998,0.00035317015,0.0005378923,0.000494185,0.0015905744,0.00032348832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011080028,0.0001891685,0.908115,0.0005288318,0.000731778,0.008365213,0.00007565711,0.0021480867,0.00045434764,0.0025780986,0.0056591686,0.07004656],"study_design_scores_gemma":[0.00010578578,0.00047882117,0.95244414,0.0005768351,0.00052633346,0.03180092,0.0003716587,0.005310105,0.0002557238,0.0019474546,0.0061555956,0.000026681893],"about_ca_topic_score_codex":0.005030406,"about_ca_topic_score_gemma":0.007194319,"teacher_disagreement_score":0.0058428934,"about_ca_system_score_codex":0.0014946522,"about_ca_system_score_gemma":0.0011974974,"threshold_uncertainty_score":0.01954645},"labels":[],"label_agreement":null},{"id":"W1972649100","doi":"10.2165/00019053-200119010-00003","title":"Glycoprotein IIb/IIIa Receptor Therapy in Percutaneous Coronary Intervention and Non???ST-Segment Elevation Acute Coronary Syndromes","year":2001,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Abciximab; Medicine; Eptifibatide; Conventional PCI; Percutaneous coronary intervention; Tirofiban; Myocardial infarction; Internal medicine; Acute coronary syndrome; Cost effectiveness; Cardiology","score_opus":0.05854457222835281,"score_gpt":0.39484833766169447,"score_spread":0.3363037654333417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972649100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015959705,0.99905306,0.00004709678,0.00016837624,0.00009025518,0.0000068965414,0.000016343452,0.000002018146,0.0004563438],"genre_scores_gemma":[0.0011392527,0.9981907,0.0001427783,0.00022884899,0.00009350253,0.000009617744,0.000026429672,5.026023e-7,0.00016834131],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9996799,0.00009288637,0.00006326379,0.000038308466,0.000106634994,0.00001897472],"domain_scores_gemma":[0.9994566,0.00036955334,0.000086032574,0.000009065829,0.000063241154,0.000015481852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009771172,0.00068639056,0.0023497583,0.0016831782,0.00018466057,0.0005584805,0.0005714524,0.0008465367,0.0031483145],"category_scores_gemma":[0.0016183517,0.00024068166,0.0008734622,0.0026076103,0.00025992436,0.0005100323,0.0003089669,0.00090031634,0.00057919754],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003247302,0.00008498637,0.00040741867,0.04445069,0.0007890812,0.00023707726,0.000037327358,0.00027142448,0.00043609008,0.0012243589,0.023172855,0.92856395],"study_design_scores_gemma":[0.0013809443,0.0007679174,0.0111428425,0.057816546,0.0080416985,0.002943004,0.00017573821,0.00042732558,0.0006258194,0.002971035,0.91365737,0.000049805458],"about_ca_topic_score_codex":0.0024273342,"about_ca_topic_score_gemma":0.007381555,"teacher_disagreement_score":0.0031483145,"about_ca_system_score_codex":0.0005747533,"about_ca_system_score_gemma":0.0010821599,"threshold_uncertainty_score":0.0105322},"labels":[],"label_agreement":null},{"id":"W1973112266","doi":"10.2165/00019053-200220090-00004","title":"Direct Medical Cost of Managing Deep Vein Thrombosis According to the Occurrence of Complications","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Deep vein; Ambulatory; Emergency medicine; Health economics; Intensive care unit; Ambulatory care; Intensive care medicine; Thrombosis; Public health; Indirect costs; Health administration; Inpatient care; Health care; Low molecular weight heparin; Surgery; Business; Nursing","score_opus":0.059229731182579216,"score_gpt":0.3531829625436581,"score_spread":0.29395323136107887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973112266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729173,0.006121961,0.0011245114,0.0034516929,0.00014213989,0.00011940842,0.0019702765,0.00002537367,0.014127142],"genre_scores_gemma":[0.99788135,0.00063772185,0.00041550558,0.00018407255,0.00011473816,0.000018506325,0.0004066665,0.0000025925262,0.000338717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823064,0.00084413664,0.0002550914,0.00010752052,0.0003519909,0.00021054927],"domain_scores_gemma":[0.9939038,0.0031075547,0.0015906007,0.00014513839,0.0005398141,0.0007129832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080676837,0.00017304612,0.00044215546,0.0012027846,0.00022051089,0.0006488186,0.000328166,0.000665808,0.0036461044],"category_scores_gemma":[0.015804537,0.00019524492,0.0009477901,0.0012921152,0.00017941366,0.00052599027,0.00036135537,0.00083810755,0.000211765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034891565,0.00033898302,0.9132786,0.00015258287,0.00085741683,0.00083573686,0.00006149815,0.0057564415,0.0005747039,0.0012592056,0.0022427374,0.07115286],"study_design_scores_gemma":[0.00022463554,0.0011137306,0.9814145,0.000065906,0.00061180186,0.0041329,0.0001349428,0.010261688,0.00022141267,0.0007925456,0.0010030637,0.0000228512],"about_ca_topic_score_codex":0.003751751,"about_ca_topic_score_gemma":0.0035993524,"teacher_disagreement_score":0.003751751,"about_ca_system_score_codex":0.0010384475,"about_ca_system_score_gemma":0.0005589805,"threshold_uncertainty_score":0.012197435},"labels":[],"label_agreement":null},{"id":"W1974629898","doi":"10.1007/s40273-014-0204-4","title":"Some Inconsistencies in NICE’s Consideration of Social Values","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta","funders":"Canadian Institutes of Health Research; Genome Canada","keywords":"Nice; Excellence; Quality-adjusted life year; Health economics; Actuarial science; Medicine; Health technology; Cost effectiveness; Economic evaluation; Health care; Economics; Public health; Economic growth; Risk analysis (engineering); Political science; Nursing; Computer science; Law","score_opus":0.29187287307462745,"score_gpt":0.4549529332373815,"score_spread":0.16308006016275406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974629898","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003004312,0.016815627,0.014344456,0.92615795,0.008632842,0.0000726096,0.00031399025,0.000101053694,0.030557161],"genre_scores_gemma":[0.21902686,0.008611815,0.049361743,0.695613,0.02190707,0.0007267127,0.0003860727,0.0006681811,0.0036985462],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.59594107,0.24636741,0.04762829,0.014453547,0.08700973,0.008599926],"domain_scores_gemma":[0.44002092,0.44190925,0.013948498,0.026481675,0.07146976,0.006169932],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.26302627,0.0014387894,0.005909593,0.01139712,0.0074345176,0.028154777,0.013201834,0.036816705,0.00414661],"category_scores_gemma":[0.50214136,0.0031945368,0.0058169616,0.012840058,0.04440934,0.019615287,0.014544864,0.049938615,0.0008542866],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014737222,0.000059925216,0.0013809495,0.0015980111,0.0008129115,0.00024599122,0.009341178,0.0010198265,0.0001063807,0.7270826,0.2177168,0.04048806],"study_design_scores_gemma":[0.00026472672,0.00011083821,0.004513455,0.0068344087,0.0005400914,0.0006224529,0.004622626,0.0019323735,0.00039504177,0.58657503,0.39316866,0.00042031048],"about_ca_topic_score_codex":0.033478837,"about_ca_topic_score_gemma":0.055840783,"teacher_disagreement_score":0.26302627,"about_ca_system_score_codex":0.019355103,"about_ca_system_score_gemma":0.021195482,"threshold_uncertainty_score":0.9088198},"labels":[],"label_agreement":null},{"id":"W1974907410","doi":"10.2165/00019053-200624100-00002","title":"QALYs","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Quality-adjusted life year; Health economics; Life expectancy; Actuarial science; Health technology; Cost–utility analysis; Economic evaluation; Cost–benefit analysis; Value (mathematics); Health administration; Cost effectiveness; Quality (philosophy); Medicine; Economics; Operations research; Public economics; Health care; Risk analysis (engineering); Computer science; Microeconomics; Population; Environmental health; Engineering","score_opus":0.32534079039432967,"score_gpt":0.4713800522101522,"score_spread":0.14603926181582255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974907410","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.059055068,0.037118264,0.053915158,0.011328283,0.0051611564,0.002330669,0.3829542,0.0024895226,0.44564763],"genre_scores_gemma":[0.6459532,0.014352247,0.025690295,0.009404457,0.0015320184,0.0036742906,0.13545951,0.0007380415,0.16319603],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958087,0.0021563964,0.0003688083,0.00040731425,0.0009684093,0.0002903206],"domain_scores_gemma":[0.9977112,0.00074385875,0.00049021695,0.00028980587,0.00065277633,0.000112132875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002740284,0.0008264627,0.001320652,0.0021835037,0.00028059623,0.001398577,0.00071687327,0.0008606181,0.097723134],"category_scores_gemma":[0.016189136,0.00023408046,0.0027440013,0.002421257,0.00029592356,0.0011377676,0.0009109071,0.002194024,0.02523364],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009979226,0.00049584446,0.02587155,0.006725126,0.0045289914,0.00014654115,0.00023954647,0.02836966,0.0015146976,0.092255816,0.3676203,0.46225265],"study_design_scores_gemma":[0.0028914332,0.0014178831,0.07260534,0.002079888,0.0025904665,0.0014812838,0.00021048418,0.015309305,0.0026718203,0.08401297,0.81457025,0.00015883482],"about_ca_topic_score_codex":0.004621084,"about_ca_topic_score_gemma":0.0027206463,"teacher_disagreement_score":0.097723134,"about_ca_system_score_codex":0.0022427165,"about_ca_system_score_gemma":0.001573306,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W1975774094","doi":"10.2165/00019053-200321130-00002","title":"Quality of Life in Patients with Rheumatoid Arthritis","year":2003,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Etanercept; Rheumatoid arthritis; Leflunomide; Quality of life (healthcare); Minimal clinically important difference; Internal medicine; Refractory (planetary science); Infliximab; Physical therapy; Polyarthritis; Rheumatology; Arthritis; Methotrexate; Disease; Randomized controlled trial","score_opus":0.04599196494103063,"score_gpt":0.36185948515112076,"score_spread":0.3158675202100901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975774094","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041488194,0.9988135,0.000053095413,0.00020403636,0.000085449,0.000005909389,0.000038117756,0.0000023042928,0.00038269334],"genre_scores_gemma":[0.0053196447,0.99388325,0.00019355121,0.0002876812,0.00010027467,0.000015413885,0.000047491787,7.1074675e-7,0.00015199717],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.999508,0.0001425762,0.00009982409,0.000055287208,0.00016522656,0.000028994113],"domain_scores_gemma":[0.9992021,0.00047199606,0.00019711672,0.000010410382,0.000092055176,0.000026325926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097626855,0.0008080964,0.0027017915,0.0019952215,0.00016287953,0.00064714596,0.0005069248,0.0006643862,0.0020099431],"category_scores_gemma":[0.0019686653,0.00021426844,0.0011274758,0.0031116193,0.00028919752,0.0005526656,0.00042830806,0.0009877096,0.00025477336],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039957504,0.00010344197,0.0019982907,0.045871425,0.001488777,0.00010464923,0.00005047026,0.00029726393,0.00026032332,0.00054716045,0.010811402,0.9380672],"study_design_scores_gemma":[0.0017831057,0.0018615123,0.117263295,0.14581004,0.020254547,0.005606098,0.00069758267,0.0013206785,0.0010595296,0.00458499,0.69956243,0.0001961883],"about_ca_topic_score_codex":0.003160365,"about_ca_topic_score_gemma":0.008095969,"teacher_disagreement_score":0.003160365,"about_ca_system_score_codex":0.00079506746,"about_ca_system_score_gemma":0.0009843998,"threshold_uncertainty_score":0.006724},"labels":[],"label_agreement":null},{"id":"W1975962137","doi":"10.2165/11537370-000000000-00000","title":"The Value of Value of Information","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Value of information; Computer science; Simplicity; Risk analysis (engineering); Management science; Value (mathematics); Operations research; Economics; Mathematics","score_opus":0.15159650207376027,"score_gpt":0.4322360465584539,"score_spread":0.28063954448469364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975962137","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13521604,0.062142316,0.28435206,0.20355864,0.0031723478,0.00019027444,0.001892914,0.0002693901,0.30920595],"genre_scores_gemma":[0.9701623,0.007129924,0.011378564,0.0025893312,0.0022443023,0.00006392139,0.00017269775,0.00007872911,0.0061802696],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98116106,0.011568152,0.0006128312,0.0011652474,0.004846043,0.00064661953],"domain_scores_gemma":[0.68318516,0.28360143,0.0077064014,0.01453696,0.009026837,0.0019431983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018190894,0.0008909739,0.001312197,0.0039077643,0.0012292045,0.010555822,0.0019540724,0.0053731464,0.007983923],"category_scores_gemma":[0.14905417,0.0006912648,0.00078255276,0.0031817604,0.009625235,0.02343051,0.0027383023,0.004613319,0.00071767264],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000334492,0.000083040795,0.0058832914,0.00029959963,0.00020225646,0.00033336374,0.00040361795,0.00937514,0.00022859439,0.8904953,0.009769302,0.08259206],"study_design_scores_gemma":[0.000019406061,0.000024531235,0.000669027,0.00013936778,0.00004988604,0.00017033395,0.00015175829,0.0098578865,0.00018068484,0.9823329,0.0063835043,0.000020748765],"about_ca_topic_score_codex":0.0015573447,"about_ca_topic_score_gemma":0.0010186305,"teacher_disagreement_score":0.018190894,"about_ca_system_score_codex":0.003731889,"about_ca_system_score_gemma":0.0017901276,"threshold_uncertainty_score":0.096203744},"labels":[],"label_agreement":null},{"id":"W1976080636","doi":"10.2165/00019053-200523020-00006","title":"Providing Systematic Guidance in Pharmacoeconomic Guidelines for Analysing Costs","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Activity-based costing; Health economics; Valuation (finance); Pharmacoeconomics; Identification (biology); Resource (disambiguation); Risk analysis (engineering); Cost driver; Process costing; Actuarial science; Computer science; Management science; Operations management; Business; Medicine; Health care; Economics; Accounting","score_opus":0.5371022765154605,"score_gpt":0.5497056761301654,"score_spread":0.012603399614704913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976080636","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0047975434,0.02207872,0.6298998,0.2689836,0.005932695,0.009850588,0.008495289,0.005902813,0.04405898],"genre_scores_gemma":[0.018041879,0.0049529327,0.94103616,0.02444192,0.0010849024,0.0048675067,0.0019688257,0.0004756727,0.003130163],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.830288,0.11395112,0.025894437,0.00173818,0.02589603,0.0022322633],"domain_scores_gemma":[0.5241799,0.33401683,0.015840918,0.013274104,0.1099224,0.0027659382],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.12126595,0.0033266386,0.006459645,0.014935001,0.0024862282,0.009081963,0.0059817303,0.023764502,0.010449739],"category_scores_gemma":[0.45490825,0.0028543388,0.005057922,0.013692266,0.0030731924,0.006822223,0.0032480576,0.01855918,0.007407707],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020311865,0.00081488595,0.0032801265,0.0044561587,0.0005482656,0.0007500995,0.0016617674,0.013530143,0.00074352726,0.053589497,0.6531423,0.2672801],"study_design_scores_gemma":[0.0019092044,0.00038202046,0.01327418,0.040660508,0.0019483294,0.0011314263,0.0019749063,0.051130325,0.0041759997,0.38586852,0.49667293,0.0008717104],"about_ca_topic_score_codex":0.029499443,"about_ca_topic_score_gemma":0.055173464,"teacher_disagreement_score":0.87873405,"about_ca_system_score_codex":0.0071132006,"about_ca_system_score_gemma":0.031053744,"threshold_uncertainty_score":0.6413233},"labels":[],"label_agreement":null},{"id":"W1977585061","doi":"10.1007/s40273-014-0146-x","title":"Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?","year":2014,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute for Health and Care Research","keywords":"Allocative efficiency; Nice; Health economics; Health administration; Quality of Life Research; Health care; Public health; Quality-adjusted life year; Public economics; Business; Medicine; Economics; Cost effectiveness; Nursing; Operations management; Microeconomics; Economic growth; Computer science","score_opus":0.24596408068605594,"score_gpt":0.4786617127778069,"score_spread":0.23269763209175096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977585061","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008050271,0.0009489193,0.00021571745,0.9954686,0.0022013749,0.000004140375,0.000014968133,0.000007091569,0.0010587155],"genre_scores_gemma":[0.0021936605,0.0006560327,0.0005864907,0.9839691,0.01131213,0.00003206621,0.000010360399,0.000019582456,0.0012206392],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.94117266,0.028143732,0.006007286,0.0045440956,0.015318885,0.004813351],"domain_scores_gemma":[0.8239119,0.13811359,0.0058623087,0.00493707,0.015479722,0.011695405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.059061468,0.0012164615,0.0047090654,0.0013838896,0.0066720787,0.012099398,0.0053348946,0.1382767,0.008323052],"category_scores_gemma":[0.18508247,0.0013656789,0.0030766902,0.0016935461,0.024687307,0.020188842,0.008214606,0.11199551,0.004360647],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103238825,0.00006645093,0.00057308516,0.00017232228,0.0000749277,0.0004294893,0.00030193676,0.00020752521,0.0000903375,0.05619348,0.9226855,0.019101737],"study_design_scores_gemma":[0.0005043295,0.00009908346,0.0014815613,0.0016783288,0.00009252096,0.0007342344,0.00095095445,0.001343026,0.00024642746,0.29624975,0.6963805,0.0002392597],"about_ca_topic_score_codex":0.017335864,"about_ca_topic_score_gemma":0.030664722,"teacher_disagreement_score":0.1382767,"about_ca_system_score_codex":0.012585742,"about_ca_system_score_gemma":0.030961469,"threshold_uncertainty_score":0.31235063},"labels":[],"label_agreement":null},{"id":"W1977937211","doi":"10.1007/s40273-014-0185-3","title":"Hospital-Based Health Technology Assessment: Developments to Date","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-François d'Assise","funders":"Canada Research Chairs","keywords":"Health technology; Multidisciplinary approach; Health economics; Health administration; Medicine; Technology assessment; Psychological intervention; Public health; Discontinuation; Pharmacoeconomics; Management science; Health care; Nursing; Intensive care medicine; Engineering; Political science","score_opus":0.24823222275365942,"score_gpt":0.49499207490877034,"score_spread":0.24675985215511093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977937211","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008524614,0.90713173,0.0356792,0.02870541,0.0018454567,0.00014756192,0.001142598,0.00027963877,0.016543774],"genre_scores_gemma":[0.17864521,0.73338276,0.061769806,0.009731822,0.009911766,0.0002340229,0.0028125483,0.00010015408,0.003411896],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99081224,0.005119527,0.00075528584,0.0008560592,0.002088301,0.00036853916],"domain_scores_gemma":[0.8963171,0.07239327,0.0078001353,0.0022826619,0.01853482,0.0026719517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022290507,0.001156137,0.0023635263,0.005875863,0.0003674503,0.0052932487,0.0024766512,0.0037210812,0.0060818386],"category_scores_gemma":[0.04048191,0.00036497138,0.0015097146,0.009254664,0.0019961807,0.0043348656,0.0017320195,0.0036758569,0.0014349457],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033257398,0.00036703967,0.011981083,0.0052297493,0.00039619382,0.00006230962,0.00009626914,0.003683301,0.0003714755,0.017168174,0.013842432,0.94646937],"study_design_scores_gemma":[0.00039980275,0.0020902292,0.14030606,0.02589907,0.0024942774,0.002790529,0.0012997577,0.034653407,0.0049843057,0.09454561,0.69003594,0.00050101813],"about_ca_topic_score_codex":0.006111727,"about_ca_topic_score_gemma":0.004600914,"teacher_disagreement_score":0.022290507,"about_ca_system_score_codex":0.005197498,"about_ca_system_score_gemma":0.006654089,"threshold_uncertainty_score":0.117884934},"labels":[],"label_agreement":null},{"id":"W1979215948","doi":"10.2165/00019053-200119002-00003","title":"Using Humanistic Health Outcomes Data in Asthma","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Quality of life (healthcare); Asthma; Disease; Clinical trial; Quality of Life Research; Physical therapy; Intensive care medicine; Family medicine; Public health; Internal medicine; Nursing","score_opus":0.7421242204092596,"score_gpt":0.5783843211896595,"score_spread":0.16373989921960008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979215948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94967246,0.0016615293,0.014419422,0.002786718,0.000110887726,0.00017104814,0.025852611,0.000099346325,0.005226023],"genre_scores_gemma":[0.9766011,0.0003356376,0.006250037,0.0003086082,0.00002973994,0.00019911888,0.0155852465,0.000016406842,0.0006741616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9880333,0.0106011,0.00027373087,0.0004195146,0.0004770711,0.00019532036],"domain_scores_gemma":[0.920415,0.0663099,0.0048415936,0.005453085,0.002086532,0.00089383556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013293432,0.00036273408,0.0006496041,0.0013468061,0.0005955356,0.0011222258,0.00084862433,0.0014206094,0.0031286948],"category_scores_gemma":[0.08182453,0.00035707513,0.0009704604,0.0026743426,0.00070797594,0.0008850313,0.0012712792,0.0012048187,0.0006153563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004816614,0.0020392349,0.62957126,0.001024025,0.0036398042,0.0010171534,0.001682607,0.20738026,0.00047601087,0.029114235,0.042479593,0.07675908],"study_design_scores_gemma":[0.0017981025,0.0014837163,0.59158534,0.0004966148,0.0010204636,0.0013004671,0.0021617722,0.30113968,0.0013387932,0.063941255,0.033482604,0.00025122825],"about_ca_topic_score_codex":0.05515439,"about_ca_topic_score_gemma":0.050340697,"teacher_disagreement_score":0.05515439,"about_ca_system_score_codex":0.0014058863,"about_ca_system_score_gemma":0.0011135192,"threshold_uncertainty_score":0.109666705},"labels":[],"label_agreement":null},{"id":"W1982028492","doi":"10.2165/00019053-200018030-00007","title":"The Economic Value of a New Insulin Preparation, Humalog?? Mix 25???","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"Eli Lilly Canada","keywords":"Willingness to pay; Insulin lispro; Medicine; Confidence interval; Insulin; Human insulin; Economics; Internal medicine; Microeconomics","score_opus":0.01617676700983851,"score_gpt":0.31315808945981577,"score_spread":0.29698132244997727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982028492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39380613,0.06836771,0.0065291417,0.2495238,0.0037116292,0.00020954882,0.002909379,0.00012944658,0.2748132],"genre_scores_gemma":[0.9475379,0.01617505,0.0031876361,0.01041966,0.0015933149,0.00006303426,0.00053405744,0.000040018665,0.020449273],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986304,0.0006643717,0.00005763237,0.00007196342,0.0004568342,0.000118856566],"domain_scores_gemma":[0.99676454,0.0019919,0.00028507452,0.00010577867,0.0003272656,0.0005255237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018469319,0.00024166789,0.00030647236,0.0011382413,0.0005749634,0.002486246,0.00035127313,0.0016139915,0.013819227],"category_scores_gemma":[0.010620917,0.00014572911,0.0005088455,0.0005591897,0.00092243496,0.0015332133,0.000778738,0.0015007778,0.00086593686],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022484865,0.0012267132,0.030839518,0.0008280551,0.00052291964,0.001376403,0.00014582166,0.008200655,0.0047626025,0.09041327,0.08693222,0.7522669],"study_design_scores_gemma":[0.003227807,0.007037315,0.17783913,0.0031879148,0.0025662365,0.0073741283,0.0032778545,0.029547151,0.01145392,0.105261356,0.6488015,0.00042558805],"about_ca_topic_score_codex":0.004306526,"about_ca_topic_score_gemma":0.0054938295,"teacher_disagreement_score":0.013819227,"about_ca_system_score_codex":0.0031194077,"about_ca_system_score_gemma":0.0021975636,"threshold_uncertainty_score":0.0462299},"labels":[],"label_agreement":null},{"id":"W1982131526","doi":"10.2165/00019053-200321060-00001","title":"Health-Related Quality of Life and Regulatory Issues in the US and Canada","year":2003,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Credibility; Transparency (behavior); Clinical trial; Quality (philosophy); Regulatory affairs; Medicine; Product (mathematics); Process (computing); Business; Risk analysis (engineering); Process management; Operations management; Computer science; Political science; Economics; Pathology","score_opus":0.41544806704401827,"score_gpt":0.49887460194409283,"score_spread":0.08342653490007457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982131526","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010446061,0.9903324,0.00009436676,0.0052186097,0.0001601957,0.000015314923,0.00035293892,0.0000048062625,0.0027766821],"genre_scores_gemma":[0.016224865,0.98088866,0.00032299152,0.0013798897,0.00015680863,0.000022247617,0.00026196518,0.0000037638,0.00073879753],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968771,0.00040383337,0.00027467986,0.00018339726,0.001972153,0.00028897214],"domain_scores_gemma":[0.98753077,0.003432728,0.0010667304,0.00011447582,0.0072709667,0.00058435585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074563967,0.00060310605,0.001891518,0.007279995,0.0014867648,0.0037110571,0.0014723745,0.0017965588,0.0024866443],"category_scores_gemma":[0.016812528,0.00035942177,0.0010882346,0.020623637,0.0020533733,0.0009450678,0.0007169928,0.001811572,0.00015495917],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031752288,0.00011366871,0.009341021,0.013460996,0.00045852814,0.00020583,0.00026582432,0.0028406125,0.000104148836,0.019187538,0.09987191,0.8538324],"study_design_scores_gemma":[0.00023671972,0.00012232452,0.1177184,0.036137678,0.00201678,0.0006144933,0.00081685424,0.0018713261,0.00039277025,0.010351652,0.82953215,0.00018900156],"about_ca_topic_score_codex":0.96372354,"about_ca_topic_score_gemma":0.97728,"teacher_disagreement_score":0.06596982,"about_ca_system_score_codex":0.06596982,"about_ca_system_score_gemma":0.14604802,"threshold_uncertainty_score":0.47864676},"labels":[],"label_agreement":null},{"id":"W1982493386","doi":"10.2165/00019053-200422090-00005","title":"A Cost-Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous Thromboembolism","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"U.S. Food and Drug Administration","keywords":"Fondaparinux; Medicine; Enoxaparin sodium; Low molecular weight heparin; Venous thrombosis; Regimen; Emergency medicine; Anesthesia; Surgery; Venous thromboembolism; Intensive care medicine; Heparin; Thrombosis","score_opus":0.03669305115081794,"score_gpt":0.3306948623787169,"score_spread":0.294001811227899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982493386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719549,0.019533461,0.0020526238,0.0014227412,0.0003842964,0.0006936337,0.0012262854,0.000058021407,0.0026740318],"genre_scores_gemma":[0.9963393,0.0017569298,0.0008616107,0.00022148894,0.00009395226,0.00013224207,0.0002678192,0.000005936079,0.00032073696],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99404126,0.004577812,0.00031344002,0.00030563658,0.0003845394,0.00037726143],"domain_scores_gemma":[0.99051005,0.00791989,0.0006912431,0.0001554958,0.00022883622,0.00049452524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003822295,0.0014882747,0.0035645408,0.0020501348,0.00038103719,0.0018154926,0.0012450526,0.002142394,0.0060544596],"category_scores_gemma":[0.012920715,0.00088695734,0.0068117594,0.0016650415,0.0009086229,0.0018311962,0.00076150795,0.0022184555,0.00021509969],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86654717,0.003759531,0.0122473985,0.0025699988,0.020843854,0.00045439118,0.00008563044,0.03853403,0.0019831534,0.0017722433,0.0009279229,0.050274618],"study_design_scores_gemma":[0.4438969,0.19058876,0.082877,0.0010999652,0.112379804,0.0017014535,0.0007302624,0.15524572,0.0033488928,0.0045347805,0.0031746572,0.0004218924],"about_ca_topic_score_codex":0.007849855,"about_ca_topic_score_gemma":0.004855539,"teacher_disagreement_score":0.007849855,"about_ca_system_score_codex":0.004605535,"about_ca_system_score_gemma":0.0018153216,"threshold_uncertainty_score":0.033415616},"labels":[],"label_agreement":null},{"id":"W1983479493","doi":"10.2165/11589240-000000000-00000","title":"Health Economic and Infectious Disease Modelling","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Public Health; University of Toronto","funders":"GlaxoSmithKline","keywords":"Health economics; Public health; Quality of Life Research; Health administration; Infectious disease (medical specialty); Disease; Medicine; Environmental health; Nursing; Pathology","score_opus":0.412451901260778,"score_gpt":0.4483275977605574,"score_spread":0.0358756964997794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983479493","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048195507,0.03432669,0.70947343,0.051488746,0.002883085,0.0005168542,0.00827725,0.00037097372,0.14446747],"genre_scores_gemma":[0.78846145,0.028665947,0.062445793,0.0031298285,0.0029302253,0.0008640683,0.0030762197,0.00016454335,0.11026187],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.997647,0.0016380149,0.000082623155,0.00017275807,0.00025985652,0.0001997581],"domain_scores_gemma":[0.9948112,0.0040814835,0.0003386734,0.00021288737,0.00036261516,0.00019315818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003957525,0.0012309907,0.0015162403,0.0017553061,0.00049106235,0.0022565683,0.0015588691,0.0030936792,0.0121553205],"category_scores_gemma":[0.017023295,0.00049467204,0.0012444314,0.0028071497,0.0011913248,0.0018990228,0.0011726823,0.002488838,0.0015077213],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004763065,0.00012001438,0.0030059563,0.00021932069,0.00013818302,0.00028100665,0.00013463538,0.4442898,0.0000831949,0.5081357,0.017055515,0.026489057],"study_design_scores_gemma":[0.000049817616,0.000038248145,0.0016086125,0.00008443881,0.000061657505,0.00018266635,0.00008982218,0.44498023,0.00004870106,0.5311618,0.021670135,0.000023856592],"about_ca_topic_score_codex":0.017881887,"about_ca_topic_score_gemma":0.010243786,"teacher_disagreement_score":0.017881887,"about_ca_system_score_codex":0.002258654,"about_ca_system_score_gemma":0.0015985683,"threshold_uncertainty_score":0.0406636},"labels":[],"label_agreement":null},{"id":"W1983800857","doi":"10.2165/11585910-000000000-00000","title":"Consistently Estimating Absolute Risk Difference when Translating Evidence to Jurisdictions of Interest","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto","funders":"","keywords":"Absolute risk reduction; Relative risk; Jurisdiction; Odds; Medicine; Framing effect; Odds ratio; Actuarial science; Econometrics; Demography; Psychology; Economics; Confidence interval; Internal medicine; Logistic regression; Social psychology; Law; Political science","score_opus":0.49827847882706383,"score_gpt":0.48029319655707564,"score_spread":0.01798528226998819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983800857","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2503824,0.04437707,0.62728083,0.03592195,0.006590461,0.0021764406,0.011548322,0.0014134385,0.020309076],"genre_scores_gemma":[0.7850481,0.0024291605,0.201425,0.0051803607,0.0010788334,0.001143202,0.002703894,0.00019260135,0.000798807],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.6647748,0.26677406,0.03720459,0.014661898,0.014587378,0.0019973256],"domain_scores_gemma":[0.16808115,0.7713252,0.021776067,0.021270042,0.016597236,0.0009503347],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.24329463,0.0012483358,0.004614101,0.0070722047,0.00077690656,0.0062669413,0.0030601986,0.004173331,0.0028055843],"category_scores_gemma":[0.7249722,0.001229581,0.004977766,0.008046944,0.0020493923,0.005904544,0.003718801,0.0049685705,0.00055955304],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005506086,0.0006535139,0.39383593,0.0067654364,0.052739367,0.0014531057,0.0019472734,0.039928865,0.0013610595,0.03254049,0.03092671,0.4323422],"study_design_scores_gemma":[0.005764248,0.006151208,0.22602479,0.008844622,0.07418022,0.0031557847,0.0042377226,0.18595749,0.020205567,0.39387566,0.07084719,0.00075547554],"about_ca_topic_score_codex":0.005394713,"about_ca_topic_score_gemma":0.0042292173,"teacher_disagreement_score":0.7567054,"about_ca_system_score_codex":0.0016631118,"about_ca_system_score_gemma":0.005528407,"threshold_uncertainty_score":0.93315244},"labels":[],"label_agreement":null},{"id":"W1983841278","doi":"10.1007/s40273-014-0167-5","title":"A Review of the Psychometric Properties of Generic Utility Measures in Multiple Sclerosis","year":2014,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Health Utilities Index; Quality of Life Research; Statistic; EQ-5D; Discriminative model; Ceiling effect; Statistics; Psychometrics; Reliability (semiconductor); Quality of life (healthcare); Quality-adjusted life year; Convergent validity; Index (typography); Psychology; Medicine; Health related quality of life; Cost effectiveness; Mathematics; Public health; Computer science; Artificial intelligence; Alternative medicine; Nursing","score_opus":0.43205942516604046,"score_gpt":0.4150444235009553,"score_spread":0.017015001665085183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983841278","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016200647,0.9994104,0.00010400838,0.00012829353,0.00003681084,0.000015047135,0.000053108655,0.0000015247746,0.00008876519],"genre_scores_gemma":[0.0020592015,0.9969022,0.0006609776,0.0001965987,0.000048833463,0.0000334781,0.00006323197,0.0000015579549,0.00003396333],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9925143,0.0024426419,0.002739323,0.000531232,0.001653419,0.00011912396],"domain_scores_gemma":[0.96941906,0.026034998,0.0022697314,0.00031251114,0.0018342618,0.00012940589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0149243055,0.0015165204,0.006495192,0.008998788,0.00046155107,0.0024618567,0.0018911473,0.0015782282,0.0022183203],"category_scores_gemma":[0.035536453,0.0007973296,0.00497266,0.011744452,0.0011470693,0.0021731104,0.0016156652,0.0019216182,0.0002712963],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029941875,0.000078009114,0.0023056814,0.32568294,0.0048502693,0.00010628946,0.0002193492,0.0003846639,0.00026123712,0.0016225844,0.0048346096,0.6593549],"study_design_scores_gemma":[0.00044678207,0.00062657386,0.04081343,0.65683526,0.041941922,0.0022295706,0.00093581644,0.00079792953,0.0011267752,0.005423233,0.24850853,0.00031417076],"about_ca_topic_score_codex":0.0063997507,"about_ca_topic_score_gemma":0.01148186,"teacher_disagreement_score":0.0149243055,"about_ca_system_score_codex":0.0024657298,"about_ca_system_score_gemma":0.0057052607,"threshold_uncertainty_score":0.07892817},"labels":[],"label_agreement":null},{"id":"W1984160769","doi":"10.1007/s40273-013-0079-9","title":"Impacts of Health Insurance Benefit Design on Percutaneous Coronary Intervention Use and Inpatient Costs among Patients with Acute Myocardial Infarction in Shanghai, China","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Healthcare Systems and Reforms","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Health economics; Percutaneous coronary intervention; Myocardial infarction; Health administration; China; Emergency medicine; Public health; Intensive care medicine; Medical emergency; Environmental health; Internal medicine; Nursing","score_opus":0.021425713652811474,"score_gpt":0.251050596510918,"score_spread":0.2296248828581065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984160769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991373,0.00016782514,0.000036490128,0.0002453632,0.000007423763,0.0000051791535,0.00019601201,0.000002553121,0.0002019379],"genre_scores_gemma":[0.9995931,0.00004265283,0.000011433636,0.00003442444,0.000006044279,0.0000027283638,0.0001875828,5.8163727e-7,0.000121403755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984389,0.0004982272,0.00011034416,0.00014082054,0.00013779361,0.0006739131],"domain_scores_gemma":[0.99688345,0.00046745373,0.00088747917,0.000117390104,0.00037163091,0.0012725968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010355746,0.0004179149,0.0005008937,0.0012261677,0.0007436412,0.0014142725,0.00060469063,0.00063766295,0.0019442841],"category_scores_gemma":[0.0028500154,0.00032818542,0.0012455104,0.0015806276,0.0008704869,0.0005036348,0.0010877915,0.00080609747,0.00010286594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001932044,0.00011278706,0.99699557,0.000010965019,0.00016410546,0.00016302321,0.00012767926,0.00074695755,0.00007670672,0.00017488922,0.00022938427,0.0010047719],"study_design_scores_gemma":[0.000022536937,0.000066783774,0.99761546,0.0000047007866,0.00011738883,0.00003055826,0.00044468162,0.0014914058,0.000024077197,0.00007619888,0.000098158875,0.000008161457],"about_ca_topic_score_codex":0.23593377,"about_ca_topic_score_gemma":0.27571484,"teacher_disagreement_score":0.23593377,"about_ca_system_score_codex":0.005058167,"about_ca_system_score_gemma":0.0052242572,"threshold_uncertainty_score":0.46912098},"labels":[],"label_agreement":null},{"id":"W1984717160","doi":"10.2165/00019053-200018040-00007","title":"The Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV/AIDS","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; HIV Legal Network; St. Paul's Hospital","funders":"Centers for Disease Control and Prevention","keywords":"Didanosine; Zalcitabine; Stavudine; Lamivudine; Zidovudine; Medicine; Indinavir; Cost effectiveness; Reverse-transcriptase inhibitor; Internal medicine; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral disease; Virus","score_opus":0.02345318179831839,"score_gpt":0.3238373498151319,"score_spread":0.3003841680168135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984717160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5395322,0.3253115,0.0048878677,0.048047714,0.0010372114,0.0002341228,0.003299061,0.00005284884,0.07759745],"genre_scores_gemma":[0.9579094,0.03760468,0.0013873028,0.0011658699,0.00045328223,0.00004330167,0.00031148968,0.000008780613,0.0011159135],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99562645,0.003082848,0.00016102057,0.00004806996,0.00093026,0.00015130869],"domain_scores_gemma":[0.99187917,0.006695675,0.00066945417,0.00012846521,0.0004386784,0.00018854876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022033877,0.00025403308,0.00040271765,0.0009607295,0.00024644117,0.00093908986,0.00032316925,0.00069476187,0.0028984149],"category_scores_gemma":[0.018623056,0.0001253295,0.0008009265,0.0013159466,0.00041443342,0.0008696355,0.0003604455,0.0009509179,0.00011616322],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008742792,0.00079251797,0.055148575,0.0020150528,0.0018160891,0.0005799316,0.00018559987,0.056839913,0.0013200239,0.040845767,0.0130790975,0.8186346],"study_design_scores_gemma":[0.0022576195,0.007109883,0.68309456,0.0035022863,0.006457738,0.006210189,0.0017341475,0.11010493,0.0036011466,0.08004426,0.09567549,0.00020783125],"about_ca_topic_score_codex":0.0052068606,"about_ca_topic_score_gemma":0.00914443,"teacher_disagreement_score":0.0052068606,"about_ca_system_score_codex":0.0024824336,"about_ca_system_score_gemma":0.0013523201,"threshold_uncertainty_score":0.018011391},"labels":[],"label_agreement":null},{"id":"W1984921391","doi":"10.2165/00019053-200826020-00005","title":"The Burden of Schizophrenia on Caregivers","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Family Caregiving in Mental Illness","field":"Psychology","cited_by":808,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; McMaster University; University of Toronto","funders":"","keywords":"Caregiver burden; Psychosocial; Embarrassment; Shame; Feeling; Economic cost; Blame; Psychology; Psychiatry; Indirect costs; Medicine; Clinical psychology; Dementia; Psychotherapist; Social psychology","score_opus":0.05579451945753411,"score_gpt":0.386098591713241,"score_spread":0.3303040722557069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984921391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018938855,0.9986619,0.0000327489,0.00047196881,0.00010620859,0.0000018632917,0.000013465986,0.0000015805635,0.00052080886],"genre_scores_gemma":[0.0011096478,0.9984023,0.000059902668,0.00019034668,0.00012336124,0.0000027121969,0.000011116686,3.6683443e-7,0.00010025602],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99965715,0.0001107742,0.000054790056,0.00003489806,0.000113897426,0.00002847615],"domain_scores_gemma":[0.99858487,0.00087960256,0.0002801484,0.000022833983,0.00017101318,0.00006154848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001009953,0.00068810815,0.0017181026,0.0021039476,0.00024020733,0.00095137145,0.0005036538,0.00094456185,0.0029789275],"category_scores_gemma":[0.0024394256,0.00022990225,0.0007595862,0.0028646118,0.0004107855,0.0007184257,0.00057638454,0.0009562283,0.00040656418],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010251513,0.00005829655,0.00081658835,0.018941294,0.00034361903,0.00015283555,0.000056653498,0.00018123433,0.00018983685,0.001024406,0.019419929,0.95871276],"study_design_scores_gemma":[0.00026791357,0.00032186502,0.031817526,0.06899099,0.0026317653,0.004107522,0.00056040834,0.00031480598,0.0003602638,0.0036448701,0.8869136,0.000068537905],"about_ca_topic_score_codex":0.004471172,"about_ca_topic_score_gemma":0.011336686,"teacher_disagreement_score":0.004471172,"about_ca_system_score_codex":0.00090872345,"about_ca_system_score_gemma":0.0020390365,"threshold_uncertainty_score":0.009965479},"labels":[],"label_agreement":null},{"id":"W1985149660","doi":"10.2165/11591570-000000000-00000","title":"Challenges in Health State Valuation in Paediatric Economic Evaluation","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"Hospital for Sick Children","keywords":"Health economics; Preference; Valuation (finance); Health Utilities Index; Economic evaluation; Proxy (statistics); Medicine; Health administration; Quality-adjusted life year; Cost–utility analysis; Health care; EQ-5D; Actuarial science; Public economics; Public health; Cost effectiveness; Economics; Risk analysis (engineering); Computer science; Economic growth; Nursing; Microeconomics; Disease","score_opus":0.6867786026475992,"score_gpt":0.5036153730572293,"score_spread":0.1831632295903699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985149660","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03593622,0.09470008,0.34021607,0.46747616,0.002351734,0.0006730304,0.0019236834,0.00024352947,0.0564795],"genre_scores_gemma":[0.8038887,0.033085022,0.14311662,0.009822143,0.0046269083,0.0009944617,0.0007125037,0.00024121154,0.0035125182],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.8923908,0.09180499,0.0055975174,0.0020728342,0.0069183325,0.0012155247],"domain_scores_gemma":[0.3863445,0.5834751,0.007221678,0.0040621166,0.015355728,0.0035408267],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.21274857,0.0013777084,0.005178973,0.006059523,0.0017894453,0.018984083,0.0057116994,0.007899915,0.0077263494],"category_scores_gemma":[0.45073846,0.00163397,0.0018533197,0.009504975,0.011704057,0.01780062,0.0071517183,0.011226985,0.000780883],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024677248,0.00029195054,0.00870398,0.0014266992,0.00040615795,0.00031662593,0.001113137,0.08699054,0.0000786002,0.7039116,0.0260079,0.17050616],"study_design_scores_gemma":[0.00009233702,0.000058622598,0.0018250869,0.0016399266,0.000058351976,0.00013451726,0.0015723947,0.07206004,0.00007686595,0.91012526,0.012263048,0.000093591145],"about_ca_topic_score_codex":0.019496879,"about_ca_topic_score_gemma":0.015092681,"teacher_disagreement_score":0.21274857,"about_ca_system_score_codex":0.011528465,"about_ca_system_score_gemma":0.014482908,"threshold_uncertainty_score":0.97082114},"labels":[],"label_agreement":null},{"id":"W1985428484","doi":"10.2165/00019053-200422100-00005","title":"Warfarin in the Secondary Prevention of Thromboembolism in Atrial Fibrillation","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"United States Pharmacopeia","keywords":"Warfarin; Atrial fibrillation; Medicine; Stroke (engine); Rivaroxaban; Internal medicine; Cardiology; Intensive care medicine","score_opus":0.06516114370617322,"score_gpt":0.3804681444717699,"score_spread":0.3153070007655967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985428484","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28289255,0.5542472,0.0019307809,0.105290465,0.0031754728,0.00009279069,0.0006170429,0.00006142549,0.05169225],"genre_scores_gemma":[0.8697155,0.11517411,0.00091445807,0.0050121243,0.007185851,0.000048265938,0.00020847574,0.0000072167045,0.0017340528],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974909,0.0015227791,0.0002772631,0.00010067523,0.0004979322,0.00011052003],"domain_scores_gemma":[0.9943362,0.0038221176,0.00086666463,0.000087234854,0.00034235485,0.00054537755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026650869,0.00022187732,0.0011344207,0.0009921229,0.000307967,0.0010944047,0.00030722274,0.0013866606,0.0017874177],"category_scores_gemma":[0.011951059,0.00014341118,0.0006388896,0.0009482612,0.00032445844,0.00040706346,0.0002916335,0.0021674496,0.00018370907],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014687209,0.0022350156,0.24781916,0.0029141621,0.002517309,0.0029877168,0.0005544418,0.0032047944,0.0017954812,0.01462021,0.039863642,0.66680086],"study_design_scores_gemma":[0.005521838,0.0074944026,0.84893084,0.0036432527,0.0052759787,0.0080688875,0.00065753824,0.009013435,0.0018485745,0.020897435,0.088532664,0.000115181705],"about_ca_topic_score_codex":0.0035362947,"about_ca_topic_score_gemma":0.0075125364,"teacher_disagreement_score":0.0035362947,"about_ca_system_score_codex":0.00073457847,"about_ca_system_score_gemma":0.0015004842,"threshold_uncertainty_score":0.014094472},"labels":[],"label_agreement":null},{"id":"W1986793930","doi":"10.2165/00019053-200523070-00003","title":"Evaluating Health-Related Quality-of-Life Studies in Paediatric Populations","year":2005,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Centre for Advancing Health Outcomes; Vancouver General Hospital; University of British Columbia; McGill University","funders":"","keywords":"Normative; Context (archaeology); Quality of life (healthcare); Consistency (knowledge bases); Medicine; Focus group; Health related quality of life; Quality of Life Research; Quality (philosophy); Psychology; Gerontology; Public health; Applied psychology; Nursing; Disease; Sociology; Computer science; Pathology","score_opus":0.6052144855470185,"score_gpt":0.6085773217654783,"score_spread":0.003362836218459786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986793930","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014711419,0.9977736,0.00017188347,0.00012327204,0.00004452329,0.00007513152,0.00013808052,0.0000020950467,0.00020024201],"genre_scores_gemma":[0.015395552,0.9824629,0.0014632901,0.00017152715,0.00006072707,0.00017325224,0.0002148857,0.0000021092021,0.000055790155],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9913141,0.004633869,0.002144695,0.00045330354,0.0012852544,0.00016867627],"domain_scores_gemma":[0.9546884,0.037855648,0.004636156,0.0003804565,0.0022072273,0.00023218789],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.019024504,0.0011492271,0.006597102,0.005773233,0.00033774896,0.002415874,0.001274532,0.0010600585,0.0019421865],"category_scores_gemma":[0.045925137,0.00059272797,0.005107976,0.0090003405,0.0005481061,0.0014729481,0.001072294,0.0009653967,0.00017817463],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007915935,0.00011414589,0.01385581,0.31643313,0.027022429,0.0002108968,0.00029311134,0.00081095746,0.00049436017,0.00064905745,0.0024466407,0.63687795],"study_design_scores_gemma":[0.001799813,0.0021056822,0.10446877,0.6086165,0.15120493,0.0019465408,0.0014936964,0.0008299674,0.0020237048,0.0028524676,0.1224913,0.0001665834],"about_ca_topic_score_codex":0.004404357,"about_ca_topic_score_gemma":0.012920564,"teacher_disagreement_score":0.9809755,"about_ca_system_score_codex":0.0022590668,"about_ca_system_score_gemma":0.004316626,"threshold_uncertainty_score":0.1006124},"labels":[],"label_agreement":null},{"id":"W1987205549","doi":"10.2165/00019053-200119050-00009","title":"Economic Evaluation of a New Acellular Vaccine for Pertussis in Canada","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Bacterial Infections and Vaccines","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Golder Associates (Canada); Institut National de Santé Publique du Québec; University of Toronto; SickKids Foundation; Kingston Health Sciences Centre; Hospital for Sick Children; McMaster University; PharmIdeas (Canada)","funders":"Health Canada","keywords":"Medicine; Whooping cough; Pertussis vaccine; Vaccination; Health economics; Cohort; Public health; Pediatrics; Health care; Incidence (geometry); Environmental health; Immunology; Immunization; Nursing; Internal medicine","score_opus":0.03546658025033926,"score_gpt":0.307517927745233,"score_spread":0.27205134749489374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987205549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9580641,0.0062707635,0.0012208909,0.007326205,0.00025674992,0.0016817407,0.0069861943,0.000060701335,0.018132571],"genre_scores_gemma":[0.99210984,0.0019040268,0.00082200277,0.0005349553,0.000038160626,0.000116685005,0.0011997238,0.0000066457314,0.0032680286],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99552554,0.0012833605,0.00016531697,0.0001890561,0.0017230714,0.0011137001],"domain_scores_gemma":[0.9948915,0.0011881535,0.00032766306,0.00007478494,0.0022357674,0.0012821459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036008114,0.0006832832,0.00079091516,0.0015075627,0.0013043726,0.0020866047,0.0014588229,0.0011539393,0.0031391375],"category_scores_gemma":[0.010282593,0.00033503407,0.0009835772,0.0013892892,0.00075729296,0.00064339733,0.0008226791,0.0010643562,0.0001191894],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13009068,0.00895091,0.1619843,0.0040179132,0.0028239803,0.0018561677,0.00071379746,0.33099446,0.011335497,0.018169506,0.031852398,0.29721037],"study_design_scores_gemma":[0.02270357,0.055781335,0.5886347,0.0008250335,0.0055506993,0.00094056054,0.004279844,0.23996861,0.009368147,0.0027561362,0.068847276,0.00034396647],"about_ca_topic_score_codex":0.95996356,"about_ca_topic_score_gemma":0.95704,"teacher_disagreement_score":0.09975161,"about_ca_system_score_codex":0.09975161,"about_ca_system_score_gemma":0.09801818,"threshold_uncertainty_score":0.72375196},"labels":[],"label_agreement":null},{"id":"W1987378502","doi":"10.2165/11587130-000000000-00000","title":"Sample Size Determination for Cost-Effectiveness Trials","year":2011,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto","funders":"","keywords":"Sample size determination; Bayesian probability; Cost effectiveness; Computer science; Sample (material); Value of information; Health administration; Decision theory; Statistics; Econometrics; Mathematics; Medicine; Public health; Artificial intelligence","score_opus":0.830530749302641,"score_gpt":0.6175450279615677,"score_spread":0.2129857213410733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987378502","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020798761,0.49968377,0.37329444,0.008468189,0.009958387,0.06817321,0.0061149644,0.00088941795,0.012618955],"genre_scores_gemma":[0.37438723,0.08889492,0.31756446,0.011695338,0.0036117006,0.19173668,0.0067824903,0.00047452474,0.004852634],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.74306977,0.1945138,0.037086703,0.0075173336,0.016789671,0.001022738],"domain_scores_gemma":[0.54570764,0.4252539,0.011401529,0.010085271,0.0066178897,0.00093381596],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.21249902,0.0024721164,0.014583962,0.0033339856,0.00075217354,0.0031245884,0.0037242377,0.0046362355,0.010893369],"category_scores_gemma":[0.43452322,0.001522154,0.011448418,0.0024617044,0.0021302628,0.0035011203,0.0023915865,0.0052792453,0.001238651],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042307205,0.00050769874,0.012501083,0.16634202,0.079818316,0.00056000036,0.0009042185,0.008157696,0.001920073,0.02906445,0.025423301,0.63249403],"study_design_scores_gemma":[0.11194942,0.016288973,0.04840155,0.07271461,0.19765544,0.0028482853,0.0006680792,0.04855601,0.006671325,0.26584613,0.22780779,0.0005924021],"about_ca_topic_score_codex":0.0007213971,"about_ca_topic_score_gemma":0.0007694546,"teacher_disagreement_score":0.787501,"about_ca_system_score_codex":0.0018760704,"about_ca_system_score_gemma":0.0026245757,"threshold_uncertainty_score":0.9711289},"labels":[],"label_agreement":null},{"id":"W1987719831","doi":"10.2165/00019053-200725110-00007","title":"The Economic Impact of Introducing Serotonin-Noradrenaline Reuptake Inhibitors into the Brazilian National Drug Formulary","year":2007,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; PharmIdeas (Canada)","funders":"","keywords":"Formulary; Health economics; Quality of Life Research; Pharmacoeconomics; Drug; Public health; Reuptake inhibitor; Serotonin; Medicine; Psychiatry; Pharmacology; Intensive care medicine; Internal medicine","score_opus":0.037351443414151496,"score_gpt":0.4217582958759115,"score_spread":0.38440685246176004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987719831","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00079428026,0.9969913,0.00005194358,0.0010746499,0.00009441194,0.000006587883,0.000029406794,0.0000014469533,0.0009560555],"genre_scores_gemma":[0.008015787,0.9911521,0.0002102876,0.00034722648,0.000064028194,0.000007166308,0.000028677649,8.5187645e-7,0.00017384047],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9992673,0.00026813228,0.00008568199,0.000046717563,0.00027578522,0.000056480778],"domain_scores_gemma":[0.99812096,0.0011862065,0.00031240648,0.000024856425,0.0002972303,0.00005822064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021425325,0.00061817496,0.0012883052,0.0018956385,0.00023300163,0.0009185388,0.0007493661,0.0008932869,0.0028708593],"category_scores_gemma":[0.004084449,0.00019596018,0.0009710274,0.0030725568,0.0004144127,0.00061730004,0.00047739127,0.00093010784,0.00016666565],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004208308,0.000086454835,0.0013963587,0.039141852,0.00064438616,0.00025739684,0.00006151497,0.00084251206,0.00047447157,0.0055858074,0.0077088447,0.9433795],"study_design_scores_gemma":[0.00080211746,0.00064207776,0.033669285,0.08693822,0.00671868,0.0031338574,0.000460688,0.0012574714,0.001403101,0.0050256425,0.8598792,0.00006968747],"about_ca_topic_score_codex":0.018608786,"about_ca_topic_score_gemma":0.04042252,"teacher_disagreement_score":0.018608786,"about_ca_system_score_codex":0.0027904238,"about_ca_system_score_gemma":0.005561495,"threshold_uncertainty_score":0.037000954},"labels":[],"label_agreement":null},{"id":"W1988339481","doi":"10.1007/s40273-013-0096-8","title":"Systematic Literature Review of the Costs of Pregnancy in the US","year":2013,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Reproductive Health and Contraception","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Pregnancy; Systematic review; Medicine; Unintended pregnancy; Health economics; Pharmacoeconomics; Family medicine; Cost effectiveness; Public health; MEDLINE; Obstetrics; Environmental health; Intensive care medicine; Family planning; Population; Nursing; Risk analysis (engineering); Political science","score_opus":0.043577986719561944,"score_gpt":0.39209591380124914,"score_spread":0.3485179270816872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988339481","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010515334,0.9976568,0.000069676615,0.00022937208,0.00008738973,0.00008621286,0.0005887426,0.0000034905722,0.00022669829],"genre_scores_gemma":[0.012098335,0.98692816,0.00028298635,0.00027442578,0.00005377222,0.00009660556,0.00019579247,0.000002252352,0.00006764284],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99436235,0.0016510352,0.0022909886,0.0003258557,0.001166824,0.00020288603],"domain_scores_gemma":[0.98290586,0.012297968,0.0032297266,0.00018643861,0.0011861585,0.00019394442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00523746,0.0016171356,0.006083744,0.011014911,0.00044396627,0.0021030097,0.0015295299,0.0016492232,0.004984355],"category_scores_gemma":[0.028929366,0.0010271545,0.0076130787,0.013696801,0.000604899,0.0017733697,0.0015408414,0.0014399168,0.0002045539],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003391313,0.000026965388,0.0020069627,0.91979706,0.024421062,0.00022004974,0.00010217992,0.00030420805,0.00007517609,0.0003417095,0.0025502588,0.049815383],"study_design_scores_gemma":[0.0005624777,0.00018900372,0.013868424,0.7658117,0.18956581,0.00095077784,0.00036544233,0.0002057133,0.00012900247,0.0006181203,0.027669387,0.00006406881],"about_ca_topic_score_codex":0.02162715,"about_ca_topic_score_gemma":0.05215433,"teacher_disagreement_score":0.02162715,"about_ca_system_score_codex":0.0046160836,"about_ca_system_score_gemma":0.011508854,"threshold_uncertainty_score":0.043002546},"labels":[],"label_agreement":null},{"id":"W1988459290","doi":"10.2165/00019053-200220002-00002","title":"Information Barriers to the Implementation of Economic Evaluations in Japan","year":2002,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada); McMaster University","funders":"","keywords":"Health economics; Health administration; Guideline; Health care; Economic evaluation; Business; Data collection; Quality of Life Research; Health technology; Public health; Risk analysis (engineering); Public economics; Economic growth; Medicine; Economics; Nursing","score_opus":0.3551933142264207,"score_gpt":0.5475350555330352,"score_spread":0.19234174130661447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988459290","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015447485,0.9652025,0.0010801627,0.012106938,0.00024074607,0.00009263707,0.00016890482,0.000017330805,0.0056433496],"genre_scores_gemma":[0.1160987,0.8755701,0.0027008383,0.0037530572,0.0005888123,0.00028284182,0.00028505584,0.000018178678,0.000702439],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9749156,0.012869879,0.0053164936,0.000948925,0.005178878,0.0007702289],"domain_scores_gemma":[0.8499211,0.1125402,0.019048713,0.0022498372,0.014617662,0.001622624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.045135498,0.000543154,0.0021495393,0.0058114985,0.00072236673,0.00439663,0.001090324,0.0018162169,0.0021092182],"category_scores_gemma":[0.101237,0.00077889534,0.0011543394,0.0097270375,0.0016861212,0.0030552666,0.001974011,0.0018245139,0.00018689586],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006990451,0.00019906089,0.020167554,0.029440252,0.0006968585,0.00053959753,0.0014432388,0.0012623328,0.00030472394,0.010207462,0.018757321,0.91628253],"study_design_scores_gemma":[0.00088222744,0.00093960064,0.32019314,0.0895791,0.008942869,0.0024737269,0.00314793,0.0026689407,0.0028260602,0.016709952,0.5513342,0.0003023014],"about_ca_topic_score_codex":0.019183947,"about_ca_topic_score_gemma":0.028632682,"teacher_disagreement_score":0.045135498,"about_ca_system_score_codex":0.0060578063,"about_ca_system_score_gemma":0.017458066,"threshold_uncertainty_score":0.23870218},"labels":[],"label_agreement":null},{"id":"W1990285876","doi":"10.2165/00019053-200220120-00004","title":"UK Department of Health Guidance on Prescribing for Impotence Following the Introduction of Sildenafil","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pharmaceutical Quality and Counterfeiting","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Mary's Hospital Centre","funders":"National Institutes of Health","keywords":"Medicine; Health economics; Sildenafil; Health care; Pound (networking); Health administration; Primary care; Family medicine; Public health; Medical emergency; Nursing; Economic growth","score_opus":0.10781810422991114,"score_gpt":0.39035931512567534,"score_spread":0.2825412108957642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990285876","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011187043,0.06662363,0.009017114,0.5496855,0.061921153,0.0020059894,0.023229942,0.0025751323,0.2737546],"genre_scores_gemma":[0.06871261,0.046726026,0.043586813,0.53157413,0.019982226,0.0035021794,0.016943809,0.00094332494,0.26802886],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9842917,0.0042923405,0.0033129118,0.00057192927,0.0059007495,0.0016304258],"domain_scores_gemma":[0.952674,0.021211343,0.005342997,0.0011861041,0.01613259,0.0034529434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069317254,0.0010146782,0.002786536,0.0032359846,0.0016405993,0.0028093518,0.003628206,0.03009879,0.014278545],"category_scores_gemma":[0.04287669,0.0015925849,0.003995328,0.0028790147,0.001423403,0.0017005572,0.001750661,0.012623588,0.0057235053],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029586334,0.0001911648,0.0017009783,0.0008691348,0.000055742592,0.00051718607,0.0003218763,0.00034789072,0.00051236496,0.0024771215,0.9574385,0.03527213],"study_design_scores_gemma":[0.00080637063,0.00035461466,0.035452675,0.0036441456,0.00030462816,0.0011296736,0.00016035256,0.00058264774,0.0004970732,0.0016300728,0.95526356,0.00017422813],"about_ca_topic_score_codex":0.11527182,"about_ca_topic_score_gemma":0.24218778,"teacher_disagreement_score":0.11527182,"about_ca_system_score_codex":0.005771295,"about_ca_system_score_gemma":0.013644592,"threshold_uncertainty_score":0.22920167},"labels":[],"label_agreement":null},{"id":"W1991319128","doi":"10.2165/00019053-200523060-00008","title":"Development of an Economic Model to Assess the Cost Effectiveness of Treatment Interventions for Chronic Obstructive Pulmonary Disease","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada); University of Toronto","funders":"GlaxoSmithKline","keywords":"Salmeterol; Fluticasone propionate; Medicine; COPD; Quality-adjusted life year; Exacerbation; Cost effectiveness; Fluticasone; Life expectancy; Placebo; Intensive care medicine; Internal medicine; Corticosteroid; Population; Environmental health","score_opus":0.09286242364850257,"score_gpt":0.4167017950636132,"score_spread":0.32383937141511066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991319128","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31386825,0.00268606,0.62641084,0.0070347595,0.000464237,0.0020744307,0.0040996545,0.0004876452,0.042874064],"genre_scores_gemma":[0.92299086,0.0010231655,0.0673966,0.0003217122,0.000076478274,0.0014722234,0.00091456465,0.000050935403,0.005753509],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.998359,0.0011709007,0.000048124126,0.0001182376,0.000129078,0.00017459491],"domain_scores_gemma":[0.9927315,0.0064856657,0.00018860049,0.00007583155,0.0003287216,0.00018960284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004843674,0.001483685,0.0023688222,0.0019198558,0.0007189281,0.0026374075,0.0023108283,0.0029075146,0.006214645],"category_scores_gemma":[0.013675398,0.0010890891,0.0015151139,0.0016248146,0.00089780166,0.0017931338,0.0011154759,0.0024465234,0.00030938722],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015036754,0.0000821879,0.00055643666,0.00005088113,0.00008084389,0.000054708657,0.000011760232,0.98683083,0.000062914594,0.008352702,0.00044052745,0.003325872],"study_design_scores_gemma":[0.00012367648,0.00006912407,0.00020815119,0.000013255667,0.000061628445,0.000022119204,0.0000132843315,0.99505556,0.000045954737,0.0040225196,0.0003571829,0.0000074906234],"about_ca_topic_score_codex":0.02685815,"about_ca_topic_score_gemma":0.01079521,"teacher_disagreement_score":0.02685815,"about_ca_system_score_codex":0.004870083,"about_ca_system_score_gemma":0.005201874,"threshold_uncertainty_score":0.053403616},"labels":[],"label_agreement":null},{"id":"W1991474680","doi":"10.2165/00019053-200725030-00004","title":"Do Drugs Reduce Utilisation of Other Healthcare Resources?","year":2007,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Global Health Care Issues","field":"Health Professions","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis; Université du Québec à Montréal","funders":"","keywords":"Life expectancy; Per capita; Health care; Consumption (sociology); Health economics; Population; Panel data; Environmental health; Medicine; Economics; Economic growth","score_opus":0.09060899737625107,"score_gpt":0.5068280098437068,"score_spread":0.41621901246745574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991474680","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2619744,0.106705286,0.0008270949,0.5235878,0.003090725,0.0000845124,0.0018180883,0.00007117445,0.10184085],"genre_scores_gemma":[0.89940697,0.047918137,0.0008717757,0.043705057,0.002578594,0.000055003657,0.00034151194,0.000024368672,0.005098651],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99687505,0.001665791,0.00019207533,0.00014601622,0.0005987361,0.0005224277],"domain_scores_gemma":[0.99016273,0.0052211774,0.0022515587,0.00029039424,0.0011018233,0.0009722514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028109015,0.00023262227,0.0008069959,0.00093161286,0.00043184817,0.0013834224,0.0006327689,0.0022767836,0.014307438],"category_scores_gemma":[0.01995474,0.00016017287,0.0011359499,0.0017062665,0.00096477603,0.0019006848,0.0005096525,0.0011885212,0.0009867445],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029359704,0.0036726943,0.26045564,0.00344159,0.0025460885,0.00046673833,0.0010058155,0.00085228926,0.0011715872,0.015287512,0.06705596,0.6411081],"study_design_scores_gemma":[0.0012261092,0.0018275717,0.8056055,0.003557989,0.0018898399,0.0007745277,0.003233644,0.0009716932,0.0010141573,0.016190609,0.16364591,0.00006244262],"about_ca_topic_score_codex":0.016738635,"about_ca_topic_score_gemma":0.041759796,"teacher_disagreement_score":0.016738635,"about_ca_system_score_codex":0.0016016306,"about_ca_system_score_gemma":0.0030317525,"threshold_uncertainty_score":0.047863126},"labels":[],"label_agreement":null},{"id":"W1992312698","doi":"10.1007/s40273-013-0053-6","title":"Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis","year":2013,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Programs for Assessment of Technology in Health Research Institute","funders":"","keywords":"Health economics; Quality of Life Research; Transferability; Public health; Health administration; Pharmacoeconomics; Meta-analysis; Medicine; Intensive care medicine; Economics; Econometrics; Internal medicine; Pathology","score_opus":0.6010832373460577,"score_gpt":0.5294009854553547,"score_spread":0.07168225189070299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992312698","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006880816,0.98955953,0.0016841579,0.00023118753,0.00022129624,0.00021831275,0.0008416518,0.000027564793,0.00033548975],"genre_scores_gemma":[0.37596858,0.61454284,0.0051569915,0.0010830191,0.00053129613,0.00085878983,0.0013775309,0.00006783309,0.0004131221],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.96479136,0.020562023,0.007440526,0.0029308859,0.003749041,0.0005262404],"domain_scores_gemma":[0.9233126,0.063856766,0.0070914314,0.0032795558,0.0022095537,0.00024999477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03608268,0.0029656433,0.01731419,0.0056272573,0.00044534658,0.0038225746,0.0029150597,0.0025145963,0.004452787],"category_scores_gemma":[0.109809585,0.001764742,0.03830877,0.0071983053,0.0013416391,0.0033387996,0.0027317968,0.0033328023,0.00029747252],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023925933,0.000029983219,0.006928277,0.16134779,0.80775183,0.000097170654,0.000077802826,0.00089420495,0.00007409265,0.000432207,0.0005219782,0.01945204],"study_design_scores_gemma":[0.0012516904,0.00021231535,0.009549477,0.01886499,0.96616167,0.00023325952,0.000059065223,0.0004585561,0.000120937075,0.0011742138,0.0018685792,0.000045184635],"about_ca_topic_score_codex":0.0054923706,"about_ca_topic_score_gemma":0.0077328156,"teacher_disagreement_score":0.03608268,"about_ca_system_score_codex":0.003287083,"about_ca_system_score_gemma":0.0026603257,"threshold_uncertainty_score":0.19082576},"labels":[],"label_agreement":null},{"id":"W1992882473","doi":"10.2165/11537760-000000000-00000","title":"The Analysis of Multinational Cost-Effectiveness Data for Reimbursement Decisions","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Programs for Assessment of Technology in Health Research Institute","funders":"Wellcome Trust","keywords":"Multinational corporation; Generalizability theory; Reimbursement; Health administration; Cost effectiveness; Health care; Jurisdiction; Actuarial science; Benchmarking; Business; Economics; Risk analysis (engineering); Marketing; Psychology; Finance; Political science; Economic growth","score_opus":0.576343542811226,"score_gpt":0.5646879305875006,"score_spread":0.011655612223725464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992882473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77679247,0.016146189,0.03734264,0.0072023207,0.00032468414,0.0008894548,0.14079005,0.00041031674,0.02010189],"genre_scores_gemma":[0.93744904,0.0015848692,0.011598535,0.00052688445,0.0002014329,0.0006565368,0.046379104,0.000087650835,0.0015160091],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9662564,0.025509013,0.0020067755,0.0014235944,0.0040382687,0.00076597114],"domain_scores_gemma":[0.6073429,0.35019374,0.02188704,0.012675872,0.006850317,0.0010501641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.047149256,0.0012825156,0.0023850198,0.005770272,0.00061834615,0.003340644,0.001788439,0.0016197184,0.006878671],"category_scores_gemma":[0.22699256,0.00076541485,0.0029343672,0.011594716,0.00090227637,0.0029537333,0.0012477641,0.0028794885,0.00069636607],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007977115,0.0011085066,0.4948557,0.0026819347,0.0078055565,0.00073279504,0.00075518235,0.25529763,0.0005072531,0.04235768,0.04677597,0.13914455],"study_design_scores_gemma":[0.0013395585,0.0017714816,0.5489938,0.0015490425,0.0037637053,0.0012079377,0.0015098667,0.32854646,0.0021775884,0.051469393,0.057404682,0.00026649574],"about_ca_topic_score_codex":0.029290251,"about_ca_topic_score_gemma":0.02597654,"teacher_disagreement_score":0.047149256,"about_ca_system_score_codex":0.00513024,"about_ca_system_score_gemma":0.0037943712,"threshold_uncertainty_score":0.2493521},"labels":[],"label_agreement":null},{"id":"W1993997366","doi":"10.2165/00019053-200220001-00002","title":"The Role of Models Within Economic Analysis","year":2002,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital; University of Ottawa","funders":"Eli Lilly Canada","keywords":"Health economics; Psychological intervention; Transparency (behavior); Risk analysis (engineering); Economic model; Health administration; Relevance (law); Cost–benefit analysis; Disease; Public economics; Economic analysis; Medicine; Actuarial science; Health care; Management science; Computer science; Economics; Microeconomics; Economic growth; Political science","score_opus":0.4714536748754177,"score_gpt":0.5009097687648176,"score_spread":0.029456093889399904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993997366","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016078567,0.827974,0.13470764,0.02051836,0.001448389,0.000045265762,0.00017823535,0.00011804671,0.013402148],"genre_scores_gemma":[0.07580595,0.87174356,0.043365907,0.0030952916,0.0033069258,0.00023661825,0.00017849234,0.00008897291,0.0021782096],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99268335,0.0053707333,0.00030902075,0.00042416507,0.0010584743,0.00015429767],"domain_scores_gemma":[0.9616536,0.03531511,0.0008597746,0.0010166654,0.0009582839,0.00019658067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013045878,0.0025065574,0.0049911207,0.0038234373,0.0006352657,0.005388236,0.0028248443,0.0038932853,0.0032282698],"category_scores_gemma":[0.024081856,0.0010769089,0.0016713731,0.0064599323,0.006140059,0.009415591,0.002060241,0.006660238,0.00088674354],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005440952,0.000104033956,0.000654339,0.003272745,0.00034274007,0.00011238823,0.00010864551,0.04180497,0.00008146133,0.80246454,0.013526094,0.13747354],"study_design_scores_gemma":[0.000031336785,0.000029499168,0.00023113996,0.0014108298,0.00008997617,0.0001008015,0.00006468663,0.021570208,0.00008102742,0.9127831,0.06357381,0.00003359055],"about_ca_topic_score_codex":0.0049896906,"about_ca_topic_score_gemma":0.0030288182,"teacher_disagreement_score":0.013045878,"about_ca_system_score_codex":0.0038714465,"about_ca_system_score_gemma":0.0038926457,"threshold_uncertainty_score":0.068994045},"labels":[],"label_agreement":null},{"id":"W1996028644","doi":"10.2165/00019053-200422040-00006","title":"The NICE Reference Case Requirement","year":2004,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Nuclear and radioactivity studies","field":"Engineering","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Quality of Life Research; Nice; Health economics; Health administration; Public health; Medicine; Computer science; Nursing","score_opus":0.034961927505383315,"score_gpt":0.27705090510886454,"score_spread":0.24208897760348122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996028644","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009426497,0.0008510159,0.0005423312,0.886588,0.012449886,0.000110272835,0.00012940339,0.00013014757,0.09825641],"genre_scores_gemma":[0.0042799716,0.00017549982,0.00041272544,0.94912106,0.0041511976,0.00010213041,0.00004057263,0.000052823052,0.04166398],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.96868193,0.0076111644,0.0023416863,0.0038766044,0.010224588,0.0072640222],"domain_scores_gemma":[0.9638554,0.019203993,0.0014433864,0.0020949459,0.007902783,0.005499591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017067885,0.0012222059,0.00303407,0.0017154196,0.012515497,0.017272562,0.006765261,0.23724529,0.0349821],"category_scores_gemma":[0.09096687,0.002166766,0.003637317,0.0012659554,0.007737464,0.0056999503,0.006648972,0.07641532,0.019080283],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052778854,0.000040012168,0.00023668712,0.00005995915,0.000016757167,0.0019130682,0.00029069014,0.00009551858,0.00016508996,0.04068951,0.95321137,0.0032285198],"study_design_scores_gemma":[0.000110729474,0.00007431764,0.001085283,0.0004554229,0.000045626453,0.0017190423,0.0007536472,0.00035584802,0.00020165076,0.025636392,0.9694458,0.00011622547],"about_ca_topic_score_codex":0.036243174,"about_ca_topic_score_gemma":0.0882834,"teacher_disagreement_score":0.23724529,"about_ca_system_score_codex":0.011724793,"about_ca_system_score_gemma":0.028567966,"threshold_uncertainty_score":0.117026806},"labels":[],"label_agreement":null},{"id":"W1998739853","doi":"10.2165/11586420-000000000-00000","title":"Health Technology Funding Decision-Making Processes Around the World","year":2011,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Health economics; Quality of Life Research; Health administration; Public health; Health informatics; Health services research; Business; Medicine; Nursing","score_opus":0.555836418940262,"score_gpt":0.5556271042711015,"score_spread":0.00020931466916052077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998739853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007174314,0.9891806,0.0008430933,0.0061529567,0.0001916463,0.0000140501,0.000069415444,0.000009038845,0.0028216806],"genre_scores_gemma":[0.018045299,0.97784674,0.0012165998,0.0016417177,0.0005251886,0.0000452569,0.000114255796,0.0000066049947,0.00055843766],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934795,0.0036067327,0.0005660941,0.00042965176,0.0015438194,0.00037431138],"domain_scores_gemma":[0.9691594,0.024807755,0.0025816003,0.00032660997,0.0027242638,0.00040038678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014527535,0.0011011589,0.0021365993,0.004224469,0.0004660226,0.004340896,0.0014554447,0.0031001125,0.004573174],"category_scores_gemma":[0.031285215,0.0004311288,0.0008904923,0.008207376,0.0019549746,0.003356518,0.0015904042,0.00195889,0.0008109937],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016693435,0.00007090481,0.0014835,0.010290482,0.00045913845,0.00007467831,0.0001168684,0.0028014304,0.00014096616,0.031180067,0.018851515,0.9343635],"study_design_scores_gemma":[0.0002573804,0.00018816008,0.012268018,0.05806901,0.0014570013,0.0008183379,0.00073069695,0.0017690642,0.0007996357,0.10712654,0.8163959,0.000120260054],"about_ca_topic_score_codex":0.009385911,"about_ca_topic_score_gemma":0.010985477,"teacher_disagreement_score":0.014527535,"about_ca_system_score_codex":0.0057744044,"about_ca_system_score_gemma":0.012538808,"threshold_uncertainty_score":0.07682985},"labels":[],"label_agreement":null},{"id":"W1998954570","doi":"10.2165/00019053-200220040-00003","title":"Putting Your Money Where Your Mouth Is","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Dental Anxiety and Anesthesia Techniques","field":"Dentistry","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dalhousie University","funders":"AstraZeneca","keywords":"Medicine; Population; Recall; Willingness to pay; Beneficiary; Dentistry; General anaesthetic; Surgery; Environmental health; Psychology; General anaesthesia; Business; Finance; Economics","score_opus":0.04991906757695675,"score_gpt":0.31053717336119824,"score_spread":0.2606181057842415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998954570","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02506117,0.008912571,0.002749212,0.5072935,0.018667981,0.000065794935,0.00016815751,0.00047869052,0.43660298],"genre_scores_gemma":[0.26238242,0.00842698,0.005039553,0.2143173,0.0073623913,0.000083343875,0.00018172267,0.00037742115,0.50182885],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99774206,0.0007977486,0.000098201854,0.00010320933,0.000825723,0.00043304896],"domain_scores_gemma":[0.9939323,0.001060711,0.00060264504,0.00039039523,0.0017358363,0.0022781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015272312,0.00034415364,0.0005558663,0.0008193783,0.003961211,0.006164135,0.0005667431,0.0030992841,0.07716534],"category_scores_gemma":[0.0144841755,0.00026706973,0.0004932092,0.0005730475,0.0019380547,0.003320657,0.002032923,0.0047994857,0.029991765],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015082787,0.00035087866,0.0065695546,0.00013419642,0.00006229688,0.00064205664,0.0018111682,0.000034992674,0.0009697878,0.02792473,0.7127432,0.24860632],"study_design_scores_gemma":[0.00006485074,0.00024697746,0.011644642,0.0005009366,0.000057748242,0.0025127707,0.0080283,0.00009115232,0.0010284169,0.02302698,0.95271814,0.000079010206],"about_ca_topic_score_codex":0.0020603077,"about_ca_topic_score_gemma":0.0040289536,"teacher_disagreement_score":0.07716534,"about_ca_system_score_codex":0.0012321444,"about_ca_system_score_gemma":0.0027251951,"threshold_uncertainty_score":0.25814378},"labels":[],"label_agreement":null},{"id":"W1999044673","doi":"10.2165/00019053-200422100-00001","title":"An Economic Model of 2-Hour Post-Dose Ciclosporin Monitoring in Renal Transplantation","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Dalhousie University; University of British Columbia","funders":"Novartis Pharma","keywords":"Ciclosporin; Medicine; Transplantation; Therapeutic drug monitoring; Kidney transplantation; Azathioprine; Intensive care medicine; Surgery; Urology; Internal medicine; Pharmacokinetics; Disease","score_opus":0.03410034828414198,"score_gpt":0.3522375280277698,"score_spread":0.3181371797436278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999044673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.529824,0.005847245,0.25197846,0.048073716,0.0014134964,0.0024373166,0.016058793,0.00095386454,0.14341299],"genre_scores_gemma":[0.9492557,0.0012987939,0.008013562,0.00090492034,0.00028086136,0.00048195975,0.0010057308,0.00007204536,0.038686413],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9929791,0.0038048893,0.00018086827,0.000863546,0.0004620893,0.0017094641],"domain_scores_gemma":[0.97530454,0.019940125,0.0019008057,0.00034419258,0.0008470193,0.0016633109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008566576,0.0030361328,0.0058628838,0.0026299863,0.0021289971,0.008232235,0.0059087183,0.011073392,0.018341092],"category_scores_gemma":[0.026230518,0.003563479,0.0027340972,0.0026344438,0.0044998983,0.0048710243,0.0032677196,0.0070810504,0.0013867933],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015166196,0.000574151,0.002976457,0.00015018522,0.00021718856,0.00064260757,0.00008114606,0.9397135,0.00025344206,0.045719452,0.0032966284,0.0048586377],"study_design_scores_gemma":[0.00078926806,0.00043396375,0.0019815562,0.00005206808,0.0002550003,0.0002417483,0.00017092029,0.97681034,0.00012278718,0.017446436,0.0015983001,0.000097584365],"about_ca_topic_score_codex":0.08990427,"about_ca_topic_score_gemma":0.037962694,"teacher_disagreement_score":0.08990427,"about_ca_system_score_codex":0.012753104,"about_ca_system_score_gemma":0.007902542,"threshold_uncertainty_score":0.17876196},"labels":[],"label_agreement":null},{"id":"W1999652777","doi":"10.1007/s40273-015-0277-8","title":"Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration","year":2015,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute of Health Economics","funders":"","keywords":"Elaboration; Quality of Life Research; Health economics; Health administration; Public health; Pharmacoeconomics; Actuarial science; Public economics; Medicine; Business; Economics; Nursing; Intensive care medicine; Philosophy","score_opus":0.3777948078585878,"score_gpt":0.49237525681750066,"score_spread":0.11458044895891284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999652777","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015079917,0.00033059166,0.000053163603,0.9928114,0.0056649847,0.000010363074,0.00007820076,0.000020447176,0.00087996584],"genre_scores_gemma":[0.0009405621,0.00015505686,0.000087072294,0.991456,0.0058167404,0.000025676007,0.000018926992,0.000011285581,0.0014887973],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99116147,0.0028578755,0.0014288486,0.0010590318,0.0025235438,0.0009691734],"domain_scores_gemma":[0.96953124,0.018305328,0.0024445413,0.00084900844,0.0059170127,0.0029529321],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012235857,0.0009076578,0.0019720052,0.0010988655,0.004432227,0.0050060498,0.0034190353,0.08664893,0.008668639],"category_scores_gemma":[0.08379108,0.0012706763,0.0020201392,0.0013658825,0.004050316,0.0057827793,0.0023455557,0.05091548,0.010685403],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064584245,0.000015146225,0.00044815667,0.00003515479,0.000011456142,0.00029637697,0.00009686473,0.0000324048,0.00006907093,0.001316045,0.9950068,0.0026079046],"study_design_scores_gemma":[0.00029071615,0.00010063221,0.0025778792,0.0007923649,0.00007254816,0.0016853281,0.0007252741,0.00072781625,0.00054243876,0.014465165,0.97782826,0.00019155297],"about_ca_topic_score_codex":0.011928047,"about_ca_topic_score_gemma":0.016738974,"teacher_disagreement_score":0.9877641,"about_ca_system_score_codex":0.0065205097,"about_ca_system_score_gemma":0.008451635,"threshold_uncertainty_score":0.06471014},"labels":[],"label_agreement":null},{"id":"W2002448686","doi":"10.2165/11537420-000000000-00000","title":"No Head-to-Head Trial? Simulate the Missing Arms","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Replicate; Missing data; Head (geology); Psychological intervention; Clinical trial; Index (typography); Placebo; Computer science; Econometrics; Medicine; Operations research; Statistics; Mathematics; Machine learning; Alternative medicine","score_opus":0.3929399017357939,"score_gpt":0.5105554715258175,"score_spread":0.11761556979002358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002448686","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31810755,0.009679584,0.52299505,0.043474134,0.009641645,0.027263492,0.018610936,0.003559467,0.046668258],"genre_scores_gemma":[0.8745785,0.0008260808,0.08380976,0.010647398,0.000834318,0.015076474,0.0028492787,0.00024521348,0.011132963],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9475912,0.045658458,0.0011520848,0.003140598,0.00085350964,0.0016041308],"domain_scores_gemma":[0.8516189,0.12679993,0.004808323,0.011363859,0.001981842,0.0034270734],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.09622141,0.0023732448,0.008032428,0.0011873625,0.0009880188,0.003042447,0.0040714135,0.006659468,0.03386328],"category_scores_gemma":[0.15379204,0.0017553931,0.0052746874,0.0010972505,0.0025300027,0.0051084654,0.0029489682,0.007621671,0.0042038206],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28380373,0.0037808,0.018206859,0.0028122775,0.006121658,0.0009006836,0.0006502962,0.42435694,0.00067026826,0.060938403,0.05389595,0.14386219],"study_design_scores_gemma":[0.13923375,0.013955685,0.0042099142,0.0010189475,0.009063281,0.00052464206,0.00026130694,0.5092181,0.0017425928,0.30197373,0.01849063,0.0003073852],"about_ca_topic_score_codex":0.0040000617,"about_ca_topic_score_gemma":0.003768438,"teacher_disagreement_score":0.9037786,"about_ca_system_score_codex":0.0020874587,"about_ca_system_score_gemma":0.0053216848,"threshold_uncertainty_score":0.5088735},"labels":[],"label_agreement":null},{"id":"W2003190574","doi":"10.2165/11537560-000000000-00000","title":"Cost Effectiveness of Leukotriene Receptor Antagonists versus Long-Acting Beta-2 Agonists as Add-On Therapy to Inhaled Corticosteroids for Asthma","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Asthma; Quality-adjusted life year; Quality of life (healthcare); Cost effectiveness; Clinical endpoint; Randomized controlled trial; B2 receptor; Pediatrics; Cost-effectiveness analysis; Economic evaluation; Health economics; Internal medicine; Intensive care medicine; Physical therapy; Public health","score_opus":0.05528417132397774,"score_gpt":0.39068709915799066,"score_spread":0.33540292783401293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003190574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96290946,0.025899412,0.00048949977,0.0032634656,0.0004991419,0.00020446314,0.00092224305,0.000052810545,0.0057595763],"genre_scores_gemma":[0.99658906,0.002081006,0.00024439854,0.00031516148,0.00011610507,0.00003136935,0.00020883832,0.0000063365737,0.00040771],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99778336,0.0014546645,0.0001311491,0.00009934952,0.00028128672,0.00025017658],"domain_scores_gemma":[0.9959558,0.002878122,0.00044745763,0.00007982088,0.0001429307,0.00049586757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020476056,0.0008316015,0.0022446774,0.00097593706,0.00031930162,0.0014094186,0.00076473824,0.0018139153,0.008112318],"category_scores_gemma":[0.008606132,0.00045937157,0.003968212,0.0007363376,0.0004873967,0.001357786,0.00063746976,0.0015926454,0.00027865992],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66779554,0.005876017,0.031889897,0.0025924237,0.010536786,0.00071058254,0.00018123396,0.039863672,0.0032485342,0.0025073013,0.0040364657,0.23076154],"study_design_scores_gemma":[0.1773707,0.15563956,0.4369979,0.0016494021,0.086456165,0.0026984834,0.0019706478,0.11483615,0.005884538,0.008249838,0.0077931965,0.00045346015],"about_ca_topic_score_codex":0.007283135,"about_ca_topic_score_gemma":0.007107804,"teacher_disagreement_score":0.008112318,"about_ca_system_score_codex":0.0034542212,"about_ca_system_score_gemma":0.0014328265,"threshold_uncertainty_score":0.027138412},"labels":[],"label_agreement":null},{"id":"W2003344015","doi":"10.1007/s40273-014-0238-7","title":"Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes?","year":2014,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Bayer Canada","keywords":"Reimbursement; Health economics; Health administration; Quality of Life Research; Process (computing); Resource allocation; Public health; Public economics; Business; Medicine; Actuarial science; Economics; Health care; Computer science; Economic growth; Nursing; Management","score_opus":0.5122120980658947,"score_gpt":0.5829441577757695,"score_spread":0.07073205970987473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003344015","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016061027,0.89752805,0.0063566677,0.08071579,0.0027245074,0.00025172895,0.00026543642,0.000026883192,0.010524824],"genre_scores_gemma":[0.0910192,0.7915537,0.022919713,0.081470884,0.008684557,0.0010280893,0.00041485316,0.00004964666,0.0028594078],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9738995,0.01748348,0.0021392342,0.00088862434,0.004683367,0.0009057975],"domain_scores_gemma":[0.91074353,0.074408814,0.0070133917,0.0018844729,0.005164914,0.0007849021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.053418387,0.0005509799,0.002661582,0.0022812106,0.0004993791,0.0045426795,0.0019881555,0.005518559,0.0068406058],"category_scores_gemma":[0.093532234,0.000484911,0.0024538613,0.0035324525,0.0032137886,0.003598561,0.00148244,0.0056318003,0.0010405846],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010282417,0.00024612696,0.0020831004,0.027989086,0.0031712954,0.00015744736,0.00010709161,0.0016767242,0.00032324853,0.18073854,0.04961849,0.7328606],"study_design_scores_gemma":[0.0024958444,0.0004448426,0.008621892,0.07932586,0.004802681,0.0018490963,0.00027209858,0.0019482085,0.00066917896,0.10520815,0.7942368,0.00012529365],"about_ca_topic_score_codex":0.0036285506,"about_ca_topic_score_gemma":0.006535289,"teacher_disagreement_score":0.053418387,"about_ca_system_score_codex":0.003985163,"about_ca_system_score_gemma":0.013548365,"threshold_uncertainty_score":0.28250676},"labels":[],"label_agreement":null},{"id":"W2003446384","doi":"10.2165/00019053-200321030-00001","title":"NICE Methodological Guidelines and Decision Making in the National Health Service in England and Wales","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Nice; Excellence; Health economics; Equity (law); Health care rationing; Health technology; Economic evaluation; Service (business); Actuarial science; Public economics; Health care; Medicine; Operations research; Economics; Business; Computer science; Marketing; Political science; Economic growth; Microeconomics","score_opus":0.7631365332457298,"score_gpt":0.5923564086783528,"score_spread":0.170780124567377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003446384","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0069015557,0.27819872,0.1937916,0.42776427,0.023549749,0.01750747,0.009821416,0.0011231583,0.041342027],"genre_scores_gemma":[0.085077785,0.07232871,0.6726164,0.08355375,0.0056937085,0.065071754,0.007956316,0.0013315777,0.006369946],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.24736595,0.60071826,0.10717105,0.004149654,0.037815295,0.0027798205],"domain_scores_gemma":[0.30610058,0.5264776,0.03193089,0.024593255,0.10595674,0.0049409256],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.4375064,0.00283028,0.009931798,0.013518084,0.0035408107,0.020260308,0.011256942,0.020888457,0.0060938755],"category_scores_gemma":[0.797197,0.0056094914,0.0120946355,0.015315282,0.008359347,0.0099503035,0.01093312,0.018314851,0.0020159753],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015421836,0.00023439644,0.006304671,0.031724244,0.004089083,0.0008729411,0.005246125,0.010372943,0.0001727962,0.15044016,0.52768266,0.2613177],"study_design_scores_gemma":[0.0055954037,0.0006684159,0.020269435,0.19498876,0.004826024,0.002762327,0.0042647007,0.01715495,0.00096851046,0.31320766,0.43421614,0.0010775538],"about_ca_topic_score_codex":0.061547298,"about_ca_topic_score_gemma":0.07290928,"teacher_disagreement_score":0.56249356,"about_ca_system_score_codex":0.020809153,"about_ca_system_score_gemma":0.05856143,"threshold_uncertainty_score":0.6936548},"labels":[],"label_agreement":null},{"id":"W2004704164","doi":"10.2165/00019053-200826100-00004","title":"Quality-of-Life Assessment in Rheumatoid Arthritis","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Rheumatoid arthritis; Public health; Quality of life (healthcare); Health administration; Medicine; Pharmacoeconomics; Quality (philosophy); Quality-adjusted life year; Intensive care medicine; Internal medicine; Nursing; Risk analysis (engineering); Cost effectiveness","score_opus":0.09301655368558759,"score_gpt":0.43957224455821947,"score_spread":0.3465556908726319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004704164","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011389758,0.9994192,0.000064781256,0.00009807261,0.000051881325,0.000007439368,0.000022147644,0.0000022788,0.00022042677],"genre_scores_gemma":[0.0018839336,0.99740916,0.000317861,0.00016854881,0.00007221015,0.000014266929,0.000037779108,8.0890584e-7,0.00009549281],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9990042,0.00030549528,0.00021074279,0.00009867769,0.0003405028,0.000040365412],"domain_scores_gemma":[0.9981152,0.0013291407,0.00032066245,0.000021901935,0.00017667083,0.000036399928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020920138,0.0010094114,0.0038053126,0.0029456401,0.00016674481,0.0010052449,0.001063414,0.00091774756,0.002570528],"category_scores_gemma":[0.0034927889,0.00033206533,0.0017596419,0.004229862,0.00045662202,0.0008727238,0.00067182886,0.0014740995,0.0004169762],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021370775,0.000080674734,0.00060211046,0.061451156,0.0013088566,0.00006540071,0.00003244085,0.00032109403,0.00016962214,0.0006574748,0.008084303,0.92701316],"study_design_scores_gemma":[0.0017468255,0.0012305506,0.0441223,0.22921775,0.019460268,0.004289475,0.000529094,0.0018479456,0.0010307878,0.008580402,0.6877073,0.0002373048],"about_ca_topic_score_codex":0.0031085014,"about_ca_topic_score_gemma":0.0066470895,"teacher_disagreement_score":0.0038053126,"about_ca_system_score_codex":0.0009396023,"about_ca_system_score_gemma":0.0012492398,"threshold_uncertainty_score":0.011063814},"labels":[],"label_agreement":null},{"id":"W2005305338","doi":"10.2165/00019053-200422110-00001","title":"The Measurement of Contingent Valuation for Health Economics","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":119,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Contingent valuation; Valuation (finance); Actuarial science; Health economics; Willingness to pay; Payment card; Willingness to accept; Economics; Public economics; Payment; Business; Health care; Microeconomics; Accounting; Finance","score_opus":0.5143036724427065,"score_gpt":0.4939732345693773,"score_spread":0.020330437873329166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005305338","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013579772,0.0050747823,0.9591667,0.004474377,0.00046166487,0.00015196501,0.0004857184,0.0001866585,0.016418321],"genre_scores_gemma":[0.74953806,0.0052656825,0.23768115,0.00048678985,0.0011086356,0.0005975601,0.0006309464,0.00011862177,0.004572584],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9837855,0.012210199,0.0007506106,0.0009888327,0.0018726357,0.000392232],"domain_scores_gemma":[0.90220946,0.07632706,0.0052169054,0.010513919,0.0039123395,0.0018203503],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017569201,0.0017990798,0.0021177037,0.003776203,0.0015822215,0.0073913164,0.0020845553,0.0028109215,0.0067496873],"category_scores_gemma":[0.13300927,0.0010607005,0.0016965364,0.0058627175,0.0072817146,0.015720833,0.003487734,0.0053612944,0.00071016874],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018524184,0.000038962953,0.00073197,0.00007851353,0.00003476065,0.00003429482,0.000088023524,0.0055602114,0.00014956766,0.9741237,0.0012270947,0.017914388],"study_design_scores_gemma":[0.000007181114,0.00002045912,0.00047442183,0.00006250301,0.000013916612,0.00005146155,0.000038485436,0.02505641,0.000108695654,0.9717036,0.0024477406,0.000015250221],"about_ca_topic_score_codex":0.0020218003,"about_ca_topic_score_gemma":0.00072236464,"teacher_disagreement_score":0.9824308,"about_ca_system_score_codex":0.0030140022,"about_ca_system_score_gemma":0.0024159395,"threshold_uncertainty_score":0.09291589},"labels":[],"label_agreement":null},{"id":"W2005333158","doi":"10.1007/s40273-013-0048-3","title":"Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Darunavir; Lopinavir; Emtricitabine; Medicine; Ritonavir; Regimen; Lopinavir/ritonavir; Cost effectiveness; Clinical trial; Viral load; Cost-effectiveness analysis; Intensive care medicine; Internal medicine; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy; Risk analysis (engineering)","score_opus":0.06119449999214679,"score_gpt":0.3712327756547588,"score_spread":0.31003827566261205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005333158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93196875,0.05182252,0.0021058384,0.002205942,0.0002687011,0.00080991804,0.0041967956,0.00008886921,0.0065324763],"genre_scores_gemma":[0.99094,0.005964334,0.0011132944,0.0005422561,0.00006372558,0.000118856755,0.00070490583,0.000013497031,0.0005391972],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99537104,0.0036543394,0.00016935123,0.0002064623,0.00028028653,0.00031849768],"domain_scores_gemma":[0.99563473,0.0033308403,0.0005301765,0.00007614323,0.00012208265,0.00030595926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004675139,0.0011909379,0.0027925477,0.0022034894,0.0003304837,0.0020426277,0.00089552946,0.0011737093,0.005404534],"category_scores_gemma":[0.008790286,0.000744733,0.007703192,0.002338956,0.00064612046,0.0017986945,0.00085005973,0.0018807306,0.00018228542],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5227784,0.0044657555,0.052447822,0.007269485,0.052866265,0.0008311526,0.00024856135,0.11609906,0.0023992378,0.0049075596,0.0070070843,0.2286796],"study_design_scores_gemma":[0.15828574,0.10578645,0.22882071,0.0039643324,0.25076345,0.0025790387,0.0028391448,0.21913378,0.003967404,0.008504529,0.014808056,0.0005473764],"about_ca_topic_score_codex":0.015363351,"about_ca_topic_score_gemma":0.019954216,"teacher_disagreement_score":0.015363351,"about_ca_system_score_codex":0.0045384425,"about_ca_system_score_gemma":0.0021144534,"threshold_uncertainty_score":0.032928884},"labels":[],"label_agreement":null},{"id":"W2006447179","doi":"10.1007/s40273-012-0022-5","title":"The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Cancer Care Ontario; Canadian Centre for Applied Research in Cancer Control; St. Michael's Hospital","funders":"","keywords":"Reimbursement; Health economics; Medicine; Pharmacoeconomics; Economic evaluation; Advisory committee; Cancer drugs; Cost effectiveness; MEDLINE; Family medicine; Actuarial science; Public health; Health care; Drug; Business; Intensive care medicine; Political science; Risk analysis (engineering); Economics; Nursing; Pharmacology; Economic growth; Public administration; Pathology","score_opus":0.47535048308160655,"score_gpt":0.5047315089868688,"score_spread":0.02938102590526226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006447179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35945022,0.1832268,0.005199521,0.33329695,0.0014693332,0.0011613604,0.018541222,0.00011243583,0.0975422],"genre_scores_gemma":[0.9569755,0.028704593,0.0044210334,0.005679151,0.000249693,0.0001524094,0.0018152418,0.000032265452,0.0019700823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9672161,0.015443772,0.0025867396,0.00083420775,0.011534448,0.002384704],"domain_scores_gemma":[0.75258356,0.13782819,0.012959799,0.0023365587,0.08393538,0.010356568],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.036670174,0.0005382813,0.0012322658,0.009668837,0.0026326755,0.008357759,0.001911862,0.0017586456,0.0024601968],"category_scores_gemma":[0.22817296,0.00059457263,0.00096326414,0.01282396,0.003231535,0.0019975426,0.0021986063,0.0033719013,0.00008779235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0028929682,0.00058466854,0.3471195,0.007966118,0.003858301,0.000762589,0.001724412,0.06471912,0.00033793645,0.1064067,0.1251815,0.33844623],"study_design_scores_gemma":[0.0026234135,0.0005698806,0.5964247,0.021391341,0.0056234305,0.00039845472,0.004551887,0.13208483,0.0018746438,0.05255801,0.1812469,0.00065257197],"about_ca_topic_score_codex":0.987242,"about_ca_topic_score_gemma":0.9913019,"teacher_disagreement_score":0.96332985,"about_ca_system_score_codex":0.18881196,"about_ca_system_score_gemma":0.3432018,"threshold_uncertainty_score":0.94086313},"labels":[],"label_agreement":null},{"id":"W2007015456","doi":"10.2165/00019053-200725060-00002","title":"Estimation, Power and Sample Size Calculations for Stochastic Cost and Effectiveness Analysis","year":2007,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Confidence interval; Sample size determination; Statistics; Rectangle; Null hypothesis; Value (mathematics); Mathematics; Sample (material); Null (SQL); Econometrics; Statistical power; Computer science; Data mining","score_opus":0.3875913884959831,"score_gpt":0.5439592198493887,"score_spread":0.15636783135340554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007015456","genre_codex":"methods","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005063966,0.21497147,0.76756585,0.0027515793,0.0007980073,0.0025790657,0.001297664,0.00048156,0.004490902],"genre_scores_gemma":[0.16250859,0.12570474,0.6873871,0.0026274617,0.002235873,0.0136658065,0.0027038513,0.00049451407,0.0026720779],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.8750216,0.10040067,0.007302674,0.0030822176,0.013719571,0.00047330442],"domain_scores_gemma":[0.543949,0.44074926,0.0059037018,0.0049932506,0.004125229,0.00027951974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10655719,0.0025041623,0.011275048,0.0051629995,0.00038382033,0.0029270605,0.0044359462,0.0030951635,0.0069311676],"category_scores_gemma":[0.33546907,0.0014436679,0.0064156796,0.004221856,0.0017962988,0.0027865162,0.0018510037,0.005406936,0.0011755901],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001403853,0.00019600868,0.0038293013,0.014863886,0.0064683245,0.00014606553,0.00019035226,0.037408628,0.00038576033,0.036747113,0.013058246,0.88530236],"study_design_scores_gemma":[0.0043345997,0.0031128372,0.017725628,0.020054536,0.0223737,0.003581108,0.00024911747,0.28323808,0.0047690626,0.5216914,0.118500896,0.00036904283],"about_ca_topic_score_codex":0.0014479954,"about_ca_topic_score_gemma":0.001055558,"teacher_disagreement_score":0.10655719,"about_ca_system_score_codex":0.0019529075,"about_ca_system_score_gemma":0.0024812485,"threshold_uncertainty_score":0.56353503},"labels":[],"label_agreement":null},{"id":"W2007217751","doi":"10.2165/00019053-200321140-00004","title":"A Cost Comparison of Oral Tegafur Plus Uracil/Folinic Acid and Parenteral Fluorouracil for Colorectal Cancer in Canada","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); Simon Fraser University; Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation","funders":"","keywords":"Folinic acid; Medicine; Regimen; Fluorouracil; Concomitant; Internal medicine; Tegafur; Surgery; Chemotherapy","score_opus":0.06386310239425377,"score_gpt":0.38521957971072845,"score_spread":0.32135647731647465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007217751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670533,0.01961765,0.00023862773,0.0030549779,0.00021991698,0.00055121153,0.0032731353,0.000026002252,0.0059652124],"genre_scores_gemma":[0.99368894,0.0039382414,0.00036128328,0.00039765824,0.00004129976,0.0000595581,0.00061728933,0.0000053977788,0.0008901581],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9977107,0.00086858147,0.000161125,0.00013250457,0.0006448645,0.0004821984],"domain_scores_gemma":[0.9964897,0.0009774063,0.0004349732,0.00005503526,0.0011455144,0.00089731376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013798815,0.0005684491,0.0012802943,0.0011337132,0.0010946853,0.0014486505,0.0010377023,0.0009247427,0.003987272],"category_scores_gemma":[0.008241397,0.0004005341,0.0018469865,0.0030401018,0.0007690416,0.00056156574,0.00070444855,0.0011264215,0.000089819354],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43596667,0.0044286335,0.21768153,0.01048684,0.009996944,0.0013104206,0.0009340642,0.038770515,0.0030457368,0.0053615733,0.016882358,0.2551348],"study_design_scores_gemma":[0.09066357,0.038121387,0.7709033,0.0026783738,0.029410964,0.0011235144,0.0042814394,0.03662777,0.0024403285,0.0013780665,0.021940943,0.00043035287],"about_ca_topic_score_codex":0.9693673,"about_ca_topic_score_gemma":0.978125,"teacher_disagreement_score":0.07481924,"about_ca_system_score_codex":0.07481924,"about_ca_system_score_gemma":0.061754044,"threshold_uncertainty_score":0.5428541},"labels":[],"label_agreement":null},{"id":"W2007373992","doi":"10.2165/00019053-200018050-00004","title":"Cost Analysis of an Adult Outpatient Parenteral Antibiotic Therapy (OPAT) Programme","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Antibiotics Pharmacokinetics and Efficacy","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver Hospital and Health Sciences Centre","funders":"","keywords":"Medicine; Cloxacillin; Emergency medicine; Discontinuation; Intensive care medicine; Antibiotics; Surgery","score_opus":0.048288349272671734,"score_gpt":0.35609680249651904,"score_spread":0.3078084532238473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007373992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99232894,0.0007098955,0.0009189574,0.0006432529,0.000032332293,0.00022588344,0.0013117146,0.000030411611,0.0037987193],"genre_scores_gemma":[0.9984452,0.00015228214,0.0004526439,0.00006952079,0.000012893825,0.00005732177,0.00033156647,0.000004885131,0.000473671],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9983601,0.00087303546,0.000075414944,0.00009039209,0.0002564019,0.00034468208],"domain_scores_gemma":[0.99639785,0.0021908314,0.0003721003,0.000073673225,0.00049056154,0.00047488618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010947634,0.0009246648,0.00096727395,0.0015028364,0.0007109295,0.001324868,0.0010507095,0.0011842196,0.004185375],"category_scores_gemma":[0.0068981587,0.00044547842,0.0016971665,0.0021900702,0.00047327855,0.0007819944,0.0008571547,0.0010507591,0.00018255033],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04666166,0.0082991775,0.25350899,0.0015053817,0.0020366928,0.003658374,0.00040690255,0.535615,0.0032636987,0.00812486,0.0076455893,0.1292736],"study_design_scores_gemma":[0.0032331867,0.017567165,0.47778141,0.0002470243,0.0023472956,0.0025895787,0.0022890233,0.48663554,0.0017007907,0.0024797353,0.0029446376,0.00018471577],"about_ca_topic_score_codex":0.0869058,"about_ca_topic_score_gemma":0.04975401,"teacher_disagreement_score":0.0869058,"about_ca_system_score_codex":0.009488438,"about_ca_system_score_gemma":0.0035721057,"threshold_uncertainty_score":0.17279994},"labels":[],"label_agreement":null},{"id":"W2007393518","doi":"10.2165/00019053-200523120-00005","title":"Cost-Effectiveness Acceptability Curves and a Reluctance to Lose","year":2005,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Willingness to pay; Willingness to accept; Health economics; Contingent valuation; Incremental cost-effectiveness ratio; Cost effectiveness; Econometrics; Economics; Valuation (finance); Cost-effectiveness analysis; Actuarial science; Medicine; Statistics; Health care; Mathematics; Microeconomics","score_opus":0.6243452194347576,"score_gpt":0.5808348646582401,"score_spread":0.043510354776517546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007393518","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009869429,0.9311915,0.021971883,0.019872857,0.00055008737,0.0003103083,0.00059147377,0.00008496457,0.015557579],"genre_scores_gemma":[0.41423526,0.5224842,0.029155686,0.02417956,0.0027306434,0.0017676108,0.000933064,0.00019051148,0.004323501],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.93495905,0.04845729,0.004107643,0.0018265801,0.01008416,0.00056531257],"domain_scores_gemma":[0.55380666,0.4178865,0.014441474,0.004165849,0.008905326,0.0007941856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.089500755,0.0010382596,0.004675572,0.003544928,0.0004126095,0.0042090514,0.0022407763,0.0050215716,0.0070051784],"category_scores_gemma":[0.31818175,0.0007504216,0.0037971241,0.0042038024,0.0028546427,0.0066996543,0.0018797403,0.007003553,0.00084868906],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026553096,0.00016228695,0.007378604,0.017876737,0.0043793856,0.00020866634,0.00061997847,0.007515302,0.00024001868,0.08749321,0.02756159,0.8439089],"study_design_scores_gemma":[0.0019781562,0.0021697,0.03585412,0.035836663,0.009297644,0.004572085,0.0011910986,0.010781002,0.0009808335,0.5968481,0.30022976,0.0002608703],"about_ca_topic_score_codex":0.0010334969,"about_ca_topic_score_gemma":0.0009500636,"teacher_disagreement_score":0.089500755,"about_ca_system_score_codex":0.0026786001,"about_ca_system_score_gemma":0.0018165747,"threshold_uncertainty_score":0.47333091},"labels":[],"label_agreement":null},{"id":"W2007661673","doi":"10.2165/00019053-200119020-00001","title":"Direct-to-Consumer Promotion of Prescription Drugs","year":2001,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"","keywords":"Medical prescription; Promotion (chess); Revenue; Direct-to-consumer advertising; Advertising; Newspaper; Prescription drug; Business; Government (linguistics); Marketing; Public health; Pharmacy; Food and drug administration; Medicine; Environmental health; Family medicine; Pharmacology; Political science","score_opus":0.5404877927635222,"score_gpt":0.5898891784635181,"score_spread":0.04940138569999586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007661673","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021165037,0.98181,0.0003253598,0.00068630296,0.00034569198,0.00002268495,0.000086017535,0.000026086298,0.014581295],"genre_scores_gemma":[0.007856308,0.9857017,0.00052869343,0.0006113164,0.00039374284,0.000014549,0.00008122771,0.00000338362,0.004809069],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99969864,0.000060484326,0.000024771896,0.000048301707,0.00014275976,0.00002507332],"domain_scores_gemma":[0.99940145,0.00033453552,0.00011859415,0.000014276244,0.00009773279,0.00003349906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005678253,0.0006791361,0.0008176476,0.0022865443,0.0002659033,0.0007179699,0.00046651374,0.001134557,0.011219152],"category_scores_gemma":[0.00088008656,0.00020049904,0.00042558103,0.0020601351,0.00028615617,0.00074173737,0.00039221617,0.000829119,0.0026095978],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000963543,0.00017349135,0.00064159004,0.008902406,0.000043524033,0.0003061354,0.00005479688,0.00008628409,0.0015923681,0.0009475365,0.012653106,0.9745024],"study_design_scores_gemma":[0.00007322198,0.00058153464,0.01742524,0.006211321,0.0002691215,0.0054239277,0.00018650922,0.00017796682,0.0031648686,0.0007890331,0.96566975,0.000027426102],"about_ca_topic_score_codex":0.0015897539,"about_ca_topic_score_gemma":0.0047150073,"teacher_disagreement_score":0.011219152,"about_ca_system_score_codex":0.0004040853,"about_ca_system_score_gemma":0.0006252924,"threshold_uncertainty_score":0.037531793},"labels":[],"label_agreement":null},{"id":"W2007798395","doi":"10.1007/s40273-013-0071-4","title":"Constructing Indirect Utility Models: Some Observations on the Principles and Practice of Mapping to Obtain Health State Utilities","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute for Health and Care Research","keywords":"Sophistication; Quality-adjusted life year; Health economics; Valuation (finance); Health administration; Computer science; Health care; Actuarial science; Reimbursement; Conflation; Risk analysis (engineering); Econometrics; Management science; Data mining; Economics; Medicine; Cost effectiveness; Accounting","score_opus":0.665575177705313,"score_gpt":0.45862933502476355,"score_spread":0.2069458426805495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007798395","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0112208715,0.0013094929,0.9799927,0.0029604235,0.000029366205,0.00007906525,0.00018108089,0.00010284062,0.004124168],"genre_scores_gemma":[0.27370527,0.0037697146,0.7174802,0.0007741111,0.0001826638,0.00056504237,0.0005223934,0.00024797636,0.002752669],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9824278,0.015295013,0.0003687984,0.00066233723,0.0010512199,0.00019481045],"domain_scores_gemma":[0.86888456,0.12056558,0.0015367086,0.0066889958,0.0020102414,0.00031384],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.023281405,0.001645299,0.0019454883,0.0028850976,0.0009139281,0.005555528,0.0031005943,0.0021939967,0.0042085517],"category_scores_gemma":[0.11117569,0.0013132596,0.0029264148,0.0047056694,0.004860491,0.0072421106,0.004090031,0.007108235,0.0004981974],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103476654,0.00021041826,0.009142005,0.00040246962,0.00025513608,0.00013986618,0.0014417995,0.11465708,0.00025517723,0.7333566,0.0029586344,0.13707729],"study_design_scores_gemma":[0.000024065466,0.000036890477,0.0012944276,0.00013454242,0.000036696572,0.00009173395,0.00020678027,0.118719876,0.00038718095,0.8750988,0.0039279256,0.00004109061],"about_ca_topic_score_codex":0.0062829526,"about_ca_topic_score_gemma":0.004911701,"teacher_disagreement_score":0.9767186,"about_ca_system_score_codex":0.001856838,"about_ca_system_score_gemma":0.0023768018,"threshold_uncertainty_score":0.123125315},"labels":[],"label_agreement":null},{"id":"W2009528141","doi":"10.2165/00019053-200321070-00003","title":"Measuring the Outcomes and Pharmacoeconomic Consequences of Venous Thromboembolism Prophylaxis in Major Orthopaedic Surgery","year":2003,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Antithrombotic; Intensive care medicine; Health economics; Venous thromboembolism; Pharmacoeconomics; Orthopedic surgery; Vascular surgery; Quality of Life Research; Public health; Surgery; Thrombosis; Cardiac surgery; Internal medicine","score_opus":0.08033706881388836,"score_gpt":0.3475524195523622,"score_spread":0.26721535073847386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009528141","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016989558,0.9974293,0.00014245838,0.00027983892,0.0000624059,0.000014991894,0.00005871585,0.0000025018537,0.0003108119],"genre_scores_gemma":[0.011055456,0.9881363,0.0004637791,0.00013548082,0.000048368205,0.000018359322,0.00006848987,7.52669e-7,0.000072951465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99805605,0.00064029876,0.00042582312,0.00016303515,0.00066917826,0.000045645284],"domain_scores_gemma":[0.9942291,0.004043733,0.000971273,0.00006260484,0.00063087704,0.00006238832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030177727,0.0007408268,0.0026237722,0.0025009876,0.00014072198,0.0009679081,0.00081522303,0.0008186849,0.00091910386],"category_scores_gemma":[0.0110655995,0.0003107512,0.0014740623,0.0048872586,0.00028272488,0.00085867476,0.00035539336,0.00061098934,0.00015699763],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023924958,0.000085549924,0.010111792,0.055422544,0.0030084008,0.00014098626,0.000077524724,0.000663891,0.00022362678,0.00056845456,0.0030837944,0.9263741],"study_design_scores_gemma":[0.0013809609,0.0025254893,0.26762185,0.2599734,0.05520399,0.00799718,0.001331838,0.0031705913,0.004209643,0.0069875224,0.3893243,0.0002732182],"about_ca_topic_score_codex":0.00649429,"about_ca_topic_score_gemma":0.01365424,"teacher_disagreement_score":0.00649429,"about_ca_system_score_codex":0.0011880503,"about_ca_system_score_gemma":0.0033309923,"threshold_uncertainty_score":0.01595968},"labels":[],"label_agreement":null},{"id":"W2010913334","doi":"10.2165/00019053-200826090-00004","title":"The NICE Cost-Effectiveness Threshold","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":846,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Nice; Reimbursement; Excellence; Equity (law); Actuarial science; Cost effectiveness; Medicine; Health economics; Psychological intervention; Health care; Economics; Public economics; Risk analysis (engineering); Computer science; Economic growth; Political science; Nursing","score_opus":0.6331953834987152,"score_gpt":0.5585722418347147,"score_spread":0.07462314166400053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010913334","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015451248,0.9366292,0.01029626,0.016417764,0.0035300963,0.0005368336,0.0015200452,0.00017050393,0.029354233],"genre_scores_gemma":[0.21451347,0.62858534,0.048146047,0.08308243,0.008600957,0.007094206,0.0037534002,0.00033778508,0.0058863955],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9466486,0.027147435,0.008812339,0.002170448,0.013665222,0.0015559539],"domain_scores_gemma":[0.93269473,0.057066508,0.0037434248,0.0011704742,0.004551258,0.00077353854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03210127,0.0018393954,0.012895921,0.0054107993,0.0007330205,0.0047407337,0.004143246,0.006031555,0.013827892],"category_scores_gemma":[0.10647192,0.0011075737,0.006667946,0.0036802902,0.0032179276,0.0067546954,0.003697352,0.007991963,0.0025030905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027419804,0.00015232264,0.001903091,0.090625964,0.0064005647,0.0004128446,0.00027807942,0.0034322068,0.00060384406,0.1583361,0.1308846,0.6042284],"study_design_scores_gemma":[0.003194093,0.0014952933,0.01448896,0.11644173,0.014948508,0.004636373,0.00043248147,0.004732427,0.0012144446,0.39575925,0.44234678,0.0003094611],"about_ca_topic_score_codex":0.0033151123,"about_ca_topic_score_gemma":0.0035050986,"teacher_disagreement_score":0.03210127,"about_ca_system_score_codex":0.006060517,"about_ca_system_score_gemma":0.0065133683,"threshold_uncertainty_score":0.16976976},"labels":[],"label_agreement":null},{"id":"W2011129617","doi":"10.1007/s40273-015-0271-1","title":"Simulation and Matching-Based Approaches for Indirect Comparison of Treatments","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TransCanada (Canada)","funders":"","keywords":"Matching (statistics); Reliability (semiconductor); Confounding; Econometrics; Complement (music); Medicine; Treatment effect; Population; Statistics; Computer science; Mathematics; Environmental health","score_opus":0.7091266408074673,"score_gpt":0.5280108896812138,"score_spread":0.18111575112625355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011129617","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014481336,0.0007383569,0.9799601,0.00068461406,0.000208817,0.00066225976,0.0004853268,0.00024889392,0.0025304803],"genre_scores_gemma":[0.48467308,0.0010240619,0.50234544,0.0005580225,0.00039914757,0.004063367,0.001292054,0.0002014413,0.005443389],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.943468,0.0514366,0.0010257486,0.0018468775,0.0016105374,0.0006121859],"domain_scores_gemma":[0.6783799,0.30745453,0.003346101,0.00754911,0.0024182678,0.00085217087],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.05913726,0.0017834498,0.0047312602,0.0038693578,0.0010268898,0.002526221,0.0054612346,0.00391145,0.021919264],"category_scores_gemma":[0.22929324,0.0014674789,0.0039375443,0.0040571094,0.0017994659,0.0037471342,0.0032415295,0.004170575,0.0011303191],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026609362,0.00071259803,0.005338118,0.00050585734,0.0020398262,0.00018015562,0.00031244897,0.6926979,0.00018318665,0.17394939,0.003551227,0.117868386],"study_design_scores_gemma":[0.00037331623,0.0001868985,0.0005553292,0.00006110369,0.0002139453,0.000050740484,0.000029086916,0.829392,0.00011577487,0.16805704,0.0009398344,0.000024962255],"about_ca_topic_score_codex":0.0071020955,"about_ca_topic_score_gemma":0.004390627,"teacher_disagreement_score":0.9408627,"about_ca_system_score_codex":0.0023940052,"about_ca_system_score_gemma":0.0039209663,"threshold_uncertainty_score":0.3127514},"labels":[],"label_agreement":null},{"id":"W2011259658","doi":"10.2165/11539960-000000000-00000","title":"Modelling the Epidemiology of Infectious Diseases for Decision Analysis","year":2011,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"COVID-19 epidemiological studies","field":"Mathematics","cited_by":124,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Canada Research Chairs","keywords":"Infectious disease (medical specialty); Psychological intervention; Health economics; Epidemiology; Disease; Public health; Natural history; Medicine; Intensive care medicine; Risk analysis (engineering); Pathology","score_opus":0.563839307484957,"score_gpt":0.5446055309012252,"score_spread":0.01923377658373182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011259658","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00071834045,0.9555586,0.037006527,0.00324405,0.00032314874,0.000027529164,0.00015818237,0.000060072478,0.0029035388],"genre_scores_gemma":[0.015986046,0.96839696,0.013934784,0.00030212413,0.00054486014,0.000047508656,0.00015416251,0.000012884649,0.0006206327],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9986381,0.0008272074,0.00010667961,0.00011500611,0.00027346128,0.000039558847],"domain_scores_gemma":[0.99215174,0.0068258126,0.00044291117,0.00017000157,0.00034394788,0.00006561487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031338017,0.0019207251,0.0026771966,0.0026181815,0.00020962888,0.0019779445,0.0018221204,0.0019347297,0.0035279167],"category_scores_gemma":[0.011415923,0.0004744803,0.0015658627,0.0034881665,0.0010658005,0.0021696857,0.0010580058,0.0023313907,0.00092162454],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010549721,0.000202979,0.001258178,0.01943301,0.0009400134,0.00014851124,0.000080366575,0.087025,0.00037878854,0.11723565,0.023205256,0.7499868],"study_design_scores_gemma":[0.00012661432,0.00018444355,0.0014766006,0.015628217,0.00087774347,0.00091566076,0.00019573208,0.065782554,0.0009492553,0.5605515,0.3531582,0.00015343758],"about_ca_topic_score_codex":0.0040120212,"about_ca_topic_score_gemma":0.0037400334,"teacher_disagreement_score":0.0040120212,"about_ca_system_score_codex":0.0016067795,"about_ca_system_score_gemma":0.0026567173,"threshold_uncertainty_score":0.01657331},"labels":[],"label_agreement":null},{"id":"W2011961341","doi":"10.2165/11591170-000000000-00000","title":"Economic and Humanistic Burden of External Genital Warts","year":2011,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Female Genital Mutilation/Cutting Issues","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care Research Institute; Providence Health Care; BC Centre for Disease Control; Centre for Advancing Health Outcomes; University of British Columbia","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Health economics; Quality of Life Research; Genital warts; Genital herpes; Health administration; Public health; Humanism; Medicine; Quality-adjusted life year; Cost effectiveness; Political science; Family medicine; Nursing; Virology; Risk analysis (engineering)","score_opus":0.078036945444984,"score_gpt":0.3824648000097444,"score_spread":0.3044278545647604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011961341","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002790105,0.9970511,0.000042329586,0.0014424301,0.00014028473,0.0000025567913,0.000026393029,0.0000011294703,0.0010147501],"genre_scores_gemma":[0.0021995446,0.9970861,0.00006411184,0.0002884245,0.00020356018,0.0000026907328,0.00001659982,4.551455e-7,0.00013851539],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99950314,0.00016700066,0.000054728665,0.000041275052,0.00018645749,0.000047379526],"domain_scores_gemma":[0.99844486,0.0010039103,0.00031710448,0.000014021011,0.00018024046,0.000039937422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010986935,0.0005847711,0.0012328682,0.0020886906,0.00025754017,0.0012038248,0.0005702103,0.001346352,0.005347312],"category_scores_gemma":[0.0031260294,0.00023638157,0.0007944105,0.003319172,0.00057596964,0.00087247393,0.00055217405,0.001271097,0.0003581755],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015970178,0.0000863028,0.0015750611,0.025961993,0.0005979501,0.00050258794,0.000054502805,0.00066923565,0.0002244994,0.0061400477,0.028621325,0.93540674],"study_design_scores_gemma":[0.00021041663,0.00028373068,0.026488611,0.08008336,0.0023578664,0.0077646957,0.00077450456,0.00069825404,0.0004854703,0.0090764165,0.87168264,0.000094075156],"about_ca_topic_score_codex":0.00606137,"about_ca_topic_score_gemma":0.011045496,"teacher_disagreement_score":0.00606137,"about_ca_system_score_codex":0.0011870672,"about_ca_system_score_gemma":0.0026049092,"threshold_uncertainty_score":0.017888546},"labels":[],"label_agreement":null},{"id":"W2012983297","doi":"10.2165/00019053-200220020-00004","title":"Health-Related Quality of Life in a UK-Based Population of Men with Erectile Dysfunction","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Sexual function and dysfunction studies","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northwood","funders":"","keywords":"Medicine; Quality of life (healthcare); Erectile dysfunction; Marital status; Population; Gerontology; Demography; Public health; Physical therapy; Internal medicine; Environmental health","score_opus":0.08000241966388037,"score_gpt":0.3445059483275316,"score_spread":0.26450352866365123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012983297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99875295,0.0007248201,0.000017380948,0.00005081814,0.0000045220127,0.000008716723,0.0001777229,4.7223244e-7,0.00026258655],"genre_scores_gemma":[0.99917656,0.00034462987,0.000022115275,0.00006221387,0.000007989085,0.0000127049925,0.00025067216,5.4431774e-7,0.00012252208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879766,0.0006021222,0.00011992669,0.00013663796,0.00017444057,0.00016923621],"domain_scores_gemma":[0.9985812,0.00043518227,0.00044940494,0.00007826986,0.00021159119,0.00024450154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010234154,0.00041232756,0.0009537584,0.00145013,0.0007573005,0.0012366811,0.0004018791,0.0008228653,0.00131462],"category_scores_gemma":[0.0038797304,0.00044724252,0.0010753968,0.0023987656,0.0006248105,0.00084495475,0.0010563225,0.000994403,0.00019529539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005603873,0.00013386075,0.99601436,0.00005149804,0.00035875238,0.000245919,0.0008142277,0.000026415468,0.00021260564,0.000022538585,0.00010328176,0.0014560564],"study_design_scores_gemma":[0.000031622236,0.00034397957,0.9984226,0.00001473939,0.00009915439,0.0002100294,0.00070005696,0.00003237186,0.000016005635,0.000009498014,0.00011381265,0.000006144269],"about_ca_topic_score_codex":0.028350757,"about_ca_topic_score_gemma":0.030172942,"teacher_disagreement_score":0.028350757,"about_ca_system_score_codex":0.00074825325,"about_ca_system_score_gemma":0.00038490584,"threshold_uncertainty_score":0.05637151},"labels":[],"label_agreement":null},{"id":"W2013022047","doi":"10.2165/11539840-000000000-00000","title":"To Fund or Not to Fund","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Health economics; Quality of Life Research; Investment fund; Health administration; Business; Economics; Public health; Finance; Medicine; Nursing","score_opus":0.7491966194607523,"score_gpt":0.530442776108682,"score_spread":0.21875384335207038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013022047","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043183327,0.0077214963,0.006991872,0.5962692,0.028123375,0.0007768372,0.0022803724,0.00048402973,0.31416947],"genre_scores_gemma":[0.50321543,0.009693687,0.011018648,0.20475282,0.03131484,0.0012946035,0.003074554,0.00042254262,0.2352129],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99257857,0.0024026034,0.00040786745,0.00038666633,0.002267531,0.0019567297],"domain_scores_gemma":[0.9640106,0.009766831,0.0056662606,0.0037597092,0.005945885,0.010850662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009636305,0.00057907,0.00055650354,0.0013196436,0.0009659487,0.0038239062,0.0011980571,0.009785594,0.039013218],"category_scores_gemma":[0.08249748,0.00033098506,0.00082239887,0.00068341155,0.0015699944,0.003765816,0.002819049,0.0026219608,0.013589096],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009840043,0.00076109427,0.0239617,0.0008107255,0.00034308704,0.0006192847,0.0004911976,0.0009516423,0.0013889899,0.045271557,0.66634655,0.25807008],"study_design_scores_gemma":[0.0007552728,0.00031381485,0.014454363,0.0009518315,0.00027589174,0.0021849824,0.00075957796,0.0027051899,0.0015077664,0.029230183,0.9467713,0.00008972692],"about_ca_topic_score_codex":0.0021970659,"about_ca_topic_score_gemma":0.0023333048,"teacher_disagreement_score":0.039013218,"about_ca_system_score_codex":0.0016297138,"about_ca_system_score_gemma":0.013667933,"threshold_uncertainty_score":0.13051218},"labels":[],"label_agreement":null},{"id":"W2013340278","doi":"10.1007/s40273-014-0215-1","title":"Are We Lacking Economic Evaluations in Gastric Cancer Treatment?","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Sunnybrook Hospital; Queen's University","funders":"","keywords":"Medicine; Cancer; MEDLINE; Health economics; Intensive care medicine; Nursing research; Health care; Breast cancer; Cost–benefit analysis; Quality of Life Research; Quality-adjusted life year; Cost effectiveness; Public health; Risk analysis (engineering); Pathology; Internal medicine","score_opus":0.07026263137955564,"score_gpt":0.39791730637204265,"score_spread":0.327654674992487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013340278","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006434242,0.10978707,0.0030859464,0.86412185,0.0052136024,0.0001349423,0.001135463,0.000032714703,0.010054131],"genre_scores_gemma":[0.41991472,0.1472516,0.018741667,0.39316994,0.015942229,0.0015150222,0.0016886103,0.00019409833,0.0015820015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.82407767,0.14984956,0.011826581,0.002377551,0.0078736,0.0039951135],"domain_scores_gemma":[0.33952755,0.5571887,0.033648632,0.008107908,0.037749738,0.023777563],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.19076554,0.0012863899,0.0048563806,0.0040601683,0.0021821142,0.014019384,0.0038004464,0.0087816315,0.016135218],"category_scores_gemma":[0.595184,0.0013317886,0.0028024577,0.0071127587,0.008052731,0.021466294,0.007257564,0.0149775855,0.0010768187],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045867586,0.0013951492,0.03794679,0.018388737,0.005195984,0.0006054004,0.0014622627,0.014809196,0.00011841714,0.18713006,0.30206352,0.42629772],"study_design_scores_gemma":[0.0043212036,0.0012185387,0.025457703,0.107472785,0.0059795957,0.0008395417,0.0055796644,0.01428015,0.00052841735,0.5506703,0.28298962,0.0006623965],"about_ca_topic_score_codex":0.02287664,"about_ca_topic_score_gemma":0.021688923,"teacher_disagreement_score":0.80923444,"about_ca_system_score_codex":0.018720195,"about_ca_system_score_gemma":0.043234754,"threshold_uncertainty_score":0.99793017},"labels":[],"label_agreement":null},{"id":"W2013468959","doi":"10.1007/s40273-014-0209-z","title":"Estimating Productivity Costs in Health Economic Evaluations: A Review of Instruments and Psychometric Evidence","year":2014,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Health economics; Quality of Life Research; Public health; Health administration; Productivity; Public economics; Economics; Quality-adjusted life year; Environmental health; Actuarial science; Medicine; Cost effectiveness; Economic growth; Nursing; Operations management","score_opus":0.5176089015945724,"score_gpt":0.5871666219186712,"score_spread":0.06955772032409879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013468959","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042818484,0.99728775,0.001034991,0.00060836185,0.00008286267,0.000062861494,0.00018388219,0.00000550916,0.00030558236],"genre_scores_gemma":[0.0120263845,0.98199856,0.0046500457,0.0005695576,0.00023065467,0.00021136108,0.0002246175,0.000010440382,0.00007826456],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9564129,0.022581235,0.009316137,0.001936831,0.009226684,0.0005261733],"domain_scores_gemma":[0.7337489,0.2408283,0.0148331495,0.0018400312,0.008245386,0.0005041907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06009411,0.0036588,0.01184282,0.016381275,0.00064027426,0.005803641,0.003710761,0.0034275397,0.0037034894],"category_scores_gemma":[0.19881956,0.0014433484,0.008301775,0.021189796,0.0023597875,0.0054192073,0.002997702,0.0036216443,0.0004110658],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005316928,0.00015129679,0.006144942,0.1814045,0.008449069,0.00007247069,0.00019574909,0.00273431,0.00007652424,0.0055825026,0.0062553505,0.78840154],"study_design_scores_gemma":[0.0010008805,0.00074295676,0.03551167,0.70131856,0.06115183,0.0015184414,0.0010555004,0.0059290933,0.0010381835,0.046655994,0.14361553,0.0004613889],"about_ca_topic_score_codex":0.007832013,"about_ca_topic_score_gemma":0.010741606,"teacher_disagreement_score":0.06009411,"about_ca_system_score_codex":0.00640242,"about_ca_system_score_gemma":0.009141946,"threshold_uncertainty_score":0.3178118},"labels":[],"label_agreement":null},{"id":"W2014890077","doi":"10.2165/00019053-200725060-00008","title":"Being Led Down the Wrong Garden PATH: the Importance of Knowledge and Facts for the Crossroads","year":2007,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Healthcare Policy and Management","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Programs for Assessment of Technology in Health Research Institute","funders":"","keywords":"Health economics; Quality of Life Research; Health administration; Public health; Path (computing); Gerontology; Medicine; Nursing; Computer science","score_opus":0.056419758293608756,"score_gpt":0.3405667232654615,"score_spread":0.28414696497185277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014890077","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022803182,0.027237445,0.017835015,0.8619887,0.0034837222,0.00003980717,0.00018660033,0.00006309775,0.06636241],"genre_scores_gemma":[0.85023534,0.03802295,0.018890062,0.076723255,0.0050668046,0.00011675213,0.00022308361,0.00022672591,0.010495114],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98366046,0.008395922,0.0008539271,0.0020731185,0.0033435137,0.0016731732],"domain_scores_gemma":[0.8541306,0.11338113,0.007345114,0.006415223,0.0111556165,0.007572339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.030929089,0.00067612086,0.0016211623,0.004793909,0.00889984,0.022963084,0.0027873802,0.01494347,0.013317333],"category_scores_gemma":[0.101096645,0.00084343884,0.00073877984,0.003308073,0.040191274,0.058470875,0.009360969,0.019225823,0.0014286675],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011680317,0.00010955683,0.0038728954,0.00037278514,0.00011090175,0.0010071843,0.010742321,0.0011714726,0.00013742107,0.8703767,0.043092888,0.06888906],"study_design_scores_gemma":[0.000009440256,0.000013261815,0.0006512339,0.0006397153,0.000016412756,0.0001479974,0.0044552,0.00037973822,0.00008250637,0.9403333,0.053238418,0.000032763604],"about_ca_topic_score_codex":0.010837422,"about_ca_topic_score_gemma":0.008362605,"teacher_disagreement_score":0.030929089,"about_ca_system_score_codex":0.0072543593,"about_ca_system_score_gemma":0.015024053,"threshold_uncertainty_score":0.16357058},"labels":[],"label_agreement":null},{"id":"W2015092746","doi":"10.2165/00019053-200119070-00001","title":"Highly Active Antiretroviral Therapy","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Antiretroviral therapy; Medicine; Intensive care medicine; Indinavir; Health economics; Quality of Life Research; Human immunodeficiency virus (HIV); Public health; Immunology; Viral load; Nursing","score_opus":0.04197461033679368,"score_gpt":0.3861028409825094,"score_spread":0.34412823064571574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015092746","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04043864,0.055290185,0.0030027751,0.015399542,0.0038887712,0.000888852,0.009515446,0.0006247429,0.870951],"genre_scores_gemma":[0.30429295,0.042909876,0.005435446,0.03713534,0.004604856,0.0009220684,0.014956153,0.000127758,0.5896156],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996836,0.00009491224,0.000021543477,0.00003804846,0.00009895927,0.00006297959],"domain_scores_gemma":[0.99958366,0.000107550906,0.000055199715,0.000056377827,0.00005195513,0.0001452575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030716357,0.0002920275,0.0003957715,0.0004977806,0.00063107203,0.00070610066,0.00029737075,0.0005020545,0.09115418],"category_scores_gemma":[0.0010261206,0.000072236355,0.00037234454,0.0006313412,0.00015907109,0.0002983664,0.0004112245,0.0009301512,0.025231387],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011912527,0.0010996031,0.008426898,0.00053613324,0.00012703557,0.0007823073,0.00006484451,0.000079283316,0.002208003,0.006558546,0.19864346,0.7802826],"study_design_scores_gemma":[0.00039810868,0.000648261,0.022999171,0.00037393213,0.00012468641,0.002636067,0.00004087786,0.00012445179,0.0011191651,0.0031046704,0.96841776,0.000012804775],"about_ca_topic_score_codex":0.00047613314,"about_ca_topic_score_gemma":0.001299579,"teacher_disagreement_score":0.09115418,"about_ca_system_score_codex":0.00030456943,"about_ca_system_score_gemma":0.0007890122,"threshold_uncertainty_score":0.30494112},"labels":[],"label_agreement":null},{"id":"W2015570846","doi":"10.2165/11594180-000000000-00000","title":"The General Publicʼs Willingness to Pay for Tax Increases to Support Unrestricted Access to an Alzheimerʼs Disease Medication","year":2012,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Programs for Assessment of Technology in Health Research Institute; McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Willingness to pay; Public health; Health economics; Medicine; Disease; Adverse effect; Telephone interview; Actuarial science; Environmental health; Economics; Internal medicine","score_opus":0.431547687135586,"score_gpt":0.5252481835544757,"score_spread":0.09370049641888967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015570846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85671437,0.0026602712,0.0011506963,0.06770128,0.00037461513,0.000076882054,0.0038667095,0.000046178284,0.0674091],"genre_scores_gemma":[0.9949634,0.00059581647,0.00017107194,0.0015517765,0.00011889858,0.0000077205705,0.00034638256,0.0000026536172,0.0022423116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837506,0.00072553253,0.000070577094,0.00008277386,0.00036906335,0.00037697752],"domain_scores_gemma":[0.9926723,0.0041610654,0.0015629447,0.00023688027,0.0006281197,0.0007385962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029284356,0.00017457746,0.00032322193,0.00082337635,0.00034075876,0.0018390844,0.00035275274,0.0016058688,0.007463133],"category_scores_gemma":[0.020600583,0.00020453225,0.00045563545,0.0010108593,0.0007212098,0.0008623785,0.0007452484,0.0016595229,0.0003501252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032145039,0.0013366783,0.6719073,0.0003313794,0.000975714,0.0018726501,0.0008361338,0.012186898,0.0012505687,0.046808492,0.0926127,0.16666701],"study_design_scores_gemma":[0.0007055768,0.0010989016,0.8606858,0.00032530483,0.0007548086,0.0024801556,0.004194247,0.023324074,0.0008120829,0.02857122,0.07695935,0.000088520464],"about_ca_topic_score_codex":0.024697578,"about_ca_topic_score_gemma":0.03373869,"teacher_disagreement_score":0.024697578,"about_ca_system_score_codex":0.0026536349,"about_ca_system_score_gemma":0.0028755616,"threshold_uncertainty_score":0.04910761},"labels":[],"label_agreement":null},{"id":"W2015874148","doi":"10.2165/00019053-200220120-00002","title":"Long Term Cost-of-Illness in Stroke","year":2002,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Radiation Oncology","funders":"","keywords":"Health economics; Stroke (engine); Medicine; Indirect costs; Total cost; Public health; Incidence (geometry); Cost estimate; Health care; Quality of Life Research; Cost–benefit analysis; Demography; Economics; Accounting","score_opus":0.0667940689031264,"score_gpt":0.3815905539314578,"score_spread":0.3147964850283314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015874148","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024020973,0.99853206,0.0000687942,0.0004801474,0.00015544554,0.0000047584845,0.000029933251,0.0000020211276,0.00048663002],"genre_scores_gemma":[0.003019262,0.9961035,0.00019108984,0.000285745,0.00018631858,0.000009016976,0.000029474259,7.390983e-7,0.00017478924],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99936956,0.00017197084,0.00014010655,0.000052187203,0.00023680498,0.000029380592],"domain_scores_gemma":[0.99842864,0.0009328951,0.0003977142,0.000019585235,0.00018574797,0.00003525749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001188009,0.0007526173,0.0022061004,0.0023347593,0.00017880039,0.0010434159,0.0005778964,0.0009485336,0.0025295755],"category_scores_gemma":[0.0038913093,0.00028037612,0.0009668427,0.0042263567,0.00033698237,0.0010438885,0.0003851822,0.0010594992,0.00030671264],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025985576,0.0000811858,0.0015109972,0.04188032,0.0011886716,0.00024349551,0.00004279203,0.0007017902,0.00017376865,0.0029401504,0.022639744,0.9283373],"study_design_scores_gemma":[0.0005935388,0.00063997036,0.033714563,0.08926605,0.008334216,0.005172666,0.0003479578,0.0012342588,0.0004345793,0.0075828447,0.8525798,0.00009947628],"about_ca_topic_score_codex":0.00477658,"about_ca_topic_score_gemma":0.011574537,"teacher_disagreement_score":0.00477658,"about_ca_system_score_codex":0.0015748753,"about_ca_system_score_gemma":0.0023704015,"threshold_uncertainty_score":0.011426568},"labels":[],"label_agreement":null},{"id":"W2016319444","doi":"10.1007/s40273-013-0112-z","title":"Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-Trimoxazole: An Economic Evaluation Alongside a Randomised Controlled Trial","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"National Institute for Health and Care Research","keywords":"Medicine; Quality-adjusted life year; Pirfenidone; Placebo; Cost effectiveness; Clinical endpoint; Health economics; Idiopathic pulmonary fibrosis; Economic evaluation; Quality of life (healthcare); Randomized controlled trial; Incremental cost-effectiveness ratio; Internal medicine; Physical therapy; Public health; Intensive care medicine; Lung; Nursing; Alternative medicine; Pathology","score_opus":0.01546096084820266,"score_gpt":0.3043373580715766,"score_spread":0.28887639722337394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016319444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8991529,0.06255056,0.004241895,0.0045750076,0.0038256925,0.019587941,0.0013841352,0.00015283057,0.0045290026],"genre_scores_gemma":[0.971179,0.012239938,0.004404031,0.0015219954,0.000769042,0.0080335075,0.0005714846,0.000017603385,0.0012634522],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98719656,0.009991709,0.000776017,0.0006648865,0.0006828781,0.0006879672],"domain_scores_gemma":[0.9874821,0.008114466,0.0019501147,0.00051698746,0.0006207841,0.0013154979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010734038,0.0022645881,0.007000255,0.0013371533,0.0007400252,0.0019566081,0.001540757,0.005015281,0.007832435],"category_scores_gemma":[0.018758174,0.0010679216,0.00942489,0.0012766144,0.0024493216,0.0024514894,0.0011973509,0.004612332,0.0005073144],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9828668,0.002076732,0.00025546458,0.0022799687,0.0028895675,0.00004821564,0.000034170353,0.0005396351,0.00023762486,0.00018237236,0.00018923996,0.0084002605],"study_design_scores_gemma":[0.96523815,0.02888627,0.00065062696,0.0003374193,0.0035543274,0.00002756879,0.00003173784,0.00058248674,0.00008543969,0.0002082994,0.0003742661,0.000023313982],"about_ca_topic_score_codex":0.0037687244,"about_ca_topic_score_gemma":0.0041462635,"teacher_disagreement_score":0.010734038,"about_ca_system_score_codex":0.003355226,"about_ca_system_score_gemma":0.003032851,"threshold_uncertainty_score":0.056767702},"labels":[],"label_agreement":null},{"id":"W2016354863","doi":"10.2165/00019053-200321070-00005","title":"Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Orlistat; Medicine; Overweight; Diabetes mellitus; Population; Internal medicine; Type 2 diabetes; Metformin; Placebo; Obesity; Type 2 Diabetes Mellitus; Weight loss; Pharmacoeconomics; Intensive care medicine; Endocrinology; Environmental health","score_opus":0.01564541919626944,"score_gpt":0.3081739561632776,"score_spread":0.29252853696700815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016354863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93617153,0.03829299,0.0014179789,0.008512472,0.00049384846,0.000897989,0.0021271773,0.000034849374,0.0120512],"genre_scores_gemma":[0.9958937,0.0026047735,0.00033877965,0.00035815753,0.00007444457,0.00007722997,0.0003407073,0.0000027911751,0.00030947363],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9951893,0.0038744558,0.00026526788,0.000098157354,0.00032964355,0.00024308432],"domain_scores_gemma":[0.99331796,0.004420709,0.0010733486,0.00012459353,0.00028581492,0.0007776016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041148895,0.0005892251,0.0015735481,0.0008189724,0.00037687187,0.0012161545,0.0004598719,0.0009072609,0.0037101987],"category_scores_gemma":[0.01720839,0.00027404467,0.0025547165,0.0007861318,0.00039874643,0.0006724474,0.0006936478,0.001159909,0.000112184876],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5625095,0.006310753,0.14410813,0.0048495065,0.013486973,0.0011598741,0.00016360098,0.038125347,0.00091703696,0.0043192357,0.0062278872,0.21782209],"study_design_scores_gemma":[0.20921677,0.12652183,0.4371336,0.0036969178,0.04706924,0.003271593,0.002055734,0.13874932,0.0020696681,0.006742248,0.023121044,0.00035201843],"about_ca_topic_score_codex":0.006975786,"about_ca_topic_score_gemma":0.006853628,"teacher_disagreement_score":0.006975786,"about_ca_system_score_codex":0.0034523455,"about_ca_system_score_gemma":0.002904105,"threshold_uncertainty_score":0.025048614},"labels":[],"label_agreement":null},{"id":"W2017172077","doi":"10.2165/11589260-000000000-00000","title":"Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Gilead Sciences","keywords":"Lamivudine; Medicine; Tenofovir; Chronic hepatitis; Public health; Hepatitis B virus; Entecavir; Hepatitis B; Cirrhosis; Internal medicine; Family medicine; Virology; Human immunodeficiency virus (HIV); Virus; Nursing","score_opus":0.08835373679432976,"score_gpt":0.3395906074555045,"score_spread":0.2512368706611747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017172077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5327321,0.289382,0.0011005999,0.08202322,0.0012419552,0.00044113238,0.020113222,0.000062459694,0.0729033],"genre_scores_gemma":[0.9753196,0.019340692,0.0004411428,0.0018683438,0.00031314927,0.00003513203,0.0013944044,0.000006605225,0.001281083],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956713,0.001984682,0.00021432336,0.00012212207,0.0013284835,0.0006790486],"domain_scores_gemma":[0.99272025,0.0036372724,0.0006747458,0.00012108733,0.0020701757,0.0007764743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043432894,0.00057326275,0.0012554786,0.0018720637,0.00071296014,0.0022134832,0.0010092508,0.0013893472,0.0039862418],"category_scores_gemma":[0.01719438,0.0002933334,0.0024017342,0.0028922516,0.00066020514,0.0007145025,0.00048708412,0.0019225403,0.000088837034],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08084615,0.0017336014,0.27406862,0.012167567,0.027696451,0.0015140828,0.00069944235,0.08827613,0.0026281206,0.049200054,0.07524288,0.38592693],"study_design_scores_gemma":[0.013247059,0.0046228264,0.810286,0.0056861276,0.037716866,0.0009884613,0.0025418526,0.04684025,0.0013130049,0.012249347,0.06404581,0.00046242043],"about_ca_topic_score_codex":0.89750046,"about_ca_topic_score_gemma":0.92624056,"teacher_disagreement_score":0.102499545,"about_ca_system_score_codex":0.039044403,"about_ca_system_score_gemma":0.036772285,"threshold_uncertainty_score":0.2832883},"labels":[],"label_agreement":null},{"id":"W2017564455","doi":"10.2165/00019053-200119080-00006","title":"Incremental Cost Analysis of Ambulatory Clinic and Home-Based Intravenous Therapy for Patients with Multiple Myeloma","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program; University of Toronto","funders":"","keywords":"Medicine; Ambulatory; Multiple myeloma; Cancer; Physical therapy; Emergency medicine; Surgery; Internal medicine","score_opus":0.030471698388158434,"score_gpt":0.33638224249804316,"score_spread":0.3059105441098847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017564455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978831,0.0033985286,0.005090239,0.0014868617,0.0001430958,0.00027294835,0.0034161392,0.00010469403,0.0072565684],"genre_scores_gemma":[0.99747425,0.0003350892,0.0009242444,0.00009174643,0.000027549402,0.00004189008,0.0006059297,0.0000065462154,0.00049266365],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.998871,0.00062566815,0.000041634605,0.00007757929,0.00017581442,0.00020818692],"domain_scores_gemma":[0.9971903,0.0020787865,0.00019281561,0.00006480392,0.00025529938,0.0002179333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013104585,0.0010272929,0.0014981327,0.0011653167,0.00039472684,0.0014801563,0.0012861082,0.0011469721,0.0059222397],"category_scores_gemma":[0.00655173,0.0004754562,0.0030459533,0.0016513962,0.00040167262,0.00091948354,0.0005662185,0.0011387088,0.00020817686],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05275852,0.0019029948,0.08383372,0.00088385475,0.0036649522,0.0011378396,0.00010161852,0.73215294,0.0025568209,0.0071426216,0.0051655904,0.108698525],"study_design_scores_gemma":[0.004302005,0.00937677,0.15425089,0.00022342024,0.008387038,0.0015775062,0.00060903054,0.81063914,0.001953327,0.005515092,0.0030243623,0.00014150083],"about_ca_topic_score_codex":0.03903397,"about_ca_topic_score_gemma":0.02394803,"teacher_disagreement_score":0.03903397,"about_ca_system_score_codex":0.00690025,"about_ca_system_score_gemma":0.0031673533,"threshold_uncertainty_score":0.07761353},"labels":[],"label_agreement":null},{"id":"W2018229747","doi":"10.1007/s40273-013-0046-5","title":"The Authors’ Reply to van Baal et al.: “Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.”","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; St. Michael's Hospital","funders":"","keywords":"Health economics; Quality of Life Research; Medical costs; Medicine; Pharmacoeconomics; Health administration; Inclusion (mineral); Indirect costs; Intensive care medicine; Public health; Economics; Psychology; Health care; Accounting; Nursing","score_opus":0.3467508769534195,"score_gpt":0.5215144405189353,"score_spread":0.17476356356551576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018229747","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010593414,0.00057391694,0.00005730807,0.9793179,0.019542264,0.0000065883632,0.00008177412,0.000017393902,0.00029691524],"genre_scores_gemma":[0.0007884244,0.00039435903,0.0001098009,0.98455137,0.013287544,0.00002135965,0.0000240381,0.000015125216,0.00080795545],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99282277,0.0020290816,0.0013101022,0.0010561,0.0020091692,0.0007728399],"domain_scores_gemma":[0.94986564,0.029246185,0.003271749,0.001051505,0.013420018,0.00314496],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009602738,0.0012077251,0.0024050407,0.0012875121,0.004098549,0.0056661484,0.0039590965,0.05816515,0.009835613],"category_scores_gemma":[0.08847424,0.0015679866,0.0020486524,0.0019357759,0.004044482,0.0054739555,0.0026156812,0.07224482,0.008280466],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040324456,0.000011023378,0.00022062741,0.00005878173,0.000015797596,0.00014014827,0.00011042154,0.000033438853,0.00005132489,0.0006932585,0.99700314,0.0016218005],"study_design_scores_gemma":[0.00021107796,0.00006645056,0.0022300794,0.0010211265,0.00009912943,0.0012482767,0.0014800332,0.00052518613,0.00068116403,0.008459952,0.98372746,0.000249953],"about_ca_topic_score_codex":0.007748033,"about_ca_topic_score_gemma":0.011716215,"teacher_disagreement_score":0.9903973,"about_ca_system_score_codex":0.0033443721,"about_ca_system_score_gemma":0.0070726033,"threshold_uncertainty_score":0.050784767},"labels":[],"label_agreement":null},{"id":"W2018803491","doi":"10.1007/s40273-014-0179-1","title":"Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; Vancouver Coastal Health; Centre for Advancing Health Outcomes; St. Paul's Hospital; McMaster University; University of British Columbia","funders":"","keywords":"Placebo; Pharmacotherapy; Medicine; Meta-analysis; Randomized controlled trial; Pairwise comparison; Quality-adjusted life year; Random effects model; Bayesian probability; Internal medicine; Statistics; Cost effectiveness; Mathematics","score_opus":0.7468746274918396,"score_gpt":0.5769829321063179,"score_spread":0.16989169538552173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018803491","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1524018,0.05820824,0.6903429,0.04603845,0.0014611379,0.005272371,0.0019000095,0.0003264257,0.044048633],"genre_scores_gemma":[0.71991307,0.0072104735,0.26652485,0.0024399406,0.00041871084,0.0023992716,0.00021253763,0.00014448912,0.00073657307],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.55733454,0.41558096,0.009807885,0.005730504,0.0106174275,0.00092872867],"domain_scores_gemma":[0.16683707,0.8123629,0.0085331155,0.007145807,0.0045235977,0.0005974914],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.24529731,0.00240266,0.0031523951,0.0050216666,0.0015648655,0.004940664,0.0025750215,0.0039826026,0.005022784],"category_scores_gemma":[0.58213377,0.0009142203,0.005814348,0.0046095303,0.002943105,0.009462654,0.004794666,0.0062266304,0.00026224405],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014980101,0.0008473895,0.029168464,0.034724344,0.05516094,0.0016244552,0.0057026898,0.071777634,0.0019026259,0.2931056,0.0060883528,0.4849173],"study_design_scores_gemma":[0.004556339,0.003320632,0.007677388,0.011918833,0.052203584,0.0016377682,0.0017836567,0.16662548,0.0038659265,0.7306245,0.015512443,0.00027338785],"about_ca_topic_score_codex":0.002750035,"about_ca_topic_score_gemma":0.0047284006,"teacher_disagreement_score":0.7547027,"about_ca_system_score_codex":0.004812161,"about_ca_system_score_gemma":0.005069367,"threshold_uncertainty_score":0.9306828},"labels":[],"label_agreement":null},{"id":"W2018866297","doi":"10.2165/00019053-200422050-00002","title":"Longitudinal versus Cross-Sectional Methodology for Estimating the Economic Burden of Breast Cancer","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Cross-sectional study; Longitudinal study; Cross-sectional data; Reimbursement; Medicine; Health economics; Health administration; Health care; Quarter (Canadian coin); Medical Expenditure Panel Survey; Public health; Gerontology; Actuarial science; Cancer; Econometrics; Economics; Economic growth; Health insurance; Geography; Nursing","score_opus":0.1505092119136746,"score_gpt":0.39837215346886634,"score_spread":0.24786294155519173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018866297","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6175576,0.0061669117,0.36359262,0.0017734689,0.0003681246,0.00040650685,0.007350198,0.0003106671,0.0024739818],"genre_scores_gemma":[0.913293,0.0026738988,0.07084961,0.0004166649,0.00022962304,0.0009915917,0.006269922,0.000053772725,0.005221897],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99358726,0.0050495,0.00037956782,0.00045013882,0.00029784892,0.00023555027],"domain_scores_gemma":[0.9647624,0.025128564,0.005043328,0.0030858803,0.0011958772,0.000783967],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.023261603,0.0005035011,0.0006932004,0.0022976387,0.00043302056,0.0009693676,0.0011852324,0.0011105721,0.003102741],"category_scores_gemma":[0.053522654,0.00048200542,0.0011075537,0.0021220683,0.00035344416,0.0010439929,0.00093588996,0.0009873473,0.00065800414],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044167993,0.00032998188,0.93932265,0.000084637235,0.0015243737,0.00014264627,0.00020531369,0.0075514014,0.00042976555,0.0040166606,0.0012659719,0.044684775],"study_design_scores_gemma":[0.00020121723,0.0024509013,0.8255043,0.00024846868,0.0015169863,0.0014556028,0.0013762641,0.13662076,0.0023044704,0.018348465,0.009873751,0.0000987756],"about_ca_topic_score_codex":0.009383792,"about_ca_topic_score_gemma":0.007483435,"teacher_disagreement_score":0.9767384,"about_ca_system_score_codex":0.00041808904,"about_ca_system_score_gemma":0.0014194774,"threshold_uncertainty_score":0.12302059},"labels":[],"label_agreement":null},{"id":"W2019655913","doi":"10.2165/00019053-200624060-00006","title":"Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph's Hospital; Ottawa Regional Cancer Foundation; Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Warfarin; Low molecular weight heparin; Population; Anticoagulant; Emergency medicine; Internal medicine; Intensive care medicine; Heparin; Surgery; Environmental health","score_opus":0.04274829190689254,"score_gpt":0.3629977748597806,"score_spread":0.320249482952888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019655913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829432,0.012397517,0.00014722197,0.0018102112,0.00020833207,0.00006225275,0.00016258606,0.000024444344,0.0022443105],"genre_scores_gemma":[0.99644876,0.0023222063,0.00021734736,0.00039197772,0.00012703113,0.000024467274,0.0000946376,0.000002580244,0.00037110044],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995072,0.00022844363,0.00006417694,0.00006655892,0.00006303018,0.00007051765],"domain_scores_gemma":[0.99913675,0.0004465382,0.00014901353,0.000022056094,0.000026339825,0.0002193277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006172242,0.0002591879,0.0016187215,0.00030757062,0.0002659809,0.0005544289,0.00028571484,0.00080738124,0.0017174681],"category_scores_gemma":[0.0032407208,0.00019093274,0.00075906236,0.00034139448,0.00020093328,0.00047775774,0.0001795891,0.0014217733,0.00014788246],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6876037,0.0042253053,0.04418156,0.0007279041,0.003334131,0.0005457245,0.00024525225,0.0017671563,0.004373437,0.00068631954,0.002508996,0.24980046],"study_design_scores_gemma":[0.37313867,0.2201855,0.36005273,0.00043154403,0.012641784,0.0025973811,0.00061422633,0.01326321,0.0051745865,0.0025106375,0.009233783,0.00015600918],"about_ca_topic_score_codex":0.001541426,"about_ca_topic_score_gemma":0.0039431513,"teacher_disagreement_score":0.0017174681,"about_ca_system_score_codex":0.0005218116,"about_ca_system_score_gemma":0.00074903236,"threshold_uncertainty_score":0.00574553},"labels":[],"label_agreement":null},{"id":"W2019716535","doi":"10.1007/s40273-014-0235-x","title":"Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework","year":2014,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; National Institute for Health and Care Research; Genome Canada","keywords":"Reimbursement; Orphan drug; Health economics; Transparency (behavior); Value (mathematics); Health care; Actuarial science; Medicine; Management science; Business; Economics; Computer science","score_opus":0.45359984577742674,"score_gpt":0.5688167359387032,"score_spread":0.11521689016127645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019716535","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016163701,0.5971247,0.19169791,0.10345701,0.0023218938,0.028652694,0.0034390832,0.00023469559,0.056908287],"genre_scores_gemma":[0.24478054,0.29574126,0.4153495,0.006561196,0.00075736357,0.032080375,0.0022623814,0.00009135026,0.0023759783],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"systematic_review","domain_scores_codex":[0.7355089,0.20304881,0.03331193,0.0059932373,0.0182836,0.0038535371],"domain_scores_gemma":[0.6319923,0.3249556,0.014910781,0.003512856,0.022428518,0.0022000037],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.2041621,0.0045672064,0.008213577,0.06611811,0.008653728,0.02452805,0.008404536,0.011905073,0.0055504222],"category_scores_gemma":[0.29308358,0.0028079466,0.010154175,0.04891458,0.013551934,0.018973084,0.013207917,0.0064947335,0.00087898836],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029721466,0.00020536142,0.0028153195,0.20428431,0.0024764761,0.0012264941,0.019622415,0.025041567,0.00047716958,0.483909,0.015790826,0.2438538],"study_design_scores_gemma":[0.00019669952,0.00026260602,0.0014791199,0.516036,0.0034907812,0.00041914132,0.01889122,0.012937761,0.00069699663,0.32934347,0.11595892,0.0002873053],"about_ca_topic_score_codex":0.019913279,"about_ca_topic_score_gemma":0.026383696,"teacher_disagreement_score":0.2041621,"about_ca_system_score_codex":0.056481037,"about_ca_system_score_gemma":0.090745166,"threshold_uncertainty_score":0.9814098},"labels":[],"label_agreement":null},{"id":"W2021642387","doi":"10.2165/00019053-200624110-00004","title":"Utility Measurement in Healthcare","year":2006,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Health economics; Expected utility hypothesis; Certainty; Axiom; Health care; Health administration; Property (philosophy); Economics; Field (mathematics); Scale (ratio); Decision theory; Management science; Actuarial science; Positive economics; Public economics; Microeconomics; Mathematical economics; Mathematics","score_opus":0.7363133382407497,"score_gpt":0.5558515791593466,"score_spread":0.18046175908140316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021642387","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010867947,0.9692638,0.020714508,0.0028342952,0.00053218624,0.00003804229,0.00017254472,0.000031840435,0.0053261025],"genre_scores_gemma":[0.08706122,0.88493747,0.020561066,0.002209792,0.0024512827,0.00021861779,0.00034450422,0.00003295382,0.0021831163],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.993075,0.0039240257,0.00062068127,0.0006017019,0.0016178627,0.00016070645],"domain_scores_gemma":[0.98550016,0.011575099,0.00094387826,0.00054991734,0.0012949503,0.00013599407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009596191,0.001169004,0.0030852112,0.0053196335,0.0004064886,0.003746851,0.0014797047,0.0018995174,0.0034659686],"category_scores_gemma":[0.025958106,0.0005613693,0.0009917893,0.008943938,0.0030170167,0.003769095,0.0018132239,0.0029068582,0.0008153567],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007320093,0.000089815694,0.0023472498,0.006831763,0.00024463545,0.000074527605,0.00016527546,0.0033388073,0.00019469138,0.1208864,0.017747227,0.8480063],"study_design_scores_gemma":[0.000072700546,0.00029906054,0.016075797,0.018014371,0.00051313016,0.0018301404,0.00065750815,0.0110342335,0.0011387711,0.54273677,0.40745893,0.00016863098],"about_ca_topic_score_codex":0.0033367008,"about_ca_topic_score_gemma":0.0023270992,"teacher_disagreement_score":0.009596191,"about_ca_system_score_codex":0.0024591954,"about_ca_system_score_gemma":0.0023834636,"threshold_uncertainty_score":0.050750077},"labels":[],"label_agreement":null},{"id":"W2021743374","doi":"10.2165/00019053-200321120-00003","title":"Defining Monetary Values for Quality of Life Improvements","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Willingness to pay; Respondent; Health economics; Quality of life (healthcare); Psychological intervention; Quality of Life Research; Medicine; Intervention (counseling); Variance (accounting); Sample (material); Health administration; Actuarial science; Public health; Environmental health; Demography; Economics; Nursing","score_opus":0.37360829233665666,"score_gpt":0.48650149270084375,"score_spread":0.1128932003641871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021743374","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23091407,0.024328746,0.5656171,0.024748478,0.0016903991,0.0005208077,0.0011096373,0.00023125121,0.15083951],"genre_scores_gemma":[0.95254225,0.0029293085,0.04099713,0.00048525116,0.0004854845,0.00032504022,0.00017842151,0.000037467442,0.002019716],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9911985,0.0056705964,0.00055765966,0.0006322087,0.0012891627,0.00065181695],"domain_scores_gemma":[0.9782518,0.01565847,0.0028198163,0.0008644435,0.0018544949,0.00055110554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013539281,0.0013619168,0.001082061,0.003379263,0.0006802583,0.0065339017,0.0014484242,0.0027011505,0.003822083],"category_scores_gemma":[0.055752236,0.00045264084,0.0006543545,0.0031559647,0.0032449747,0.008412059,0.0023783806,0.0030400946,0.0003395929],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003790074,0.00015379206,0.0051208665,0.00039957106,0.0001465978,0.0001666874,0.00041334215,0.03915375,0.0005186935,0.8437035,0.0041299523,0.10571427],"study_design_scores_gemma":[0.0000802174,0.00022113656,0.004438598,0.0005290417,0.00008823544,0.00022175917,0.0005938387,0.038959894,0.00059298583,0.94586307,0.0083569,0.000054338663],"about_ca_topic_score_codex":0.0004403508,"about_ca_topic_score_gemma":0.00044548904,"teacher_disagreement_score":0.013539281,"about_ca_system_score_codex":0.0028053976,"about_ca_system_score_gemma":0.0009939617,"threshold_uncertainty_score":0.07160342},"labels":[],"label_agreement":null},{"id":"W2022259512","doi":"10.2165/00019053-200422050-00001","title":"Economic Impact of Respiratory Syncytial Virus-Related Illness in the US","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Respiratory viral infections research","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Health economics; Quality of Life Research; Public health; Virus; Health administration; Respiratory system; Medicine; Virology; Environmental health; Internal medicine; Nursing","score_opus":0.03891501728550519,"score_gpt":0.4134410688946323,"score_spread":0.3745260516091271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022259512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96238923,0.005873408,0.00017681472,0.017701516,0.00018230255,0.000022756014,0.0044477507,0.000008814965,0.009197348],"genre_scores_gemma":[0.9965251,0.0016820505,0.00003955949,0.00040209907,0.000057828427,0.0000051644947,0.0007817954,0.0000012685249,0.0005050978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989373,0.0004907831,0.00007819644,0.000034209745,0.00020902936,0.0002504879],"domain_scores_gemma":[0.998604,0.0003520161,0.00045362432,0.000022731649,0.00025228405,0.0003153803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007179733,0.00014812278,0.00017241662,0.0009007697,0.00034206346,0.00076611753,0.00023496887,0.0005756977,0.0015519476],"category_scores_gemma":[0.004083675,0.00011063818,0.00048341826,0.0012461666,0.00029709924,0.00046549074,0.00062958006,0.00063510134,0.000054901317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012094701,0.00036635163,0.94618464,0.00012982683,0.00038219776,0.0008160903,0.00013419577,0.0073719393,0.0002958224,0.0043853843,0.008255571,0.030468479],"study_design_scores_gemma":[0.000047521804,0.00015207108,0.9864015,0.000072862356,0.00014899486,0.0003997458,0.00097211066,0.0048046415,0.00012621994,0.0008888841,0.005973129,0.000012256421],"about_ca_topic_score_codex":0.124174364,"about_ca_topic_score_gemma":0.17634141,"teacher_disagreement_score":0.124174364,"about_ca_system_score_codex":0.004032949,"about_ca_system_score_gemma":0.0025540506,"threshold_uncertainty_score":0.24690318},"labels":[],"label_agreement":null},{"id":"W2023872131","doi":"10.2165/00019053-200220050-00005","title":"The Practice of Splitting Tablets","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pharmacy; Medical prescription; Medicine; Product (mathematics); Business; Risk analysis (engineering); Operations management; Family medicine; Pharmacology; Mathematics; Engineering","score_opus":0.06657594678489463,"score_gpt":0.3978907093335888,"score_spread":0.33131476254869413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023872131","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12485576,0.048718806,0.04815921,0.42021087,0.014084353,0.00055721443,0.00040017144,0.0012141479,0.34179947],"genre_scores_gemma":[0.5742116,0.024526592,0.07029999,0.19656831,0.009822134,0.0004788403,0.00041894804,0.00071818166,0.12295543],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98550284,0.006717821,0.0012580914,0.0022064068,0.0036769258,0.0006378637],"domain_scores_gemma":[0.97337544,0.010791733,0.0040846462,0.0058978656,0.0027910203,0.0030593055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008595858,0.00053234294,0.00050867675,0.0015900036,0.00393689,0.003718586,0.0019159138,0.005070235,0.018890927],"category_scores_gemma":[0.039551944,0.0004885277,0.0010490603,0.0015172788,0.006732418,0.004750506,0.0050055487,0.010034851,0.0061194394],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095324713,0.0007221604,0.014323907,0.0009969444,0.0001648406,0.0025898109,0.009564777,0.00031228407,0.006422415,0.044317875,0.1507856,0.7688462],"study_design_scores_gemma":[0.00026212327,0.0008484343,0.01683441,0.0018061204,0.0001495024,0.010840645,0.008882019,0.00070973625,0.004635358,0.038879547,0.9160034,0.00014877021],"about_ca_topic_score_codex":0.0019735827,"about_ca_topic_score_gemma":0.0044424892,"teacher_disagreement_score":0.018890927,"about_ca_system_score_codex":0.0018781394,"about_ca_system_score_gemma":0.00388403,"threshold_uncertainty_score":0.06319642},"labels":[],"label_agreement":null},{"id":"W2024683988","doi":"10.2165/00019053-200017030-00005","title":"Assessing Health Utilities in Schizophrenia","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University","funders":"Ministère de l’Éducation, Gouvernement de l’Ontario; Bộ Giáo dục và Ðào tạo","keywords":"Health economics; Schizophrenia (object-oriented programming); Quality of life (healthcare); Quality-adjusted life year; Preference; Health care; Health administration; Rating scale; Medicine; Willingness to pay; Psychiatry; Mental illness; Health Utilities Index; Quality of Life Research; Time-trade-off; Public health; Economic evaluation; Scale (ratio); Psychology; Mental health; Cost effectiveness; Nursing; Health related quality of life; Economics; Risk analysis (engineering); Developmental psychology; Disease","score_opus":0.4158554268910543,"score_gpt":0.5122417427117003,"score_spread":0.096386315820646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024683988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99601126,0.00077090465,0.0011110263,0.00037175417,0.000007502124,0.000029973402,0.00037949253,0.000005842448,0.0013123639],"genre_scores_gemma":[0.9993894,0.00013697417,0.0002954692,0.000012300243,0.000002504603,0.000006842683,0.00010115526,6.50946e-7,0.00005468117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786156,0.0015030982,0.00019821955,0.000056754034,0.00021956059,0.00016080901],"domain_scores_gemma":[0.99491274,0.0030562095,0.0010968054,0.0001284041,0.0003730696,0.00043262224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005243704,0.0004916019,0.0006541658,0.0020731231,0.00033726264,0.0010810524,0.00023075014,0.0004240604,0.00097523147],"category_scores_gemma":[0.019363945,0.00017895168,0.0010599868,0.0015147221,0.0004333003,0.0008057734,0.0009468366,0.0006543223,0.000093891365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020022476,0.00027278403,0.93444496,0.0001581355,0.0007464626,0.00027156147,0.00036439806,0.01248982,0.00032211377,0.0023773762,0.000521791,0.0460284],"study_design_scores_gemma":[0.00017900071,0.0013793468,0.912909,0.00022294445,0.00072532357,0.0006356769,0.0014560206,0.064931236,0.000663315,0.015901959,0.0009289805,0.00006733075],"about_ca_topic_score_codex":0.012310557,"about_ca_topic_score_gemma":0.013976146,"teacher_disagreement_score":0.012310557,"about_ca_system_score_codex":0.0016487844,"about_ca_system_score_gemma":0.0012062611,"threshold_uncertainty_score":0.027731717},"labels":[],"label_agreement":null},{"id":"W2024733263","doi":"10.2165/00019053-200624110-00005","title":"Pharmacoeconomics and Pharmacoepidemiology","year":2006,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pharmacoeconomics; Pharmacoepidemiology; Health economics; Medicine; Quality of Life Research; Health administration; Economic evaluation; Public health; Management science; Risk analysis (engineering); Economics; Intensive care medicine; Pharmacology; Nursing","score_opus":0.5675004273166744,"score_gpt":0.5703214458833197,"score_spread":0.0028210185666452947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024733263","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007906784,0.9978561,0.0001915316,0.0010880734,0.00016272385,0.0000068303866,0.000028579536,0.0000036333588,0.0005834099],"genre_scores_gemma":[0.0021682263,0.9959228,0.0003882604,0.0006690869,0.00044203727,0.000017843584,0.00005093563,0.0000017053661,0.0003391731],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980399,0.0007675108,0.00021940222,0.00015531383,0.00073065475,0.00008725994],"domain_scores_gemma":[0.9936673,0.0045274245,0.000572349,0.00010431493,0.0009885785,0.00013997166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005220532,0.0010800888,0.0038342313,0.0042843535,0.00032185696,0.0023908322,0.0009833515,0.0021424121,0.00613557],"category_scores_gemma":[0.010216198,0.00038068174,0.00081160484,0.009334934,0.0012511594,0.0014598693,0.0007580973,0.0028705415,0.001232216],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012012061,0.00011210287,0.0008376846,0.01688975,0.0005744795,0.00014282984,0.000028170283,0.0007777542,0.00013182897,0.007960637,0.046613436,0.92581123],"study_design_scores_gemma":[0.00040391335,0.00018253086,0.011512655,0.03626659,0.0020649252,0.0022886838,0.00024348883,0.001283433,0.00042856488,0.037983984,0.9072642,0.000076974924],"about_ca_topic_score_codex":0.0063269823,"about_ca_topic_score_gemma":0.010783728,"teacher_disagreement_score":0.0063269823,"about_ca_system_score_codex":0.002445624,"about_ca_system_score_gemma":0.004430186,"threshold_uncertainty_score":0.02760917},"labels":[],"label_agreement":null},{"id":"W2024882643","doi":"10.2165/00019053-200624040-00007","title":"Post-Exposure Influenza Prophylaxis with Oseltamivir","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Oseltamivir; Medicine; Neuraminidase inhibitor; Life expectancy; Emergency medicine; Health economics; Neuraminidase; Zanamivir; Internal medicine; Intensive care medicine; Public health; Pediatrics; Environmental health; Virology; Coronavirus disease 2019 (COVID-19); Virus; Infectious disease (medical specialty); Disease","score_opus":0.03437580619583032,"score_gpt":0.35248804743410134,"score_spread":0.31811224123827103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024882643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982018,0.011490548,0.00026432375,0.0005666081,0.00012952823,0.00026894629,0.00084348914,0.000009707588,0.004408969],"genre_scores_gemma":[0.9953662,0.0024247454,0.00025877383,0.00025578027,0.000110345005,0.000121092075,0.00040458798,0.0000018476367,0.0010564958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967604,0.0021578665,0.00026023565,0.0002122809,0.00035866347,0.00025058692],"domain_scores_gemma":[0.99631137,0.002075023,0.0006769639,0.00029724961,0.00027119633,0.00036816718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003187043,0.00038150334,0.0006383546,0.00062195805,0.00047169882,0.0004853961,0.0002879136,0.00071688043,0.0032156052],"category_scores_gemma":[0.006980094,0.0001451796,0.0008619916,0.0008269083,0.00019549622,0.0006640808,0.00026271303,0.0007531744,0.00028637808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18873334,0.007660992,0.4793711,0.0015484907,0.0055494504,0.0005617645,0.00052551314,0.0004137131,0.00628872,0.00091577374,0.0022643409,0.3061668],"study_design_scores_gemma":[0.009005148,0.09316939,0.8773869,0.00034500164,0.003220417,0.0007909889,0.00040156613,0.00033492947,0.005480962,0.00038213265,0.009451706,0.00003088105],"about_ca_topic_score_codex":0.0016542114,"about_ca_topic_score_gemma":0.0023922783,"teacher_disagreement_score":0.0032156052,"about_ca_system_score_codex":0.00046580745,"about_ca_system_score_gemma":0.0008960274,"threshold_uncertainty_score":0.016854882},"labels":[],"label_agreement":null},{"id":"W2026751503","doi":"10.2165/00019053-200119001-00004","title":"An Economic Model for Determining the Costs and Consequences of Using Various Treatment Alternatives for the Management of Arthritis in Canada","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada); University of Alberta","funders":"","keywords":"Health economics; Quality of Life Research; Health administration; Public health; Arthritis; Pharmacoeconomics; Health care management; Medicine; Intensive care medicine; Nursing; Internal medicine","score_opus":0.03857266971576977,"score_gpt":0.3372385351255037,"score_spread":0.29866586540973394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026751503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6451062,0.007474339,0.0974786,0.02964038,0.0006658122,0.0023758553,0.019664664,0.0005464264,0.19704774],"genre_scores_gemma":[0.9460805,0.0023799192,0.014763994,0.00059688656,0.00010981832,0.00051947276,0.001855302,0.000052882202,0.033641268],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9979779,0.0007423151,0.000053285305,0.00016838232,0.00029688512,0.00076131575],"domain_scores_gemma":[0.9949254,0.0032209964,0.0002852114,0.0000726784,0.0009019037,0.00059383386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003252572,0.0015958378,0.0026918,0.0037795927,0.0029448532,0.005737311,0.004238972,0.0049306457,0.012328416],"category_scores_gemma":[0.011966526,0.001768068,0.001867261,0.00456237,0.002780736,0.0020591198,0.0018494469,0.0033098923,0.00049981725],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004026287,0.00011107646,0.0036319932,0.00008180514,0.000120718694,0.00025211723,0.000081045466,0.9466001,0.00009746049,0.040062387,0.003551707,0.005007005],"study_design_scores_gemma":[0.00027606988,0.000066441855,0.0021483426,0.00004496371,0.000154182,0.00009385874,0.0002809538,0.9824876,0.00005255201,0.011550611,0.0027928166,0.000051650553],"about_ca_topic_score_codex":0.91296417,"about_ca_topic_score_gemma":0.8370397,"teacher_disagreement_score":0.087035835,"about_ca_system_score_codex":0.04881999,"about_ca_system_score_gemma":0.03356611,"threshold_uncertainty_score":0.35421544},"labels":[],"label_agreement":null},{"id":"W2027483687","doi":"10.1007/s40273-013-0115-9","title":"Cost Effectiveness of a 21-Gene Recurrence Score Assay Versus Canadian Clinical Practice in Post-Menopausal Women with Early-Stage Estrogen or Progesterone-Receptor-Positive, Axillary Lymph-Node Positive Breast Cancer","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Medicine; Breast cancer; Gynecology; Oncology; Progesterone receptor; Internal medicine; Cost effectiveness; Population; Stage (stratigraphy); Public health; Estrogen receptor; Cancer; Pathology; Biology","score_opus":0.022698309579264612,"score_gpt":0.33830955152828124,"score_spread":0.31561124194901663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027483687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794515,0.009356232,0.0002714496,0.0032306083,0.00016096451,0.00037267487,0.0014666759,0.00002422768,0.005665673],"genre_scores_gemma":[0.9969721,0.0013285076,0.0003209921,0.00033625346,0.000037261012,0.000042410156,0.00035102598,0.0000027058977,0.0006086958],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9973303,0.0015271656,0.0001273888,0.0002607649,0.00038207875,0.00037230845],"domain_scores_gemma":[0.994985,0.002366659,0.00088173215,0.0001262558,0.0005273372,0.0011129585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002549616,0.000803498,0.0014087335,0.0006883417,0.0007580203,0.0011773524,0.0011691527,0.0018289291,0.003379406],"category_scores_gemma":[0.015790192,0.0004055724,0.001970256,0.0014319508,0.0008124304,0.0006940925,0.00090006884,0.0012507335,0.00012546127],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4172705,0.00472867,0.3088235,0.0019047156,0.005650994,0.00039713737,0.00049413607,0.0451363,0.0010106573,0.0025945504,0.006472118,0.20551665],"study_design_scores_gemma":[0.04235208,0.057724655,0.81300783,0.000877862,0.012589006,0.00046169263,0.0015394349,0.06326636,0.00077586574,0.0015310032,0.005565325,0.00030890902],"about_ca_topic_score_codex":0.7949937,"about_ca_topic_score_gemma":0.80564106,"teacher_disagreement_score":0.2050063,"about_ca_system_score_codex":0.025353212,"about_ca_system_score_gemma":0.021085184,"threshold_uncertainty_score":0.4124272},"labels":[],"label_agreement":null},{"id":"W2028342787","doi":"10.2165/00019053-200422050-00005","title":"Cost Effectiveness of Representatives of Three Classes of Antidepressants Used in Major Depression in the UK","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Venlafaxine; Fluoxetine; Venlafaxine Hydrochloride; Fluvoxamine; Pharmacoeconomics; Amitriptyline; Medicine; Psychiatry; Paroxetine; Depression (economics); Cost effectiveness; Antidepressant; Internal medicine; Psychology; Intensive care medicine; Serotonin","score_opus":0.06534176464295775,"score_gpt":0.3946588932483937,"score_spread":0.32931712860543594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028342787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855156,0.008162726,0.00009676841,0.002048516,0.00009656836,0.00012538345,0.00044815894,0.000013469647,0.0034928627],"genre_scores_gemma":[0.99779785,0.001050374,0.00014543784,0.00032974256,0.000036069247,0.00005490172,0.00022787077,0.0000019079573,0.00035599005],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9960961,0.0027396374,0.00032819214,0.00015490758,0.00044623466,0.00023491144],"domain_scores_gemma":[0.99280614,0.0036276667,0.0014003967,0.00013506744,0.0004994592,0.0015314141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019518639,0.0002597356,0.0010467601,0.0006152109,0.00048628298,0.0009176797,0.00040132398,0.001688269,0.0031150528],"category_scores_gemma":[0.0156719,0.0002278879,0.0013376419,0.00068101176,0.00037301533,0.0006539832,0.0007359385,0.0010060741,0.00016775285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.380315,0.0065467423,0.18135387,0.004526021,0.0049017733,0.00082767854,0.0016765879,0.015409962,0.0020468386,0.0022976757,0.010902227,0.38919565],"study_design_scores_gemma":[0.04031477,0.063671224,0.8550993,0.0013546612,0.006130989,0.0015010184,0.003435253,0.016625773,0.0012445565,0.0010141581,0.009386857,0.00022137826],"about_ca_topic_score_codex":0.017252056,"about_ca_topic_score_gemma":0.02480286,"teacher_disagreement_score":0.017252056,"about_ca_system_score_codex":0.00393394,"about_ca_system_score_gemma":0.0015171878,"threshold_uncertainty_score":0.034303308},"labels":[],"label_agreement":null},{"id":"W2029403036","doi":"10.2165/00019053-200119050-00010","title":"Cost Effectiveness of Nasal Calcitonin in Postmenopausal Women","year":2001,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Cost effectiveness; Cost-effectiveness analysis; Randomized controlled trial; Calcitonin; Internal medicine; Physical therapy","score_opus":0.12189264107641917,"score_gpt":0.48413106340409684,"score_spread":0.36223842232767767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029403036","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001325115,0.99775,0.00005160239,0.00037785206,0.0000671107,0.00000774562,0.000044296547,0.000002149302,0.0003741769],"genre_scores_gemma":[0.017963214,0.9809909,0.0002586021,0.00037554538,0.00016473874,0.000019206085,0.000055730692,0.0000017328175,0.00017044795],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9991773,0.00033802917,0.00013189188,0.000052857897,0.00026910662,0.000030920695],"domain_scores_gemma":[0.99785703,0.0016489523,0.0003168788,0.00001968843,0.00012869854,0.000028677907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001235645,0.00056759804,0.0028923948,0.0013951588,0.00012317697,0.0007101866,0.00060923817,0.00091674813,0.0024707092],"category_scores_gemma":[0.004429871,0.00024178703,0.0017985489,0.0021903347,0.00026171654,0.000462427,0.00027046935,0.0007836893,0.00016417967],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037135328,0.0001537544,0.002297786,0.06736839,0.0049741967,0.00036837204,0.000040707502,0.0013393788,0.00050211523,0.0010332846,0.007217473,0.91099095],"study_design_scores_gemma":[0.02319075,0.011786645,0.12774034,0.16260895,0.117965244,0.015576707,0.0009660306,0.007955762,0.0035871777,0.011578065,0.5167463,0.0002980669],"about_ca_topic_score_codex":0.005383896,"about_ca_topic_score_gemma":0.012341046,"teacher_disagreement_score":0.005383896,"about_ca_system_score_codex":0.0014379354,"about_ca_system_score_gemma":0.0013632092,"threshold_uncertainty_score":0.010705113},"labels":[],"label_agreement":null},{"id":"W2031350791","doi":"10.2165/00019053-200119060-00005","title":"International Validation of the CLAU-S Quality-of-Life Questionnaire for Use in Patients with Intermittent Claudication","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Peripheral Artery Disease Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Public Health Association","funders":"","keywords":"Quality of Life Research; Health economics; Quality of life (healthcare); Health administration; Intermittent claudication; Medicine; Health care management; Public health; Claudication; Physical therapy; Nursing; Surgery; Arterial disease; Vascular disease","score_opus":0.0374428898214138,"score_gpt":0.3335150779606571,"score_spread":0.2960721881392433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031350791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98746,0.0012995378,0.0020361864,0.00050605723,0.00013401076,0.0008812665,0.0021077897,0.00003440555,0.005540722],"genre_scores_gemma":[0.9931257,0.000303374,0.0025508907,0.00026688664,0.000049830633,0.0007042406,0.0023302133,0.000016356382,0.00065252214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951132,0.0020680218,0.000791883,0.0003745275,0.0012687721,0.0003837803],"domain_scores_gemma":[0.9883436,0.003974864,0.003066808,0.0005841136,0.0033118557,0.00071860495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010948605,0.0007204099,0.0007572158,0.0024110372,0.0007277521,0.001327083,0.0008374111,0.0011786395,0.0012728864],"category_scores_gemma":[0.018390613,0.00030610297,0.0015093057,0.0017724524,0.0007558326,0.0009656574,0.0012709511,0.0013239275,0.0003648117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006228657,0.00059505814,0.97994804,0.000091514084,0.00033213073,0.000048942635,0.0006911137,0.00034997927,0.00045405462,0.00016999125,0.0010673867,0.01562896],"study_design_scores_gemma":[0.0001544997,0.000779166,0.9960252,0.00006271866,0.00010556915,0.00013611802,0.00032561,0.0007455711,0.00023502985,0.00007645854,0.0013363754,0.000017724655],"about_ca_topic_score_codex":0.0040608165,"about_ca_topic_score_gemma":0.0046448563,"teacher_disagreement_score":0.010948605,"about_ca_system_score_codex":0.0009942737,"about_ca_system_score_gemma":0.0014041301,"threshold_uncertainty_score":0.057902396},"labels":[],"label_agreement":null},{"id":"W2032207957","doi":"10.2165/00019053-200119050-00011","title":"Gastrointestinal-Related Healthcare Resource Usage Associated with a Fixed Combination of Diclofenac and Misoprostol versus Other NSAIDs","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"Merck Canada","keywords":"Misoprostol; Diclofenac; Medicine; Medical prescription; Logistic regression; Health care; Health administration; Internal medicine; Emergency medicine; Anesthesia; Public health; Pharmacology; Abortion; Pregnancy","score_opus":0.018451037199828827,"score_gpt":0.28520704669899216,"score_spread":0.26675600949916334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032207957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99884593,0.00051128486,0.000042626234,0.000060557926,0.0000111583,0.000014369907,0.0001047958,0.000001518508,0.00040765846],"genre_scores_gemma":[0.9994066,0.00020114421,0.00009619963,0.00003664852,0.00001735059,0.000008276568,0.00012279084,9.95849e-7,0.00010999344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918276,0.0003910067,0.00011212694,0.00009490957,0.000105923515,0.000113322676],"domain_scores_gemma":[0.997759,0.0012711226,0.00047807314,0.0000587728,0.000116131014,0.00031696557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075947045,0.00015319955,0.00073017034,0.00045515597,0.00019456568,0.00036471,0.0002501641,0.00040032878,0.0031030271],"category_scores_gemma":[0.0059935595,0.00013777414,0.00095532445,0.0005751443,0.000161298,0.00036020423,0.00023543574,0.00047226498,0.00010718407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25248116,0.00257065,0.6555921,0.0005015247,0.0029343525,0.00079374306,0.00021643234,0.0024234569,0.0050661913,0.00017241869,0.0006527518,0.0765953],"study_design_scores_gemma":[0.0037672792,0.047711946,0.9375994,0.0000818661,0.0028018008,0.0011423485,0.0004270063,0.0039354065,0.0016590641,0.00011310932,0.00072432397,0.00003659952],"about_ca_topic_score_codex":0.0031235565,"about_ca_topic_score_gemma":0.0045323414,"teacher_disagreement_score":0.0031235565,"about_ca_system_score_codex":0.0006286617,"about_ca_system_score_gemma":0.0004895325,"threshold_uncertainty_score":0.010380626},"labels":[],"label_agreement":null},{"id":"W2032287810","doi":"10.2165/00019053-200624110-00007","title":"???Lost in Translation???","year":2006,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; Population Health Research Institute","funders":"Wellcome Trust","keywords":"Health administration; Health economics; Health care; Multinational corporation; Medicine; Cost effectiveness; Actuarial science; Computer science; Risk analysis (engineering); Public health; Business; Economics; Finance; Nursing","score_opus":0.6193967510465721,"score_gpt":0.5494153435115084,"score_spread":0.06998140753506366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032287810","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000116716576,0.89182407,0.0008981905,0.035484415,0.064746715,0.000045049084,0.0008591838,0.00006299906,0.0059626326],"genre_scores_gemma":[0.002567975,0.92297226,0.0023643887,0.028763618,0.033989344,0.00011491548,0.0008467366,0.00009564989,0.008285167],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994532,0.0016892237,0.0013034849,0.00046668792,0.0017486608,0.00025997474],"domain_scores_gemma":[0.95717204,0.025194334,0.0036870798,0.001969031,0.011005199,0.00097229943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012673449,0.0015352417,0.0053474465,0.006508603,0.0008148367,0.0087619135,0.002369343,0.004513397,0.043149546],"category_scores_gemma":[0.06796559,0.0010351603,0.0016623123,0.011510047,0.0043142946,0.008581128,0.0030339397,0.007320197,0.025631802],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114817085,0.000034623103,0.00016747533,0.04146712,0.0001778076,0.0002460362,0.00022962115,0.00019342668,0.00026736577,0.012118506,0.50570744,0.4392757],"study_design_scores_gemma":[0.00006369518,0.000027714312,0.00062397507,0.017855518,0.00022427013,0.00070921914,0.00020975588,0.00006903491,0.00009229967,0.007069195,0.9730195,0.000036047135],"about_ca_topic_score_codex":0.005464642,"about_ca_topic_score_gemma":0.0059770257,"teacher_disagreement_score":0.043149546,"about_ca_system_score_codex":0.002666384,"about_ca_system_score_gemma":0.0098664155,"threshold_uncertainty_score":0.14434963},"labels":[],"label_agreement":null},{"id":"W2034014431","doi":"10.2165/11588350-000000000-00000","title":"Adjuvant Trastuzumab for Breast Cancer","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Cancer Centre; Atlantic School of Theology; Cancer Care Nova Scotia; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Trastuzumab; Breast cancer; Adjuvant; Quality of Life Research; Medicine; Oncology; Health economics; Internal medicine; Public health; Cancer; Pathology","score_opus":0.1428086307434459,"score_gpt":0.43489554137371356,"score_spread":0.29208691063026765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034014431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5330793,0.2163814,0.0035019137,0.15994008,0.0019507803,0.0002761466,0.0021639233,0.00011624249,0.08259017],"genre_scores_gemma":[0.9566142,0.027055752,0.00078601285,0.008429543,0.0021643275,0.000082028,0.0005189776,0.000011244026,0.0043378538],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990689,0.00055892987,0.000060644794,0.000043275624,0.00016937873,0.000098942386],"domain_scores_gemma":[0.99755967,0.0016783836,0.00033258423,0.00007129222,0.00011832875,0.0002396803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013278807,0.000107629596,0.00025421384,0.00031488374,0.0001373443,0.00042126878,0.00017168316,0.0004780181,0.004169399],"category_scores_gemma":[0.006795987,0.00005054677,0.00028844277,0.0005266146,0.0001274703,0.00028582325,0.00021289932,0.00076166796,0.00019470505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0144395735,0.0007416878,0.021224786,0.000832696,0.00045853673,0.0005684253,0.0000673944,0.0036415663,0.0022910633,0.0057389135,0.027616864,0.9223785],"study_design_scores_gemma":[0.012804866,0.010654566,0.36621097,0.0041068257,0.0047731423,0.005102387,0.00055014837,0.021970298,0.009854874,0.03709656,0.5267997,0.00007583273],"about_ca_topic_score_codex":0.0016317695,"about_ca_topic_score_gemma":0.004619338,"teacher_disagreement_score":0.004169399,"about_ca_system_score_codex":0.0015566858,"about_ca_system_score_gemma":0.0015271446,"threshold_uncertainty_score":0.013948023},"labels":[],"label_agreement":null},{"id":"W2035696027","doi":"10.2165/00019053-200220060-00005","title":"Reporting Heterogeneity in the Measurement of Health and Health-Related Quality of Life","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health disparities and outcomes","field":"Social Sciences","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Categorical variable; Quality of life (healthcare); Socioeconomic status; Population; Public health; Sample (material); Psychology; Econometrics; Medicine; Gerontology; Environmental health; Statistics; Mathematics","score_opus":0.3980112718076854,"score_gpt":0.4694687805807528,"score_spread":0.07145750877306739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035696027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80876225,0.015763037,0.11353314,0.01830453,0.001707779,0.0015259144,0.013441787,0.0003304391,0.026631232],"genre_scores_gemma":[0.9828042,0.0008138079,0.009203895,0.0025462937,0.00034073985,0.00078656676,0.0031412004,0.000055314948,0.00030803017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.6495689,0.24767624,0.054913044,0.014864624,0.029724466,0.0032526841],"domain_scores_gemma":[0.32614285,0.5255612,0.06555544,0.060514797,0.021357967,0.00086765236],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.21032046,0.0006235018,0.0015736589,0.0038397175,0.001167366,0.0029377257,0.001855913,0.0020875004,0.0010442765],"category_scores_gemma":[0.54994565,0.0006613075,0.0030321332,0.0050826166,0.002299328,0.002617935,0.004126958,0.0023112502,0.00016922218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070974283,0.00016175254,0.8990188,0.0023994632,0.007814077,0.0002663366,0.0063138087,0.0021336342,0.0011027867,0.010277765,0.0081733335,0.061628524],"study_design_scores_gemma":[0.0002879762,0.00041007655,0.89601225,0.0030626198,0.006395167,0.0021172683,0.0049173883,0.008763201,0.00813133,0.0469997,0.02263329,0.00026989466],"about_ca_topic_score_codex":0.0050040125,"about_ca_topic_score_gemma":0.0045512267,"teacher_disagreement_score":0.7896795,"about_ca_system_score_codex":0.002092448,"about_ca_system_score_gemma":0.0018365197,"threshold_uncertainty_score":0.97381544},"labels":[],"label_agreement":null},{"id":"W2039074033","doi":"10.2165/11539450-000000000-00000","title":"A Systematic Review to Assess the Policy-Making Relevance of Dementia Cost-of-Illness Studies in the US and Canada","year":2010,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Stroke Network; McMaster University","funders":"","keywords":"Dementia; CINAHL; Relevance (law); EconLit; Cochrane Library; MEDLINE; Medicaid; Medicine; Health administration; Public health; Psychology; Gerontology; Psychiatry; Health care; Nursing; Alternative medicine; Psychological intervention; Political science; Pathology","score_opus":0.49726007890058127,"score_gpt":0.5555469059657333,"score_spread":0.058286827065152036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039074033","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014584048,0.9950169,0.00022462814,0.00080196466,0.0002572264,0.0006888248,0.00095932593,0.000008135371,0.00058464543],"genre_scores_gemma":[0.04488227,0.94961023,0.0021546264,0.0013148916,0.00013374239,0.0010940306,0.0005640073,0.000009676291,0.00023656731],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9781888,0.007620295,0.0060202647,0.0009171962,0.00641465,0.0008387003],"domain_scores_gemma":[0.9264592,0.04366636,0.010171524,0.0011816943,0.01691109,0.0016100964],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.03250075,0.0017599971,0.0105247,0.020757036,0.0017784974,0.004902055,0.0026790714,0.0024808308,0.0036912132],"category_scores_gemma":[0.14820777,0.0011777781,0.008945387,0.024082534,0.0017407667,0.0021370212,0.0025183966,0.0023727934,0.00017293495],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010425113,0.000042782216,0.003809635,0.8721782,0.04261493,0.00018426136,0.0003116527,0.00059779134,0.00016989771,0.0014409265,0.0060836067,0.07152375],"study_design_scores_gemma":[0.0014371435,0.00017771377,0.016258342,0.74373364,0.20384048,0.00025577095,0.00032970367,0.00037783233,0.00019979393,0.0010838254,0.032230016,0.000075759126],"about_ca_topic_score_codex":0.44286045,"about_ca_topic_score_gemma":0.71803045,"teacher_disagreement_score":0.96749926,"about_ca_system_score_codex":0.042487554,"about_ca_system_score_gemma":0.12173506,"threshold_uncertainty_score":0.88056546},"labels":[],"label_agreement":null},{"id":"W2040131196","doi":"10.1007/s40273-013-0077-y","title":"Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Capital District Health Authority","funders":"National Institute for Health and Care Research","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Health informatics; Health services research; Medicine; Data science; Management science; Computer science; Nursing; Economics","score_opus":0.18154876757317873,"score_gpt":0.47075395266461867,"score_spread":0.28920518509143994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040131196","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023425788,0.10995544,0.305655,0.5204493,0.004820859,0.00037574256,0.0030038387,0.0009761555,0.03133794],"genre_scores_gemma":[0.48667824,0.12482282,0.36091882,0.014748765,0.0052530393,0.0012048306,0.0020219607,0.00039858138,0.003952924],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.986963,0.00823324,0.0013980045,0.0010265994,0.0018601409,0.0005191238],"domain_scores_gemma":[0.83989835,0.12681021,0.011122865,0.0042766477,0.0148381125,0.003053814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029615367,0.0023862864,0.003362791,0.013038174,0.0028482312,0.017586486,0.004261825,0.0073484033,0.011061025],"category_scores_gemma":[0.1702049,0.0013521746,0.0021926172,0.013887026,0.008601711,0.06807337,0.008199969,0.009196983,0.0018462796],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006806119,0.0004043955,0.016195618,0.005900635,0.0010957244,0.00082221,0.0067618955,0.041070785,0.0003239128,0.24561156,0.061577734,0.6195548],"study_design_scores_gemma":[0.00007375453,0.00013586949,0.0024938097,0.0022724506,0.00023869162,0.00021943025,0.007548104,0.014092922,0.00017425287,0.9208976,0.051644232,0.00020877646],"about_ca_topic_score_codex":0.024624176,"about_ca_topic_score_gemma":0.025487576,"teacher_disagreement_score":0.029615367,"about_ca_system_score_codex":0.00690172,"about_ca_system_score_gemma":0.014662821,"threshold_uncertainty_score":0.15662295},"labels":[],"label_agreement":null},{"id":"W2040573992","doi":"10.2165/00019053-200321080-00004","title":"The Cost Effectiveness of ACE Inhibitors as First-Line Antihypertensive Therapy","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Observational study; Left ventricular hypertrophy; Combination therapy; Internal medicine; Cost effectiveness; Pharmacotherapy; Fenoldopam; ACE inhibitor; Antihypertensive drug; Pharmacoeconomics; Cardiology; Intensive care medicine; Physical therapy; Blood pressure; Angiotensin-converting enzyme","score_opus":0.044894476780071635,"score_gpt":0.33491569550029837,"score_spread":0.29002121872022674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040573992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9209402,0.069171034,0.00014800987,0.0018424449,0.0002478602,0.000102112834,0.0021445532,0.0000072520693,0.0053964835],"genre_scores_gemma":[0.98646486,0.01135519,0.00017950512,0.00050337793,0.00017182162,0.000052148927,0.0008240189,0.000004496923,0.00044468557],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99481297,0.003961816,0.00028283635,0.0001383138,0.0005015888,0.00030238874],"domain_scores_gemma":[0.9879787,0.009143044,0.001381031,0.0003739228,0.0006055892,0.00051772885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004036668,0.0005652606,0.001756743,0.001369752,0.00035649523,0.0013220318,0.0007265786,0.0012277482,0.0025115209],"category_scores_gemma":[0.018850977,0.00045354723,0.0039666216,0.002145205,0.0004967284,0.00171351,0.0006176558,0.001497386,0.00012139952],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4318121,0.0049309027,0.29326668,0.0076457495,0.047124404,0.0006926296,0.00047875932,0.009365278,0.0014380213,0.0052124932,0.004658898,0.1933741],"study_design_scores_gemma":[0.033442102,0.027847435,0.85704,0.0014306593,0.05985156,0.0011101459,0.0011794615,0.0046769762,0.0012968045,0.002730891,0.009205764,0.0001882427],"about_ca_topic_score_codex":0.015704054,"about_ca_topic_score_gemma":0.022153957,"teacher_disagreement_score":0.015704054,"about_ca_system_score_codex":0.0033667837,"about_ca_system_score_gemma":0.0017000904,"threshold_uncertainty_score":0.031225324},"labels":[],"label_agreement":null},{"id":"W2042919218","doi":"10.1007/s40273-014-0183-5","title":"Decision-Analytic Models: Current Methodological Challenges","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Computer science; Health care; Probabilistic logic; Management science; Risk analysis (engineering); Operations research; Set (abstract data type); Actuarial science; Economics; Medicine; Artificial intelligence; Engineering","score_opus":0.8275456816076244,"score_gpt":0.5732696120548255,"score_spread":0.2542760695527989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042919218","genre_codex":"methods","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050804787,0.0639295,0.7531652,0.16627415,0.00244111,0.00049172,0.001060558,0.00027762767,0.0072796918],"genre_scores_gemma":[0.31611434,0.10844445,0.52090126,0.03203834,0.013439543,0.0036924924,0.0012687007,0.00040764624,0.0036932211],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.88918746,0.09525705,0.0040359055,0.00397331,0.0067225145,0.0008237378],"domain_scores_gemma":[0.41078955,0.55903256,0.0068548294,0.0080009075,0.013318315,0.0020039214],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.18265967,0.002485774,0.0062371227,0.0041469624,0.001908297,0.017557783,0.012732917,0.008310656,0.007297667],"category_scores_gemma":[0.39372653,0.0022579634,0.002283684,0.006639153,0.013376497,0.015925286,0.0062370873,0.016186856,0.002070539],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023030014,0.0005242239,0.0029300035,0.002692403,0.0007378352,0.00009069173,0.0006153455,0.029895838,0.00006212043,0.8433447,0.016727082,0.10214956],"study_design_scores_gemma":[0.0001186464,0.000036406742,0.00031356394,0.00090632803,0.000092135204,0.00003532336,0.00042785943,0.054850675,0.000038438186,0.9315258,0.011621086,0.000033613687],"about_ca_topic_score_codex":0.013758513,"about_ca_topic_score_gemma":0.01017711,"teacher_disagreement_score":0.8173403,"about_ca_system_score_codex":0.0078645125,"about_ca_system_score_gemma":0.013755764,"threshold_uncertainty_score":0.9660082},"labels":[],"label_agreement":null},{"id":"W2043000760","doi":"10.2165/11584810-000000000-00000","title":"Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Astellas Pharma; Pfizer","keywords":"Anidulafungin; Fluconazole; Invasive candidiasis; Health economics; Pharmacoeconomics; Quality of Life Research; Public health; Resource (disambiguation); Health administration; Medicine; Business; Intensive care medicine; Antifungal; Computer science; Nursing; Caspofungin","score_opus":0.0969956000448805,"score_gpt":0.33484317685723564,"score_spread":0.23784757681235513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043000760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938584,0.0029809736,0.00026744462,0.0021075073,0.000034627017,0.000018040437,0.0019019933,0.000010685323,0.0032927778],"genre_scores_gemma":[0.99844533,0.0006161802,0.00012714165,0.00010049066,0.000017527225,0.000008670146,0.0005031438,0.0000020892344,0.0001794829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99940526,0.00028696895,0.00005543668,0.000032568016,0.00009248964,0.0001273393],"domain_scores_gemma":[0.99852055,0.00070323556,0.00039401467,0.00003966737,0.00011264545,0.00023000303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042162757,0.00016881138,0.00029557306,0.0007445311,0.00021755355,0.00056220515,0.00036134676,0.00057688024,0.0035541467],"category_scores_gemma":[0.00485804,0.00016823516,0.0013021599,0.0011834155,0.00018154926,0.00046119795,0.0003554659,0.0005970505,0.0001546958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003936017,0.0006112743,0.9127145,0.0001962444,0.0012476105,0.001387227,0.00010202729,0.015879145,0.00096941536,0.0023730032,0.004191343,0.05639213],"study_design_scores_gemma":[0.00015356913,0.00050079497,0.9727623,0.0001016324,0.00052489416,0.0020974453,0.00053649786,0.01999807,0.0002707206,0.0011141822,0.0019145983,0.000025268406],"about_ca_topic_score_codex":0.025511239,"about_ca_topic_score_gemma":0.025952877,"teacher_disagreement_score":0.025511239,"about_ca_system_score_codex":0.0023149224,"about_ca_system_score_gemma":0.00096866925,"threshold_uncertainty_score":0.05072546},"labels":[],"label_agreement":null},{"id":"W2043132614","doi":"10.2165/00019053-200018050-00003","title":"Health-Related Quality-of-Life Measurement in Hypertension","year":2000,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval","funders":"","keywords":"Medicine; Quality of life (healthcare); Tolerability; Adverse effect; MEDLINE; Health economics; Alternative medicine; Disease; Gerontology; Public health; Intensive care medicine; Physical therapy; Internal medicine; Pathology; Nursing","score_opus":0.3210045973917947,"score_gpt":0.4249187854935109,"score_spread":0.10391418810171621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043132614","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031762323,0.99937636,0.000031459847,0.00006670435,0.000030761454,0.0000068318345,0.000034442328,0.0000012613517,0.00013474535],"genre_scores_gemma":[0.003637214,0.9959203,0.00020111252,0.00011640698,0.000036435966,0.000015701295,0.000031816162,4.4761344e-7,0.000040588533],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99897087,0.00035020098,0.00026847076,0.000105867526,0.0002731421,0.00003148429],"domain_scores_gemma":[0.9970145,0.00229228,0.00043666505,0.000034313834,0.00018273167,0.000039530707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002393765,0.0007910587,0.0038163627,0.0036530213,0.00018354903,0.0009096083,0.00068964966,0.00069847493,0.0019533082],"category_scores_gemma":[0.0046911757,0.00032440398,0.0020558545,0.006773991,0.0003784647,0.0008119836,0.00058156153,0.0007356261,0.00018553472],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040700415,0.000100199315,0.0032244413,0.16453391,0.005347507,0.00012283857,0.00009109576,0.00027953248,0.00026910874,0.000615122,0.005034974,0.81997424],"study_design_scores_gemma":[0.0018656565,0.0017145321,0.1460657,0.37102172,0.07106549,0.0035693354,0.001022777,0.0010289008,0.00148494,0.004595881,0.39632577,0.00023933977],"about_ca_topic_score_codex":0.004037157,"about_ca_topic_score_gemma":0.010726906,"teacher_disagreement_score":0.004037157,"about_ca_system_score_codex":0.0008981092,"about_ca_system_score_gemma":0.0013386027,"threshold_uncertainty_score":0.012659609},"labels":[],"label_agreement":null},{"id":"W2043943400","doi":"10.1007/s40273-013-0035-8","title":"A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Dabigatran; Medicine; Warfarin; Quality-adjusted life year; Stroke (engine); Cost effectiveness; Atrial fibrillation; Health economics; Markov model; Actuarial science; Statistics; Public health; Markov chain; Risk analysis (engineering); Internal medicine; Mathematics","score_opus":0.2647009948908782,"score_gpt":0.46447964092576055,"score_spread":0.19977864603488232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043943400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74363613,0.06731589,0.14213537,0.0038301507,0.0011986126,0.0034309272,0.009996162,0.00072077906,0.027736034],"genre_scores_gemma":[0.9590124,0.008014532,0.027189834,0.00032713043,0.00011668267,0.0019100485,0.0020684195,0.00012932332,0.0012316116],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.97953475,0.016644798,0.001108918,0.0007732837,0.0013568781,0.00058139785],"domain_scores_gemma":[0.85670066,0.1330286,0.0032083835,0.002024253,0.0045048282,0.0005332273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.038195726,0.0027949973,0.0031496766,0.005876627,0.00062812754,0.0028979613,0.0029990803,0.0027194526,0.004198823],"category_scores_gemma":[0.105229124,0.0012059204,0.008885227,0.0031727417,0.00058103015,0.0023379037,0.0014974581,0.0022198807,0.00027377202],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037677211,0.00041429957,0.007792752,0.002615101,0.0064170943,0.00020355884,0.00014769954,0.94321233,0.00021676351,0.009907056,0.0015989734,0.02370668],"study_design_scores_gemma":[0.0012432395,0.0038418681,0.00859487,0.0017162801,0.007204499,0.0002473082,0.00025897042,0.95969164,0.00060433336,0.013098826,0.0033104667,0.00018777039],"about_ca_topic_score_codex":0.015205205,"about_ca_topic_score_gemma":0.007948256,"teacher_disagreement_score":0.038195726,"about_ca_system_score_codex":0.009496453,"about_ca_system_score_gemma":0.0036195712,"threshold_uncertainty_score":0.20200074},"labels":[],"label_agreement":null},{"id":"W2044932116","doi":"10.1007/s40273-013-0123-9","title":"Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Programs for Assessment of Technology in Health Research Institute","funders":"","keywords":"Computer science; Parametric statistics; Statistics; Statistical model; Parametric model; Logistic regression; Data mining; Econometrics; Machine learning; Mathematics","score_opus":0.585087396856932,"score_gpt":0.5634263158170457,"score_spread":0.021661081039886287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044932116","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016910433,0.006601256,0.9916174,0.00056130206,0.00015548861,0.000025597761,0.000087021224,0.00023418888,0.00054873293],"genre_scores_gemma":[0.016040156,0.02766004,0.94802964,0.000906778,0.0016962643,0.000631662,0.0006031518,0.00059560436,0.0038367359],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9941485,0.0039999527,0.00047210287,0.0005365419,0.00072447845,0.00011839492],"domain_scores_gemma":[0.9635969,0.03349503,0.00062664173,0.00085598737,0.0012279708,0.00019755699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017459393,0.003305833,0.0037493904,0.003171365,0.0005076697,0.0024835935,0.0036836434,0.0038399547,0.0068862094],"category_scores_gemma":[0.04650182,0.0024590036,0.003933174,0.0041694464,0.002080533,0.004041051,0.00269051,0.009640633,0.0041385996],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009964009,0.00023109655,0.0011906459,0.0017500604,0.0005434209,0.0003439777,0.0004567609,0.17422745,0.0011909406,0.5150424,0.034091264,0.27083242],"study_design_scores_gemma":[0.000049409107,0.00007017523,0.00032726483,0.0004163409,0.00008487714,0.00026491864,0.000041974457,0.41650277,0.0004963829,0.5484274,0.03321831,0.00010020064],"about_ca_topic_score_codex":0.004788597,"about_ca_topic_score_gemma":0.0036284626,"teacher_disagreement_score":0.017459393,"about_ca_system_score_codex":0.0016834994,"about_ca_system_score_gemma":0.0021345802,"threshold_uncertainty_score":0.092335224},"labels":[],"label_agreement":null},{"id":"W2045226478","doi":"10.2165/00019053-200523120-00002","title":"Comment on ???The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and the Timing of Development???","year":2005,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Health Economics","funders":"","keywords":"Drug development; Drug; Pharmaceutical industry; Competition (biology); Drug class; Medicine; Marketing; Pharmacology; Business; Actuarial science","score_opus":0.17386903855911948,"score_gpt":0.36626858022991754,"score_spread":0.19239954167079806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045226478","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003523272,0.0005126563,0.0000670012,0.98435366,0.011631911,0.000016246364,0.0002893733,0.000022747387,0.0027540138],"genre_scores_gemma":[0.0017201825,0.00027652443,0.00007874183,0.97818416,0.012997053,0.000027061571,0.000038429982,0.000013439368,0.0066645434],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946044,0.0011300063,0.0008327512,0.00083446765,0.0013706676,0.0012276529],"domain_scores_gemma":[0.9796907,0.012654208,0.0018645218,0.00050764176,0.002939349,0.0023436546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008057238,0.0010540024,0.0024326942,0.0012711805,0.004376702,0.006700984,0.0035773234,0.105521895,0.010311934],"category_scores_gemma":[0.040201202,0.0012734218,0.002039575,0.0016142926,0.0033609888,0.0049821655,0.0020354532,0.05021001,0.00817336],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000819176,0.00002902419,0.0006951816,0.000042896358,0.000019635136,0.0003695296,0.00010109071,0.00007081425,0.00006267766,0.0028745707,0.99300283,0.0026498726],"study_design_scores_gemma":[0.00027758002,0.00013759239,0.0069192005,0.00063268776,0.00012330904,0.000632227,0.00102612,0.0011116625,0.0004476534,0.015169331,0.9733334,0.00018915761],"about_ca_topic_score_codex":0.051275145,"about_ca_topic_score_gemma":0.074519366,"teacher_disagreement_score":0.105521895,"about_ca_system_score_codex":0.010257457,"about_ca_system_score_gemma":0.009346694,"threshold_uncertainty_score":0.10195339},"labels":[],"label_agreement":null},{"id":"W2046221591","doi":"10.2165/00019053-200523110-00003","title":"Antiviral Agents for Influenza","year":2005,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Programs for Assessment of Technology in Health Research Institute; University of British Columbia","funders":"","keywords":"Medicine; Zanamivir; Rimantadine; Intensive care medicine; Oseltamivir; Economic evaluation; MEDLINE; Population; Cost effectiveness; Health economics; Vaccination; Amantadine; Public health; Influenza A virus; Disease; Environmental health; Internal medicine; Immunology; Virology; Virus; Infectious disease (medical specialty)","score_opus":0.3813457548146653,"score_gpt":0.5646355491973175,"score_spread":0.1832897943826522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046221591","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007577878,0.99818844,0.000065803666,0.0003118391,0.0002514399,0.000014304926,0.000027427934,0.000004438586,0.0010605021],"genre_scores_gemma":[0.0008092594,0.99734336,0.00020322877,0.0005807842,0.00028552147,0.000018726143,0.00003590901,9.0243043e-7,0.000722205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995123,0.0001499856,0.00010646531,0.00004856973,0.00014232348,0.00004034652],"domain_scores_gemma":[0.9992889,0.00031397253,0.00023227601,0.00002381484,0.000102811595,0.00003815321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012161407,0.0012092101,0.0021378847,0.0032700421,0.0002464985,0.00090173323,0.00072271755,0.001276663,0.0076032933],"category_scores_gemma":[0.0016916984,0.00032216427,0.0009851828,0.0027103224,0.00039902076,0.0010594033,0.0006641605,0.001613621,0.0018744647],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016081132,0.00007123692,0.00012399201,0.024883969,0.0002861129,0.00017063868,0.000031554267,0.00015731265,0.000717863,0.0013052396,0.032894716,0.9391966],"study_design_scores_gemma":[0.00023549015,0.00028967633,0.0015264995,0.019036831,0.0010369361,0.0011788754,0.00005696074,0.000086429805,0.00039841517,0.0010672194,0.97507167,0.000014926819],"about_ca_topic_score_codex":0.0019263568,"about_ca_topic_score_gemma":0.0070266556,"teacher_disagreement_score":0.0076032933,"about_ca_system_score_codex":0.0008804519,"about_ca_system_score_gemma":0.0015955826,"threshold_uncertainty_score":0.025435507},"labels":[],"label_agreement":null},{"id":"W2047003881","doi":"10.2165/00019053-200119070-00002","title":"A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs","year":2001,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Fogarty International Center","keywords":"Health economics; Quality of Life Research; Antirheumatic drugs; Medicine; Public health; Health administration; Antirheumatic Agents; Disease; Pharmacoeconomics; Intensive care medicine; Internal medicine; Pathology","score_opus":0.08164672349616478,"score_gpt":0.45443617150456594,"score_spread":0.3727894480084012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047003881","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009631667,0.99897385,0.000041044896,0.0004393988,0.00011653673,0.000009381423,0.00002616143,0.0000013370637,0.0002959082],"genre_scores_gemma":[0.001783919,0.99736494,0.00020261429,0.0003294612,0.00016392485,0.000014889893,0.000031759682,7.8970373e-7,0.00010765865],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99698997,0.0009941135,0.00057928805,0.0001473444,0.0011767846,0.00011252492],"domain_scores_gemma":[0.9930606,0.0045505115,0.001268579,0.000079349345,0.0008967332,0.00014426226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048122457,0.0010295734,0.003373679,0.0051490897,0.00028546076,0.0016710907,0.0009986312,0.0013798047,0.0033903099],"category_scores_gemma":[0.012002786,0.00042882055,0.0013690379,0.008220059,0.00056447263,0.0011358367,0.00062714383,0.0014305714,0.00035354157],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007858685,0.000120421035,0.00066238386,0.11174993,0.0017975745,0.00019980688,0.00004614803,0.00070133194,0.0002635178,0.0034701903,0.042289905,0.837913],"study_design_scores_gemma":[0.0012834767,0.00063025544,0.013496451,0.13181368,0.010756098,0.002376948,0.00017263004,0.0008767804,0.00033897228,0.0048168446,0.83337104,0.00006674817],"about_ca_topic_score_codex":0.0038156393,"about_ca_topic_score_gemma":0.010062206,"teacher_disagreement_score":0.0051490897,"about_ca_system_score_codex":0.002626073,"about_ca_system_score_gemma":0.004522224,"threshold_uncertainty_score":0.025449872},"labels":[],"label_agreement":null},{"id":"W2047186977","doi":"10.1007/s40273-014-0145-y","title":"Methods for Adjusting for Bias Due to Crossover in Oncology Trials","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TransCanada (Canada)","funders":"Pfizer","keywords":"Crossover; Crossover study; Censoring (clinical trials); Medicine; Randomized controlled trial; Treatment effect; Computer science; Statistics; Intensive care medicine; Mathematics; Internal medicine; Machine learning","score_opus":0.8723868667747371,"score_gpt":0.7400603947834757,"score_spread":0.13232647199126135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047186977","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019560817,0.0044338335,0.98904574,0.0015327011,0.0005691119,0.0009853385,0.00036301045,0.00048875023,0.0006253858],"genre_scores_gemma":[0.10381452,0.0034571243,0.87521666,0.002415489,0.0015942968,0.010011347,0.00072933565,0.0005115539,0.002249687],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.5509043,0.41446084,0.013131419,0.009111953,0.011258361,0.0011332108],"domain_scores_gemma":[0.17319365,0.770964,0.01711216,0.031722207,0.005976224,0.0010317153],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.37857318,0.0032360784,0.006703095,0.005790197,0.0011760427,0.0047439723,0.0065265144,0.0054495153,0.008846895],"category_scores_gemma":[0.66350883,0.0026757799,0.007896032,0.005749519,0.0041127503,0.005715091,0.0043766,0.009208065,0.0011528598],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063058897,0.0004328941,0.018415054,0.007837432,0.026791355,0.00056946283,0.0014597328,0.05155476,0.00070539484,0.30323508,0.021300364,0.56139266],"study_design_scores_gemma":[0.0036359732,0.0008552172,0.0049756714,0.0017876861,0.0064763273,0.000660248,0.000121500685,0.19306183,0.0013274988,0.7678697,0.019035116,0.00019320815],"about_ca_topic_score_codex":0.0020507337,"about_ca_topic_score_gemma":0.001587618,"teacher_disagreement_score":0.6214268,"about_ca_system_score_codex":0.0029926994,"about_ca_system_score_gemma":0.006269831,"threshold_uncertainty_score":0.7663299},"labels":[],"label_agreement":null},{"id":"W2047422349","doi":"10.2165/00019053-200523100-00003","title":"Pharmacological Management of Overactive Bladder","year":2005,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; McGill University; Canadian Association of Radiation Oncology","funders":"","keywords":"Overactive bladder; Oxybutynin; Tolterodine; Medicine; Discontinuation; Pharmacoeconomics; Cost effectiveness; Intensive care medicine; Urinary incontinence; Health economics; Economic evaluation; Pharmacotherapy; Urology; Internal medicine; Public health; Alternative medicine; Nursing","score_opus":0.14290427449321239,"score_gpt":0.4967414699887055,"score_spread":0.3538371954954931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047422349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010775138,0.9990621,0.00007717355,0.0001398459,0.000097913486,0.000006067785,0.000014181525,0.0000038657568,0.00049108296],"genre_scores_gemma":[0.000884231,0.9982855,0.0001892464,0.00024971453,0.0001293624,0.0000069159514,0.000023211347,7.715541e-7,0.0002309942],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99967885,0.00006868299,0.000072948154,0.000052175827,0.000104936014,0.000022335518],"domain_scores_gemma":[0.9993536,0.00038970754,0.00014851577,0.000010896979,0.000071890034,0.000025406742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067745405,0.00096418284,0.0026243324,0.0030557022,0.00022569355,0.0008348786,0.0008672667,0.0011127071,0.0040038875],"category_scores_gemma":[0.0013429705,0.00033779553,0.0011016589,0.0025193393,0.00034749683,0.0008180037,0.00048505754,0.0015853619,0.00079919666],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018700569,0.00011269967,0.00024787863,0.0426014,0.0006010285,0.00027491647,0.000037510013,0.00027149677,0.0005969385,0.00079860236,0.01256013,0.94171035],"study_design_scores_gemma":[0.0006238811,0.00068575377,0.00856376,0.052826855,0.0042407876,0.0053708497,0.00018285676,0.0004624827,0.0008465357,0.002016198,0.9241068,0.000073220624],"about_ca_topic_score_codex":0.002083871,"about_ca_topic_score_gemma":0.005395043,"teacher_disagreement_score":0.0040038875,"about_ca_system_score_codex":0.0005440725,"about_ca_system_score_gemma":0.0009556841,"threshold_uncertainty_score":0.013394296},"labels":[],"label_agreement":null},{"id":"W2052610701","doi":"10.2165/00019053-200624110-00010","title":"Building Bridges Between Academic Research and Policy Formulation","year":2006,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Health and Long Term Care; University of Toronto; McMaster University","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Health services research; Health care management; Management science; Public economics; Economics; Political science; Engineering ethics; Medicine; Engineering; Nursing","score_opus":0.5756712662218212,"score_gpt":0.6532551146880488,"score_spread":0.07758384846622757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052610701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018078231,0.9494082,0.0027814796,0.039329078,0.0017222861,0.000030941246,0.000016923179,0.000030159506,0.0065002767],"genre_scores_gemma":[0.009617395,0.96514434,0.009069337,0.013244512,0.0012810866,0.00013096462,0.000032417625,0.0000137936995,0.0014662392],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9793173,0.013604035,0.0012584704,0.000986686,0.0038788023,0.00095461943],"domain_scores_gemma":[0.90619135,0.079682894,0.0042916457,0.002047047,0.006440659,0.001346409],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.055533566,0.0019643577,0.004467593,0.010047691,0.0019877146,0.014016393,0.0036053653,0.011672137,0.009019708],"category_scores_gemma":[0.06849072,0.0014088209,0.0012448154,0.013763217,0.009280285,0.02345339,0.0073818243,0.011505265,0.0020819928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068160996,0.0001233275,0.00035372726,0.024135556,0.0004293786,0.00026082026,0.0013773384,0.0014595245,0.00030345158,0.48756725,0.062075272,0.4218462],"study_design_scores_gemma":[0.00010256034,0.000049656177,0.00066034705,0.04415437,0.0002710665,0.00016124977,0.0021308071,0.00045050957,0.00022248605,0.22873455,0.7230227,0.000039744005],"about_ca_topic_score_codex":0.0074598035,"about_ca_topic_score_gemma":0.016233243,"teacher_disagreement_score":0.9444664,"about_ca_system_score_codex":0.012233973,"about_ca_system_score_gemma":0.037858266,"threshold_uncertainty_score":0.29369313},"labels":[],"label_agreement":null},{"id":"W2053187674","doi":"10.2165/00019053-200220110-00002","title":"Cost Effectiveness of Implantable Cardioverter Defibrillator Therapy versus Drug Therapy for Patients at High Risk of Sudden Cardiac Death","year":2002,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Cardiac pacing and defibrillation studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Health and Medical Research Council","keywords":"Medicine; Ventricular fibrillation; Ventricular tachycardia; Implantable cardioverter-defibrillator; Sudden cardiac death; Amiodarone; Cost effectiveness; Intensive care medicine; Clinical trial; Pharmacotherapy; Internal medicine; Emergency medicine; Atrial fibrillation; Risk analysis (engineering)","score_opus":0.08632814917779946,"score_gpt":0.3784360256998538,"score_spread":0.29210787652205433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053187674","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045985254,0.99448735,0.00007813848,0.00018295011,0.00007885729,0.000026740643,0.00015656195,0.0000023958123,0.00038849824],"genre_scores_gemma":[0.055829167,0.9427849,0.0005076878,0.0003561259,0.00013551237,0.000057298235,0.00014777192,0.0000027036733,0.00017876072],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99897885,0.00051763223,0.00019089485,0.000082069266,0.00019387549,0.000036690875],"domain_scores_gemma":[0.99681455,0.0026044778,0.00038766343,0.000023166518,0.000132926,0.000037188285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019630324,0.00064480526,0.003897282,0.0013125014,0.00012399553,0.0007108248,0.0006387448,0.0006862048,0.0034170044],"category_scores_gemma":[0.006113697,0.00029779572,0.0035345207,0.0019510466,0.00023467804,0.00053734117,0.00029854538,0.0008797471,0.00012156148],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019401303,0.00028159612,0.005920523,0.32338458,0.06141229,0.000318831,0.00012164766,0.0023655568,0.000763072,0.0014199921,0.005199654,0.579411],"study_design_scores_gemma":[0.03132711,0.011450932,0.08050162,0.16100164,0.5733425,0.0032126799,0.0005728508,0.0027856375,0.0020659596,0.0047715423,0.12878448,0.00018303824],"about_ca_topic_score_codex":0.0028694007,"about_ca_topic_score_gemma":0.007765836,"teacher_disagreement_score":0.003897282,"about_ca_system_score_codex":0.0012928722,"about_ca_system_score_gemma":0.0010770372,"threshold_uncertainty_score":0.011431038},"labels":[],"label_agreement":null},{"id":"W2054744500","doi":"10.2165/00019053-200119090-00006","title":"The Cost of Palliative Care for Hepatocellular Carcinoma in Hong Kong","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Palliative care; Health economics; Liver cancer; Health care; Health administration; Cost effectiveness; Observational study; Total cost; Emergency medicine; Public health; Demography; Internal medicine; Nursing; Business","score_opus":0.1413662426449138,"score_gpt":0.43021783059366614,"score_spread":0.2888515879487523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054744500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962204,0.0010009565,0.000042662272,0.0010293523,0.000024237119,0.000018039,0.00052869134,0.0000024277774,0.00113328],"genre_scores_gemma":[0.99864024,0.00062272546,0.00004249935,0.000118101605,0.000012267613,0.000009952833,0.00016390187,9.562361e-7,0.00038922814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995683,0.00014085324,0.00007180816,0.000025202928,0.000047851066,0.00014589807],"domain_scores_gemma":[0.9982133,0.00033500232,0.0005568286,0.000046074947,0.00021844936,0.0006304113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044417623,0.00019291569,0.00032991768,0.00065385574,0.00061510125,0.0010399019,0.00041124568,0.00052834844,0.0016116872],"category_scores_gemma":[0.0020613365,0.0003208172,0.0007617638,0.0012708155,0.0005080993,0.0005650567,0.0008303663,0.0007251988,0.0000718456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005504971,0.00012915123,0.9802398,0.00020385631,0.0002805049,0.0031603468,0.00068189704,0.0026741533,0.00025782094,0.00076963595,0.0018507569,0.00920163],"study_design_scores_gemma":[0.00005672017,0.00019720141,0.989027,0.000104359686,0.00017896328,0.0012482106,0.0030414243,0.0045237094,0.00008672763,0.00011130569,0.0013954412,0.000028790173],"about_ca_topic_score_codex":0.38615558,"about_ca_topic_score_gemma":0.34802377,"teacher_disagreement_score":0.38615558,"about_ca_system_score_codex":0.012241799,"about_ca_system_score_gemma":0.0046545025,"threshold_uncertainty_score":0.7678158},"labels":[],"label_agreement":null},{"id":"W2054892688","doi":"10.2165/00019053-200826020-00002","title":"Management of Anaemia","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Darbepoetin alfa; Epoetin alfa; Intensive care medicine; Health economics; Disease; Kidney disease; Pharmacoeconomics; Cost effectiveness; Erythropoietin; Anemia; Clinical trial; Public health; Internal medicine; Risk analysis (engineering); Pathology","score_opus":0.06135507168500458,"score_gpt":0.3980985499857165,"score_spread":0.3367434783007119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054892688","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013559831,0.99784005,0.00028429093,0.00041844905,0.0001802239,0.000010166896,0.000015551857,0.000008365836,0.0011072988],"genre_scores_gemma":[0.002439393,0.99446976,0.00084571436,0.0009331483,0.00041451803,0.000019501867,0.00007812458,0.0000027185092,0.0007970634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99953365,0.000118395896,0.00008307328,0.00006669583,0.00016053175,0.000037681923],"domain_scores_gemma":[0.99958295,0.00020541974,0.00009310261,0.000011739179,0.000080127305,0.000026790085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078182784,0.0010008872,0.002045354,0.0024995997,0.00027401227,0.0009748232,0.0010450318,0.0011771073,0.0040679425],"category_scores_gemma":[0.0015762713,0.00027321742,0.00093248533,0.0015686227,0.00041769826,0.00072033604,0.0007390157,0.0020197635,0.0011641934],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011103005,0.00008493735,0.00033492173,0.0136388,0.00021404399,0.00030767094,0.000031150066,0.00018949417,0.0004702889,0.0012183513,0.020931052,0.9624682],"study_design_scores_gemma":[0.00036333103,0.0002611311,0.0057085035,0.036003016,0.001351588,0.009400671,0.000121789824,0.00041090112,0.0009689687,0.0037751584,0.94158584,0.0000490919],"about_ca_topic_score_codex":0.0023700488,"about_ca_topic_score_gemma":0.0035168552,"teacher_disagreement_score":0.0040679425,"about_ca_system_score_codex":0.00061065255,"about_ca_system_score_gemma":0.0012016469,"threshold_uncertainty_score":0.013608575},"labels":[],"label_agreement":null},{"id":"W2055026645","doi":"10.1007/s40273-014-0239-6","title":"Objectivity and Equity: Clarity Required. A Response to Hill and Olson","year":2014,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta","funders":"Canadian Institutes of Health Research; Health Research Board","keywords":"CLARITY; Quality of Life Research; Equity (law); Health economics; Objectivity (philosophy); Positive economics; Public health; Economics; Political science; Sociology; Epistemology; Philosophy; Medicine; Law; Nursing; Chemistry","score_opus":0.39183422357754366,"score_gpt":0.4890259197931236,"score_spread":0.09719169621557994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055026645","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000339096,0.00049589324,0.000055702738,0.9959319,0.0030334457,0.0000033465753,0.000010083218,0.0000044182802,0.00043135835],"genre_scores_gemma":[0.0006906968,0.00020787082,0.00009504902,0.9932861,0.004773448,0.000015612124,0.0000053488866,0.000008274758,0.0009175929],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.96313244,0.015789645,0.0037091887,0.004426521,0.009714034,0.0032282835],"domain_scores_gemma":[0.8637183,0.10645523,0.00531137,0.0032457116,0.014030537,0.0072390027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.045572657,0.0015071731,0.004227912,0.0013895399,0.009280421,0.015518635,0.008268332,0.1253191,0.009699697],"category_scores_gemma":[0.15564422,0.0019448607,0.003208422,0.0018264097,0.026290331,0.023456028,0.009273132,0.15917014,0.00554408],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033035583,0.000022362246,0.00013319436,0.00005910881,0.000013680866,0.00022045881,0.0003851037,0.00003192908,0.000041552717,0.017869515,0.9775034,0.0036866618],"study_design_scores_gemma":[0.00020663533,0.00004233718,0.00076024764,0.0010895778,0.00003806062,0.0006444862,0.001830816,0.00052787876,0.00023406032,0.07101183,0.923439,0.00017508538],"about_ca_topic_score_codex":0.019889953,"about_ca_topic_score_gemma":0.026133869,"teacher_disagreement_score":0.1253191,"about_ca_system_score_codex":0.013028429,"about_ca_system_score_gemma":0.021031043,"threshold_uncertainty_score":0.24101412},"labels":[],"label_agreement":null},{"id":"W2055508765","doi":"10.2165/00019053-200725030-00007","title":"Modelling Cost Effectiveness of Insulin Glargine for the Treatment of Type 1 and 2 Diabetes in Canada","year":2007,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sanofi (Canada)","funders":"Institute for Clinical Evaluative Sciences","keywords":"Medicine; Insulin glargine; Diabetes mellitus; Insulin; Type 2 diabetes; NPH insulin; Internal medicine; United Kingdom Prospective Diabetes Study; Type 1 diabetes; Type 2 Diabetes Mellitus; Quality of Life Research; Intensive care medicine; Endocrinology; Pediatrics; Public health","score_opus":0.04198260012634948,"score_gpt":0.33509967947392305,"score_spread":0.2931170793475736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055508765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95674694,0.0050984905,0.0035983492,0.006629078,0.0002315209,0.00038105075,0.009729271,0.00012683419,0.01745841],"genre_scores_gemma":[0.9922444,0.0011565201,0.0013323696,0.00024037434,0.000028416183,0.000078425786,0.0012033673,0.000023458259,0.0036926551],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99839044,0.00059025397,0.00006271681,0.00014448844,0.00018421492,0.0006278976],"domain_scores_gemma":[0.99072534,0.00626197,0.0005462506,0.0001287152,0.0014132657,0.0009245972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022966494,0.0014509803,0.0020608911,0.0018184234,0.001520447,0.0029309148,0.0029884698,0.0029413104,0.007624005],"category_scores_gemma":[0.0137700355,0.0011599638,0.0024339026,0.0038932299,0.0014183086,0.0010899039,0.0009152436,0.002797142,0.0002572165],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010847469,0.00018915768,0.012101243,0.00016728167,0.0003571876,0.00018440899,0.00007956582,0.974033,0.00007978016,0.0048038494,0.002737142,0.0041827084],"study_design_scores_gemma":[0.0010727572,0.0003217612,0.013464268,0.0001224733,0.00065871305,0.000096518976,0.0005444125,0.9772446,0.00015131167,0.0035512277,0.002677863,0.00009411126],"about_ca_topic_score_codex":0.98407435,"about_ca_topic_score_gemma":0.96970963,"teacher_disagreement_score":0.0677027,"about_ca_system_score_codex":0.0677027,"about_ca_system_score_gemma":0.04413559,"threshold_uncertainty_score":0.49121982},"labels":[],"label_agreement":null},{"id":"W2058547566","doi":"10.2165/11531590-000000000-00000","title":"A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment","year":2010,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Programs for Assessment of Technology in Health Research Institute","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Term (time); Medicine; Diabetes mellitus; Public health; Pharmacoeconomics; Cost effectiveness; Intensive care medicine; Quality-adjusted life year; Type 2 Diabetes Mellitus; Risk analysis (engineering); Nursing; Endocrinology","score_opus":0.20669767070550096,"score_gpt":0.5208117208390047,"score_spread":0.3141140501335038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058547566","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013524161,0.9974491,0.0014402274,0.00029030035,0.0000898065,0.000040081868,0.00011856787,0.00000812361,0.00042844855],"genre_scores_gemma":[0.0018036815,0.99438876,0.0033487163,0.00013735694,0.000080263824,0.00007169002,0.00006555155,0.0000038907383,0.00009996238],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99448204,0.0027228256,0.001107495,0.00036089987,0.0012224166,0.000104312676],"domain_scores_gemma":[0.9796348,0.017620035,0.0013620207,0.00027104147,0.0010188255,0.00009324998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0104958,0.0028765544,0.0079700025,0.007045581,0.0003944632,0.0032931657,0.0036066878,0.0021153097,0.0049889996],"category_scores_gemma":[0.019861355,0.0011119642,0.005785784,0.0120958835,0.00090194936,0.0031337882,0.0009955979,0.0022173284,0.0007485899],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002706103,0.00016089912,0.0005964267,0.19387113,0.004770754,0.00012581596,0.00009648402,0.005962902,0.00019296647,0.015087146,0.009079629,0.7697853],"study_design_scores_gemma":[0.00064345455,0.00089909957,0.008935046,0.31119028,0.037918504,0.0022844495,0.00041527182,0.01259854,0.0011409415,0.056412388,0.5671711,0.00039094547],"about_ca_topic_score_codex":0.006566678,"about_ca_topic_score_gemma":0.010409379,"teacher_disagreement_score":0.0104958,"about_ca_system_score_codex":0.0038763355,"about_ca_system_score_gemma":0.004933086,"threshold_uncertainty_score":0.05550772},"labels":[],"label_agreement":null},{"id":"W2060265964","doi":"10.2165/11530860-000000000-00000","title":"Principles of Design of Access with Evidence Development Approaches","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Assistive Technology in Communication and Mobility","field":"Health Professions","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Business; Medicine; Management science; Economics; Nursing","score_opus":0.5435838607676401,"score_gpt":0.5010077940784446,"score_spread":0.042576066689195446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060265964","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00093734195,0.0027820836,0.9756934,0.004735461,0.00024220759,0.004908705,0.00038041463,0.0001899163,0.0101303775],"genre_scores_gemma":[0.02610785,0.0018184487,0.9600175,0.00066689396,0.00009481715,0.010252595,0.00017240048,0.000031150437,0.0008384276],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.7929871,0.16097097,0.017713746,0.0062400773,0.020410296,0.0016777345],"domain_scores_gemma":[0.66945076,0.29419822,0.007597051,0.0103546865,0.01649246,0.0019068992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.14570795,0.0030878256,0.004156832,0.010266746,0.0027761885,0.013007511,0.007277617,0.0069569233,0.0093701985],"category_scores_gemma":[0.2001968,0.0032612681,0.006816852,0.004584565,0.011008316,0.0051466865,0.00791508,0.0057603777,0.0023436707],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003083258,0.00023638604,0.0009358456,0.01000639,0.0013045897,0.00027734519,0.0031731655,0.014118737,0.00048260618,0.8491318,0.0048470926,0.11517771],"study_design_scores_gemma":[0.0008657315,0.00036585887,0.0003873933,0.008113637,0.0010208314,0.00041336,0.0008679904,0.016615737,0.0016566663,0.8866588,0.08290972,0.00012428529],"about_ca_topic_score_codex":0.002711418,"about_ca_topic_score_gemma":0.0023135925,"teacher_disagreement_score":0.14570795,"about_ca_system_score_codex":0.00740945,"about_ca_system_score_gemma":0.02417121,"threshold_uncertainty_score":0.7705865},"labels":[],"label_agreement":null},{"id":"W2060836363","doi":"10.1007/s40273-014-0244-9","title":"Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis","year":2014,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; AbbVie Canada; Michael Smith Health Research BC; Pfizer","keywords":"Medicine; MEDLINE; Time horizon; Health economics; Health care; Health administration; Cost effectiveness; Economic evaluation; Public health; Risk analysis (engineering); Nursing; Business; Pathology","score_opus":0.12097548477240598,"score_gpt":0.43272456523198516,"score_spread":0.31174908045957916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060836363","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015003309,0.9972771,0.00017638617,0.00015167246,0.00008663806,0.00012190399,0.00046197293,0.000008317686,0.00021572181],"genre_scores_gemma":[0.049281627,0.9482878,0.0010747182,0.00048242323,0.000107104344,0.00018482689,0.0004376261,0.000008205974,0.0001356283],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9918434,0.0038304678,0.0023043163,0.00051263213,0.0012792092,0.0002299082],"domain_scores_gemma":[0.9834705,0.012468516,0.0027222538,0.00028535546,0.0008678371,0.00018551052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008491889,0.0017474723,0.0107189445,0.004810983,0.0003091596,0.0018092212,0.001853885,0.0013493083,0.005244742],"category_scores_gemma":[0.027951296,0.0009477016,0.014241156,0.00647667,0.00061713095,0.0013130234,0.0013067618,0.0017025198,0.00022221774],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025200504,0.000043558157,0.0012426903,0.78255373,0.1527405,0.0001328272,0.000066401095,0.00063471374,0.00022214373,0.00034672412,0.0018175249,0.057679255],"study_design_scores_gemma":[0.00316775,0.000651879,0.010195815,0.17956755,0.7888449,0.00048802394,0.00013585451,0.0003681343,0.0002461326,0.0008362313,0.015435529,0.00006229845],"about_ca_topic_score_codex":0.008262141,"about_ca_topic_score_gemma":0.021086687,"teacher_disagreement_score":0.0107189445,"about_ca_system_score_codex":0.0028205293,"about_ca_system_score_gemma":0.0043879887,"threshold_uncertainty_score":0.044909954},"labels":[],"label_agreement":null},{"id":"W2060853834","doi":"10.2165/00019053-200725050-00003","title":"The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD)","year":2007,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Gastroesophageal reflux and treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; AstraZeneca (Canada); McGill University; McMaster University","funders":"","keywords":"GERD; Reflux; Medicine; Work productivity; Productivity; Esomeprazole; Physical therapy; Internal medicine; Disease","score_opus":0.008155376778851982,"score_gpt":0.28626728982741695,"score_spread":0.278111913048565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060853834","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9578663,0.0037323595,0.00081898714,0.0012400845,0.00026472867,0.0012014144,0.023094561,0.00010484725,0.0116768805],"genre_scores_gemma":[0.9769984,0.0017065504,0.002124832,0.00065858476,0.00012909998,0.0011323853,0.013363193,0.000017364724,0.0038696604],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988418,0.00024601293,0.0003627281,0.00008728176,0.00030431544,0.00015788882],"domain_scores_gemma":[0.99648416,0.0005395451,0.0018152912,0.00010525049,0.00053639134,0.00051941106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016255133,0.000886823,0.0017462531,0.002211822,0.00058770983,0.00082295004,0.00074892817,0.00079532893,0.0036345152],"category_scores_gemma":[0.0055922423,0.00026071686,0.0020638295,0.0019233713,0.00027689952,0.00096063234,0.0014573615,0.0013860659,0.0007673326],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010396409,0.00056699757,0.9682663,0.00041330003,0.0010529401,0.00024091742,0.00021886069,0.0005233668,0.00035623426,0.000106307336,0.0055404487,0.021674749],"study_design_scores_gemma":[0.00010346184,0.00033400595,0.99723816,0.00003081067,0.000102195925,0.00024278928,0.00011148369,0.0002729079,0.00005906879,0.000052650823,0.001437288,0.000015165389],"about_ca_topic_score_codex":0.004876165,"about_ca_topic_score_gemma":0.008689731,"teacher_disagreement_score":0.004876165,"about_ca_system_score_codex":0.00075052603,"about_ca_system_score_gemma":0.00055212807,"threshold_uncertainty_score":0.012158632},"labels":[],"label_agreement":null},{"id":"W2062898140","doi":"10.2165/00019053-200220090-00003","title":"Cost Effectiveness of Tinzaparin Sodium Versus Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Radiation Oncology","funders":"","keywords":"Medicine; Deep vein; Heparin; Enoxaparin sodium; Low molecular weight heparin; Thrombosis; Pharmacoeconomics; Quality-adjusted life year; Cost effectiveness; Clinical trial; Intensive care medicine; Economic evaluation; Internal medicine","score_opus":0.09383213385810416,"score_gpt":0.36446008411330133,"score_spread":0.27062795025519715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062898140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864487,0.008582961,0.00040130946,0.0015240461,0.00016173227,0.00006687719,0.0001713098,0.000023539726,0.0026196267],"genre_scores_gemma":[0.99824905,0.0010251717,0.00017340423,0.00013859868,0.00005302656,0.000016773216,0.000073914496,0.0000018602155,0.00026824555],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99900705,0.0007054379,0.00005696416,0.000055475826,0.00008461482,0.000090508394],"domain_scores_gemma":[0.9987186,0.0007928727,0.00018364916,0.000022621192,0.000037890593,0.00024430818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007477443,0.0004291207,0.0011859919,0.00042250848,0.00022923092,0.00063233543,0.00039831048,0.0008664065,0.0029783838],"category_scores_gemma":[0.0040466012,0.0001721587,0.0011277522,0.00043361145,0.00037426077,0.00059136446,0.00028550977,0.00102264,0.000119035845],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7008674,0.0046548718,0.020990267,0.0009899137,0.004498874,0.0008110041,0.00013421873,0.027902089,0.002589612,0.0023152125,0.002450651,0.23179576],"study_design_scores_gemma":[0.22342178,0.27387992,0.30569908,0.0006743072,0.024244042,0.004069398,0.0010630754,0.1490208,0.004814162,0.005948563,0.0068365084,0.00032833818],"about_ca_topic_score_codex":0.0054374286,"about_ca_topic_score_gemma":0.005615958,"teacher_disagreement_score":0.0054374286,"about_ca_system_score_codex":0.0018679695,"about_ca_system_score_gemma":0.001009357,"threshold_uncertainty_score":0.013553083},"labels":[],"label_agreement":null},{"id":"W2063141697","doi":"10.2165/11587430-000000000-00000","title":"The Impact of Disease Stage on Direct Medical Costs of HIV Management","year":2010,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Advancing Health Outcomes; St. Paul's Hospital; Dalhousie University","funders":"Johnson and Johnson","keywords":"Health economics; Health administration; Public health; Quality of Life Research; Medicine; Pharmacoeconomics; Health care management; Disease; Disease management; Human immunodeficiency virus (HIV); Stage (stratigraphy); Environmental health; Intensive care medicine; Virology; Internal medicine; Nursing","score_opus":0.05005736980866225,"score_gpt":0.47091810087675184,"score_spread":0.4208607310680896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063141697","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00049455516,0.9987908,0.000041241663,0.00015516023,0.00005035567,0.0000031069255,0.000038780403,0.0000011234021,0.00042485594],"genre_scores_gemma":[0.006191975,0.9933751,0.00013963747,0.00008293502,0.000068629895,0.000004589067,0.000034960714,9.104469e-7,0.00010124179],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993606,0.00021199964,0.000087385415,0.00005456203,0.00024003425,0.00004528457],"domain_scores_gemma":[0.99680495,0.0025477132,0.0003456691,0.000023379605,0.00023673377,0.000041637017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013919823,0.00084167655,0.002140188,0.0019551401,0.0001370123,0.0010485346,0.0007868231,0.0008748198,0.00416346],"category_scores_gemma":[0.0045478684,0.0003256146,0.0018789753,0.0031090588,0.0002848871,0.0007173103,0.00042688448,0.0011030792,0.00033840066],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028134813,0.000077727724,0.0022189943,0.049933728,0.003081052,0.000117314004,0.0000397939,0.0009636905,0.00021738536,0.0020859244,0.006959453,0.9340236],"study_design_scores_gemma":[0.0007967967,0.0012066184,0.11986442,0.21118464,0.0494696,0.0055714617,0.0007114454,0.0029948475,0.0016766031,0.011111963,0.59522665,0.00018499437],"about_ca_topic_score_codex":0.0059814863,"about_ca_topic_score_gemma":0.012196689,"teacher_disagreement_score":0.0059814863,"about_ca_system_score_codex":0.0011455357,"about_ca_system_score_gemma":0.0017506492,"threshold_uncertainty_score":0.013928235},"labels":[],"label_agreement":null},{"id":"W2063252993","doi":"10.2165/00019053-200220001-00004","title":"Economic Evaluation of Pioglitazone Hydrochloride in the Management of Type 2 Diabetes Mellitus in Canada","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Eli Lilly (Canada); Ottawa Hospital; University of Ottawa","funders":"Eli Lilly Canada","keywords":"Pioglitazone; Medicine; Type 2 diabetes; Metformin; Rosiglitazone; Diabetes mellitus; Type 2 Diabetes Mellitus; Internal medicine; Repaglinide; Intensive care medicine; Endocrinology","score_opus":0.030143520336680916,"score_gpt":0.2844244656490735,"score_spread":0.25428094531239254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063252993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93966,0.022736084,0.00047574003,0.012637116,0.00027192055,0.00095210504,0.004188353,0.000032937347,0.01904566],"genre_scores_gemma":[0.9946622,0.0031285181,0.00033914432,0.0005426381,0.00004971003,0.00006346573,0.000498333,0.00000399675,0.0007119944],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99529356,0.0023284773,0.0003126516,0.000119211254,0.0013719848,0.0005742065],"domain_scores_gemma":[0.99268734,0.0028521596,0.0008593404,0.00008009884,0.001980112,0.0015409036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003079977,0.00035033605,0.0007896131,0.0014796659,0.0011024477,0.0020028348,0.0008626801,0.000890295,0.002038884],"category_scores_gemma":[0.019698422,0.0002630863,0.0009989514,0.0025360652,0.00056780636,0.00041218195,0.00069421716,0.0010315194,0.00004472515],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.115780324,0.0061514163,0.4235285,0.004851519,0.005670126,0.0020106474,0.0006159097,0.108286485,0.0013545938,0.010140629,0.028200515,0.29340932],"study_design_scores_gemma":[0.019613266,0.010570475,0.79456717,0.001652898,0.0074689025,0.0009030544,0.0023410204,0.1350024,0.0010645869,0.0016761103,0.024916532,0.00022357346],"about_ca_topic_score_codex":0.9207291,"about_ca_topic_score_gemma":0.93638355,"teacher_disagreement_score":0.0792709,"about_ca_system_score_codex":0.060132448,"about_ca_system_score_gemma":0.0763917,"threshold_uncertainty_score":0.43629348},"labels":[],"label_agreement":null},{"id":"W2063999798","doi":"10.2165/00019053-200523120-00008","title":"A Willingness-To-Pay Assessment of Parents?? Preference for Shorter Duration Treatment of Acute Otitis Media in Children","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Ear Surgery and Otitis Media","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Health economics; Quality of Life Research; Willingness to pay; Acute otitis media; Medicine; Public health; Health administration; Duration (music); Otitis; Preference; Environmental health; Economics; Nursing; Surgery","score_opus":0.03556059862634995,"score_gpt":0.35106162035920363,"score_spread":0.31550102173285366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063999798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99804497,0.00023112122,0.00011326145,0.00045140865,0.000011490749,0.000016553606,0.00011770568,0.000001347749,0.0010121108],"genre_scores_gemma":[0.9996265,0.000064729895,0.00012533448,0.000055055083,0.000007016899,0.000009704481,0.000047775877,5.331732e-7,0.00006332578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984114,0.0010046037,0.0001540526,0.00007696465,0.0002256065,0.00012729384],"domain_scores_gemma":[0.9904241,0.0051486115,0.00298456,0.0002259225,0.00044103194,0.00077587535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031596813,0.00020076474,0.0003850229,0.00046485002,0.0002536826,0.0006842692,0.0002971845,0.00087235513,0.0030413782],"category_scores_gemma":[0.018812232,0.00012758301,0.0009202478,0.00055682665,0.0003211872,0.0007404291,0.00033537907,0.0008635651,0.00017354745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017741699,0.00033958885,0.9803618,0.00008250828,0.00020004698,0.00021776902,0.00048458998,0.00035630376,0.00024847884,0.00015248306,0.00036391988,0.015418306],"study_design_scores_gemma":[0.00017841866,0.0021195367,0.9908606,0.00006947904,0.00020362648,0.00097442133,0.0024503912,0.0019304743,0.0002875973,0.00028826843,0.00060804124,0.000029098506],"about_ca_topic_score_codex":0.0027181183,"about_ca_topic_score_gemma":0.0030909877,"teacher_disagreement_score":0.0031596813,"about_ca_system_score_codex":0.0006390175,"about_ca_system_score_gemma":0.00047654816,"threshold_uncertainty_score":0.016710222},"labels":[],"label_agreement":null},{"id":"W2064406802","doi":"10.2165/00019053-200220002-00001","title":"Why Has the Use of Health Economic Evaluation in Japan Lagged Behind that in Other Developed Countries?","year":2002,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada); McMaster University","funders":"","keywords":"Formulary; Reimbursement; Health care; Health economics; Economic evaluation; Business; Health technology; Population health; Health administration; Population; Public economics; Economic growth; Medicine; Economics; Environmental health","score_opus":0.8097905546259976,"score_gpt":0.5352025390544429,"score_spread":0.27458801557155466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064406802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018320815,0.9774244,0.00051047624,0.017783504,0.0005640717,0.000013992564,0.000212173,0.000009929351,0.0016493805],"genre_scores_gemma":[0.033061314,0.9547329,0.002036964,0.008011701,0.0015963076,0.00004001352,0.00024100057,0.00001789669,0.0002617943],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925567,0.0030791971,0.001365105,0.00079254684,0.0017833163,0.00042311553],"domain_scores_gemma":[0.90944827,0.058919966,0.008585744,0.0018850827,0.019502476,0.0016583728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0373873,0.00066793995,0.0029522397,0.0046308017,0.0005550282,0.003787589,0.001506675,0.002564209,0.0020720274],"category_scores_gemma":[0.05229633,0.0005879068,0.0013566408,0.012957939,0.00182795,0.0038948504,0.001112617,0.0043823305,0.0004525697],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005137272,0.00011567821,0.015901707,0.019225989,0.0010903635,0.00015162535,0.00023997262,0.0010421614,0.00025041838,0.02018586,0.027128188,0.9141543],"study_design_scores_gemma":[0.00046354273,0.0007625405,0.26256347,0.060187742,0.004385998,0.0014453594,0.0011437938,0.001830309,0.0011352212,0.017160948,0.648682,0.00023900297],"about_ca_topic_score_codex":0.030024754,"about_ca_topic_score_gemma":0.04448719,"teacher_disagreement_score":0.0373873,"about_ca_system_score_codex":0.0059931045,"about_ca_system_score_gemma":0.014794107,"threshold_uncertainty_score":0.1977253},"labels":[],"label_agreement":null},{"id":"W2064604288","doi":"10.2165/00019053-200119010-00002","title":"The Cost of HIV Treatment and Care","year":2001,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"University of Nottingham","keywords":"Purchasing power parity; Health economics; Context (archaeology); Medicine; Indirect costs; Health care; Total cost; Population; Public health; Purchasing power; Health administration; Economic cost; Formulary; Productivity; Pharmacoeconomics; Environmental health; Gross domestic product; Cost driver; Economics; Economic growth; Intensive care medicine; Family medicine; Geography; Accounting; Nursing","score_opus":0.09981778601993617,"score_gpt":0.46138635784955967,"score_spread":0.3615685718296235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064604288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028371415,0.9958603,0.00009775973,0.0017011571,0.0003700429,0.000007686781,0.0000584821,0.000004074297,0.0016168066],"genre_scores_gemma":[0.0033188183,0.9953561,0.00019211126,0.00045517486,0.00028455578,0.00000920973,0.000037482696,0.0000016621466,0.00034494518],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876606,0.0004063365,0.00014926582,0.00007752535,0.00051447225,0.000086289045],"domain_scores_gemma":[0.99787617,0.0013239232,0.00040637868,0.000036369765,0.00028954825,0.000067646244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014519439,0.0011796408,0.002160592,0.0035127301,0.0003177859,0.0019443757,0.00084835035,0.0018357612,0.0071842247],"category_scores_gemma":[0.0058089728,0.00046483762,0.001196929,0.006827365,0.0007088245,0.001784969,0.0008850157,0.0019845483,0.00071527844],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020451145,0.00006704383,0.0008841512,0.03915213,0.0009759031,0.00018883236,0.00005852822,0.0010192704,0.00021107116,0.0103584,0.04453441,0.9023457],"study_design_scores_gemma":[0.00026082853,0.00019378916,0.012337424,0.090631016,0.0036407206,0.0029716536,0.00033547214,0.00087148725,0.00042439895,0.008856051,0.87941843,0.000058791873],"about_ca_topic_score_codex":0.010629916,"about_ca_topic_score_gemma":0.019806046,"teacher_disagreement_score":0.010629916,"about_ca_system_score_codex":0.0032205181,"about_ca_system_score_gemma":0.0045515983,"threshold_uncertainty_score":0.024033666},"labels":[],"label_agreement":null},{"id":"W2066651696","doi":"10.2165/00019053-200523100-00005","title":"Using Policy Simulation to Predict Drug Plan Expenditure when Planning Reimbursement Changes","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Health","funders":"National Institute on Aging","keywords":"Reimbursement; Pharmacy; Medical prescription; Health policy; Prescription drug; Actuarial science; Finance; Public health; Medicine; Database; Business; Computer science; Economics; Health care; Family medicine; Economic growth; Nursing","score_opus":0.4817690817088586,"score_gpt":0.5174527065581008,"score_spread":0.0356836248492422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066651696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.868207,0.00051324867,0.11185144,0.0031060134,0.00020005324,0.00036681295,0.0027079713,0.0006015135,0.0124460105],"genre_scores_gemma":[0.98747605,0.00011981607,0.0107785165,0.00009259356,0.000027778598,0.00012418459,0.00057435385,0.000022004564,0.00078468374],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9985202,0.0009819659,0.0000764601,0.00013329575,0.00013936196,0.00014877791],"domain_scores_gemma":[0.9656068,0.031247437,0.0010798167,0.00048096967,0.0009745215,0.0006103619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003954729,0.00088090246,0.0013651197,0.0015320407,0.00059449667,0.0018522032,0.00089048967,0.0021315273,0.0045062834],"category_scores_gemma":[0.022411088,0.0010139062,0.0009163962,0.0013310335,0.0005486709,0.0014482918,0.0005855134,0.001818246,0.00031693387],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081364466,0.00005903065,0.0027028832,0.000009211737,0.000029725476,0.000023624683,0.000011782869,0.99430734,0.000022467988,0.0010481895,0.00026307988,0.0014412502],"study_design_scores_gemma":[0.000029377607,0.000018689561,0.00031188445,0.000003307046,0.000009740903,0.000004810604,0.000010674574,0.9982146,0.000039106002,0.0012678292,0.0000860925,0.000003830479],"about_ca_topic_score_codex":0.056276485,"about_ca_topic_score_gemma":0.036074944,"teacher_disagreement_score":0.056276485,"about_ca_system_score_codex":0.0033537275,"about_ca_system_score_gemma":0.0036872623,"threshold_uncertainty_score":0.111897886},"labels":[],"label_agreement":null},{"id":"W2066712604","doi":"10.2165/00019053-200523020-00004","title":"The Case for Stratified Cost-Effectiveness Analysis by Baseline Health-Related QOL","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"","keywords":"Medicine; Pharmacotherapy; Health economics; Quality of life (healthcare); Quality-adjusted life year; Cost-effectiveness analysis; Pharmacoeconomics; Quality of Life Research; Cost effectiveness; Public health; Physical therapy; Intensive care medicine; Internal medicine; Pathology","score_opus":0.2908016787876391,"score_gpt":0.4913464064672718,"score_spread":0.20054472767963272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066712604","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17778604,0.0508977,0.6130662,0.08620796,0.022295343,0.0071373438,0.008932748,0.0013865783,0.032290112],"genre_scores_gemma":[0.7419243,0.005199028,0.1485458,0.07860635,0.007962786,0.005051268,0.003514579,0.00091970025,0.008276194],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.65462047,0.29728547,0.012877553,0.015588365,0.013847308,0.0057807686],"domain_scores_gemma":[0.5824599,0.34812164,0.010713097,0.050154537,0.006200501,0.002350317],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.31694752,0.0031090335,0.01213584,0.0031122272,0.0012648862,0.0060625253,0.006497248,0.007348696,0.0140596405],"category_scores_gemma":[0.41778007,0.00196876,0.0236798,0.003689481,0.003842642,0.01039004,0.0041964054,0.013025419,0.0018017594],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052524902,0.0014301138,0.14274658,0.009145207,0.2525576,0.0030154237,0.003596146,0.01820705,0.0031426155,0.12211375,0.061347093,0.33017358],"study_design_scores_gemma":[0.009437247,0.009130209,0.07235059,0.0042892997,0.081689894,0.00283297,0.0017511417,0.11251599,0.0037685877,0.6521866,0.049399976,0.0006476767],"about_ca_topic_score_codex":0.0030856833,"about_ca_topic_score_gemma":0.0028952926,"teacher_disagreement_score":0.31694752,"about_ca_system_score_codex":0.0019137711,"about_ca_system_score_gemma":0.0035132207,"threshold_uncertainty_score":0.8423253},"labels":[],"label_agreement":null},{"id":"W2067068357","doi":"10.2165/00019053-200826060-00003","title":"Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Child and Family Research Institute; McMaster University; St. Joseph's Hospital","funders":"","keywords":"Reimbursement; Guideline; Agency (philosophy); Advisory committee; Medicine; Process management; Business; Health care; Political science; Public administration","score_opus":0.8838236794225288,"score_gpt":0.6563261702826145,"score_spread":0.2274975091399143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067068357","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0080965655,0.15586635,0.06763282,0.10613015,0.012616487,0.14235342,0.19695027,0.0061749374,0.30417904],"genre_scores_gemma":[0.031794373,0.13113292,0.5376442,0.027214406,0.001750587,0.08994045,0.074888155,0.0017853525,0.10384951],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.93282187,0.017227119,0.014193974,0.0012325706,0.029925216,0.0045993035],"domain_scores_gemma":[0.7515273,0.036203906,0.0145040015,0.0056620045,0.18511847,0.0069843046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08002769,0.0023812877,0.0043535144,0.023031222,0.0053270613,0.00981476,0.008397978,0.004563453,0.027911738],"category_scores_gemma":[0.16817418,0.0035536722,0.00679637,0.03490094,0.0023325933,0.0033232379,0.00382373,0.0062561324,0.009203277],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001568701,0.0001393855,0.0027531693,0.005766984,0.00023002735,0.0001588075,0.0005474365,0.0014713848,0.00017043961,0.0055896402,0.81553537,0.16748048],"study_design_scores_gemma":[0.00058306876,0.00007232238,0.03542149,0.020055505,0.00054886454,0.00015864718,0.00074963673,0.0012965662,0.0006231003,0.004379721,0.93590164,0.00020945982],"about_ca_topic_score_codex":0.91022074,"about_ca_topic_score_gemma":0.95281047,"teacher_disagreement_score":0.929536,"about_ca_system_score_codex":0.070464,"about_ca_system_score_gemma":0.4021719,"threshold_uncertainty_score":0.5112545},"labels":[],"label_agreement":null},{"id":"W2068218519","doi":"10.2165/00019053-200523070-00007","title":"Costs and Medical Care Consequences Associated with the Diagnosis of Peripheral Arterial Disease","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Peripheral Artery Disease Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Radiation Oncology; McGill University","funders":"","keywords":"Medicine; Myocardial infarction; Emergency medicine; Population; Arterial disease; Disease; Health economics; Medical care; Public health; Internal medicine; Pediatrics; Vascular disease","score_opus":0.01408995194429847,"score_gpt":0.2922336100092169,"score_spread":0.2781436580649184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068218519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9588631,0.009612993,0.0005093408,0.010870766,0.00020162451,0.000044219025,0.0025684584,0.000014422426,0.01731515],"genre_scores_gemma":[0.99724776,0.001310594,0.00017912201,0.00020087171,0.00017315829,0.000009393604,0.0006023023,0.000001519196,0.0002752003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976665,0.0012376406,0.00019455423,0.00009065023,0.00049612677,0.0003145312],"domain_scores_gemma":[0.99158585,0.004045623,0.0021904567,0.00015493807,0.0010034353,0.0010197116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009302566,0.00021036653,0.0003243882,0.0012761641,0.0005107406,0.00088430254,0.00031719444,0.00088105403,0.0027861558],"category_scores_gemma":[0.019306803,0.0001896185,0.0008814394,0.0014316317,0.00034794468,0.000615191,0.0006059654,0.0014454466,0.00015598071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001086666,0.00035372167,0.9473729,0.00014876586,0.0005391693,0.001417667,0.00009900025,0.0032197773,0.00018927344,0.0029941185,0.0038034266,0.038775466],"study_design_scores_gemma":[0.000040958963,0.00022537958,0.99017113,0.00009137859,0.00024614923,0.0017574648,0.0003759602,0.004034228,0.00007495066,0.0014863646,0.0014749501,0.000021076808],"about_ca_topic_score_codex":0.012839695,"about_ca_topic_score_gemma":0.01754471,"teacher_disagreement_score":0.012839695,"about_ca_system_score_codex":0.0019983458,"about_ca_system_score_gemma":0.0009747614,"threshold_uncertainty_score":0.025529921},"labels":[],"label_agreement":null},{"id":"W2070111960","doi":"10.2165/11531510-000000000-00000","title":"We Know Accurately Only When We Know Little","year":2010,"lang":"en","type":"editorial","venue":"PharmacoEconomics","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; Provincial Health Services Authority; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"","keywords":"Need to know; Quality of Life Research; Health economics; Public health; Health administration; Medicine; Actuarial science; Business; Computer science; Nursing","score_opus":0.5312092419018025,"score_gpt":0.5345524901447978,"score_spread":0.003343248242995256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070111960","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019266356,0.016730295,0.00028347853,0.08322364,0.89908165,0.00002855617,0.00007927302,0.000058826994,0.000494986],"genre_scores_gemma":[0.0006062045,0.010867312,0.00069613394,0.08921099,0.8954002,0.00011494861,0.0000460114,0.00007156215,0.0029865603],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9578467,0.016617851,0.007367287,0.0022827243,0.014767535,0.0011178738],"domain_scores_gemma":[0.71415454,0.19049016,0.01576862,0.0070547294,0.062671214,0.009860798],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.058634587,0.0064566038,0.011241858,0.009655578,0.004683885,0.012271882,0.0069618467,0.032914225,0.011320797],"category_scores_gemma":[0.24235712,0.0044084997,0.0049345233,0.0056926426,0.005952988,0.008222671,0.0032601664,0.041672625,0.009404239],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004242405,0.000009162969,0.000030942927,0.0009844584,0.00015404375,0.00006518885,0.000022612265,0.000022096292,0.000022856568,0.00025246997,0.99337465,0.005019105],"study_design_scores_gemma":[0.0006636402,0.00006141178,0.0005873827,0.0068230247,0.0014202021,0.00053936924,0.00013038822,0.0005455786,0.00020999655,0.0057796766,0.9831254,0.00011388779],"about_ca_topic_score_codex":0.0036723628,"about_ca_topic_score_gemma":0.013901667,"teacher_disagreement_score":0.9413654,"about_ca_system_score_codex":0.0061678197,"about_ca_system_score_gemma":0.010699056,"threshold_uncertainty_score":0.3100931},"labels":[],"label_agreement":null},{"id":"W2070320826","doi":"10.1007/s40273-013-0032-y","title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":214,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute of Health Economics; University of Ottawa","funders":"","keywords":"Checklist; Health economics; Government (linguistics); Delphi method; Consolidated Standards of Reporting Trials; Statement (logic); Systematic review; Economic evaluation; Medicine; Public relations; Psychological intervention; Public health; Delphi; MEDLINE; Medical education; Political science; Psychology; Nursing; Computer science; Law","score_opus":0.45454325920949434,"score_gpt":0.5560167446385411,"score_spread":0.10147348542904677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070320826","genre_codex":"dataset","genre_gemma":"methods","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007847957,0.042262595,0.18098792,0.18390168,0.04360332,0.08142654,0.34973928,0.0073770364,0.10285367],"genre_scores_gemma":[0.05494624,0.032294407,0.34613606,0.060248528,0.009692366,0.15319766,0.3224654,0.0025151544,0.018504238],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.7360828,0.13228947,0.06968513,0.0034311197,0.054036144,0.0044753947],"domain_scores_gemma":[0.34824243,0.28426507,0.06677559,0.045339394,0.24821806,0.0071594324],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.24485,0.0034526654,0.007551317,0.0151305515,0.001683392,0.011036823,0.007983639,0.011563396,0.01607601],"category_scores_gemma":[0.60536385,0.0028251975,0.009440128,0.025071248,0.0046776445,0.004723267,0.006014917,0.018613882,0.010865327],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002383023,0.00051148713,0.006274338,0.014281715,0.0022306968,0.00018963417,0.0003173907,0.0034496125,0.00023460103,0.03188346,0.81886125,0.11938281],"study_design_scores_gemma":[0.0051569133,0.0004875909,0.028822144,0.038963757,0.0043885796,0.00073314685,0.0005144255,0.007789125,0.0020936253,0.05808637,0.8526508,0.0003134587],"about_ca_topic_score_codex":0.0098802885,"about_ca_topic_score_gemma":0.0059615066,"teacher_disagreement_score":0.75515,"about_ca_system_score_codex":0.007567126,"about_ca_system_score_gemma":0.041173846,"threshold_uncertainty_score":0.9312344},"labels":[],"label_agreement":null},{"id":"W2070353359","doi":"10.2165/11530820-000000000-00000","title":"Funding the Unfundable","year":2010,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":132,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; New York Academy of Medicine","keywords":"Health care; Stakeholder; Health technology; Scarcity; Health administration; Health economics; Grey literature; Knowledge management; Business; Public relations; Management science; Computer science; Medicine; MEDLINE; Political science; Economics","score_opus":0.6552266900290561,"score_gpt":0.5597536411938446,"score_spread":0.09547304883521146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070353359","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020397247,0.31516495,0.0044869194,0.45659232,0.0594659,0.00035054513,0.0026664494,0.0002530776,0.15898009],"genre_scores_gemma":[0.109633885,0.3431898,0.012040622,0.19588669,0.03620847,0.0012448941,0.0070248214,0.00037947032,0.29439127],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926847,0.0026985856,0.0005215991,0.0006293654,0.0023876994,0.0010780187],"domain_scores_gemma":[0.9878641,0.0034030834,0.0018747194,0.0010653852,0.0032454927,0.0025472583],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01318166,0.0006704269,0.0012091266,0.0015335083,0.0007930714,0.003403633,0.0015950456,0.004888534,0.07684979],"category_scores_gemma":[0.041070107,0.00031356624,0.00070663856,0.0014707827,0.0018069914,0.002990697,0.0047996975,0.004239694,0.012925351],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002170883,0.000038527778,0.0006826659,0.0022185268,0.00008489415,0.00013006659,0.00008837037,0.000089082576,0.00020014012,0.063296854,0.55098784,0.38196594],"study_design_scores_gemma":[0.00010132619,0.000020547574,0.0010192009,0.003233528,0.000034179902,0.00027228968,0.000071115464,0.00008650967,0.000054755084,0.009614065,0.98548555,0.000006880521],"about_ca_topic_score_codex":0.0044057313,"about_ca_topic_score_gemma":0.0053639626,"teacher_disagreement_score":0.9868183,"about_ca_system_score_codex":0.0029091726,"about_ca_system_score_gemma":0.018050482,"threshold_uncertainty_score":0.25708812},"labels":[],"label_agreement":null},{"id":"W2070921516","doi":"10.1007/s40273-013-0117-7","title":"Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus","year":2013,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Diabetes mellitus; Type 2 Diabetes Mellitus; Health administration; Medicine; Public health; Pharmacoeconomics; Intensive care medicine; Endocrinology; Nursing","score_opus":0.28139725041198266,"score_gpt":0.47458829889532744,"score_spread":0.19319104848334478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070921516","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029930717,0.9947935,0.003017554,0.0005041889,0.00016028322,0.00003285389,0.00024504875,0.000014381658,0.0009328985],"genre_scores_gemma":[0.007242408,0.98888636,0.0029922999,0.00024822948,0.00018947678,0.00009600522,0.00014026531,0.000011940051,0.00019314497],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9955558,0.003043753,0.00047588907,0.00021402707,0.0005950182,0.00011540632],"domain_scores_gemma":[0.9812371,0.017099611,0.0008440096,0.00020035033,0.0005447832,0.00007418591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008611378,0.003255905,0.0061933217,0.0038668846,0.00027965265,0.0024132046,0.0036419875,0.0019385326,0.0060561984],"category_scores_gemma":[0.020933786,0.0010695043,0.005335717,0.005976108,0.00063571514,0.0019686879,0.0010189475,0.0023655724,0.0006027874],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007013224,0.00025824556,0.0010631059,0.18340628,0.0096237715,0.00028475447,0.00009822689,0.06994998,0.00018151953,0.072507,0.03078541,0.63114035],"study_design_scores_gemma":[0.0010292089,0.00063043024,0.004918716,0.2569067,0.03696706,0.0015004993,0.00025406203,0.07182267,0.00076673354,0.14875531,0.47607872,0.00036984286],"about_ca_topic_score_codex":0.011758721,"about_ca_topic_score_gemma":0.011736401,"teacher_disagreement_score":0.011758721,"about_ca_system_score_codex":0.0033982932,"about_ca_system_score_gemma":0.0040720035,"threshold_uncertainty_score":0.045541883},"labels":[],"label_agreement":null},{"id":"W2072395026","doi":"10.2165/11597890-000000000-00000","title":"A Parent-Child Dyad Approach to the Assessment of Health Status and Health-Related Quality of Life in Children with Asthma","year":2012,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; SickKids Foundation; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Dyad; Quality of life (healthcare); Medicine; Asthma; Convergent validity; Health Utilities Index; Clinical psychology; Pediatrics; Psychometrics; Psychology; Health related quality of life; Developmental psychology; Disease; Nursing","score_opus":0.0550603518973729,"score_gpt":0.38134509092638647,"score_spread":0.32628473902901356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072395026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875832,0.0018688374,0.0026257203,0.0021642204,0.00008382132,0.0002857947,0.00042543586,0.0000128498805,0.0049499925],"genre_scores_gemma":[0.99206185,0.0015315005,0.004728986,0.00016380433,0.000021028069,0.00055575394,0.0002364361,0.000004661276,0.0006959491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956204,0.003623952,0.00013034318,0.00014956867,0.00025823465,0.0002174761],"domain_scores_gemma":[0.9977552,0.0011305948,0.0002643766,0.00013518319,0.0003650155,0.00034951605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003946876,0.00042347034,0.00076315226,0.0017608226,0.0026656636,0.0018455856,0.0010252646,0.00067622453,0.001650857],"category_scores_gemma":[0.006980881,0.00043195774,0.00053660566,0.0012424038,0.0005667158,0.0011191805,0.002540235,0.0017927932,0.00019744747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035265225,0.0016860929,0.9013571,0.0002741356,0.00033766558,0.0016338534,0.03879549,0.00045117774,0.00070740114,0.002500089,0.0030860908,0.048818216],"study_design_scores_gemma":[0.00015106918,0.0013913668,0.8318698,0.000452569,0.0005884121,0.0031670323,0.14912914,0.0034051144,0.0007579454,0.002751985,0.006248958,0.000086623506],"about_ca_topic_score_codex":0.032998633,"about_ca_topic_score_gemma":0.077795856,"teacher_disagreement_score":0.032998633,"about_ca_system_score_codex":0.0020609067,"about_ca_system_score_gemma":0.004150883,"threshold_uncertainty_score":0.06561309},"labels":[],"label_agreement":null},{"id":"W2072493460","doi":"10.1007/s40273-014-0176-4","title":"Transparency in Reimbursement Decisions: In Whose Best Interest?","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Law, Economics, and Judicial Systems","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Transparency (behavior); Reimbursement; Health economics; Quality of Life Research; Health administration; Business; Accounting; Public health; Public interest; Actuarial science; Medicine; Economics; Health care; Nursing; Political science","score_opus":0.0801949536739273,"score_gpt":0.29556486691926864,"score_spread":0.21536991324534133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072493460","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00764321,0.009323465,0.0067599816,0.95376277,0.0015697444,0.000030988595,0.0001458011,0.000043748463,0.020720193],"genre_scores_gemma":[0.76967657,0.009424734,0.0044844314,0.19679475,0.015696889,0.00012957478,0.00012059087,0.00010583263,0.0035666348],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9196678,0.048266593,0.0040919203,0.0051246826,0.015204185,0.0076448154],"domain_scores_gemma":[0.5577381,0.3371497,0.04965529,0.010514139,0.031149246,0.0137934275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.09345756,0.0005650896,0.0023449478,0.0026336748,0.0037298454,0.025960023,0.0033739223,0.027392441,0.008813233],"category_scores_gemma":[0.365931,0.00090764783,0.0011330545,0.0031117497,0.017856313,0.029635994,0.003999511,0.02617157,0.0012438311],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003395485,0.00018948404,0.0079740165,0.0004440698,0.00020929094,0.00027957253,0.0015339282,0.0016955121,0.00022408651,0.8284533,0.09692398,0.06173319],"study_design_scores_gemma":[0.00020002671,0.00005399364,0.0054759593,0.0011581776,0.00010335787,0.00019733768,0.0014298325,0.0032535126,0.00035526507,0.9485295,0.03912589,0.000117116564],"about_ca_topic_score_codex":0.013754048,"about_ca_topic_score_gemma":0.012551213,"teacher_disagreement_score":0.09345756,"about_ca_system_score_codex":0.0130534135,"about_ca_system_score_gemma":0.024507806,"threshold_uncertainty_score":0.49425673},"labels":[],"label_agreement":null},{"id":"W2073038050","doi":"10.2165/00019053-200725100-00001","title":"Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions","year":2007,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Health economics; Willingness to pay; Psychological intervention; Actuarial science; Economic evaluation; Cost effectiveness; Health administration; Outcome (game theory); Relevance (law); Medicine; Cost–benefit analysis; Public health; Public economics; Economics; Risk analysis (engineering); Nursing; Microeconomics","score_opus":0.6989318515623156,"score_gpt":0.6222232909191193,"score_spread":0.07670856064319631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073038050","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036234617,0.16094564,0.33524194,0.41726422,0.016113415,0.00309062,0.0037976017,0.0011887293,0.02612333],"genre_scores_gemma":[0.68486845,0.04302846,0.13973708,0.104657315,0.015731217,0.005756197,0.0015795898,0.0011300069,0.003511641],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.5928132,0.37261453,0.0142538,0.005257184,0.012685251,0.0023760267],"domain_scores_gemma":[0.21804671,0.7501975,0.0065717273,0.011082939,0.011842824,0.0022582612],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.34688208,0.005359042,0.014480093,0.004724237,0.0018465978,0.010068035,0.010111112,0.015901877,0.010471358],"category_scores_gemma":[0.68744105,0.0029551268,0.011609742,0.0055705165,0.0073922924,0.015793653,0.005350745,0.020885108,0.00118262],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018434767,0.0018079244,0.019718343,0.017792363,0.059652556,0.0019623027,0.002968992,0.08733483,0.0007090634,0.2946522,0.13768409,0.35728255],"study_design_scores_gemma":[0.009238273,0.0017186152,0.0051907534,0.006378525,0.013154724,0.00044368158,0.0009377756,0.04775936,0.0008793009,0.88218415,0.03180127,0.00031357794],"about_ca_topic_score_codex":0.011674498,"about_ca_topic_score_gemma":0.01111905,"teacher_disagreement_score":0.34688208,"about_ca_system_score_codex":0.007459542,"about_ca_system_score_gemma":0.01238203,"threshold_uncertainty_score":0.8054107},"labels":[],"label_agreement":null},{"id":"W2074041399","doi":"10.1007/s40273-014-0149-7","title":"Health-Related Productivity Loss: NICE to Recognize Soon, Good to Discuss Now","year":2014,"lang":"en","type":"editorial","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Nice; Health economics; Quality of Life Research; Health administration; Public health; Productivity; Quality-adjusted life year; Medicine; Public economics; Economics; Business; Cost effectiveness; Operations management; Economic growth; Computer science; Nursing","score_opus":0.15961372067196816,"score_gpt":0.4497081695783074,"score_spread":0.29009444890633923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074041399","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012423592,0.011159125,0.00010815706,0.080733925,0.9070804,0.000013140638,0.0000657324,0.000037494003,0.0007895508],"genre_scores_gemma":[0.00024587853,0.0055782218,0.00015231289,0.0460686,0.9440005,0.00003371758,0.00003825599,0.00003826442,0.003844336],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9839549,0.0040728985,0.0025580435,0.0016435381,0.00693934,0.00083132496],"domain_scores_gemma":[0.9134544,0.043991122,0.004411863,0.0024137534,0.029908124,0.005820753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021392206,0.0047125933,0.009361054,0.005914524,0.0048572146,0.014027632,0.005793121,0.038530584,0.013155159],"category_scores_gemma":[0.10874468,0.0021338225,0.004664644,0.0044176714,0.006349144,0.008657631,0.003149639,0.054167356,0.010283005],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015762726,0.000008491448,0.000014427932,0.00014821521,0.000022984157,0.000024524,0.000006860366,0.000013491615,0.000006410959,0.0002576072,0.99691087,0.0025704438],"study_design_scores_gemma":[0.00019864728,0.00003517959,0.0004663664,0.0019612114,0.00021585551,0.00017932104,0.00008326662,0.0002473639,0.00005737827,0.0045149997,0.99197716,0.000063343316],"about_ca_topic_score_codex":0.0062518204,"about_ca_topic_score_gemma":0.015514715,"teacher_disagreement_score":0.038530584,"about_ca_system_score_codex":0.0068675326,"about_ca_system_score_gemma":0.009284451,"threshold_uncertainty_score":0.113134205},"labels":[],"label_agreement":null},{"id":"W2074344385","doi":"10.2165/00019053-200624110-00008","title":"Information Created to Evade Reality (ICER)","year":2006,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Medicine; Health informatics; Nursing","score_opus":0.5486522672038072,"score_gpt":0.543804526969932,"score_spread":0.004847740233875242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074344385","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015119492,0.9449667,0.0039803074,0.01974664,0.0016882913,0.000086821165,0.0004708152,0.00007570336,0.027472766],"genre_scores_gemma":[0.028941823,0.94280887,0.0069417525,0.013302621,0.00319378,0.00010145108,0.0006573757,0.000033202232,0.0040191147],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99387544,0.0028696368,0.0005643939,0.00026836424,0.002164643,0.0002575007],"domain_scores_gemma":[0.95605147,0.03650614,0.003231633,0.0011115473,0.0025344642,0.0005647496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012305752,0.00051560317,0.0013189317,0.0033148355,0.0003104959,0.0029586272,0.0011804922,0.002580569,0.013771163],"category_scores_gemma":[0.038592085,0.00028303155,0.0010840477,0.0038919547,0.0016305471,0.005066124,0.0019526185,0.002933543,0.0021166538],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001203048,0.000045556593,0.00052707706,0.010527557,0.00018924165,0.00013709569,0.00011644139,0.00033602765,0.00014082665,0.023386925,0.0561574,0.9083155],"study_design_scores_gemma":[0.00011228622,0.000121825804,0.0030680504,0.029621435,0.00046716063,0.0012388971,0.0001398942,0.00021725525,0.0006005974,0.021891035,0.9424858,0.00003578377],"about_ca_topic_score_codex":0.0020057238,"about_ca_topic_score_gemma":0.0021477728,"teacher_disagreement_score":0.013771163,"about_ca_system_score_codex":0.0017279637,"about_ca_system_score_gemma":0.004109383,"threshold_uncertainty_score":0.06507981},"labels":[],"label_agreement":null},{"id":"W2074907399","doi":"10.1007/s40273-013-0025-x","title":"What Evidence Is There for the Reimbursement of Personalised Medicine?","year":2013,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Capital District Health Authority","funders":"National Institute for Health and Care Research","keywords":"Health economics; Reimbursement; Quality of Life Research; Health administration; Public health; Medicine; Alternative medicine; Pharmacoeconomics; MEDLINE; Family medicine; Business; Health care; Intensive care medicine; Nursing; Economics; Political science; Economic growth","score_opus":0.5874732654311046,"score_gpt":0.5081335896968592,"score_spread":0.07933967573424539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074907399","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019107678,0.0012353745,0.000073063486,0.9943508,0.0026712404,0.000003890798,0.000032220567,0.000004168067,0.0014381772],"genre_scores_gemma":[0.0034751554,0.0016400504,0.00027286913,0.972014,0.021190986,0.00002014164,0.00002491006,0.000014442832,0.0013474377],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9725562,0.011886961,0.003434576,0.0020207588,0.0071323565,0.0029692487],"domain_scores_gemma":[0.77645457,0.17608075,0.010648469,0.0031968632,0.019867914,0.013751444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.037542306,0.00083981233,0.0036840616,0.0022507205,0.0044029276,0.010777473,0.0040352633,0.102100715,0.012725097],"category_scores_gemma":[0.19494918,0.001132035,0.0027800433,0.0024744256,0.010840715,0.012666178,0.00398095,0.07705828,0.0047424687],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040802997,0.00011056548,0.0029407942,0.00045935367,0.00016671089,0.0017062103,0.00028072816,0.00023612259,0.00024977123,0.04821495,0.9153623,0.029864484],"study_design_scores_gemma":[0.0006994717,0.00013806726,0.004544666,0.004083003,0.00028406098,0.0019450331,0.0011734536,0.0015960255,0.0003903824,0.13154702,0.8533225,0.0002763515],"about_ca_topic_score_codex":0.022015488,"about_ca_topic_score_gemma":0.035593346,"teacher_disagreement_score":0.102100715,"about_ca_system_score_codex":0.013322314,"about_ca_system_score_gemma":0.021556968,"threshold_uncertainty_score":0.19854504},"labels":[],"label_agreement":null},{"id":"W2075355967","doi":"10.2165/11314780-000000000-00000","title":"Case-Control Studies in Pharmacoeconomic Research","year":2009,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Historical and modern epidemiology studies","field":"Social Sciences","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Confounding; Health economics; Pharmacoeconomics; Cohort study; Cohort; Epidemiology; Quality of life (healthcare); Public health; Intensive care medicine; Health administration; Pathology; Nursing","score_opus":0.6567926222189158,"score_gpt":0.6275752726192679,"score_spread":0.029217349599647835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075355967","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000118348056,0.9990631,0.00027521973,0.00020565251,0.000193536,0.000010985599,0.000021005082,0.0000012059022,0.000111023975],"genre_scores_gemma":[0.002929978,0.9950395,0.00090022787,0.0004660472,0.00050998194,0.00004565142,0.00004340468,0.0000013200206,0.00006387502],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9807097,0.009941975,0.004056441,0.0022376303,0.0028065448,0.00024774674],"domain_scores_gemma":[0.84821653,0.13970768,0.0063979914,0.0019577453,0.0033164595,0.00040356015],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.03612634,0.0017260786,0.006861457,0.010788159,0.00066860736,0.0030986303,0.0035972053,0.0042435494,0.0043988116],"category_scores_gemma":[0.090783134,0.0010957045,0.0031299922,0.015275188,0.0026497508,0.00427016,0.0015992557,0.0023879942,0.0004424352],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005303151,0.00034654708,0.00853916,0.18682645,0.0066064876,0.0007932338,0.0003839773,0.00045067712,0.00023414359,0.013447192,0.011950255,0.76989144],"study_design_scores_gemma":[0.001314431,0.0010205649,0.050355908,0.37847078,0.041280933,0.010752905,0.0020464081,0.0014780518,0.0009131523,0.07128976,0.44070044,0.00037665883],"about_ca_topic_score_codex":0.0033355402,"about_ca_topic_score_gemma":0.0053587826,"teacher_disagreement_score":0.9638737,"about_ca_system_score_codex":0.0019411073,"about_ca_system_score_gemma":0.003831608,"threshold_uncertainty_score":0.19105667},"labels":[],"label_agreement":null},{"id":"W2076869933","doi":"10.1007/s40273-014-0241-z","title":"Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline; Eli Lilly and Company","keywords":"Dabrafenib; Dacarbazine; Vemurafenib; Medicine; Oncology; Progression-free survival; Internal medicine; Hazard ratio; Metastatic melanoma; Melanoma; Cancer research; Overall survival; Confidence interval","score_opus":0.013149909881605824,"score_gpt":0.26533107913349996,"score_spread":0.25218116925189416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076869933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96561897,0.0092356065,0.00017353246,0.01023829,0.00013173293,0.00009654115,0.004725686,0.000028374334,0.009751325],"genre_scores_gemma":[0.99483585,0.0024184678,0.00013677047,0.0005480683,0.000031974716,0.000013491334,0.00088935037,0.0000058747355,0.0011201608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99942076,0.00010781484,0.000034816483,0.00004785678,0.00016066861,0.0002281054],"domain_scores_gemma":[0.9983688,0.00022816299,0.00026184774,0.000016732185,0.00037826534,0.00074629846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031985308,0.00024774185,0.0005120258,0.0006260277,0.00076494954,0.0013354168,0.00074524706,0.00055207097,0.0029165875],"category_scores_gemma":[0.0031739378,0.00018171726,0.0010242512,0.0015666225,0.00043376506,0.00026955162,0.00043855282,0.0009010749,0.00009284965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011788206,0.0008655529,0.79027575,0.0007731606,0.001583427,0.001452455,0.0003503521,0.028193293,0.0012346143,0.0043817614,0.029973475,0.129128],"study_design_scores_gemma":[0.0022135968,0.0010329969,0.9557512,0.00037364123,0.0014905062,0.00086633314,0.0015140915,0.024763554,0.00054917095,0.00075548136,0.01059549,0.00009400939],"about_ca_topic_score_codex":0.97865456,"about_ca_topic_score_gemma":0.9876293,"teacher_disagreement_score":0.06315782,"about_ca_system_score_codex":0.06315782,"about_ca_system_score_gemma":0.045615,"threshold_uncertainty_score":0.4582442},"labels":[],"label_agreement":null},{"id":"W2077033962","doi":"10.2165/11586120-000000000-00000","title":"Unit Costs for Delivery of Antiretroviral Treatment and Prevention of Mother-to-Child Transmission of HIV","year":2011,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fogarty International Center; Association of Canadian Universities for Northern Studies","keywords":"Activity-based costing; Medicine; Health economics; Psychological intervention; Unit cost; Environmental health; Total cost; Public health; Indirect costs; Service delivery framework; Nursing; Business; Service (business); Economics","score_opus":0.09002927836267538,"score_gpt":0.42066742773724575,"score_spread":0.33063814937457037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077033962","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007983959,0.99719596,0.0001880857,0.00045348224,0.00015651075,0.000015202077,0.00014510925,0.000006881786,0.0010403433],"genre_scores_gemma":[0.0066538635,0.9921407,0.00050922664,0.00014353398,0.00010535538,0.00002165333,0.0001611995,0.0000024139324,0.00026203517],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99919695,0.0002771568,0.000107701395,0.000047592584,0.00030341212,0.000067208275],"domain_scores_gemma":[0.99837995,0.0010634601,0.00032908397,0.000020562764,0.00016051858,0.000046430032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012317894,0.0008534937,0.0017188945,0.0020440484,0.00015925443,0.0008422638,0.0011507444,0.0009332889,0.0047836597],"category_scores_gemma":[0.0040253717,0.00030961118,0.0012499469,0.003401285,0.0002703987,0.0007147255,0.00044448586,0.0011899195,0.0004986552],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027345272,0.00009480323,0.0009894563,0.05712324,0.0020075962,0.00014729977,0.0000507002,0.0015350188,0.00046382938,0.007414702,0.022001795,0.907898],"study_design_scores_gemma":[0.0008096458,0.0006784608,0.03948658,0.14020918,0.011348815,0.005294451,0.0004964542,0.0025349024,0.002091522,0.010969959,0.78597087,0.00010921003],"about_ca_topic_score_codex":0.0068985634,"about_ca_topic_score_gemma":0.008360383,"teacher_disagreement_score":0.0068985634,"about_ca_system_score_codex":0.0019144671,"about_ca_system_score_gemma":0.0022491063,"threshold_uncertainty_score":0.016002953},"labels":[],"label_agreement":null},{"id":"W2077085544","doi":"10.2165/00019053-200119010-00001","title":"Enteroviral Meningitis","year":2001,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Viral Infections and Immunology Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Medicine; Meningitis; Aseptic meningitis; Lumbar puncture; Viral meningitis; Psychological intervention; Intensive care medicine; Emergency medicine; Public health; Population; Pediatrics; Bacterial meningitis; Environmental health; Internal medicine; Psychiatry; Nursing","score_opus":0.1309644883297103,"score_gpt":0.4774486924316285,"score_spread":0.3464842041019182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077085544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013405125,0.9965095,0.0001470131,0.0004307678,0.0007041161,0.0000067854385,0.000013737756,0.000010113061,0.0020439432],"genre_scores_gemma":[0.0012512975,0.9954709,0.0002591147,0.00073580025,0.00089536415,0.000010011616,0.00003643046,0.0000019219992,0.0013391351],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99969065,0.00007720148,0.00006303887,0.000040933573,0.00009131794,0.0000369528],"domain_scores_gemma":[0.99950624,0.00020448283,0.00011637155,0.000026088148,0.00009378107,0.000053049353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006067808,0.0013638285,0.0021199025,0.002774725,0.0003616292,0.001285409,0.0007868313,0.0014067347,0.004619788],"category_scores_gemma":[0.0012786095,0.0002496116,0.0005077372,0.0025308789,0.00058007735,0.0014015556,0.00078037236,0.0018021179,0.00203562],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010663031,0.000068343244,0.00020076375,0.006043116,0.00006335387,0.0010634597,0.00002040396,0.00012779712,0.00044791598,0.0009875533,0.035354234,0.95551646],"study_design_scores_gemma":[0.00010765087,0.00017590282,0.001615095,0.0075931777,0.00030998205,0.013244581,0.00007572437,0.00010859477,0.000577586,0.0014042062,0.97476405,0.00002343278],"about_ca_topic_score_codex":0.0015486446,"about_ca_topic_score_gemma":0.0037183596,"teacher_disagreement_score":0.004619788,"about_ca_system_score_codex":0.00071056676,"about_ca_system_score_gemma":0.0015147979,"threshold_uncertainty_score":0.0154547095},"labels":[],"label_agreement":null},{"id":"W2077682525","doi":"10.2165/11535270-000000000-00000","title":"Perspective and Desire in Comparative Effectiveness Research","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Perspective (graphical); Health economics; Value (mathematics); Foundation (evidence); Quality of Life Research; Context (archaeology); Positive economics; Health administration; Outcome (game theory); Sociology; Psychology; Management science; Public health; Epistemology; Actuarial science; Medicine; Economics; Political science; Computer science; Law; Nursing; Microeconomics","score_opus":0.6765631596578086,"score_gpt":0.6128368200944262,"score_spread":0.06372633956338236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077682525","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013414384,0.26235738,0.0887345,0.5015318,0.0050946465,0.000281088,0.00048403314,0.000063780695,0.1280384],"genre_scores_gemma":[0.7395748,0.056613855,0.044255726,0.13967603,0.013538138,0.0017890045,0.00018482324,0.00009895658,0.004268639],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.8027312,0.16500062,0.0078024417,0.00612652,0.016535591,0.0018036844],"domain_scores_gemma":[0.4806502,0.4894473,0.008621176,0.010221285,0.0076950537,0.0033650158],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.23467688,0.0013118458,0.00481204,0.007318949,0.0027868939,0.012779559,0.0039935336,0.014190918,0.008191814],"category_scores_gemma":[0.27203858,0.001096774,0.0012696788,0.0058446024,0.040496476,0.024759369,0.0068952483,0.01172356,0.00055879087],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103383645,0.000042366737,0.00043735185,0.00084784,0.00015041801,0.00004380608,0.0006428447,0.00032666422,0.000030463889,0.98203236,0.00320154,0.012140944],"study_design_scores_gemma":[0.00014114822,0.00006848263,0.00023418301,0.0010509181,0.0000745942,0.00011091928,0.00051158346,0.00034525825,0.000053306412,0.98502874,0.01236508,0.0000157821],"about_ca_topic_score_codex":0.0010656451,"about_ca_topic_score_gemma":0.0012650008,"teacher_disagreement_score":0.7653231,"about_ca_system_score_codex":0.008354463,"about_ca_system_score_gemma":0.0047621126,"threshold_uncertainty_score":0.94377965},"labels":[],"label_agreement":null},{"id":"W2078342884","doi":"10.2165/00019053-200523080-00008","title":"An Economic Evaluation of Rizatriptan in the Treatment of Migraine","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); Nexus Clinical Research (Canada); Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Rizatriptan; Quality of Life Research; Health economics; Migraine; Medicine; Pharmacoeconomics; Public health; Intensive care medicine; Sumatriptan; Internal medicine","score_opus":0.07230910605407972,"score_gpt":0.4273265135412343,"score_spread":0.3550174074871546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078342884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83079773,0.14877874,0.0014359064,0.0039642374,0.00068221195,0.00303656,0.0026161063,0.000036159392,0.00865241],"genre_scores_gemma":[0.98025227,0.016920213,0.0006783047,0.00046261566,0.0001968257,0.0005311391,0.0004140717,0.00000419157,0.00054051116],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.98175186,0.016235651,0.0007487208,0.00017639202,0.00072038843,0.0003671049],"domain_scores_gemma":[0.98105615,0.015113916,0.0022330584,0.00042410445,0.00066952914,0.0005032126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011289511,0.001023467,0.002399303,0.0014183903,0.000436396,0.0010700846,0.00070719136,0.0014811193,0.0039926516],"category_scores_gemma":[0.028090322,0.0004956767,0.0046043023,0.001372555,0.0007102235,0.0009115548,0.0007031568,0.0015125631,0.00015881451],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86024743,0.0041589695,0.007995855,0.010802345,0.025895854,0.0004016899,0.00011960014,0.006844105,0.0009417674,0.0022884142,0.0012818179,0.079022124],"study_design_scores_gemma":[0.56366783,0.1967422,0.07115278,0.0046909037,0.11769058,0.001201864,0.000893898,0.017881678,0.0018456063,0.0034821476,0.020461068,0.0002894914],"about_ca_topic_score_codex":0.0064382306,"about_ca_topic_score_gemma":0.0062723598,"teacher_disagreement_score":0.011289511,"about_ca_system_score_codex":0.004166739,"about_ca_system_score_gemma":0.0026405274,"threshold_uncertainty_score":0.059705317},"labels":[],"label_agreement":null},{"id":"W2078517534","doi":"10.2165/00019053-200523120-00006","title":"Willingness to Pay for Inhaled Insulin","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Insulin; Medicine; Diabetes mellitus; Willingness to pay; Insulin analog; Type 1 diabetes; Contingent valuation; Internal medicine; Endocrinology; Human insulin; Economics","score_opus":0.026291284379856828,"score_gpt":0.3449360948945748,"score_spread":0.31864481051471794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078517534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8970672,0.0018128053,0.005619693,0.013681744,0.00026024444,0.000112643036,0.0009845962,0.00007668002,0.080384314],"genre_scores_gemma":[0.9951212,0.00013832604,0.00029404066,0.00042245153,0.00007772726,0.00001331499,0.00015999054,0.000005155699,0.0037678056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985373,0.00066023826,0.000105354746,0.00011143821,0.00029926404,0.00028641502],"domain_scores_gemma":[0.99221706,0.0055345427,0.00081898266,0.00045208292,0.00040225737,0.0005749933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016290395,0.00022371819,0.000430054,0.0005110674,0.00030095704,0.0016485435,0.0003601927,0.0022082974,0.02019104],"category_scores_gemma":[0.012048783,0.00020510935,0.0014803333,0.0002864264,0.0002777652,0.0007924908,0.00045208482,0.0015143018,0.0016416517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012154621,0.0028559738,0.5565524,0.00040826332,0.0017935368,0.0019289244,0.00060636795,0.017509174,0.0063272333,0.04176337,0.014898174,0.3432019],"study_design_scores_gemma":[0.0010018034,0.0046442687,0.84043384,0.0003596664,0.0014491592,0.011124486,0.002926909,0.05500516,0.00414309,0.0455234,0.03323054,0.0001577243],"about_ca_topic_score_codex":0.001022436,"about_ca_topic_score_gemma":0.00068945123,"teacher_disagreement_score":0.02019104,"about_ca_system_score_codex":0.00079671404,"about_ca_system_score_gemma":0.0005083055,"threshold_uncertainty_score":0.06754577},"labels":[],"label_agreement":null},{"id":"W2078569420","doi":"10.2165/00019053-200725030-00003","title":"Enzyme Replacement Therapy in Orphan and Ultra-Orphan Diseases","year":2007,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Shire Human Genetic Therapies; University of Manitoba","keywords":"Orphan drug; Enzyme replacement therapy; Quality-adjusted life year; Medicine; Health economics; EQ-5D; Cost effectiveness; Quality of life (healthcare); Fabry disease; Public health; Disease; Internal medicine; Bioinformatics; Pathology","score_opus":0.026851018753520705,"score_gpt":0.3524826568531943,"score_spread":0.3256316380996736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078569420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5817607,0.36530396,0.007034697,0.013239138,0.0007760722,0.0000331715,0.0004578621,0.000081740094,0.03131271],"genre_scores_gemma":[0.9509312,0.042715345,0.001849938,0.0011495489,0.0005027417,0.000025345234,0.00019518127,0.000007592955,0.0026231806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996414,0.00016913802,0.00007029117,0.00002727922,0.00006119513,0.00003061267],"domain_scores_gemma":[0.99923396,0.00053003326,0.00009006789,0.0000378203,0.00003793474,0.00007031587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090006925,0.00015486848,0.00043161627,0.0004151426,0.00018476254,0.00042445894,0.00011800794,0.00041602392,0.0020706002],"category_scores_gemma":[0.0016037334,0.000040043218,0.00026060775,0.00044336423,0.0002866698,0.0003194386,0.0002845296,0.0003260759,0.00019202069],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012780857,0.00048019303,0.09535606,0.0012389835,0.00063472136,0.010963823,0.00036611798,0.0009303736,0.015176645,0.021600096,0.0073315063,0.83314055],"study_design_scores_gemma":[0.0046508852,0.011586025,0.3528604,0.0020223283,0.0026451668,0.1288999,0.0016328975,0.004530436,0.04853005,0.06043632,0.3821018,0.000103867205],"about_ca_topic_score_codex":0.00025394614,"about_ca_topic_score_gemma":0.00026942955,"teacher_disagreement_score":0.0020706002,"about_ca_system_score_codex":0.00030921237,"about_ca_system_score_gemma":0.00037306972,"threshold_uncertainty_score":0.006926894},"labels":[],"label_agreement":null},{"id":"W2081398893","doi":"10.1007/s40273-014-0135-0","title":"Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the Literature","year":2014,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":288,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Multiple-criteria decision analysis; Psychological intervention; Reimbursement; Health care; Medicine; Decision analysis; Prior authorization; Medical prescription; Health economics; Health administration; Decision aids; Management science; Public health; Nursing; Alternative medicine; Operations research; Political science; Engineering","score_opus":0.6197602703662343,"score_gpt":0.6302883873459656,"score_spread":0.010528116979731328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081398893","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029459991,0.9982936,0.00068865,0.00038702943,0.000043888165,0.000022548493,0.000035269604,0.0000025477316,0.00023194906],"genre_scores_gemma":[0.011653738,0.9848722,0.0028090621,0.00030786602,0.00017421607,0.00006976286,0.000052963016,0.000004027629,0.00005609518],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99023366,0.0046763658,0.001665276,0.0006407513,0.0025943476,0.00018957577],"domain_scores_gemma":[0.92569876,0.06789329,0.003517468,0.00034843312,0.0022749512,0.00026719333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017024541,0.0024040947,0.007832884,0.008056716,0.00036827897,0.003944262,0.0024360395,0.0027627845,0.0032831812],"category_scores_gemma":[0.04861293,0.00072141737,0.005083747,0.0087675685,0.0011401149,0.0025923192,0.0012990556,0.0023040047,0.00026763944],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004867204,0.00022253187,0.0014446225,0.18102472,0.0063838493,0.0000995225,0.00009079023,0.007761602,0.00022746086,0.00683279,0.0040219836,0.7914034],"study_design_scores_gemma":[0.0010191505,0.001304392,0.01287539,0.6472623,0.051974595,0.001798881,0.0010536615,0.021859217,0.0017328697,0.080208465,0.17849454,0.00041659173],"about_ca_topic_score_codex":0.0036580071,"about_ca_topic_score_gemma":0.0052584196,"teacher_disagreement_score":0.017024541,"about_ca_system_score_codex":0.0038353954,"about_ca_system_score_gemma":0.0055148676,"threshold_uncertainty_score":0.0900355},"labels":[],"label_agreement":null},{"id":"W2082074737","doi":"10.1007/s40273-014-0134-1","title":"Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Capital District Health Authority","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council; National Institute for Health and Care Research","keywords":"Health administration; Health economics; Test (biology); Quality of Life Research; Cost effectiveness; Medicine; Health care; Population health; Actuarial science; Population; Risk analysis (engineering); Public health; Business; Economics; Environmental health; Nursing","score_opus":0.7227974291532423,"score_gpt":0.6577397002386661,"score_spread":0.06505772891457617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082074737","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032593012,0.00091143994,0.9940797,0.0005990937,0.00008599341,0.00030538265,0.00009649542,0.000111088644,0.00055162446],"genre_scores_gemma":[0.090874456,0.0012797496,0.90237945,0.0007137662,0.00048821163,0.0022306887,0.00028350233,0.00016092666,0.0015892148],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9617924,0.02986644,0.0017606174,0.0021646435,0.0038207285,0.00059508515],"domain_scores_gemma":[0.6765586,0.30522346,0.0046689147,0.0069661695,0.0056944615,0.0008884259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07249621,0.0026210784,0.006971298,0.009847634,0.0010492726,0.0033133754,0.004804132,0.0035363687,0.0061055114],"category_scores_gemma":[0.26519218,0.0017552,0.0040503177,0.0055833263,0.0032405884,0.0053721024,0.0041463026,0.008027175,0.00076718966],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025223952,0.000856604,0.011039517,0.0020034655,0.0016666538,0.00043043456,0.00089750875,0.1347913,0.0020172948,0.27265295,0.0079688225,0.563153],"study_design_scores_gemma":[0.00059056876,0.0006737499,0.0025794911,0.00039017855,0.00059843354,0.00052834494,0.00010392821,0.6695249,0.0012518865,0.3184469,0.005178403,0.00013313883],"about_ca_topic_score_codex":0.002112999,"about_ca_topic_score_gemma":0.0013593471,"teacher_disagreement_score":0.07249621,"about_ca_system_score_codex":0.0019976185,"about_ca_system_score_gemma":0.0041795378,"threshold_uncertainty_score":0.38340122},"labels":[],"label_agreement":null},{"id":"W2082957553","doi":"10.2165/11530850-000000000-00000","title":"Access with Evidence Development Schemes","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health; National Institute for Health and Care Research","keywords":"Reimbursement; Health economics; Health administration; Risk analysis (engineering); Health informatics; Public health; Health technology; Scheme (mathematics); Quality of Life Research; Health care; Key (lock); Business; Actuarial science; Management science; Process management; Computer science; Medicine; Economics; Nursing; Computer security","score_opus":0.5279640526757208,"score_gpt":0.5269170405202137,"score_spread":0.0010470121555070655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082957553","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0074613895,0.0060885167,0.14459996,0.07481958,0.0036695332,0.0068482915,0.019347088,0.0038085307,0.7333572],"genre_scores_gemma":[0.19126275,0.0077994615,0.19750251,0.03272852,0.0061655845,0.011376108,0.021354502,0.0020341056,0.5297765],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9449362,0.022999905,0.009347943,0.004185853,0.0152900405,0.003240069],"domain_scores_gemma":[0.72783065,0.12845539,0.01414517,0.07476352,0.04028609,0.014519194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.062621586,0.00070579624,0.0014883314,0.012300919,0.0017374934,0.010496195,0.003458541,0.007913035,0.26560816],"category_scores_gemma":[0.29720837,0.0015544433,0.0018266948,0.006414698,0.0023192402,0.010815699,0.014795072,0.005368093,0.074880295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006371714,0.0003076516,0.0023947184,0.0015787064,0.00019467324,0.00029456592,0.00046898157,0.0009876259,0.0005442682,0.3478978,0.28671777,0.35797617],"study_design_scores_gemma":[0.0005059003,0.00013730966,0.0016712488,0.0009592677,0.000085093256,0.00034554952,0.00009649928,0.00140554,0.0006679642,0.11040333,0.88367647,0.000045908924],"about_ca_topic_score_codex":0.0011837279,"about_ca_topic_score_gemma":0.0010240468,"teacher_disagreement_score":0.26560816,"about_ca_system_score_codex":0.0033094045,"about_ca_system_score_gemma":0.019548343,"threshold_uncertainty_score":0.88854784},"labels":[],"label_agreement":null},{"id":"W2082962434","doi":"10.2165/00019053-200523050-00005","title":"Valuing Patient and Caregiver Time","year":2005,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canadian Foundation for Healthcare Improvement; Hospital for Sick Children; Institute of Population and Public Health; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Valuation (finance); Health economics; Public economics; Economics; Health care; Activity-based costing; Unpaid work; Actuarial science; Productivity; Work (physics); Business; Accounting; Economic growth","score_opus":0.42404659701883957,"score_gpt":0.503347239421462,"score_spread":0.07930064240262241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082962434","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015643748,0.9947107,0.0005759944,0.0010671401,0.00010565841,0.000011686372,0.000044763634,0.0000020073514,0.0019176299],"genre_scores_gemma":[0.030079281,0.96757275,0.0010770782,0.00037974704,0.00029210444,0.000037459282,0.000071667426,0.0000022007014,0.00048777324],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9982381,0.00094563473,0.00014112575,0.000096292824,0.0005120303,0.00006679169],"domain_scores_gemma":[0.9944975,0.0039705154,0.0009145087,0.00007535773,0.00044593148,0.000096249256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038840815,0.000767856,0.0020025221,0.002520405,0.00019782757,0.0018909934,0.00073618675,0.0013720035,0.002464936],"category_scores_gemma":[0.012560168,0.00020667377,0.00073749083,0.00450762,0.0008191656,0.0013470094,0.0007231027,0.0011183417,0.00026473435],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021504409,0.00010494704,0.0029477694,0.010254294,0.00067406835,0.000067002766,0.00007593147,0.0011516421,0.00013701504,0.0109543605,0.009038727,0.9643792],"study_design_scores_gemma":[0.0005906747,0.00080711255,0.068402365,0.10388111,0.0049124435,0.0039065625,0.0013979316,0.00493909,0.0015759243,0.13202682,0.67735696,0.00020308452],"about_ca_topic_score_codex":0.0027099033,"about_ca_topic_score_gemma":0.005690651,"teacher_disagreement_score":0.0038840815,"about_ca_system_score_codex":0.0018339595,"about_ca_system_score_gemma":0.0018542762,"threshold_uncertainty_score":0.020541191},"labels":[],"label_agreement":null},{"id":"W2083791045","doi":"10.2165/00019053-200624080-00007","title":"Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Merck Canada Inc. (Canada)","funders":"","keywords":"Ezetimibe; Atorvastatin; Quality of Life Research; Health economics; Medicine; Public health; Ldl cholesterol; Pharmacotherapy; Cholesterol; Cost effectiveness; Intensive care medicine; Internal medicine; Risk analysis (engineering)","score_opus":0.021071013579764025,"score_gpt":0.29399228974178526,"score_spread":0.2729212761620212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083791045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780411,0.0045598065,0.00015126193,0.0076794853,0.00012833027,0.00016745199,0.0029582102,0.000032531745,0.0062817195],"genre_scores_gemma":[0.99618787,0.0014619249,0.00027078722,0.0006312104,0.000043541888,0.000021145328,0.00067669083,0.0000056830686,0.00070117664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998505,0.00039168427,0.000116057796,0.00011985292,0.00044336892,0.00042402372],"domain_scores_gemma":[0.9953537,0.0013070281,0.0006203169,0.000068847694,0.0012097809,0.0014402416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079575647,0.0003944829,0.0010441875,0.0006715373,0.0012235309,0.0014659021,0.0013600276,0.0011447797,0.0027257667],"category_scores_gemma":[0.0096204765,0.00037787863,0.0014483788,0.0021914074,0.0007012887,0.00044717157,0.00053331023,0.0013081671,0.00009308857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066476785,0.00285538,0.69838804,0.0015447022,0.0041641765,0.001652214,0.00057134236,0.049823925,0.0013608718,0.0038041882,0.027655656,0.14170276],"study_design_scores_gemma":[0.012395052,0.0040319767,0.9146581,0.00045360642,0.0056578224,0.00056931365,0.0015519896,0.052958943,0.00070122804,0.0011732032,0.005646018,0.00020261576],"about_ca_topic_score_codex":0.9822614,"about_ca_topic_score_gemma":0.98760104,"teacher_disagreement_score":0.07018042,"about_ca_system_score_codex":0.07018042,"about_ca_system_score_gemma":0.06352785,"threshold_uncertainty_score":0.509197},"labels":[],"label_agreement":null},{"id":"W2084273456","doi":"10.2165/00019053-200624010-00008","title":"Economic Evaluation of Rivastigmine in Patients with Parkinson??s Disease Dementia","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Programs for Assessment of Technology in Health Research Institute; Public Health Ontario; McMaster University; University of Toronto; Toronto Public Health","funders":"","keywords":"Rivastigmine; Medicine; Dementia; Quality of life (healthcare); Quality-adjusted life year; Clinical trial; Health economics; Physical therapy; Cost effectiveness; Pediatrics; Disease; Public health; Internal medicine; Donepezil","score_opus":0.014660395367932658,"score_gpt":0.2837625494827499,"score_spread":0.26910215411481725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084273456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74321187,0.1739507,0.004105975,0.03177592,0.0014052877,0.0027586278,0.00831148,0.00012089373,0.034359273],"genre_scores_gemma":[0.9880927,0.00843389,0.00078418077,0.0008964905,0.00013678671,0.00027068713,0.0007850615,0.000007179581,0.0005930365],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9899081,0.00821561,0.00061833975,0.00019264201,0.0006654124,0.0003999019],"domain_scores_gemma":[0.99160975,0.0055010435,0.0013566014,0.0001790723,0.0005536992,0.0007999255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064455704,0.00064949086,0.0020896608,0.0009737395,0.0003495134,0.0017539782,0.00055976136,0.0017457097,0.00360473],"category_scores_gemma":[0.029192492,0.00034112364,0.00340589,0.0011000816,0.0005164918,0.0010568993,0.00074586447,0.0020375145,0.00018439822],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60005754,0.0028287217,0.04099024,0.008809089,0.01689798,0.0008754563,0.00016268466,0.032750577,0.0010056027,0.0060293796,0.010870675,0.2787221],"study_design_scores_gemma":[0.34368673,0.12286812,0.2556412,0.011182336,0.057535514,0.004975542,0.0016276124,0.11176188,0.0029501244,0.015210193,0.072084546,0.00047614527],"about_ca_topic_score_codex":0.0076639014,"about_ca_topic_score_gemma":0.0055898908,"teacher_disagreement_score":0.0076639014,"about_ca_system_score_codex":0.005955101,"about_ca_system_score_gemma":0.003743656,"threshold_uncertainty_score":0.043207467},"labels":[],"label_agreement":null},{"id":"W2084655166","doi":"10.2165/00019053-200624110-00011","title":"Economic Evaluations in the Canadian Common Drug Review","year":2006,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Toronto; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Health economics; Quality of Life Research; Public health; Health administration; Drug; Medicine; Pharmacoeconomics; Intensive care medicine; Pharmacology; Nursing","score_opus":0.47903852172689615,"score_gpt":0.5609020028368904,"score_spread":0.08186348110999425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084655166","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011492268,0.99521166,0.000103858256,0.0025651301,0.00030044848,0.000036878988,0.00015023147,0.0000047880612,0.0015120859],"genre_scores_gemma":[0.0056075216,0.9915405,0.00063538546,0.0011852977,0.00036502673,0.00006480962,0.00013417997,0.000007649571,0.00045962358],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98006094,0.008396465,0.0019818125,0.0005855993,0.0083076395,0.00066760025],"domain_scores_gemma":[0.94203705,0.032059222,0.0040794965,0.00077731756,0.019656794,0.0013901606],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.03261981,0.0017506243,0.005303115,0.01663552,0.0014807887,0.005539206,0.0019971775,0.0028240776,0.0063083717],"category_scores_gemma":[0.08502646,0.00076387945,0.0019285915,0.031796467,0.002654184,0.002313434,0.0015721044,0.003157635,0.00043364495],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045899005,0.00010013248,0.0012840033,0.05702531,0.0013701873,0.00012182305,0.00012591173,0.0024439374,0.000077141056,0.023785833,0.20190705,0.71129966],"study_design_scores_gemma":[0.00045977175,0.0001282587,0.019700648,0.1540213,0.0038496582,0.00039237243,0.00026719988,0.0013090156,0.00021544735,0.017170101,0.80229884,0.00018737015],"about_ca_topic_score_codex":0.46859962,"about_ca_topic_score_gemma":0.6340214,"teacher_disagreement_score":0.96738017,"about_ca_system_score_codex":0.037618753,"about_ca_system_score_gemma":0.072976254,"threshold_uncertainty_score":0.9317441},"labels":[],"label_agreement":null},{"id":"W2085650878","doi":"10.2165/00019053-200321010-00001","title":"Generic Clozapine","year":2003,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Riverview Hospital","funders":"","keywords":"Clozapine; Quality of Life Research; Public health; Health economics; Health administration; Medicine; Psychiatry; Schizophrenia (object-oriented programming); Nursing","score_opus":0.13296359262517082,"score_gpt":0.43932258642080163,"score_spread":0.3063589937956308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085650878","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00086455286,0.99214077,0.0002699357,0.00071698934,0.00021743459,0.00003953126,0.00018272219,0.000030766692,0.0055373874],"genre_scores_gemma":[0.0069896597,0.9885733,0.0004539026,0.0009844229,0.00016899602,0.00003197567,0.00022701529,0.000003126832,0.0025675904],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998142,0.00005674272,0.000035985,0.00002722382,0.000047732425,0.000018135594],"domain_scores_gemma":[0.9997569,0.000090333495,0.00009537261,0.000008256114,0.000031425363,0.000017763867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003307548,0.00093495235,0.0016119159,0.002187782,0.00019885294,0.0005957241,0.000532668,0.00070662744,0.01246676],"category_scores_gemma":[0.0007957636,0.00019223263,0.00070685137,0.0020206373,0.00022659269,0.00040663453,0.00040068573,0.00073342083,0.0019195571],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000638137,0.00006962646,0.0002584052,0.027490826,0.00040263592,0.0004521355,0.000029866394,0.00011834883,0.0013981502,0.0008190181,0.025717704,0.94260514],"study_design_scores_gemma":[0.0017970414,0.0005771498,0.006630529,0.015729645,0.004363641,0.005291749,0.000111632304,0.00021573927,0.0014780869,0.0013525202,0.96241707,0.000035160778],"about_ca_topic_score_codex":0.0027595218,"about_ca_topic_score_gemma":0.010487859,"teacher_disagreement_score":0.01246676,"about_ca_system_score_codex":0.00068571547,"about_ca_system_score_gemma":0.0011001629,"threshold_uncertainty_score":0.04170549},"labels":[],"label_agreement":null},{"id":"W2087332353","doi":"10.1007/s40273-014-0229-8","title":"Costs of Health Resource Utilization Among HIV-Positive Individuals in British Columbia, Canada: Results From a Population-Level Study","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; AIDS Vancouver; St. Paul's Hospital; Simon Fraser University; Providence Health Care","funders":"National Institute on Drug Abuse; Canadian Institutes of Health Research","keywords":"Medicine; Health economics; Confidence interval; Demography; Population; Public health; Health care; Generalized estimating equation; Health administration; Logistic regression; Indirect costs; Gerontology; Environmental health; Internal medicine","score_opus":0.04665521805837613,"score_gpt":0.34610844860172074,"score_spread":0.2994532305433446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087332353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899038,0.0010291027,0.000055612294,0.0004315371,0.000012462385,0.00007355413,0.007034325,0.00000686488,0.0014527942],"genre_scores_gemma":[0.9948003,0.0010628317,0.00017065044,0.00021132005,0.000007757562,0.000040521627,0.0027136502,0.0000048832353,0.0009880352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985784,0.00019973192,0.0001644607,0.0001437555,0.00043083343,0.00048280563],"domain_scores_gemma":[0.9971788,0.00020645614,0.0004775915,0.00009578274,0.0013421115,0.00069929723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007216123,0.000594602,0.00077321834,0.0014991616,0.0029277564,0.002123927,0.0020311996,0.0011260862,0.0016395343],"category_scores_gemma":[0.0033122464,0.00072350865,0.0011365013,0.0073805074,0.000772228,0.00067112845,0.0011519783,0.0015421303,0.00023127349],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014292853,0.00011311808,0.9952419,0.00006214571,0.00017963997,0.00009262281,0.00039913427,0.00023858492,0.00005797724,0.000071539165,0.0010206881,0.0023797431],"study_design_scores_gemma":[0.000014837447,0.000018776336,0.9982577,0.00003836295,0.000075453456,0.00002962178,0.001009664,0.00022223391,0.000018106275,0.000018701903,0.00028518043,0.000011405477],"about_ca_topic_score_codex":0.99668545,"about_ca_topic_score_gemma":0.9980026,"teacher_disagreement_score":0.040389825,"about_ca_system_score_codex":0.040389825,"about_ca_system_score_gemma":0.03375801,"threshold_uncertainty_score":0.29305005},"labels":[],"label_agreement":null},{"id":"W2088147052","doi":"10.2165/11313640-000000000-00000","title":"The Cost Effectiveness of Rufinamide in the Treatment of Lennox-Gastaut Syndrome in the UK","year":2010,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Lamotrigine; Topiramate; Medicine; Lennox–Gastaut syndrome; Pharmacoeconomics; Placebo; Adjunctive treatment; Epilepsy; Randomized controlled trial; Pediatrics; Clinical trial; Seizure types; Psychiatry; Intensive care medicine; Surgery; Internal medicine","score_opus":0.02984183530600453,"score_gpt":0.3677046797415109,"score_spread":0.33786284443550635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088147052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8610633,0.08922587,0.000322792,0.036580335,0.00060920324,0.00007477865,0.0021038046,0.000044453394,0.009975532],"genre_scores_gemma":[0.9858635,0.011364692,0.00015836902,0.0012779732,0.00028847784,0.000026809419,0.00041916178,0.0000068943086,0.000594135],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99756336,0.0014341783,0.00027528108,0.000108354914,0.00035582052,0.00026299738],"domain_scores_gemma":[0.9953354,0.0024757418,0.0011062043,0.00005678761,0.00031985145,0.0007059906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013608639,0.00030013153,0.00074274634,0.0010967724,0.00023481701,0.0011071069,0.00039784692,0.0014571374,0.0032127362],"category_scores_gemma":[0.008470268,0.00021417612,0.0010395488,0.0011216983,0.00065729715,0.00080281036,0.0005600151,0.0012771854,0.00012406969],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10528055,0.0011381316,0.17055349,0.0069312328,0.0037589592,0.0073500266,0.0005636178,0.034803372,0.0043286197,0.009170699,0.033223055,0.6228982],"study_design_scores_gemma":[0.022392277,0.020551335,0.8613073,0.0045911768,0.0054029017,0.013530792,0.0014342914,0.021720514,0.0016779859,0.002987638,0.04406103,0.00034265677],"about_ca_topic_score_codex":0.028971633,"about_ca_topic_score_gemma":0.030296681,"teacher_disagreement_score":0.028971633,"about_ca_system_score_codex":0.0062230555,"about_ca_system_score_gemma":0.002316121,"threshold_uncertainty_score":0.05760604},"labels":[],"label_agreement":null},{"id":"W2088407458","doi":"10.2165/00019053-200826070-00003","title":"Does Direct-to-Consumer Advertising of Antidepressants Lead to a Net Social Benefit?","year":2008,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Direct-to-consumer advertising; Direct marketing; Advertising; Business; Health administration; Lead (geology); Social marketing; Marketing; Medicine; Pharmacology; Medical prescription","score_opus":0.025043897883231622,"score_gpt":0.31852818495342883,"score_spread":0.2934842870701972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088407458","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018368001,0.0007143168,0.0000587407,0.9870767,0.0021048062,0.000008349616,0.00004118555,0.0000120395225,0.008147052],"genre_scores_gemma":[0.024529226,0.0015693645,0.00020729286,0.9438201,0.01925431,0.000030238736,0.00002787772,0.000011563079,0.010549965],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9984528,0.00054685056,0.00012427129,0.00018164393,0.0004289359,0.00026550549],"domain_scores_gemma":[0.99248874,0.0054452494,0.0005093178,0.000112945425,0.00072627905,0.0007174064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021975061,0.00041391465,0.00092068105,0.0005094638,0.0021820539,0.002586772,0.001090488,0.053320542,0.013053837],"category_scores_gemma":[0.022626443,0.00032178272,0.00069849094,0.000454009,0.0020793017,0.0024111231,0.0006579502,0.018425986,0.0039503663],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006420361,0.00025744524,0.0052553173,0.000153892,0.00008770033,0.004997043,0.00030758698,0.00018151371,0.00066718226,0.018181851,0.920375,0.0488934],"study_design_scores_gemma":[0.001089731,0.00047917178,0.010219084,0.0005391351,0.0002309611,0.0074621495,0.0012173704,0.001754885,0.00080074085,0.029316964,0.9467894,0.00010043247],"about_ca_topic_score_codex":0.006873995,"about_ca_topic_score_gemma":0.015800096,"teacher_disagreement_score":0.053320542,"about_ca_system_score_codex":0.0031279724,"about_ca_system_score_gemma":0.0023734572,"threshold_uncertainty_score":0.043669403},"labels":[],"label_agreement":null},{"id":"W2090658196","doi":"10.2165/00019053-200826010-00006","title":"Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration","year":2008,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Macular degeneration; Socioeconomic status; Health care; Observational study; Public health; Medical record; Indirect costs; Environmental health; Gerontology; Surgery; Business; Ophthalmology; Population; Nursing; Economic growth","score_opus":0.019435737878942472,"score_gpt":0.29488377750688727,"score_spread":0.2754480396279448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090658196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8898686,0.018510675,0.00080996094,0.045871828,0.00047691748,0.000050689683,0.004620647,0.000017409948,0.039773185],"genre_scores_gemma":[0.98999083,0.006523183,0.00024586817,0.0007153101,0.00026650334,0.000013144514,0.00089320703,0.0000030636277,0.0013488773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991073,0.0004941149,0.00005415096,0.00002352371,0.00018144953,0.0001394399],"domain_scores_gemma":[0.9989926,0.00031394948,0.00029874648,0.00002031379,0.00015493487,0.00021941928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065664377,0.00013737023,0.000238851,0.0007571952,0.00028365286,0.0006417032,0.00018304498,0.00064334006,0.003616601],"category_scores_gemma":[0.0048034023,0.00010048434,0.00043704332,0.00092853437,0.00026405577,0.0004374695,0.00056621904,0.00072431343,0.00016558124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003629351,0.0006797914,0.6853307,0.0005603663,0.0008249,0.0052172067,0.0003379293,0.009553972,0.0011860782,0.026725342,0.033926915,0.23202755],"study_design_scores_gemma":[0.00032572472,0.00042499002,0.9302129,0.0004776298,0.00051446556,0.0071067414,0.0017873963,0.014488353,0.00023453175,0.0070616114,0.037324328,0.00004121681],"about_ca_topic_score_codex":0.019147346,"about_ca_topic_score_gemma":0.021267686,"teacher_disagreement_score":0.019147346,"about_ca_system_score_codex":0.0017328004,"about_ca_system_score_gemma":0.0013860659,"threshold_uncertainty_score":0.03807175},"labels":[],"label_agreement":null},{"id":"W2090799253","doi":"10.2165/00019053-200523050-00008","title":"Economic Evaluation of Levetiracetam as an Add-On Therapy in Patients with Refractory Epilepsy","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal General Hospital","funders":"Université Laval","keywords":"Levetiracetam; Medicine; Epilepsy; Epilepsy surgery; Placebo; Psychiatry","score_opus":0.046598821197151204,"score_gpt":0.38577601919394366,"score_spread":0.33917719799679247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090799253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9338095,0.03301524,0.0023419156,0.011391982,0.0006282332,0.0016049229,0.0023684935,0.000056446646,0.014783136],"genre_scores_gemma":[0.9954652,0.0024963394,0.000727599,0.00043073803,0.00009736522,0.00015631855,0.0003195099,0.0000047127737,0.00030224898],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9942853,0.004592346,0.00032439892,0.000109559696,0.00046174633,0.00022660349],"domain_scores_gemma":[0.9902664,0.007258394,0.0010423393,0.00015799227,0.00037904113,0.00089585315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004278777,0.00068060687,0.0015412794,0.0010699487,0.00033209892,0.0012321649,0.0005534052,0.0012259241,0.004648067],"category_scores_gemma":[0.02402839,0.0003008308,0.0025890837,0.0008731168,0.00053181394,0.00092715264,0.0007273212,0.001438201,0.00013977915],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62157404,0.005248228,0.039857477,0.0033771098,0.009209565,0.00094429863,0.00012836553,0.042463243,0.001504067,0.004966866,0.005305053,0.2654216],"study_design_scores_gemma":[0.3085939,0.17646678,0.2285354,0.00369583,0.04355172,0.0037104012,0.0016075624,0.18839951,0.0045831716,0.012241345,0.028219318,0.00039503624],"about_ca_topic_score_codex":0.0045410045,"about_ca_topic_score_gemma":0.0042564077,"teacher_disagreement_score":0.0046992665,"about_ca_system_score_codex":0.0046992665,"about_ca_system_score_gemma":0.0035398314,"threshold_uncertainty_score":0.034095705},"labels":[],"label_agreement":null},{"id":"W2091281082","doi":"10.2165/00019053-200321020-00004","title":"Cost Analysis of Ropinirole versus Levodopa in the Treatment of Parkinson??s Disease","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; PharmIdeas (Canada)","funders":"GlaxoSmithKline","keywords":"Ropinirole; Levodopa; Benserazide; Dyskinesia; Entacapone; Medicine; Pharmacoeconomics; Health economics; Selegiline; Parkinson's disease; Disease; Intensive care medicine; Public health; Internal medicine","score_opus":0.06608418641027519,"score_gpt":0.358011154427996,"score_spread":0.29192696801772083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091281082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9299913,0.036343634,0.006598233,0.006627511,0.00049531244,0.00084775477,0.0028210415,0.00013305205,0.016142078],"genre_scores_gemma":[0.99601126,0.0018339698,0.000811257,0.00031625948,0.00005987707,0.000082544975,0.00029081,0.000009000309,0.0005849964],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99613106,0.0030232398,0.0001419378,0.00011467517,0.00032127602,0.00026777547],"domain_scores_gemma":[0.9943562,0.0045126737,0.00040293473,0.00008812254,0.00027220306,0.0003679305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033425305,0.000928625,0.0022321471,0.0013302326,0.00036369046,0.0015907987,0.0009811906,0.0013906361,0.005610608],"category_scores_gemma":[0.01192213,0.0005038372,0.0028495614,0.0013879535,0.00044847332,0.0010534212,0.0005526422,0.0013115016,0.00016433361],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36940405,0.0026368082,0.018877298,0.0038576846,0.013160651,0.0015164359,0.00015307171,0.35338193,0.0032154773,0.010426151,0.0064941514,0.21687628],"study_design_scores_gemma":[0.08047876,0.06833691,0.14614059,0.0017625226,0.058226753,0.004065614,0.001473733,0.60188323,0.0038034653,0.018367572,0.014912763,0.00054803496],"about_ca_topic_score_codex":0.013802673,"about_ca_topic_score_gemma":0.009664953,"teacher_disagreement_score":0.013802673,"about_ca_system_score_codex":0.005376991,"about_ca_system_score_gemma":0.0022814753,"threshold_uncertainty_score":0.03901303},"labels":[],"label_agreement":null},{"id":"W2092033713","doi":"10.2165/00019053-200018020-00006","title":"Cost Effectiveness of Epoetin-?? to Augment Preoperative Autologous Blood Donation in Elective Cardiac Surgery","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Blood transfusion and management","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"University of Ottawa","keywords":"Medicine; Epoetin alfa; Perioperative; Donation; Erythropoietin; Blood transfusion; Augment; Cardiac surgery; Intensive care medicine; Surgery; Emergency medicine; Internal medicine","score_opus":0.025010670921858963,"score_gpt":0.3191836249523692,"score_spread":0.29417295403051025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092033713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98644596,0.006324073,0.00063008384,0.0020946546,0.00020093883,0.00020358003,0.00022001042,0.00003288201,0.0038477646],"genre_scores_gemma":[0.99828196,0.00065619964,0.00043495916,0.0002053403,0.00007652406,0.00003291092,0.00007854711,0.000002847767,0.00023077607],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9990361,0.0006354738,0.000075884,0.00005642244,0.000095489355,0.00010064538],"domain_scores_gemma":[0.99792814,0.0013577288,0.00025811314,0.000058039554,0.0000625082,0.00033544155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000929188,0.0003824585,0.0007664483,0.00046231726,0.00022768741,0.00070696656,0.0003448264,0.00081665674,0.0040003597],"category_scores_gemma":[0.0046198796,0.00016472473,0.0013133573,0.00030908594,0.00033552188,0.0005546818,0.0004610557,0.0012205325,0.00015780344],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5121616,0.012896557,0.0345899,0.0012135506,0.0026241718,0.0009511805,0.00015492525,0.025369199,0.0036582325,0.0026261534,0.0027420803,0.40101233],"study_design_scores_gemma":[0.13079704,0.30815881,0.38557675,0.0020138917,0.015393364,0.0048738834,0.0015302176,0.116142996,0.012749928,0.00866073,0.013754325,0.000348162],"about_ca_topic_score_codex":0.002378334,"about_ca_topic_score_gemma":0.0024664572,"teacher_disagreement_score":0.0040003597,"about_ca_system_score_codex":0.0015197572,"about_ca_system_score_gemma":0.0010531388,"threshold_uncertainty_score":0.013382554},"labels":[],"label_agreement":null},{"id":"W2093002176","doi":"10.2165/00019053-200119010-00007","title":"Economic Analysis of Initial HIV Treatment","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Efavirenz; Indinavir; Lamivudine; Zidovudine; Regimen; Medicine; Internal medicine; Reverse-transcriptase inhibitor; Clinical trial; Viral load; Pediatrics; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus; Viral disease","score_opus":0.028594484494454984,"score_gpt":0.36910868197365654,"score_spread":0.34051419747920153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093002176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56551135,0.030257748,0.047218647,0.04627036,0.0014667098,0.0034430956,0.016648436,0.00052496855,0.28865877],"genre_scores_gemma":[0.9702964,0.0034645647,0.002257499,0.0010142041,0.00027910428,0.0003275993,0.0010825825,0.00003774633,0.021240383],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99443984,0.0033320677,0.00012001307,0.00021904697,0.0006136228,0.001275561],"domain_scores_gemma":[0.98608845,0.011201766,0.0008937004,0.000264047,0.0006859682,0.00086613017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005354629,0.0015151066,0.0031580387,0.002359717,0.0009893916,0.0040891063,0.001990906,0.00343881,0.021171339],"category_scores_gemma":[0.025861252,0.0011978967,0.0022298014,0.0022480579,0.0012142129,0.0019353706,0.001171718,0.0038116975,0.00067851145],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016787246,0.0024362819,0.01815056,0.0016666893,0.0016717284,0.0016056829,0.000261162,0.6008222,0.0008875109,0.2146635,0.038042396,0.103005],"study_design_scores_gemma":[0.004042662,0.003251719,0.037512686,0.0007553915,0.002306352,0.0014029847,0.0012613563,0.796913,0.0014172771,0.11941196,0.03152364,0.00020087324],"about_ca_topic_score_codex":0.041890573,"about_ca_topic_score_gemma":0.024790838,"teacher_disagreement_score":0.041890573,"about_ca_system_score_codex":0.010922817,"about_ca_system_score_gemma":0.008980496,"threshold_uncertainty_score":0.08329344},"labels":[],"label_agreement":null},{"id":"W2094040162","doi":"10.2165/00019053-200220090-00006","title":"Assessment of Health Economics in Alzheimer??s Disease (AHEAD)","year":2002,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; Canadian Association of Radiation Oncology","funders":"","keywords":"Galantamine; Health economics; Medicine; Disease; Public health; Euros; Clinical trial; Gerontology; Pharmacoeconomics; Health care; Quality-adjusted life year; Dementia; Psychiatry; Cost effectiveness; Intensive care medicine; Donepezil; Internal medicine; Economics","score_opus":0.06987314835702371,"score_gpt":0.41614317746098606,"score_spread":0.3462700291039623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094040162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59822094,0.08331731,0.024998777,0.13702805,0.005229544,0.0020422211,0.05322161,0.00023292899,0.09570863],"genre_scores_gemma":[0.936939,0.016669793,0.015598234,0.0060182186,0.0019221731,0.000649729,0.006711683,0.000033035256,0.015458166],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980222,0.0011369381,0.00015088794,0.000046927104,0.0005431223,0.00009998416],"domain_scores_gemma":[0.99072963,0.0048673814,0.00088703324,0.00026393763,0.0024400526,0.00081197557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060475445,0.00035939657,0.0005433627,0.0019462752,0.0002492696,0.0017489267,0.00045490442,0.00080247,0.0064614536],"category_scores_gemma":[0.023689598,0.00019243326,0.00083885825,0.0014036823,0.00020648447,0.001434814,0.0007291065,0.0009766193,0.00071309163],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031112437,0.0016505949,0.35425684,0.0013388823,0.0008983415,0.00064581935,0.00037991983,0.009950865,0.0003588385,0.032109752,0.08596679,0.5093322],"study_design_scores_gemma":[0.0007485583,0.0026555825,0.814376,0.001855166,0.0010956159,0.0011483615,0.0013385575,0.030428423,0.0019437255,0.05343187,0.0908545,0.00012363074],"about_ca_topic_score_codex":0.009519023,"about_ca_topic_score_gemma":0.014600035,"teacher_disagreement_score":0.009519023,"about_ca_system_score_codex":0.0018119024,"about_ca_system_score_gemma":0.0035475348,"threshold_uncertainty_score":0.03198284},"labels":[],"label_agreement":null},{"id":"W2095469208","doi":"10.2165/00019053-200826050-00004","title":"Economic Evaluations in Rheumatoid Arthritis","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Advancing Health Outcomes; St. Paul's Hospital","funders":"","keywords":"Medicine; Rheumatoid arthritis; Rheumatology; MEDLINE; Physical therapy; Quality of life (healthcare); Pharmacoeconomics; Health administration; Clinical trial; Health economics; Randomized controlled trial; Internal medicine; Intensive care medicine; Public health; Pathology","score_opus":0.05338483011950388,"score_gpt":0.40762281049880084,"score_spread":0.35423798037929694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095469208","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012125817,0.9987772,0.00011628712,0.0003617919,0.0001106233,0.000020111178,0.000028467584,0.000002495853,0.000461736],"genre_scores_gemma":[0.0054849642,0.99311405,0.0004412884,0.00044213468,0.00019722665,0.000057804864,0.000036246016,0.0000026935636,0.00022361818],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919658,0.005160441,0.00095769175,0.00024588054,0.0014581581,0.00021198795],"domain_scores_gemma":[0.97903466,0.017646216,0.0021996126,0.00017774069,0.00075534574,0.00018640695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011782133,0.0017238812,0.006024104,0.006121583,0.00034158785,0.002815676,0.0011842834,0.0023134032,0.006737423],"category_scores_gemma":[0.031008566,0.0006497601,0.0029199228,0.007646836,0.0010814191,0.0017015282,0.0011658036,0.00264407,0.00037901924],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014175195,0.00018403475,0.00051832735,0.18352497,0.0055218614,0.00019448141,0.00007030577,0.0019851194,0.00013913255,0.008394978,0.022407679,0.77564156],"study_design_scores_gemma":[0.0052985866,0.0010795054,0.009622419,0.44835985,0.030355893,0.0021333885,0.0003314612,0.0026352904,0.0006251295,0.03731395,0.46210077,0.00014374495],"about_ca_topic_score_codex":0.004178697,"about_ca_topic_score_gemma":0.0077011148,"teacher_disagreement_score":0.011782133,"about_ca_system_score_codex":0.0033683777,"about_ca_system_score_gemma":0.0043770447,"threshold_uncertainty_score":0.062310636},"labels":[],"label_agreement":null},{"id":"W2096214040","doi":"10.2165/00019053-200523001-00006","title":"Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Risperidone; Compliance (psychology); Public health; Medicine; Pharmacoeconomics; Business; Intensive care medicine; Environmental health; Public economics; Psychiatry; Economics; Psychology; Nursing; Schizophrenia (object-oriented programming)","score_opus":0.04487550771609063,"score_gpt":0.34798799861995816,"score_spread":0.30311249090386755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096214040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652421,0.0013656373,0.0022033711,0.0058001433,0.000117496085,0.00023928273,0.008960276,0.00011560423,0.015956033],"genre_scores_gemma":[0.98979014,0.0005584988,0.000987367,0.0002402064,0.000022060736,0.000061489576,0.0013673282,0.000028082157,0.0069449446],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9979194,0.00057634193,0.00007948476,0.00019801206,0.0002234812,0.001003316],"domain_scores_gemma":[0.986815,0.008378831,0.0010094917,0.00024156808,0.0023458586,0.0012094323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023975277,0.0012110982,0.0019026579,0.00140775,0.0017304585,0.0035158326,0.0033121218,0.0035908904,0.010148416],"category_scores_gemma":[0.013939538,0.0014947953,0.002323703,0.0031206345,0.0016776473,0.0011776676,0.0011403799,0.0036460164,0.0004127452],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007919462,0.00025542805,0.020645976,0.00009582518,0.00026542463,0.00026906453,0.000120567674,0.9637894,0.00013276946,0.007214842,0.0030590247,0.0033597567],"study_design_scores_gemma":[0.00076135126,0.00024225605,0.020981936,0.00006976068,0.00047175374,0.00007445736,0.00070331607,0.9692919,0.0002419889,0.0034600091,0.0035984805,0.00010280977],"about_ca_topic_score_codex":0.98604196,"about_ca_topic_score_gemma":0.97519004,"teacher_disagreement_score":0.06638783,"about_ca_system_score_codex":0.06638783,"about_ca_system_score_gemma":0.05890159,"threshold_uncertainty_score":0.48167968},"labels":[],"label_agreement":null},{"id":"W2100804302","doi":"10.2165/00019053-200725060-00007","title":"Building Bridges Between Academic Research and Policy Formulation: When Costing Less Means Costing More","year":2007,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Activity-based costing; Health economics; Quality of Life Research; Health administration; Pharmacoeconomics; Public health; Business; Management science; Accounting; Economics; Medicine; Nursing","score_opus":0.6833153033704409,"score_gpt":0.5764666633956288,"score_spread":0.10684863997481209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100804302","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010874295,0.00036380134,0.00010591651,0.9966538,0.0019293219,0.0000043201962,0.00000599881,0.000005510238,0.0008226169],"genre_scores_gemma":[0.0029151838,0.0003003885,0.0003806559,0.98804957,0.0073305606,0.000026868916,0.0000057439347,0.000015024766,0.00097606156],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.932833,0.032734185,0.0051922346,0.00560257,0.0149943195,0.008643707],"domain_scores_gemma":[0.7394584,0.1922452,0.00913036,0.005380417,0.023581984,0.03020372],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.09038408,0.0013716847,0.003944311,0.0025841712,0.016803766,0.027705554,0.0059430352,0.17763372,0.01278261],"category_scores_gemma":[0.22033687,0.0019112861,0.0024185956,0.0029346868,0.03920412,0.036151323,0.013923419,0.1365503,0.0058852434],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094857045,0.000068523426,0.00054120563,0.00010924905,0.000043353033,0.0003949555,0.00079621753,0.000101056205,0.00010706949,0.070188835,0.9144247,0.013129919],"study_design_scores_gemma":[0.00053166377,0.00008709918,0.0013896095,0.0013216343,0.00010407818,0.0005904967,0.004643277,0.0011653581,0.0004240317,0.3597015,0.62977856,0.00026257566],"about_ca_topic_score_codex":0.02084111,"about_ca_topic_score_gemma":0.047571264,"teacher_disagreement_score":0.90961593,"about_ca_system_score_codex":0.02293257,"about_ca_system_score_gemma":0.06775584,"threshold_uncertainty_score":0.47800243},"labels":[],"label_agreement":null},{"id":"W2101393165","doi":"10.2165/00019053-200826010-00003","title":"Cost-Effectiveness Analyses of Hepatitis A Vaccine","year":2008,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Hepatitis Viruses Studies and Epidemiology","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de Santé Publique du Québec; Centre hospitalier universitaire de Québec; Toronto Public Health; University of Guelph; Children's Hospital of Eastern Ontario; University of Ottawa; GlaxoSmithKline (Canada); University Health Network; Institute of Population and Public Health; University of Toronto","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Medicine; Pharmacoeconomics; Hepatitis A; Cost effectiveness; Virology; Environmental health; Intensive care medicine; Hepatitis; Risk analysis (engineering); Nursing","score_opus":0.38128493480989,"score_gpt":0.5332267126210455,"score_spread":0.15194177781115548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101393165","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035713895,0.9989644,0.00008857839,0.00017783209,0.000059476206,0.000012371216,0.00007220558,0.000002118582,0.00026582045],"genre_scores_gemma":[0.00959226,0.9895421,0.00038320143,0.00019592352,0.0000891278,0.00002622085,0.00008484042,0.0000020369287,0.000084355146],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99762434,0.0011598801,0.00041449134,0.00014068137,0.00057315757,0.000087546374],"domain_scores_gemma":[0.9901177,0.008382592,0.0008534244,0.00009287501,0.00048602754,0.00006739637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044882204,0.0012393119,0.0045539625,0.0034851262,0.00013702172,0.0011749632,0.0013349933,0.0010727763,0.004274767],"category_scores_gemma":[0.014535168,0.00053234753,0.004635961,0.0045101885,0.00034259626,0.00094927044,0.0005815984,0.0012660415,0.00024186476],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001711404,0.00011610846,0.0013945817,0.24141267,0.022313723,0.00018151916,0.000047461963,0.0037350066,0.00026857253,0.002875143,0.008896289,0.7170475],"study_design_scores_gemma":[0.004332208,0.0024289803,0.03434037,0.38121307,0.22192852,0.0032607594,0.00037949314,0.004371189,0.0018187825,0.015753016,0.33001244,0.00016119168],"about_ca_topic_score_codex":0.0046734107,"about_ca_topic_score_gemma":0.008541867,"teacher_disagreement_score":0.0046734107,"about_ca_system_score_codex":0.002437484,"about_ca_system_score_gemma":0.0025301592,"threshold_uncertainty_score":0.023736238},"labels":[],"label_agreement":null},{"id":"W2107450864","doi":"10.2165/00019053-200321060-00002","title":"Health-Related Quality of Life and Regulatory Issues in the US and Canada","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Quality (philosophy); Business; Environmental health; Medicine; Nursing","score_opus":0.2480104449355913,"score_gpt":0.438640479605491,"score_spread":0.19063003466989972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107450864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44042584,0.06778158,0.0013280954,0.35255924,0.0011802597,0.00029048882,0.01957029,0.00008766382,0.11677644],"genre_scores_gemma":[0.95116794,0.012720648,0.0010142998,0.021009427,0.00028551082,0.00009455611,0.0029807095,0.00004733538,0.010679576],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9895483,0.00111944,0.0005804765,0.00048296063,0.0049131643,0.003355541],"domain_scores_gemma":[0.9612618,0.007847636,0.002591245,0.00046293237,0.020237962,0.0075983554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00897938,0.00026409808,0.0008143069,0.0045347107,0.0045677675,0.0061295023,0.0027395748,0.0029841794,0.0037523126],"category_scores_gemma":[0.034194715,0.00041814244,0.0011983007,0.009804756,0.002987552,0.0011979698,0.0014903636,0.003945995,0.00011043486],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00146893,0.0005414883,0.40455535,0.0008746293,0.0006518487,0.00086566544,0.004121035,0.011378047,0.00043407726,0.23109885,0.1831608,0.16084933],"study_design_scores_gemma":[0.00028322046,0.00008586822,0.8750449,0.0008861053,0.00032015558,0.00019324275,0.003282994,0.005437563,0.00031305433,0.009198016,0.10473397,0.00022105582],"about_ca_topic_score_codex":0.9984485,"about_ca_topic_score_gemma":0.998998,"teacher_disagreement_score":0.19618286,"about_ca_system_score_codex":0.19618286,"about_ca_system_score_gemma":0.2721732,"threshold_uncertainty_score":0.9323139},"labels":[],"label_agreement":null},{"id":"W2110633362","doi":"10.2165/00019053-200119080-00005","title":"Cost Effectiveness in Canada of a Multidrug Prepackaged Regimen (Hp-PAC??)* for Helicobacter pylori Eradication","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Helicobacter pylori-related gastroenterology studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph's Hospital","funders":"","keywords":"Lansoprazole; Clarithromycin; Copayment; Medicine; Metronidazole; Helicobacter pylori; Regimen; Amoxicillin; Pharmacoeconomics; Internal medicine; Cost effectiveness; Proton-pump inhibitor; Health economics; Health care; Intensive care medicine; Public health; Antibiotics","score_opus":0.03413564782754916,"score_gpt":0.32139746956526566,"score_spread":0.2872618217377165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110633362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95770884,0.015791837,0.00011825977,0.007080334,0.00017057183,0.00023740751,0.00973344,0.00002288614,0.009136542],"genre_scores_gemma":[0.99058294,0.004825331,0.00026097806,0.00087483675,0.000038111633,0.000048580536,0.0017776964,0.00000792128,0.0015834962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997988,0.00074280985,0.00014241275,0.0001058663,0.00056394405,0.0004569607],"domain_scores_gemma":[0.9931838,0.0017935478,0.0010914643,0.00013119541,0.002378062,0.0014218099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015080629,0.0003843789,0.0006899636,0.0008543956,0.0011290229,0.0013165257,0.0011748748,0.0008885899,0.0039892686],"category_scores_gemma":[0.014710717,0.00034417183,0.001754111,0.0031582473,0.0007406779,0.00053294405,0.0007418741,0.0011851179,0.00010517252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046132073,0.0023331621,0.79067665,0.002985586,0.0048140106,0.00057980703,0.0007410115,0.017363042,0.000514232,0.00574219,0.026064651,0.10205359],"study_design_scores_gemma":[0.005682236,0.0022692364,0.9660364,0.0006657601,0.0045403335,0.00023957055,0.0014390761,0.010658236,0.0003394369,0.0005839923,0.007438591,0.00010716178],"about_ca_topic_score_codex":0.9939434,"about_ca_topic_score_gemma":0.99457765,"teacher_disagreement_score":0.07952828,"about_ca_system_score_codex":0.07952828,"about_ca_system_score_gemma":0.07338634,"threshold_uncertainty_score":0.57702076},"labels":[],"label_agreement":null},{"id":"W2115224809","doi":"10.2165/00019053-200523060-00001","title":"Incorporation of uncertainty in health economic modelling studies","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Health economics; Quality of Life Research; Health administration; Public health; Health services research; Economics; Environmental health; Public economics; Medicine; Nursing","score_opus":0.5165894629374198,"score_gpt":0.5174184369747727,"score_spread":0.0008289740373529364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115224809","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.089537464,0.011587078,0.85464454,0.014724287,0.00091435545,0.00019102248,0.0012215986,0.00022660739,0.026953045],"genre_scores_gemma":[0.9514029,0.0052091074,0.03757475,0.00061093736,0.0005969745,0.00018424174,0.00026734735,0.00009155294,0.004062101],"study_design_codex":"simulation_or_modeling","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9884697,0.009485032,0.00041220261,0.00039952275,0.0008835147,0.00034996992],"domain_scores_gemma":[0.9306928,0.063053615,0.0028712563,0.0015064932,0.0013690208,0.0005068709],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016066154,0.0014720493,0.0021223794,0.001785417,0.00062902615,0.004469604,0.002304329,0.0038863495,0.0026808137],"category_scores_gemma":[0.08959697,0.0014560499,0.0015904215,0.0021178639,0.0013469934,0.0049112793,0.002598187,0.0031617472,0.0002394217],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005787107,0.000044933346,0.001100569,0.00011786102,0.0001979992,0.00012432635,0.00010444995,0.8867835,0.00004607359,0.103405,0.00065123773,0.007366191],"study_design_scores_gemma":[0.00002388151,0.000035882,0.0003576306,0.00010006566,0.000097769276,0.00003717385,0.000048221693,0.8189414,0.00008049939,0.17804515,0.0022010186,0.000031357962],"about_ca_topic_score_codex":0.009102624,"about_ca_topic_score_gemma":0.005671234,"teacher_disagreement_score":0.98393387,"about_ca_system_score_codex":0.0024504275,"about_ca_system_score_gemma":0.0018783547,"threshold_uncertainty_score":0.08496696},"labels":[],"label_agreement":null},{"id":"W2117460722","doi":"10.1007/s40273-013-0076-z","title":"Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective","year":2013,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Deferiprone; Medicine; Deferasirox; Cost–utility analysis; Quality-adjusted life year; Cost effectiveness; Pharmacoeconomics; Quality of life (healthcare); Intensive care medicine; Cost-effectiveness analysis; Thalassemia; Internal medicine; Risk analysis (engineering)","score_opus":0.015783703217200924,"score_gpt":0.29338491819478413,"score_spread":0.2776012149775832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117460722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88733655,0.029638011,0.03669715,0.007777258,0.00034573712,0.0009073326,0.009151613,0.00011856741,0.028027834],"genre_scores_gemma":[0.99327374,0.0019653083,0.002726612,0.00017236499,0.000023331291,0.00013939373,0.0007291084,0.000008552828,0.00096164295],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9971221,0.0022407447,0.00008861044,0.00012742516,0.00021494536,0.00020628145],"domain_scores_gemma":[0.9952034,0.003613108,0.0004754038,0.00009636976,0.00037326472,0.00023849106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035778913,0.00091498025,0.0013384166,0.0014711939,0.00030094013,0.0017304107,0.00084190554,0.0014636451,0.004561714],"category_scores_gemma":[0.012882974,0.0007114476,0.0029144345,0.0013219072,0.00047145158,0.0011123228,0.0009665738,0.001195298,0.0002488659],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044795093,0.00014909798,0.0099034645,0.001061319,0.0012520143,0.0006008797,0.00012546906,0.9515809,0.0006033903,0.009660853,0.0024941058,0.01808907],"study_design_scores_gemma":[0.0014874607,0.0027414504,0.017336188,0.0010494821,0.0018789129,0.00080961495,0.00036480723,0.9619586,0.00039094215,0.006931357,0.004923771,0.00012746819],"about_ca_topic_score_codex":0.043734483,"about_ca_topic_score_gemma":0.022309441,"teacher_disagreement_score":0.043734483,"about_ca_system_score_codex":0.00851076,"about_ca_system_score_gemma":0.0031938914,"threshold_uncertainty_score":0.08695984},"labels":[],"label_agreement":null},{"id":"W2118851499","doi":"10.2165/00019053-200422060-00004","title":"Measuring Treatment Preferences and Willingness to Pay for Docetaxel in Advanced Ovarian Cancer","year":2004,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Sunnybrook Health Science Centre; Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Docetaxel; Health economics; Willingness to pay; Quality of Life Research; Ovarian cancer; Health administration; Medicine; Public health; Oncology; Internal medicine; Economics; Intensive care medicine; Cancer; Nursing; Microeconomics","score_opus":0.06984964040290455,"score_gpt":0.3547769810316263,"score_spread":0.28492734062872177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118851499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989869,0.0001352382,0.00009553967,0.00010350231,0.000004029973,0.000012386949,0.000048501493,0.0000010634512,0.0006126704],"genre_scores_gemma":[0.99970824,0.000037205966,0.00009739549,0.000027911117,0.0000036783288,0.0000074459485,0.000032124794,5.31743e-7,0.00008550115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791366,0.0013523153,0.00015540454,0.000104075785,0.0002850623,0.00018954703],"domain_scores_gemma":[0.99181455,0.005792738,0.0014174699,0.00017916328,0.00022142161,0.00057456875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028859715,0.00026131634,0.0003988679,0.00066432793,0.00033226865,0.00085758074,0.0002656694,0.000878717,0.0019759396],"category_scores_gemma":[0.015039823,0.00018240121,0.00092639984,0.0006587323,0.00029286143,0.0005618551,0.0003080269,0.0009227528,0.00019346886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00591354,0.0012530526,0.96181464,0.00007139995,0.0005984896,0.00008748964,0.0002888658,0.002795193,0.00063640566,0.00030585178,0.00029736423,0.025937706],"study_design_scores_gemma":[0.00033137915,0.004221761,0.98070484,0.000042439307,0.0004007417,0.0005688772,0.0008813721,0.010285267,0.00093086733,0.00084294745,0.00074936275,0.000040089442],"about_ca_topic_score_codex":0.0024547917,"about_ca_topic_score_gemma":0.0033763365,"teacher_disagreement_score":0.0028859715,"about_ca_system_score_codex":0.00092698255,"about_ca_system_score_gemma":0.00048035488,"threshold_uncertainty_score":0.015262663},"labels":[],"label_agreement":null},{"id":"W2119939498","doi":"10.2165/00019053-200119110-00004","title":"Cost-Effectiveness Analysis and the Consistency of Decision Making","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":439,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Government of Canada","keywords":"Reimbursement; Listing (finance); Health economics; Actuarial science; League table; Cost effectiveness; Medicine; Quality-adjusted life year; Pharmacoeconomics; Public health; Economics; Health care; Risk analysis (engineering); Finance; Intensive care medicine; Nursing","score_opus":0.3606329120648894,"score_gpt":0.5047786977032513,"score_spread":0.14414578563836195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119939498","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1825989,0.022561964,0.75784516,0.017658848,0.0007220537,0.0011132936,0.0012662989,0.00033005764,0.015903303],"genre_scores_gemma":[0.9238252,0.0021231154,0.07092436,0.0010983335,0.0004865818,0.0004982795,0.00043334274,0.00008584118,0.0005249444],"study_design_codex":"simulation_or_modeling","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.6490692,0.3067851,0.013944434,0.008487461,0.019537438,0.0021763411],"domain_scores_gemma":[0.088996,0.8803605,0.013513394,0.011508928,0.0052056955,0.00041544766],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.25831652,0.0018019043,0.0053073624,0.0058692186,0.0009327151,0.007076007,0.0042651673,0.0049300655,0.0033604552],"category_scores_gemma":[0.7116225,0.0017223525,0.0044000833,0.0051544392,0.0069467844,0.009804691,0.0027143594,0.0060262373,0.00022882978],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005974553,0.00064159214,0.061847627,0.0020123438,0.0133388415,0.00044765198,0.0010914963,0.45503405,0.00040859936,0.30275324,0.0036180206,0.15283199],"study_design_scores_gemma":[0.00059034274,0.0006192441,0.010956405,0.00045172762,0.0016675242,0.0003008961,0.0002499826,0.33717826,0.0006770556,0.64495844,0.0022405656,0.00010951603],"about_ca_topic_score_codex":0.0035496256,"about_ca_topic_score_gemma":0.001432315,"teacher_disagreement_score":0.7416835,"about_ca_system_score_codex":0.0059735873,"about_ca_system_score_gemma":0.005348241,"threshold_uncertainty_score":0.9146278},"labels":[],"label_agreement":null},{"id":"W2120799817","doi":"10.1007/s40273-013-0057-2","title":"The Cost and Public Health Burden of Invasive Meningococcal Disease Outbreaks: A Systematic Review","year":2013,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Bacterial Infections and Vaccines","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Toronto Public Health","funders":"Canadian Institutes of Health Research; GlaxoSmithKline","keywords":"Public health; Health economics; Outbreak; Quality of Life Research; Health administration; Meningococcal disease; Medicine; Disease burden; Burden of disease; Disease; Environmental health; Quality-adjusted life year; Neisseria meningitidis; Cost effectiveness; Virology; Risk analysis (engineering); Nursing","score_opus":0.06974240109637254,"score_gpt":0.3583605125611188,"score_spread":0.28861811146474625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120799817","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028147742,0.994949,0.000102672566,0.00041818476,0.000091372705,0.00022354028,0.0010161363,0.0000070491465,0.00037730194],"genre_scores_gemma":[0.02207026,0.9763723,0.00041193137,0.00031354767,0.00007352142,0.0003238298,0.0003609142,0.0000046211753,0.00006902194],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.992663,0.0023610368,0.0028267142,0.00042751367,0.0014634965,0.00025829117],"domain_scores_gemma":[0.9598904,0.028407788,0.007558086,0.0003653327,0.0034175192,0.0003609046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006392784,0.0015374859,0.007859845,0.015414041,0.000598814,0.0028995892,0.0019125175,0.0021369471,0.004270008],"category_scores_gemma":[0.045743108,0.0013281957,0.007914323,0.018292759,0.0006715222,0.0027338865,0.0014559716,0.0011565516,0.00024062773],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022137248,0.000016242539,0.002629227,0.9549595,0.014311479,0.00018854516,0.00013092566,0.00015918972,0.00006480858,0.00018883993,0.0018861254,0.025243709],"study_design_scores_gemma":[0.00034712302,0.00020732051,0.014500772,0.8648211,0.10409677,0.0009738639,0.0005050364,0.00022988503,0.0001473175,0.000372404,0.013745979,0.000052415984],"about_ca_topic_score_codex":0.013149545,"about_ca_topic_score_gemma":0.028266072,"teacher_disagreement_score":0.015414041,"about_ca_system_score_codex":0.0050616576,"about_ca_system_score_gemma":0.011565817,"threshold_uncertainty_score":0.036725044},"labels":[],"label_agreement":null},{"id":"W2123469744","doi":"10.2165/00019053-200119090-00007","title":"A Multinational Study to Measure the Value that Patients with Cancer Place on Improved Emesis Control Following Cisplatin Chemotherapy","year":2001,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Nausea and vomiting management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research","funders":"H2020 European Research Council","keywords":"Medicine; Willingness to pay; Chemotherapy; Cisplatin; Cancer; Internal medicine; Anesthesia","score_opus":0.02062754250818304,"score_gpt":0.315755038182846,"score_spread":0.29512749567466295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123469744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99927,0.00007202022,0.000026713438,0.00008598633,0.000007874668,0.000055562286,0.00012230262,0.0000010463862,0.00035841102],"genre_scores_gemma":[0.9990865,0.000088792636,0.00013091776,0.00020008546,0.000012172348,0.00007357982,0.00020288893,0.0000011579052,0.0002039493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988336,0.0007319782,0.000087722234,0.00009779405,0.00012689439,0.000121926925],"domain_scores_gemma":[0.9948679,0.001663882,0.0018603485,0.00035447942,0.0003985844,0.0008547795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002536777,0.00033514368,0.00041441212,0.00037916418,0.00067243265,0.0007420764,0.0003744667,0.00066919264,0.0010790623],"category_scores_gemma":[0.0075509674,0.00024961968,0.00058489153,0.00087170786,0.00059900014,0.00060323137,0.0006573833,0.0010957442,0.00015461704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021783492,0.004428896,0.96283394,0.000058969887,0.00059569115,0.00006567972,0.00037042747,0.00013204289,0.0005063554,0.00005978941,0.00030782013,0.008856986],"study_design_scores_gemma":[0.0030496817,0.013211395,0.98144364,0.000024235735,0.00047153333,0.00009809961,0.0005003261,0.0002241451,0.00022088438,0.000036181737,0.00070518313,0.000014657889],"about_ca_topic_score_codex":0.01205959,"about_ca_topic_score_gemma":0.014513281,"teacher_disagreement_score":0.01205959,"about_ca_system_score_codex":0.0012652592,"about_ca_system_score_gemma":0.0014633386,"threshold_uncertainty_score":0.02397883},"labels":[],"label_agreement":null},{"id":"W2124777219","doi":"10.1007/s40273-014-0173-7","title":"Cost Effectiveness of Darunavir/ritonavir Combination Antiretroviral Therapy for Treatment-Naive Adults with HIV-1 Infection in Canada","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Darunavir; Ritonavir; Quality of Life Research; Medicine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Health economics; Public health; Health administration; Cost effectiveness; Pharmacoeconomics; Intensive care medicine; Virology; Viral load; Nursing","score_opus":0.017243557705987324,"score_gpt":0.2933875668528628,"score_spread":0.2761440091468755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124777219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611291,0.01651661,0.00012322723,0.005120856,0.00011955626,0.0001689326,0.004780495,0.000023028584,0.012018336],"genre_scores_gemma":[0.9938723,0.0035848645,0.00019645665,0.00039460594,0.000025262476,0.000016617032,0.00072399335,0.000004716113,0.0011812893],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99895465,0.00022397049,0.00008098749,0.00005705327,0.00036660724,0.0003167192],"domain_scores_gemma":[0.9983606,0.00027437546,0.00022614797,0.000017025126,0.0005347481,0.00058710313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065724633,0.00027536365,0.0006153449,0.00089085376,0.0010653868,0.0015350517,0.00093783444,0.0005807304,0.0028533468],"category_scores_gemma":[0.0036174962,0.00022259052,0.0010762443,0.0019909088,0.00040243784,0.00036297654,0.0005832065,0.0008115689,0.00007522015],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009267446,0.001300275,0.75357753,0.0015218866,0.0024853805,0.001086722,0.0007585391,0.022163272,0.00074201386,0.004594056,0.020961799,0.18154109],"study_design_scores_gemma":[0.0012665072,0.00071235263,0.96699923,0.00060808955,0.0020202543,0.0004118305,0.001940691,0.018331965,0.0002464143,0.0005136455,0.0068744407,0.00007455796],"about_ca_topic_score_codex":0.9907444,"about_ca_topic_score_gemma":0.99553525,"teacher_disagreement_score":0.06669547,"about_ca_system_score_codex":0.06669547,"about_ca_system_score_gemma":0.056303065,"threshold_uncertainty_score":0.48391175},"labels":[],"label_agreement":null},{"id":"W2126509908","doi":"10.2165/00019053-200321050-00005","title":"Peginterferon ??-2a (40kD) [Pegasys??] Improves HR-QOL Outcomes Compared with Unmodified Interferon ??-2a [Roferon??-A]","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Toronto Western Hospital; University of British Columbia; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Regimen; Alpha interferon; Internal medicine; Gastroenterology; Chronic hepatitis; Interferon; Quality of life (healthcare); Surgery; Virology; Virus","score_opus":0.0481153764406794,"score_gpt":0.3616311150536178,"score_spread":0.31351573861293835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126509908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908894,0.0034619537,0.00021852733,0.00061460875,0.00016984454,0.000066639885,0.00032495486,0.00008100694,0.0041730846],"genre_scores_gemma":[0.9961941,0.0013877357,0.00046261292,0.00034214024,0.0001259951,0.00003821,0.00041872787,0.000007347767,0.0010231863],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99987125,0.00006558121,0.000010139534,0.000014340443,0.000011707945,0.000026979827],"domain_scores_gemma":[0.9998242,0.000055638342,0.000043636024,0.000019050736,0.000006379488,0.000051032082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037207207,0.00023793364,0.0006756928,0.00017829663,0.00012343941,0.00020253033,0.00017854298,0.00034177824,0.0058470606],"category_scores_gemma":[0.00077103416,0.00010246132,0.0004991552,0.00019109958,0.00019377921,0.00039187475,0.00014104802,0.000549365,0.00047491473],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6007069,0.008298126,0.006734019,0.0004696084,0.0013278781,0.00021781537,0.000056892328,0.00075767684,0.017845837,0.00038402836,0.0030759207,0.36012533],"study_design_scores_gemma":[0.40610886,0.2822745,0.25796062,0.00043855445,0.004743367,0.0022149011,0.0003288484,0.0046007447,0.024261482,0.0026914491,0.014267682,0.00010905848],"about_ca_topic_score_codex":0.000719499,"about_ca_topic_score_gemma":0.000957568,"teacher_disagreement_score":0.0058470606,"about_ca_system_score_codex":0.00020357792,"about_ca_system_score_gemma":0.00024176446,"threshold_uncertainty_score":0.019560397},"labels":[],"label_agreement":null},{"id":"W2128419295","doi":"10.2165/00019053-200523080-00001","title":"Real-World Trials to Answer Real-World Questions","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"South Health Campus","funders":"","keywords":"Reimbursement; Health economics; Clinical trial; Health administration; Value (mathematics); Medicine; Health care; Relevance (law); Actuarial science; Management science; Public economics; Intensive care medicine; Risk analysis (engineering); Public health; Economics; Political science; Nursing; Computer science; Economic growth","score_opus":0.4318036598781997,"score_gpt":0.5269865391437449,"score_spread":0.09518287926554525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128419295","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.047625463,0.29496467,0.33644637,0.22893837,0.040726844,0.012866648,0.006550757,0.00059294736,0.031287946],"genre_scores_gemma":[0.54600656,0.054472823,0.24390784,0.10803968,0.013818773,0.027649036,0.0033212546,0.0002767005,0.002507317],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.66541445,0.30913037,0.014058551,0.0042377464,0.006454635,0.0007042336],"domain_scores_gemma":[0.14306207,0.81363803,0.0184376,0.01607481,0.007660205,0.0011273809],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.24173553,0.0022933544,0.0055218996,0.0026685111,0.00080512784,0.0048410315,0.0034154772,0.008998783,0.014864374],"category_scores_gemma":[0.6430078,0.0011289454,0.003319123,0.0033343881,0.004662528,0.009959285,0.0021120682,0.0082044145,0.0021343518],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025953803,0.0055696648,0.02440336,0.10514613,0.051564064,0.0013087039,0.0017167174,0.045572534,0.002008258,0.31041598,0.1265134,0.29982737],"study_design_scores_gemma":[0.0433415,0.009307832,0.007913204,0.030025847,0.015166338,0.0015613969,0.0015240739,0.042124137,0.0020226468,0.6807776,0.1658192,0.00041613882],"about_ca_topic_score_codex":0.00040131478,"about_ca_topic_score_gemma":0.0006960993,"teacher_disagreement_score":0.7582645,"about_ca_system_score_codex":0.0019194256,"about_ca_system_score_gemma":0.0030857727,"threshold_uncertainty_score":0.9350751},"labels":[],"label_agreement":null},{"id":"W2132649890","doi":"10.2165/00019053-200321080-00003","title":"Labour Force Participation Among Individuals with Hepatitis C in the US","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Yukon Health and Social Services; Institute of Health Economics; University of Alberta","funders":"","keywords":"Medicine; Confounding; Hepatitis C virus; Hepatitis C; Workforce; Public health; Hepatology; Demography; Internal medicine; Immunology; Virus; Pathology","score_opus":0.03471233796987222,"score_gpt":0.3608428828755597,"score_spread":0.3261305449056875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132649890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99826366,0.00020729484,0.000013269786,0.00043539278,0.000007338567,0.0000057631287,0.00039071648,8.295261e-7,0.0006756801],"genre_scores_gemma":[0.999111,0.00019011737,0.0000099667595,0.00012271552,0.000008678384,0.000009696701,0.00016626925,4.159606e-7,0.00038117383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943537,0.0001890684,0.000047804155,0.000039473936,0.000080154525,0.00020815918],"domain_scores_gemma":[0.999199,0.00014795506,0.0002817245,0.000023170764,0.0000901825,0.0002580643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043680673,0.00015296935,0.00018911905,0.0010519841,0.00063396955,0.0005190822,0.00032066737,0.00069619715,0.001567647],"category_scores_gemma":[0.0017342806,0.00016022526,0.00030265987,0.0012626046,0.0002830437,0.00042629056,0.00055428885,0.00055937545,0.00017112127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006668886,0.000054155913,0.9974011,0.0000075750245,0.000016276004,0.00007187669,0.0005229612,0.000022972687,0.00009984821,0.000023083108,0.00021292195,0.0015005589],"study_design_scores_gemma":[0.000003976526,0.000037014237,0.9975126,0.000013395596,0.000008090324,0.000058458532,0.00200348,0.00009245104,0.000016462885,0.00002639263,0.00022484154,0.0000028321167],"about_ca_topic_score_codex":0.11488343,"about_ca_topic_score_gemma":0.14081986,"teacher_disagreement_score":0.11488343,"about_ca_system_score_codex":0.00056785584,"about_ca_system_score_gemma":0.00092788786,"threshold_uncertainty_score":0.22842944},"labels":[],"label_agreement":null},{"id":"W2136793894","doi":"10.1007/s40273-015-0340-5","title":"Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; TransCanada (Canada); SNC-Lavalin (Canada)","funders":"","keywords":"Management science; Context (archaeology); Multiple-criteria decision analysis; Psychological intervention; Prioritization; Risk analysis (engineering); Adaptation (eye); Disease; Process management; Medicine; Psychology; Business; Economics; Operations research","score_opus":0.45654649083546067,"score_gpt":0.5157299019594791,"score_spread":0.059183411124018426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136793894","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012425244,0.031727694,0.42064723,0.40832347,0.0035022022,0.00502661,0.0010713019,0.00028361168,0.11699255],"genre_scores_gemma":[0.2885286,0.0147372475,0.64947534,0.033282217,0.0013101862,0.009530084,0.0005824838,0.00011760612,0.0024362558],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.7608101,0.20240371,0.0116074905,0.005152166,0.01613922,0.0038874159],"domain_scores_gemma":[0.6613936,0.27624878,0.014272488,0.016368382,0.026529375,0.005187489],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.26557794,0.0018737414,0.004361001,0.009450656,0.0031944425,0.01464005,0.005696357,0.011479204,0.0050103078],"category_scores_gemma":[0.3324403,0.0010388938,0.003989693,0.0060468744,0.015177919,0.01546642,0.011138099,0.010460346,0.0010537871],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105006984,0.00012666188,0.0009866417,0.005239253,0.00030666607,0.00017969795,0.002260498,0.007823822,0.0001381289,0.9082747,0.008834906,0.0657239],"study_design_scores_gemma":[0.00014132286,0.00012567935,0.00063380867,0.013712854,0.000215207,0.000119358134,0.0016912803,0.004831583,0.00023299936,0.9116855,0.066526294,0.00008424316],"about_ca_topic_score_codex":0.0062213806,"about_ca_topic_score_gemma":0.009941992,"teacher_disagreement_score":0.7344221,"about_ca_system_score_codex":0.017515948,"about_ca_system_score_gemma":0.063724466,"threshold_uncertainty_score":0.90567315},"labels":[],"label_agreement":null},{"id":"W2138874398","doi":"10.2165/00019053-200624100-00004","title":"Therapeutic Options for the Prevention and Treatment of Postoperative Nausea and Vomiting","year":2006,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Nausea and vomiting management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Nausea; Quality of Life Research; Medicine; Vomiting; Health economics; Health administration; Intensive care medicine; Public health; Abdominal surgery; Pharmacoeconomics; Anesthesia; Internal medicine; Nursing","score_opus":0.12778055701150198,"score_gpt":0.4377567835196323,"score_spread":0.30997622650813034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138874398","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015449569,0.9985759,0.00016661627,0.00016091677,0.00008902428,0.000008700471,0.000018027158,0.0000061836718,0.0008201321],"genre_scores_gemma":[0.0008849674,0.9982316,0.00036953975,0.00014361486,0.00008738564,0.000008422958,0.00002638537,0.0000010016424,0.00024710046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998259,0.000037935784,0.000032199678,0.00002440351,0.00006460847,0.000014999867],"domain_scores_gemma":[0.99968255,0.00017697018,0.000065317625,0.000008205344,0.000046904643,0.000020072282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004693864,0.0009504144,0.0019477097,0.0024882713,0.00027809804,0.0006966886,0.00091052917,0.0008419413,0.0049775066],"category_scores_gemma":[0.00071952376,0.00022588795,0.0007238149,0.0023020084,0.0004105518,0.0007431708,0.00054836005,0.0017727021,0.0012756045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092294846,0.00013566141,0.00016496291,0.012787765,0.00017197998,0.0002329947,0.000032989275,0.0002509456,0.00089830195,0.0010660962,0.009062683,0.9751033],"study_design_scores_gemma":[0.00021346392,0.00043998903,0.00424692,0.017068096,0.0009327839,0.0044672242,0.00018103376,0.00028134868,0.0012577935,0.0035711683,0.967283,0.000057151872],"about_ca_topic_score_codex":0.0012455276,"about_ca_topic_score_gemma":0.0029895299,"teacher_disagreement_score":0.0049775066,"about_ca_system_score_codex":0.00035401643,"about_ca_system_score_gemma":0.0005969222,"threshold_uncertainty_score":0.016651392},"labels":[],"label_agreement":null},{"id":"W2140200413","doi":"10.1007/s40273-013-0038-5","title":"Optimal Global Value of Information Trials: Better Aligning Manufacturer and Decision Maker Interests and Enabling Feasible Risk Sharing","year":2013,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Public Health Ontario; University of Toronto","funders":"","keywords":"Jurisdiction; Value of information; Payment; Actuarial science; Business; Information sharing; Health administration; Value (mathematics); Risk analysis (engineering); Cost–benefit analysis; Clinical trial; Public health; Economics; Medicine; Computer science; Finance; Nursing","score_opus":0.40964457186727316,"score_gpt":0.5135418632303225,"score_spread":0.10389729136304932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140200413","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004075117,0.9079447,0.05876704,0.016247189,0.00045322903,0.0002896779,0.0001874063,0.000053439886,0.011982313],"genre_scores_gemma":[0.25748545,0.68680245,0.04545839,0.0051548975,0.0023784412,0.0007963954,0.00022499546,0.000056019206,0.0016429895],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9673498,0.026653301,0.0013659835,0.0007877479,0.0033269776,0.000516202],"domain_scores_gemma":[0.87952226,0.11284959,0.0041083326,0.0013230542,0.001770748,0.00042602903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.035448894,0.0012785748,0.00496464,0.0023628902,0.00034762308,0.005374908,0.0021164112,0.0046765483,0.005157372],"category_scores_gemma":[0.09623307,0.00062444294,0.0022299616,0.0027857888,0.0025932537,0.0061897356,0.0023160912,0.004072787,0.0004026913],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009297625,0.00014992087,0.0010419948,0.017537396,0.0027505057,0.00013086348,0.00020532991,0.025508553,0.00024076755,0.17818718,0.006879925,0.76643777],"study_design_scores_gemma":[0.0010316289,0.00046528704,0.002009733,0.030876217,0.004248854,0.000520677,0.00026589775,0.016446833,0.0006996012,0.8775975,0.06574415,0.000093742994],"about_ca_topic_score_codex":0.0010561484,"about_ca_topic_score_gemma":0.0011230947,"teacher_disagreement_score":0.035448894,"about_ca_system_score_codex":0.0035297659,"about_ca_system_score_gemma":0.006800411,"threshold_uncertainty_score":0.1874739},"labels":[],"label_agreement":null},{"id":"W2141213392","doi":"10.2165/00019053-200927020-00005","title":"Willingness to Pay for a Treatment for Pain in Multiple Sclerosis","year":2009,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Bayer (Canada); PharmIdeas (Canada)","funders":"Bayer Canada","keywords":"Medicine; Willingness to pay; Pill; Population; Family medicine; Environmental health; Nursing","score_opus":0.17550560153952882,"score_gpt":0.3951472963703454,"score_spread":0.21964169483081658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141213392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855919,0.005040626,0.00025926004,0.0030489422,0.00011504111,0.000082558436,0.0004713057,0.0000028365052,0.0053876336],"genre_scores_gemma":[0.99795085,0.00066377496,0.00014827237,0.0004832293,0.00005978674,0.000051527546,0.00013415287,0.0000015588488,0.00050678564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.991418,0.006760328,0.000617751,0.00021224542,0.0006164733,0.00037523528],"domain_scores_gemma":[0.95729506,0.03450318,0.0051444406,0.0012439596,0.00071400194,0.0010993358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070595723,0.00020439053,0.00067217025,0.0011079842,0.0006078253,0.0013708404,0.0006261593,0.0022569313,0.008458183],"category_scores_gemma":[0.046149757,0.00032168638,0.0014382867,0.0013558528,0.0005847525,0.0012718284,0.00072702015,0.0020079797,0.00033361287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024465835,0.0038673424,0.87932265,0.001535736,0.0060198135,0.0004872314,0.0010078637,0.0014464475,0.00068326085,0.0045069125,0.0021736268,0.07448322],"study_design_scores_gemma":[0.0017665767,0.0042518014,0.97841454,0.00074109505,0.0024683587,0.0010528449,0.0022783806,0.001864341,0.00039877923,0.0032637864,0.003434577,0.00006500946],"about_ca_topic_score_codex":0.0037149147,"about_ca_topic_score_gemma":0.0037993125,"teacher_disagreement_score":0.008458183,"about_ca_system_score_codex":0.001015927,"about_ca_system_score_gemma":0.00082598254,"threshold_uncertainty_score":0.03733504},"labels":[],"label_agreement":null},{"id":"W2147206176","doi":"10.2165/00019053-200624040-00008","title":"A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of??Hypertension with Left Ventricular Hypertrophy","year":2006,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); BC Centre for Disease Control; University of British Columbia; Peace Arch Hospital; Centre for Advancing Health Outcomes","funders":"","keywords":"Atenolol; Losartan; Medicine; Left ventricular hypertrophy; Cardiology; Myocardial infarction; Internal medicine; Cost effectiveness; Stroke (engine); Angiotensin II; Blood pressure","score_opus":0.3554939530175164,"score_gpt":0.42136845188425487,"score_spread":0.06587449886673846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147206176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9507477,0.017932232,0.017252795,0.0043518995,0.00026394494,0.00084930053,0.0023402032,0.00011615078,0.0061457804],"genre_scores_gemma":[0.9965521,0.0008616714,0.0014860416,0.00019002131,0.00005317235,0.00008679448,0.00028032277,0.0000072464986,0.00048256165],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99146944,0.0074997037,0.00018876408,0.00021897684,0.0002861037,0.00033694573],"domain_scores_gemma":[0.97764117,0.020312943,0.00072539155,0.0002454135,0.00042377194,0.0006513785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009571398,0.0016770374,0.0031672718,0.0022951413,0.00039327028,0.0023110975,0.001507806,0.0017566995,0.005189383],"category_scores_gemma":[0.027421497,0.0008307224,0.0035648781,0.0018140535,0.0010803163,0.0016519027,0.001144202,0.0021677136,0.00020430071],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26674795,0.0036151353,0.030903468,0.0032247033,0.016624505,0.0011779955,0.0002794855,0.578138,0.0021596781,0.013073773,0.0044672564,0.07958811],"study_design_scores_gemma":[0.027844403,0.016712982,0.031889226,0.00052787334,0.023003185,0.00083796703,0.0006477494,0.8851664,0.00095195655,0.010033247,0.0021311673,0.00025376852],"about_ca_topic_score_codex":0.012850517,"about_ca_topic_score_gemma":0.006078519,"teacher_disagreement_score":0.012850517,"about_ca_system_score_codex":0.0053906515,"about_ca_system_score_gemma":0.0019906699,"threshold_uncertainty_score":0.050619006},"labels":[],"label_agreement":null},{"id":"W2147993182","doi":"10.2165/11599390-000000000-00000","title":"Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis","year":2012,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; St. Michael's Hospital","funders":"Amgen","keywords":"Medicine; Dialysis; Intensive care medicine; Reimbursement; Kidney disease; Peritoneal dialysis; Internal medicine; Health care","score_opus":0.3292884502491599,"score_gpt":0.4821966201663837,"score_spread":0.15290816991722378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147993182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9309471,0.03550912,0.008262357,0.006624993,0.00045186392,0.0008191318,0.0045346892,0.000073526,0.01277722],"genre_scores_gemma":[0.99609864,0.0017788671,0.0008450271,0.00019008669,0.00006748802,0.000066068285,0.00061032805,0.0000046286204,0.00033886326],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9932033,0.0053846478,0.00028730513,0.00019058399,0.00049149775,0.0004426404],"domain_scores_gemma":[0.9889875,0.009364794,0.00065412314,0.00016611742,0.00037584023,0.00045160783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053433524,0.0010104742,0.001957969,0.0017123414,0.0003431992,0.0019174571,0.000934479,0.0013209708,0.0041148136],"category_scores_gemma":[0.022042263,0.00049791165,0.0041279946,0.0016972569,0.00062057015,0.0013888546,0.0008087214,0.0017033702,0.00011487738],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07229574,0.0040176963,0.13245234,0.0058054985,0.023565702,0.00083669723,0.0003043178,0.57987875,0.0019467406,0.025714494,0.0068008834,0.14638111],"study_design_scores_gemma":[0.01727191,0.024425894,0.25519934,0.0019981787,0.038854282,0.0016749318,0.0015659791,0.6203967,0.0024520517,0.025197089,0.010672518,0.00029119375],"about_ca_topic_score_codex":0.012371869,"about_ca_topic_score_gemma":0.009228856,"teacher_disagreement_score":0.012371869,"about_ca_system_score_codex":0.0050645494,"about_ca_system_score_gemma":0.0025992326,"threshold_uncertainty_score":0.036746025},"labels":[],"label_agreement":null},{"id":"W2151010917","doi":"10.2165/11584210-000000000-00000","title":"Advances in Cancer Therapeutics and Patient Access to New Drugs","year":2010,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer; Health economics; Cancer drugs; Pharmacoeconomics; Intensive care medicine; Health care; Disease; Public health; Quality of Life Research; Population; Healthcare system; Cancer incidence; Environmental health; Economic growth; Internal medicine; Pathology","score_opus":0.09089073921970828,"score_gpt":0.39374633602052017,"score_spread":0.30285559680081187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151010917","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011904832,0.9979462,0.000109496985,0.0009954657,0.00008132827,0.0000014393917,0.000014774581,0.0000015941702,0.0007307001],"genre_scores_gemma":[0.0013358408,0.9980757,0.000078696954,0.00016429876,0.00020045113,0.0000017492864,0.000012067337,4.6536752e-7,0.00013059238],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994318,0.00018666498,0.000050467337,0.000066881315,0.0002277764,0.00003630242],"domain_scores_gemma":[0.99724567,0.0019974043,0.00033885217,0.000040607523,0.00031205962,0.00006550682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015922209,0.00076024665,0.001509139,0.0022499755,0.00019246941,0.001303109,0.0006104413,0.0014571159,0.0040871087],"category_scores_gemma":[0.0036930374,0.0002944424,0.000559464,0.005120502,0.0007093297,0.0013520413,0.0005782083,0.0018384228,0.00065280905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008980402,0.00008182898,0.0008899532,0.010551783,0.00029390396,0.00013788603,0.00002847068,0.0023671393,0.00026991242,0.019933311,0.031000022,0.934356],"study_design_scores_gemma":[0.000068481866,0.00009111651,0.0068027684,0.010592037,0.00047261745,0.0011518596,0.00014132928,0.0010735847,0.00034104058,0.028332174,0.95089096,0.000041972296],"about_ca_topic_score_codex":0.0039405865,"about_ca_topic_score_gemma":0.007540972,"teacher_disagreement_score":0.0040871087,"about_ca_system_score_codex":0.0017168132,"about_ca_system_score_gemma":0.002732093,"threshold_uncertainty_score":0.013672769},"labels":[],"label_agreement":null},{"id":"W2153235272","doi":"10.2165/00019053-200017020-00007","title":"Impact of Zanamivir Treatment on Productivity, Health Status and Healthcare Resource Use in Patients with Influenza","year":2000,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Mosquito-borne diseases and control","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Zanamivir; Medicine; Placebo; Absenteeism; Work productivity; Psychological intervention; Health care; Internal medicine; Physical therapy; Productivity; Alternative medicine; Coronavirus disease 2019 (COVID-19); Psychiatry; Disease","score_opus":0.022060285284727,"score_gpt":0.34250113768582274,"score_spread":0.32044085240109577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153235272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983064,0.00071761233,0.000015259946,0.00025972663,0.000015561085,0.0000116057345,0.00018639825,0.0000016007582,0.0004858239],"genre_scores_gemma":[0.99952507,0.00016455083,0.000026742076,0.00007552902,0.000009750927,0.0000045138795,0.00012036971,4.8179646e-7,0.00007293081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993419,0.00027940015,0.000071552466,0.000042485834,0.00007798781,0.0001865409],"domain_scores_gemma":[0.9991001,0.00031206766,0.00027571435,0.00003318452,0.00008304136,0.00019590737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007726527,0.00024082052,0.0005492184,0.000258471,0.0005228686,0.0006520182,0.00030700167,0.0005182385,0.0010037554],"category_scores_gemma":[0.003192791,0.00017357028,0.0011856237,0.00054229866,0.00022477613,0.0005170196,0.00038833846,0.00080711045,0.0000953939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006028347,0.00051841786,0.97811586,0.00009134586,0.0006584659,0.000184026,0.00016788629,0.0004295076,0.00044250544,0.000040260402,0.00031181303,0.013011653],"study_design_scores_gemma":[0.00010716491,0.0008161934,0.9980433,0.000010905403,0.00021505512,0.0000612463,0.00022554204,0.0003464073,0.000047918107,0.000020964137,0.00009936677,0.000005899564],"about_ca_topic_score_codex":0.02920238,"about_ca_topic_score_gemma":0.048266046,"teacher_disagreement_score":0.02920238,"about_ca_system_score_codex":0.0012924925,"about_ca_system_score_gemma":0.0011279318,"threshold_uncertainty_score":0.05806482},"labels":[],"label_agreement":null},{"id":"W2153993125","doi":"10.2165/11592250-000000000-00000","title":"Value of Information and Pricing New Healthcare Interventions","year":2012,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto","funders":"","keywords":"Health economics; Health administration; Psychological intervention; Health care; Quality of Life Research; Public health; Value of information; Value (mathematics); Health informatics; Actuarial science; Business; Medicine; Economics; Statistics; Nursing; Mathematics; Economic growth","score_opus":0.3765059328836996,"score_gpt":0.49256008756122993,"score_spread":0.11605415467753033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153993125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52789724,0.046515595,0.22305182,0.08465675,0.0015157494,0.00047489587,0.0029423751,0.0002572391,0.112688296],"genre_scores_gemma":[0.98676306,0.0037988988,0.0051788525,0.0005502063,0.0007438223,0.000041600462,0.0002249301,0.000028757599,0.0026699791],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9907684,0.0061973203,0.0003710482,0.00046764995,0.0016942053,0.000501349],"domain_scores_gemma":[0.8398978,0.14826335,0.0048717125,0.0026095903,0.0030147806,0.0013426903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0135597205,0.0010672819,0.0017384215,0.004014318,0.0004941923,0.007336052,0.0016875805,0.0050810277,0.0058965283],"category_scores_gemma":[0.11547301,0.0008687687,0.0009564985,0.0032278786,0.0029136674,0.0117391,0.0012792422,0.0041169594,0.00030008345],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023084464,0.0007071291,0.031636216,0.00069285894,0.0007968505,0.00087353715,0.00041468785,0.28814086,0.00062910427,0.5090257,0.011550558,0.1532241],"study_design_scores_gemma":[0.0001893206,0.00027042584,0.0090138605,0.00030335746,0.00035075124,0.00042578377,0.0003471989,0.26239756,0.000419916,0.7213307,0.004862856,0.000088181754],"about_ca_topic_score_codex":0.002664964,"about_ca_topic_score_gemma":0.002048858,"teacher_disagreement_score":0.0135597205,"about_ca_system_score_codex":0.0039210594,"about_ca_system_score_gemma":0.0018186044,"threshold_uncertainty_score":0.07171148},"labels":[],"label_agreement":null},{"id":"W2156582040","doi":"10.2165/11587100-000000000-00000","title":"Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SickKids Foundation","funders":"University of Oxford","keywords":"Reimbursement; Cost effectiveness; Inference; Risk analysis (engineering); Health economics; Health administration; Actuarial science; Computer science; Management science; Health care; Economics; Medicine; Artificial intelligence","score_opus":0.7197568518310095,"score_gpt":0.4915481136755557,"score_spread":0.22820873815545378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156582040","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03626136,0.434747,0.23968916,0.19573164,0.016523086,0.009531236,0.0319399,0.0009119103,0.0346647],"genre_scores_gemma":[0.39504635,0.11267768,0.4408876,0.024106586,0.007572951,0.010254491,0.0077084294,0.00024131115,0.0015045911],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.78331244,0.14858823,0.048217934,0.0035340488,0.015094996,0.0012523092],"domain_scores_gemma":[0.49794102,0.42635903,0.037889436,0.010095766,0.02532509,0.002389753],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.14754713,0.004502954,0.011518825,0.025802994,0.0012272432,0.014075475,0.0034595844,0.00803736,0.0111362925],"category_scores_gemma":[0.4865794,0.0011848187,0.009061826,0.016065529,0.0017714411,0.01148957,0.0039987015,0.008062697,0.0016166999],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004852291,0.00086352456,0.021195645,0.15934607,0.050754104,0.0009056973,0.0016211543,0.016627768,0.0009854704,0.080423966,0.06944811,0.59297615],"study_design_scores_gemma":[0.006041877,0.0048229937,0.01796286,0.21381901,0.100824304,0.0016061636,0.004271119,0.022349246,0.0055814637,0.46857652,0.15301426,0.0011301226],"about_ca_topic_score_codex":0.0021522953,"about_ca_topic_score_gemma":0.0044525564,"teacher_disagreement_score":0.8524529,"about_ca_system_score_codex":0.004900702,"about_ca_system_score_gemma":0.0087726135,"threshold_uncertainty_score":0.78031313},"labels":[],"label_agreement":null},{"id":"W2161334757","doi":"10.2165/00019053-200321040-00006","title":"Ontario??s Formulary Committee","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital; De Veber; University Health Network; University of Toronto; University of Saskatchewan","funders":"Government of Ontario","keywords":"Formulary; Quality of Life Research; Health economics; Health administration; Public health; Medicine; Business; Family medicine; Nursing","score_opus":0.3558578487915637,"score_gpt":0.45099031287817704,"score_spread":0.09513246408661336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161334757","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005751358,0.007355899,0.0023453245,0.19234869,0.017011523,0.0011805145,0.010272312,0.0011841798,0.76255023],"genre_scores_gemma":[0.0073219235,0.001826067,0.0012763994,0.013351819,0.0010749154,0.000114569,0.0020526059,0.00021212576,0.9727696],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99393153,0.00034371435,0.0002569113,0.0002986004,0.004289846,0.0008794091],"domain_scores_gemma":[0.983021,0.0006401157,0.00035167494,0.00083073956,0.0134718055,0.0016845828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047634006,0.00064219936,0.000842658,0.002856147,0.0048116795,0.0063980226,0.0022448665,0.0050504724,0.08719762],"category_scores_gemma":[0.011703728,0.0007891629,0.0010972912,0.002504684,0.0013095463,0.0016776434,0.0012581372,0.0023682998,0.023030547],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003097454,0.00001499097,0.00041271787,0.000035236462,0.0000049058503,0.0000399521,0.000021222873,0.000041828214,0.00013766863,0.0060602976,0.97896725,0.014232902],"study_design_scores_gemma":[0.000016661572,0.0000058813766,0.00086567795,0.00003385706,0.0000054988745,0.000022395421,0.000022844255,0.00008983133,0.0001141111,0.00036924478,0.99844736,0.0000066523194],"about_ca_topic_score_codex":0.7189345,"about_ca_topic_score_gemma":0.84410495,"teacher_disagreement_score":0.9735432,"about_ca_system_score_codex":0.026456773,"about_ca_system_score_gemma":0.08022718,"threshold_uncertainty_score":0.5654415},"labels":[],"label_agreement":null},{"id":"W216758753","doi":"10.1007/s40273-015-0287-6","title":"Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"","keywords":"Baseline (sea); Cost effectiveness; Covariate; Medicine; Health economics; Randomized controlled trial; Quality of life (healthcare); Regression analysis; Health administration; Variable (mathematics); Regression; Variable cost; Public health; Statistics; Econometrics; Economics; Surgery; Mathematics; Risk analysis (engineering)","score_opus":0.41059188024159354,"score_gpt":0.459752640167694,"score_spread":0.04916075992610047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W216758753","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.063255735,0.0655166,0.48582634,0.2583912,0.08668634,0.0019128813,0.01883047,0.009930606,0.009649821],"genre_scores_gemma":[0.47233585,0.009344983,0.34665462,0.1168233,0.016139809,0.0026956843,0.0067593358,0.008349827,0.020896705],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.92878234,0.05145546,0.0061362945,0.0065734773,0.005080619,0.0019718513],"domain_scores_gemma":[0.87409365,0.08721881,0.00850616,0.020337611,0.007515507,0.00232818],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0969702,0.0017688181,0.006127217,0.0014449374,0.0010534031,0.0040560463,0.002876192,0.0049637356,0.0092900405],"category_scores_gemma":[0.3144296,0.0013124958,0.007038439,0.0038529872,0.0018906893,0.0065034344,0.0016816364,0.010587813,0.003247178],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042871316,0.00073979143,0.100184046,0.00293837,0.039684247,0.0005478442,0.0015305076,0.0049266284,0.0022359292,0.016076023,0.49172884,0.3351206],"study_design_scores_gemma":[0.0058826962,0.0033069914,0.25448743,0.0060551874,0.03931337,0.0018902224,0.0018991966,0.060401313,0.010392195,0.20481908,0.40928516,0.0022671586],"about_ca_topic_score_codex":0.01127061,"about_ca_topic_score_gemma":0.012318776,"teacher_disagreement_score":0.9030298,"about_ca_system_score_codex":0.0009823018,"about_ca_system_score_gemma":0.0033003746,"threshold_uncertainty_score":0.5128336},"labels":[],"label_agreement":null},{"id":"W2174595477","doi":"10.1007/s40273-015-0331-6","title":"National Database for Autism Research (NDAR): Big Data Opportunities for Health Services Research and Health Technology Assessment","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Autism Spectrum Disorder Research","field":"Neuroscience","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Institutes of Health; National Institute of Mental Health; Simons Foundation Autism Research Initiative","keywords":"Autism; Data collection; Public health; Data sharing; Medicine; Identifier; Data science; Psychological intervention; Knowledge management; Computer science; Psychiatry; Nursing; Alternative medicine","score_opus":0.7495710935510302,"score_gpt":0.6006506699953719,"score_spread":0.14892042355565838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2174595477","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009832571,0.0022456853,0.0032977955,0.0068383673,0.00060216355,0.0002121394,0.9816065,0.0011286809,0.00308542],"genre_scores_gemma":[0.013509278,0.0035454119,0.020182941,0.0054533817,0.00054475653,0.0016949408,0.9531648,0.0006054354,0.0012989645],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97879636,0.006422568,0.008155569,0.0018735292,0.0039210194,0.00083099114],"domain_scores_gemma":[0.8089158,0.09585697,0.024305025,0.036000494,0.021020094,0.013901648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021747656,0.0013733722,0.004292158,0.013639658,0.0009272621,0.0078883525,0.0031263537,0.0028654304,0.0318053],"category_scores_gemma":[0.14358383,0.0015029294,0.0025521503,0.027731089,0.0007630341,0.005220968,0.0074968776,0.004117331,0.013036041],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007396376,0.00010517669,0.018343212,0.0041146246,0.0015143616,0.00010959773,0.00014903386,0.00070002105,0.00032772552,0.015815265,0.91012704,0.04795418],"study_design_scores_gemma":[0.0010965741,0.000102194936,0.04196963,0.0034091875,0.0012985717,0.00027928353,0.0004581151,0.0027638525,0.0011575074,0.046060808,0.90116405,0.00024028792],"about_ca_topic_score_codex":0.010645437,"about_ca_topic_score_gemma":0.009510948,"teacher_disagreement_score":0.0318053,"about_ca_system_score_codex":0.003218821,"about_ca_system_score_gemma":0.011886488,"threshold_uncertainty_score":0.11501402},"labels":[],"label_agreement":null},{"id":"W2190338955","doi":"10.2165/00019053-200321060-00006","title":"Cost-Benefit Model Comparing Two Alternative Immunisation Programmes Against Serogroup C Meningococcal Disease","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Bacterial Infections and Vaccines","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"Health Canada","keywords":"Medicine; Outbreak; Meningococcal disease; Epidemiology; Vaccination; Public health; Disease burden; Health economics; Environmental health; Incidence (geometry); Pediatrics; Demography; Emergency medicine; Neisseria meningitidis; Immunology; Population; Internal medicine; Virology","score_opus":0.055683705863028024,"score_gpt":0.33345267494193453,"score_spread":0.2777689690789065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2190338955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74902487,0.0088897925,0.13785058,0.017111836,0.0013877914,0.004373329,0.021947592,0.00065914396,0.05875518],"genre_scores_gemma":[0.9742778,0.001075462,0.0078095743,0.0005892643,0.00011906037,0.00094668317,0.001094695,0.000027903645,0.0140596],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.996748,0.0020364248,0.0000924483,0.00035998496,0.00014996441,0.0006131764],"domain_scores_gemma":[0.9886723,0.009620425,0.0005268278,0.00014107654,0.00037628273,0.0006630036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060663996,0.0029691616,0.004436795,0.002148342,0.0007912261,0.0031941372,0.0042553246,0.0074891183,0.027170492],"category_scores_gemma":[0.012481174,0.0019072682,0.0023934485,0.0015912486,0.0019925665,0.0023780852,0.0016078799,0.0030824302,0.0012453657],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008280157,0.0005029378,0.0015258434,0.0003843337,0.0004813185,0.00031019736,0.00003644143,0.9733122,0.0004290082,0.005893929,0.0011351322,0.007708529],"study_design_scores_gemma":[0.006222439,0.0032665979,0.003774752,0.00018051053,0.0017847754,0.0003228907,0.00016521191,0.9718545,0.000420896,0.009940637,0.0019499116,0.00011688172],"about_ca_topic_score_codex":0.029975655,"about_ca_topic_score_gemma":0.011419012,"teacher_disagreement_score":0.029975655,"about_ca_system_score_codex":0.007166832,"about_ca_system_score_gemma":0.00434233,"threshold_uncertainty_score":0.09089428},"labels":[],"label_agreement":null},{"id":"W2210591412","doi":"10.1007/s40273-015-0356-x","title":"Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"North-West University; Gilead Sciences","keywords":"Sofosbuvir; Quality of Life Research; Health economics; Genotype; Virology; Public health; Chronic hepatitis; Medicine; Hepatitis C virus; Health administration; Pharmacoeconomics; Virus; Internal medicine; Biology; Intensive care medicine; Genetics","score_opus":0.23151698398883594,"score_gpt":0.40388306249204514,"score_spread":0.1723660785032092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2210591412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690634,0.0042998516,0.0076455367,0.0025501824,0.00009267577,0.0005343875,0.0029589534,0.00005549101,0.012799572],"genre_scores_gemma":[0.99574405,0.00085270614,0.0012160117,0.00008990804,0.00001112243,0.00016727271,0.0002949563,0.000009453544,0.001614518],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9986198,0.00094339123,0.00004357332,0.0000752766,0.000059045287,0.0002588696],"domain_scores_gemma":[0.9933054,0.0057598567,0.00034372558,0.00005425228,0.00025914298,0.00027764545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027675289,0.0014019267,0.0020086037,0.0013141299,0.0005409425,0.0022225026,0.001713518,0.0021556972,0.0070489314],"category_scores_gemma":[0.011009521,0.0010916132,0.0025685604,0.0015073215,0.0008048659,0.0013299152,0.0010348097,0.0019250847,0.00023725178],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011006541,0.00011619073,0.0023251558,0.00020077432,0.00027634756,0.00019127969,0.000054242497,0.9907793,0.00013194315,0.0018558303,0.0002504629,0.0027178589],"study_design_scores_gemma":[0.0012214006,0.0011092603,0.005670809,0.0002648449,0.0010119709,0.00017321674,0.00046633885,0.9851596,0.00024487416,0.0034040452,0.0012249509,0.000048767994],"about_ca_topic_score_codex":0.11051089,"about_ca_topic_score_gemma":0.057131983,"teacher_disagreement_score":0.11051089,"about_ca_system_score_codex":0.008764166,"about_ca_system_score_gemma":0.00497783,"threshold_uncertainty_score":0.21973526},"labels":[],"label_agreement":null},{"id":"W2225256005","doi":"10.1007/s40273-015-0370-z","title":"Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Seventh Framework Programme; Health Technology Assessment international; European Commission","keywords":"Multiple-criteria decision analysis; Preference elicitation; Context (archaeology); Health technology; Management science; Decision analysis; Stakeholder; Computer science; Set (abstract data type); Process (computing); Relevance (law); Health care; Risk analysis (engineering); Knowledge management; Process management; Operations research; Preference; Medicine; Business; Engineering; Economics","score_opus":0.5383525656910848,"score_gpt":0.5885053368938988,"score_spread":0.05015277120281403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2225256005","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011186177,0.0021677343,0.9911361,0.0021384694,0.000100678044,0.00051619747,0.000068407324,0.00003177288,0.0027220638],"genre_scores_gemma":[0.059534337,0.0022386175,0.9350419,0.00041744337,0.00020528049,0.0019966825,0.00010575181,0.000043182463,0.00041676534],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.79605454,0.16917689,0.009270597,0.0062611983,0.01764024,0.0015965241],"domain_scores_gemma":[0.8572212,0.11014282,0.01069202,0.007893005,0.012378229,0.0016727494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.14769727,0.0033037364,0.0053063906,0.012712356,0.002550226,0.01811191,0.008355723,0.007766245,0.0022428508],"category_scores_gemma":[0.15737301,0.0016374275,0.0054660747,0.01245269,0.0137260575,0.010262551,0.010929584,0.011363295,0.0007363836],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031862382,0.00011207979,0.0005678725,0.0013757115,0.000262238,0.00012070696,0.001285381,0.063747026,0.00068661314,0.8924148,0.00091503945,0.038480673],"study_design_scores_gemma":[0.000031850024,0.00006878484,0.00017951838,0.0011688872,0.00006596194,0.000043731266,0.0004323611,0.08665801,0.0005599393,0.9018355,0.008881637,0.000073773896],"about_ca_topic_score_codex":0.00408596,"about_ca_topic_score_gemma":0.002936494,"teacher_disagreement_score":0.14769727,"about_ca_system_score_codex":0.010061388,"about_ca_system_score_gemma":0.015914805,"threshold_uncertainty_score":0.7811072},"labels":[],"label_agreement":null},{"id":"W2225838069","doi":"10.1007/s40273-015-0366-8","title":"Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Canadian Agency for Drugs and Technologies in Health; University of Ottawa","funders":"","keywords":"Tadalafil; Medicine; Sildenafil; Ambrisentan; Bosentan; Riociguat; Intensive care medicine; Quality-adjusted life year; Placebo; Cost effectiveness; Internal medicine; Pulmonary hypertension; Chronic thromboembolic pulmonary hypertension; Alternative medicine","score_opus":0.12560509669977174,"score_gpt":0.3724066025839423,"score_spread":0.24680150588417057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2225838069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969256,0.003388589,0.008108049,0.0017384688,0.00006686478,0.00043499764,0.0068606534,0.000077261364,0.010069078],"genre_scores_gemma":[0.9913264,0.0014066943,0.00273068,0.00014305188,0.000029504914,0.0002590068,0.001823327,0.000015239029,0.0022660154],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9988702,0.0006636965,0.00004066041,0.00010460054,0.00009078082,0.00023013864],"domain_scores_gemma":[0.9862623,0.011581599,0.0008575375,0.00028463613,0.0005566403,0.00045724885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029909627,0.0013571649,0.0016647967,0.0018381823,0.00079812814,0.0019091553,0.002628457,0.00230528,0.007105553],"category_scores_gemma":[0.010092954,0.00071089156,0.0050151977,0.0025062545,0.0007343269,0.00089609536,0.0008256394,0.0017241653,0.0004005013],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025909732,0.00089600665,0.021456521,0.000440441,0.0012150353,0.00041820493,0.00011644261,0.9582531,0.00026486765,0.004891202,0.0022605637,0.0071965954],"study_design_scores_gemma":[0.0012820347,0.00095999584,0.011128106,0.00016615882,0.0012026281,0.00024642592,0.00021417715,0.9796737,0.00017135758,0.0032344,0.0016572821,0.00006384068],"about_ca_topic_score_codex":0.2568707,"about_ca_topic_score_gemma":0.17318152,"teacher_disagreement_score":0.2568707,"about_ca_system_score_codex":0.009424611,"about_ca_system_score_gemma":0.0049775275,"threshold_uncertainty_score":0.51075107},"labels":[],"label_agreement":null},{"id":"W2281399600","doi":"10.1007/s40273-016-0388-x","title":"Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Precision medicine; Companion diagnostic; Cost–benefit analysis; Medicine; Cost effectiveness; Health economics; Diagnostic test; Quality of Life Research; Personalized medicine; Medical physics; Actuarial science; Risk analysis (engineering); Public health; Pathology; Economics; Bioinformatics; Pediatrics","score_opus":0.6000055285187244,"score_gpt":0.6131922322189319,"score_spread":0.01318670370020758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281399600","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.100500114,0.014568064,0.78826946,0.06274252,0.0013072358,0.0005818412,0.0008731523,0.00029584704,0.030861817],"genre_scores_gemma":[0.90520424,0.0033041057,0.08357997,0.0026565671,0.001424725,0.00033300518,0.00023998941,0.00010586965,0.0031515642],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9588812,0.034943856,0.000839937,0.0012886854,0.0033290242,0.0007173227],"domain_scores_gemma":[0.6503096,0.3328553,0.0049804696,0.0068255863,0.0040367027,0.0009923566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.049852565,0.001605339,0.0028256788,0.0015639412,0.00072292803,0.0059357863,0.0028304185,0.0038658176,0.0065743574],"category_scores_gemma":[0.26820385,0.00097094226,0.0014449251,0.0024237738,0.004446758,0.007040966,0.0025183258,0.0073579126,0.00037631992],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001552209,0.00030042243,0.0054950328,0.000437966,0.00041036666,0.00026040748,0.00022530953,0.19735147,0.0003227179,0.679315,0.007360691,0.10696838],"study_design_scores_gemma":[0.00028847338,0.0001858181,0.0017402291,0.00019340681,0.00018882805,0.00016743073,0.00009059472,0.27813065,0.0002584461,0.7162862,0.0024214352,0.0000485012],"about_ca_topic_score_codex":0.0032592367,"about_ca_topic_score_gemma":0.0020911372,"teacher_disagreement_score":0.049852565,"about_ca_system_score_codex":0.0042197052,"about_ca_system_score_gemma":0.0043749423,"threshold_uncertainty_score":0.2636487},"labels":[],"label_agreement":null},{"id":"W2301554896","doi":"10.1007/s40273-016-0394-z","title":"Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Dice; Computer science; Event (particle physics); Discrete event simulation; Markov chain; Microsimulation; Markov model; Series (stratigraphy); Econometrics; Mathematical optimization; Statistics; Simulation; Mathematics; Machine learning; Engineering","score_opus":0.31195139351203566,"score_gpt":0.5117991670215949,"score_spread":0.19984777350955923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301554896","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031111564,0.0006264586,0.95810074,0.0017298859,0.00025569578,0.00025396206,0.0012228299,0.0006811177,0.0060177837],"genre_scores_gemma":[0.8157179,0.0006141409,0.17538355,0.0004909092,0.00018776175,0.00083289493,0.0015213976,0.00014738167,0.0051039862],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99756706,0.0015814456,0.00011162303,0.00025887997,0.00030961662,0.00017132932],"domain_scores_gemma":[0.96327233,0.032803133,0.0009819483,0.00085529685,0.0012858924,0.0008014696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051038433,0.0007839286,0.0022146062,0.00093537336,0.0006989091,0.0017591999,0.00172944,0.0025067495,0.007870233],"category_scores_gemma":[0.029903667,0.0009182868,0.0011626785,0.0011851302,0.0012112493,0.0011604158,0.0016476475,0.003140387,0.00048656765],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007891917,0.000035188896,0.00043170768,0.000026780208,0.000030816074,0.000026574566,0.00001933798,0.98111844,0.000033176068,0.01444463,0.00059092196,0.0031635158],"study_design_scores_gemma":[0.000028432247,0.000007874181,0.00004000415,0.000004040923,0.0000048957418,0.0000044593794,0.0000024827286,0.9924049,0.000026272794,0.0072500985,0.00022316545,0.0000034630232],"about_ca_topic_score_codex":0.026914097,"about_ca_topic_score_gemma":0.012337999,"teacher_disagreement_score":0.026914097,"about_ca_system_score_codex":0.002030357,"about_ca_system_score_gemma":0.0029687523,"threshold_uncertainty_score":0.05351484},"labels":[],"label_agreement":null},{"id":"W2306623977","doi":"10.1007/s40273-016-0403-2","title":"Cancer Drugs Fund 2.0: A Missed Opportunity?","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; National Institute for Health and Care Research; University of Alberta","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Cancer; Medicine; Pharmacoeconomics; Health care management; Business; Intensive care medicine; Nursing; Internal medicine","score_opus":0.09355009280973614,"score_gpt":0.31430926112923957,"score_spread":0.22075916831950343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2306623977","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013468596,0.010838687,0.00084671803,0.9472584,0.022618663,0.000020238,0.0010398978,0.0004995274,0.015530909],"genre_scores_gemma":[0.1056459,0.046493288,0.016741382,0.6263601,0.09582104,0.0003806364,0.0054932185,0.0013851306,0.10167933],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99390244,0.0018651893,0.00036600375,0.00030329873,0.001682484,0.0018806411],"domain_scores_gemma":[0.93709445,0.013508488,0.0045355735,0.0023092597,0.009523526,0.033028733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020736426,0.0011583462,0.0015661996,0.0022980934,0.0018467931,0.01344051,0.0026837115,0.013897007,0.08598658],"category_scores_gemma":[0.06166168,0.00070898497,0.001327973,0.001624022,0.0031621468,0.015698565,0.006400115,0.011257918,0.023884093],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024453294,0.000110574554,0.0013274737,0.00014471347,0.000028658584,0.00011360847,0.00004173969,0.0001640391,0.00009529804,0.031525347,0.8905615,0.07564245],"study_design_scores_gemma":[0.00019634006,0.00013617976,0.0038321153,0.0008661439,0.000039965285,0.00032369184,0.00030905308,0.0007050204,0.00024264102,0.03940903,0.95382947,0.00011036012],"about_ca_topic_score_codex":0.004545555,"about_ca_topic_score_gemma":0.005634081,"teacher_disagreement_score":0.08598658,"about_ca_system_score_codex":0.0036415174,"about_ca_system_score_gemma":0.017590303,"threshold_uncertainty_score":0.2876538},"labels":[],"label_agreement":null},{"id":"W2307171802","doi":"10.1007/s40273-016-0401-4","title":"Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available","year":2016,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame; Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Economic evaluation; Medicine; Health economics; Proxy (statistics); Population; Quality-adjusted life year; Quality of life (healthcare); Time horizon; Clinical endpoint; Quality of Life Research; Cost effectiveness; Actuarial science; Clinical trial; Intensive care medicine; Public health; Statistics; Internal medicine; Environmental health; Risk analysis (engineering); Pathology","score_opus":0.7785772792293135,"score_gpt":0.5996900770819155,"score_spread":0.17888720214739806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307171802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011092587,0.9900379,0.0053260797,0.0009329971,0.00023065103,0.00017492051,0.00035836638,0.0000097872135,0.0018200354],"genre_scores_gemma":[0.037975855,0.94025224,0.017944044,0.0010824109,0.000531921,0.00094965444,0.0007051077,0.000026220947,0.0005325479],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9733372,0.01905367,0.0029958724,0.0009411041,0.0033107062,0.0003614115],"domain_scores_gemma":[0.9200268,0.07170153,0.0047994456,0.0010212101,0.0021718282,0.000279305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.047508985,0.0019157742,0.0065550604,0.00765587,0.00043862071,0.0050290935,0.002223428,0.002224557,0.0043381783],"category_scores_gemma":[0.077831,0.0005822634,0.006255403,0.007994689,0.0013460777,0.0030871432,0.0019299678,0.0042598383,0.00041375015],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015398148,0.00023962959,0.004287927,0.10644554,0.009961746,0.00013098026,0.00013226602,0.008937374,0.0002685893,0.046458874,0.006369801,0.8152273],"study_design_scores_gemma":[0.001985789,0.0022529284,0.032792207,0.33294412,0.044803884,0.0017871266,0.00067533954,0.013870204,0.0025436152,0.20397522,0.3618304,0.0005391033],"about_ca_topic_score_codex":0.0027314618,"about_ca_topic_score_gemma":0.0047508082,"teacher_disagreement_score":0.047508985,"about_ca_system_score_codex":0.0027371868,"about_ca_system_score_gemma":0.0045417137,"threshold_uncertainty_score":0.25125456},"labels":[],"label_agreement":null},{"id":"W2343725236","doi":"10.1007/s40273-016-0408-x","title":"Using Linear Equating to Map PROMIS® Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Utilities Kingston (Canada)","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute; National Institutes of Health","keywords":"Equating; Health Utilities Index; Quality of life (healthcare); Health economics; Explained variation; Linear regression; Medicine; Psychology; Physical therapy; Statistics; Public health; Health related quality of life; Mathematics","score_opus":0.367823668569967,"score_gpt":0.48864437328638277,"score_spread":0.12082070471641576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343725236","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038057126,0.00029640077,0.93999505,0.0007691263,0.0003020966,0.00047026062,0.004244144,0.0035335063,0.012332331],"genre_scores_gemma":[0.24419767,0.00036923794,0.7176577,0.00028798764,0.00011960292,0.0021932286,0.008592207,0.0020005505,0.024581837],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9962269,0.001910185,0.0002622401,0.00071781286,0.00069609407,0.00018679447],"domain_scores_gemma":[0.99641377,0.0017343473,0.00021221436,0.00060139986,0.0009905659,0.00004771152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006380725,0.0010082513,0.0011040407,0.0025925029,0.00045809298,0.0021869307,0.0012769994,0.0006410983,0.033092037],"category_scores_gemma":[0.03389306,0.0005762642,0.0021781144,0.0034321195,0.00043859667,0.0018555208,0.0022942263,0.0016145787,0.010092963],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061982643,0.0005232013,0.026976421,0.00050707895,0.0010349364,0.0002417161,0.0005901661,0.070523806,0.0035662614,0.058252078,0.04230849,0.7948559],"study_design_scores_gemma":[0.00015735762,0.00073855184,0.05172481,0.00024049635,0.0004214519,0.0003105312,0.0007087515,0.75223464,0.010029401,0.10290193,0.08033127,0.00020075623],"about_ca_topic_score_codex":0.012057993,"about_ca_topic_score_gemma":0.010931496,"teacher_disagreement_score":0.033092037,"about_ca_system_score_codex":0.0010255831,"about_ca_system_score_gemma":0.0021427067,"threshold_uncertainty_score":0.110703945},"labels":[],"label_agreement":null},{"id":"W2415515198","doi":"10.1007/s40273-016-0416-x","title":"Sustainable Financing of Innovative Therapies: A Review of Approaches","year":2016,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Seventh Framework Programme; Canadian Institutes of Health Research","keywords":"Externality; Health economics; Government (linguistics); Sustainability; Business; Process (computing); Finance; Health technology; Economics; Value (mathematics); Industrial organization; Health care; Public economics; Microeconomics; Economic growth","score_opus":0.5530567514504178,"score_gpt":0.5078534446458488,"score_spread":0.045203306804568966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415515198","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001878349,0.99431926,0.001138952,0.0026329262,0.0001270271,0.000021478614,0.000046497717,0.0000054821226,0.0015205663],"genre_scores_gemma":[0.003157189,0.99482286,0.0011713412,0.00040898367,0.00021133147,0.000035232326,0.000028782757,0.0000026799082,0.00016164852],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996267,0.0013647926,0.00052094617,0.000268627,0.0013679955,0.0002105841],"domain_scores_gemma":[0.98829085,0.008871498,0.0014029393,0.00024207986,0.0010242923,0.00016832791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009965295,0.0014182384,0.0024958195,0.0070082573,0.00055244786,0.0045668767,0.0020582078,0.002904646,0.0051711323],"category_scores_gemma":[0.016051786,0.0005667201,0.0013703823,0.010846965,0.0018761052,0.0045083542,0.0024670558,0.002588798,0.0005259394],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008840179,0.00011607724,0.00054626394,0.030187402,0.0003196071,0.00008329819,0.0001063794,0.0036722024,0.00020970663,0.12123348,0.016275134,0.82716215],"study_design_scores_gemma":[0.00011403877,0.000122102,0.002126912,0.092036694,0.0006958884,0.0005074674,0.00029848426,0.002104295,0.00046744387,0.10902225,0.79243314,0.00007123091],"about_ca_topic_score_codex":0.00353615,"about_ca_topic_score_gemma":0.0046723196,"teacher_disagreement_score":0.009965295,"about_ca_system_score_codex":0.0055006044,"about_ca_system_score_gemma":0.012206241,"threshold_uncertainty_score":0.05270219},"labels":[],"label_agreement":null},{"id":"W2465326294","doi":"10.1007/s40273-016-0424-x","title":"Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies","year":2016,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; McMaster University","funders":"","keywords":"Medicine; Health economics; Comparability; Indirect costs; MEDLINE; Sample size determination; Sample (material); Public health; Statistics; Accounting; Economics","score_opus":0.04593320333790884,"score_gpt":0.38918566349071826,"score_spread":0.3432524601528094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2465326294","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032274993,0.9953424,0.00019416153,0.000187826,0.00007109131,0.0001747563,0.0006398913,0.000004207237,0.00015824214],"genre_scores_gemma":[0.06250301,0.9349797,0.0010886341,0.0005088571,0.00009227463,0.00030668784,0.0004372576,0.000006436523,0.00007715954],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98585016,0.0052105803,0.005593424,0.00093927165,0.002105122,0.0003013963],"domain_scores_gemma":[0.95980287,0.03010616,0.007104011,0.0007372293,0.0019396861,0.0003099478],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.01647788,0.0016746592,0.010014501,0.008473144,0.0005813858,0.0026474646,0.0014871556,0.0014447882,0.003062252],"category_scores_gemma":[0.05608945,0.0011754322,0.012533778,0.010301468,0.0009834601,0.0018702274,0.0021795917,0.0011177976,0.0001459459],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010748244,0.000035298537,0.009214297,0.7835187,0.16398834,0.00020095197,0.00021669507,0.00023212517,0.0001431905,0.00027899593,0.0011006452,0.039995942],"study_design_scores_gemma":[0.0010473917,0.00035083512,0.03741994,0.2782226,0.6687262,0.0008360479,0.00055936456,0.00019412408,0.00017570211,0.0008725817,0.0114932535,0.00010189623],"about_ca_topic_score_codex":0.008520647,"about_ca_topic_score_gemma":0.032322384,"teacher_disagreement_score":0.9899855,"about_ca_system_score_codex":0.0027778007,"about_ca_system_score_gemma":0.006903462,"threshold_uncertainty_score":0.087144434},"labels":[],"label_agreement":null},{"id":"W2518788219","doi":"10.1007/s40273-016-0450-8","title":"Response to Letter to the Editor Regarding Discretely Integrated Condition Event Simulation for Pharmacoeconomics","year":2016,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Pharmacoeconomics; Quality of Life Research; Health economics; Health administration; Event (particle physics); Medicine; Public health; Intensive care medicine; Nursing","score_opus":0.21760063962310017,"score_gpt":0.4726194633629623,"score_spread":0.2550188237398621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518788219","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016563621,0.00042770384,0.00020642011,0.96654683,0.030769717,0.000022332844,0.00014953758,0.000046709996,0.0016650549],"genre_scores_gemma":[0.0027763948,0.0005534328,0.00036002445,0.93745846,0.05079496,0.000085936954,0.000046423575,0.000058255417,0.007866178],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99282855,0.002690547,0.0011225082,0.00080589735,0.0018822891,0.00067024736],"domain_scores_gemma":[0.9613948,0.027669609,0.0024466617,0.00077453273,0.0050589344,0.0026554377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011797334,0.0009781637,0.002474535,0.0008488468,0.0036608323,0.006102347,0.002393668,0.05588348,0.01134371],"category_scores_gemma":[0.0767275,0.000997292,0.0020193665,0.00095231377,0.0025681367,0.0027012907,0.0016781284,0.045184515,0.007811308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071781564,0.000020580848,0.00026948124,0.000036597874,0.000013061626,0.0003112784,0.000053216394,0.0001858902,0.00004189026,0.0015501246,0.99461925,0.0028267894],"study_design_scores_gemma":[0.00038264404,0.000086890344,0.0012718767,0.00069311605,0.00006472396,0.0004893751,0.00029859034,0.0034036245,0.00030223597,0.012233082,0.98066103,0.00011283043],"about_ca_topic_score_codex":0.012253332,"about_ca_topic_score_gemma":0.015383063,"teacher_disagreement_score":0.05588348,"about_ca_system_score_codex":0.0063804286,"about_ca_system_score_gemma":0.007999599,"threshold_uncertainty_score":0.062391043},"labels":[],"label_agreement":null},{"id":"W2537819449","doi":"10.1007/s40273-016-0457-1","title":"Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal","year":2016,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Technology Assessment Programme; Queen's University; Queen's University Belfast; National Institute for Health and Care Research","keywords":"Docetaxel; Cabazitaxel; Medicine; Oncology; Prostate cancer; Regimen; Quality of Life Research; Internal medicine; Health economics; Nice; Cost effectiveness; Chemotherapy; Cancer; Public health; Androgen deprivation therapy; Nursing","score_opus":0.09311260996567614,"score_gpt":0.45005130497973883,"score_spread":0.3569386950140627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537819449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015561271,0.99808073,0.000069330716,0.00088538317,0.00012629331,0.000034383243,0.00007429749,0.0000048945285,0.00056902395],"genre_scores_gemma":[0.0028930493,0.9948991,0.000587083,0.00121652,0.000115992225,0.000041216004,0.0000626909,0.000002783329,0.00018146496],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9973876,0.00092345756,0.00069939025,0.00017527596,0.00068960356,0.0001246752],"domain_scores_gemma":[0.9937774,0.00394755,0.0013899179,0.000069572416,0.0006931377,0.00012246819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006037876,0.00079566095,0.0054110843,0.0035126498,0.00024958825,0.0025490434,0.0014565408,0.0019657305,0.0032716792],"category_scores_gemma":[0.0109525705,0.00051156525,0.0045161853,0.0038396865,0.000490696,0.0014364881,0.00080590084,0.00244635,0.00044772538],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091681414,0.000060365554,0.00036455292,0.40085837,0.008252032,0.00023157924,0.000105790365,0.00064530794,0.0006512004,0.0032398386,0.027600793,0.55707335],"study_design_scores_gemma":[0.0020044004,0.0009115482,0.0044617904,0.50735235,0.059213605,0.0013635219,0.00023920914,0.0005359891,0.0006005908,0.0037580647,0.4194631,0.00009587757],"about_ca_topic_score_codex":0.0052657602,"about_ca_topic_score_gemma":0.017178705,"teacher_disagreement_score":0.006037876,"about_ca_system_score_codex":0.0030130036,"about_ca_system_score_gemma":0.0057890136,"threshold_uncertainty_score":0.0319317},"labels":[],"label_agreement":null},{"id":"W2557044136","doi":"10.1007/s40273-017-0492-6","title":"Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal","year":2017,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Health Technology Assessment Programme; National Institute for Health and Care Research","keywords":"Evolocumab; Ezetimibe; Medicine; Statin; Nice; Physical therapy; Placebo; Clinical trial; Cost effectiveness; Internal medicine; Alternative medicine; Cholesterol; Lipoprotein; Pathology","score_opus":0.11077338720664542,"score_gpt":0.4395810754571972,"score_spread":0.3288076882505518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557044136","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016747907,0.99623483,0.00013631959,0.002258305,0.00034756341,0.0000577827,0.00008836475,0.000009430896,0.00069984555],"genre_scores_gemma":[0.003481327,0.990547,0.0014251657,0.0036544204,0.00036772335,0.00009890846,0.00009334176,0.000006496446,0.00032557268],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9942966,0.0021264134,0.0014959996,0.00032144066,0.0014721054,0.00028740315],"domain_scores_gemma":[0.985586,0.008674412,0.0028961913,0.00019490755,0.0022655893,0.0003830211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01346305,0.0012041607,0.007915626,0.0042224852,0.00040002016,0.0043333923,0.002318276,0.0035333754,0.004243458],"category_scores_gemma":[0.02051702,0.00074231403,0.005991545,0.00356624,0.0006997149,0.0023711268,0.0015800025,0.0043407986,0.0008648711],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013360238,0.00007480983,0.00053617125,0.3998211,0.010725016,0.00036373702,0.00019835442,0.00049825537,0.00081967056,0.0046638,0.039977852,0.5409853],"study_design_scores_gemma":[0.0024836555,0.0008105673,0.0033519613,0.5541772,0.054617446,0.0011297101,0.00025966714,0.00043910716,0.00048286913,0.004474538,0.3776661,0.00010725202],"about_ca_topic_score_codex":0.003548145,"about_ca_topic_score_gemma":0.0126346955,"teacher_disagreement_score":0.01346305,"about_ca_system_score_codex":0.0032946623,"about_ca_system_score_gemma":0.007884809,"threshold_uncertainty_score":0.07120025},"labels":[],"label_agreement":null},{"id":"W2560119051","doi":"10.1007/s40273-016-0482-0","title":"Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Health economics; Discounting; Panel data; CLARITY; Actuarial science; Health care; Health administration; Economics; Medicine; Public economics; Econometrics; Finance","score_opus":0.4921250129035416,"score_gpt":0.5115948805198597,"score_spread":0.01946986761631808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560119051","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019265647,0.029383037,0.024294669,0.7279613,0.14334062,0.0031579917,0.016154002,0.00056593196,0.053215977],"genre_scores_gemma":[0.021700896,0.025511673,0.08841636,0.7324789,0.07576613,0.004460841,0.007021785,0.00079173216,0.04385171],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9248558,0.024036564,0.0137632415,0.0035892744,0.029435538,0.0043194923],"domain_scores_gemma":[0.6944406,0.15682176,0.012929289,0.01841159,0.107324556,0.010072224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11383404,0.0048322594,0.008609543,0.010277024,0.003148708,0.013214929,0.015495033,0.05851379,0.018901227],"category_scores_gemma":[0.3270495,0.002685762,0.016317504,0.011927288,0.004772952,0.008291096,0.005119596,0.0593633,0.012500336],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054351334,0.00015194245,0.00081645534,0.0015966117,0.00048939366,0.00014655244,0.00019547083,0.0011911044,0.00037707604,0.017176991,0.9425618,0.034752954],"study_design_scores_gemma":[0.0011764837,0.00016425522,0.006349012,0.014726638,0.002543582,0.00029003347,0.00025932785,0.003151839,0.0012118024,0.05560684,0.91409874,0.00042155216],"about_ca_topic_score_codex":0.04030654,"about_ca_topic_score_gemma":0.047166362,"teacher_disagreement_score":0.11383404,"about_ca_system_score_codex":0.0067891986,"about_ca_system_score_gemma":0.025050035,"threshold_uncertainty_score":0.60201913},"labels":[],"label_agreement":null},{"id":"W2598558594","doi":"10.1007/s40273-017-0498-0","title":"Authors’ Reply to Gandjour: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation”","year":2017,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; SNC-Lavalin (Canada)","funders":"","keywords":"Quality of Life Research; Health economics; Adaptation (eye); Context (archaeology); Health administration; Public health; Management science; Medicine; Engineering ethics; Psychology; Economics; Nursing; Engineering","score_opus":0.38170027764823494,"score_gpt":0.5104098940317277,"score_spread":0.1287096163834927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598558594","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000090095986,0.00041377623,0.00004345578,0.9930068,0.0058481637,0.000006123722,0.000038760183,0.000005881919,0.00054693554],"genre_scores_gemma":[0.0006887631,0.00017291779,0.00007429056,0.9903771,0.0075102434,0.000019394623,0.000009021557,0.000008172527,0.0011401491],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9837092,0.0054905494,0.0025127295,0.0019879953,0.0036729071,0.00262661],"domain_scores_gemma":[0.94128686,0.04091826,0.0036179016,0.0012389516,0.008092921,0.0048451996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019711792,0.0010944095,0.0033126508,0.0014200399,0.006826062,0.009242832,0.0039086514,0.13332497,0.006519308],"category_scores_gemma":[0.11285794,0.0017970753,0.0026208016,0.001974866,0.008828186,0.008003471,0.0048739603,0.11239634,0.0050085657],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005855223,0.000020875847,0.000422124,0.000063220876,0.000028174427,0.0004998389,0.00025422894,0.00006607419,0.000063867235,0.0070832125,0.98810726,0.0033325774],"study_design_scores_gemma":[0.000260247,0.00004779675,0.0016844709,0.0011418203,0.00009457703,0.0007994658,0.0010912744,0.00067508634,0.00031401962,0.037811942,0.95582175,0.00025767367],"about_ca_topic_score_codex":0.021277346,"about_ca_topic_score_gemma":0.036387406,"teacher_disagreement_score":0.13332497,"about_ca_system_score_codex":0.010605205,"about_ca_system_score_gemma":0.018337104,"threshold_uncertainty_score":0.10424715},"labels":[],"label_agreement":null},{"id":"W2600944596","doi":"10.1007/s40273-017-0491-7","title":"An Investigation of the Overlap Between the ICECAP-A and Five Preference-Based Health-Related Quality of Life Instruments","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Providence Health Care; International Collaboration On Repair Discoveries; University of British Columbia; Vancouver Coastal Health Research Institute; Vancouver Coastal Health","funders":"","keywords":"Health economics; Quality of Life Research; Public health; Health administration; Preference; Quality-adjusted life year; Quality of life (healthcare); Quality (philosophy); Health related quality of life; Psychology; Environmental health; Medicine; MEDLINE; Political science; Nursing; Economics; Cost effectiveness; Risk analysis (engineering)","score_opus":0.5169471671780879,"score_gpt":0.4647352651113755,"score_spread":0.05221190206671239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600944596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9142623,0.0039268374,0.039610885,0.0012846468,0.00015197147,0.00053954974,0.005654107,0.00008372779,0.034485973],"genre_scores_gemma":[0.9861193,0.0002270267,0.010303441,0.00017817524,0.000034841578,0.00030166464,0.0024605228,0.000019427689,0.00035567317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.94940186,0.03595292,0.0031468961,0.0024702367,0.007649332,0.0013787884],"domain_scores_gemma":[0.51545835,0.44530952,0.011792775,0.008671172,0.017011637,0.0017564599],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.08697685,0.0005773055,0.0010364258,0.0035385133,0.00065743277,0.0042614387,0.0012223556,0.0014437635,0.0035819123],"category_scores_gemma":[0.2124612,0.00033520279,0.0021784492,0.0062129903,0.0014511518,0.002898241,0.0034503774,0.0020805914,0.00037860125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024616616,0.00031408956,0.8861805,0.00057688035,0.0016167713,0.00009369673,0.0014747189,0.0062625357,0.00037718107,0.030482927,0.0014950808,0.06866392],"study_design_scores_gemma":[0.00027433725,0.0021728638,0.91155684,0.000980377,0.0009960864,0.0004335472,0.0038683082,0.039040722,0.0011112968,0.026109783,0.013333533,0.0001223618],"about_ca_topic_score_codex":0.0040577683,"about_ca_topic_score_gemma":0.0034937798,"teacher_disagreement_score":0.9130232,"about_ca_system_score_codex":0.0021116945,"about_ca_system_score_gemma":0.002479631,"threshold_uncertainty_score":0.45998305},"labels":[],"label_agreement":null},{"id":"W2607056793","doi":"10.1007/s40273-017-0509-1","title":"Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature","year":2017,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Public Health","funders":"","keywords":"Health technology; New product development; Health economics; Context (archaeology); Public health; Economic evaluation; Health administration; Health care; Business; Medicine; Risk analysis (engineering); Management science; Marketing; Engineering; Economics; Economic growth; Nursing","score_opus":0.5745355274741083,"score_gpt":0.5952101654926656,"score_spread":0.02067463801855729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607056793","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015741074,0.99777275,0.0006634739,0.00053875166,0.000116805386,0.00007437912,0.00005429184,0.0000054875554,0.00061663333],"genre_scores_gemma":[0.002796713,0.9949694,0.001408407,0.0004115338,0.00009022895,0.00016341641,0.00006174554,0.0000047638973,0.00009376199],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9797435,0.0092236735,0.0048891045,0.001110519,0.0046754335,0.00035775968],"domain_scores_gemma":[0.7982078,0.17973107,0.009170044,0.0027438917,0.009623844,0.00052323804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03044271,0.0016413415,0.0037718387,0.020317959,0.00093347434,0.005882008,0.002513709,0.0035729648,0.004724464],"category_scores_gemma":[0.10740456,0.0010688208,0.005263418,0.019441957,0.00215262,0.005699013,0.0029180648,0.0032891443,0.00072929374],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008201166,0.00005424099,0.00056387857,0.46003717,0.0011315952,0.00011758545,0.00072996406,0.00059319084,0.00023252696,0.009444072,0.0048415414,0.52217215],"study_design_scores_gemma":[0.000029779083,0.00008525071,0.0014050199,0.8421479,0.0034264226,0.0003698661,0.00047130362,0.00033558483,0.00030380138,0.005448558,0.14593022,0.000046274967],"about_ca_topic_score_codex":0.0063263555,"about_ca_topic_score_gemma":0.011091448,"teacher_disagreement_score":0.03044271,"about_ca_system_score_codex":0.0058341194,"about_ca_system_score_gemma":0.019821923,"threshold_uncertainty_score":0.1609984},"labels":[],"label_agreement":null},{"id":"W2613741907","doi":"10.1007/s40273-017-0510-8","title":"A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models","year":2017,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Risk and Safety Analysis","field":"Decision Sciences","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; University of Alberta Hospital; University of Alberta","funders":"Faculty of Medicine and Dentistry, University of Alberta; Canadian Institutes of Health Research; Genome Canada","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Cost effectiveness; Computer science; Software; Quality-adjusted life year; Management science; Risk analysis (engineering); Business; Medicine; Engineering; Nursing","score_opus":0.6970348946451114,"score_gpt":0.6133700622966806,"score_spread":0.0836648323484308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613741907","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11203551,0.5267138,0.32425556,0.004213696,0.0009938116,0.0070912233,0.0038937435,0.00253034,0.018272275],"genre_scores_gemma":[0.39171433,0.18254478,0.4123333,0.00093416433,0.00027483312,0.0082678385,0.0020390875,0.00038690766,0.0015046455],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97677046,0.016038965,0.0021391374,0.0007395658,0.0039566723,0.0003553037],"domain_scores_gemma":[0.889924,0.1029406,0.002646682,0.0012179447,0.0028418323,0.0004288637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026810233,0.0027189287,0.0043504047,0.0065967366,0.00039853418,0.0031849758,0.0033585825,0.0016968788,0.0050949557],"category_scores_gemma":[0.07860007,0.0012048424,0.0059760315,0.0053351247,0.00054245687,0.0022031132,0.0017878456,0.0030277444,0.00037891034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047924826,0.0008083713,0.0033936908,0.027914807,0.010695579,0.00006511761,0.00033442242,0.050319664,0.0002851472,0.01347637,0.003574847,0.8843396],"study_design_scores_gemma":[0.015863212,0.013857793,0.033735733,0.07503804,0.107449956,0.0011201851,0.0011474472,0.56804436,0.0058463844,0.07390102,0.103138305,0.0008574996],"about_ca_topic_score_codex":0.0078925,"about_ca_topic_score_gemma":0.008105637,"teacher_disagreement_score":0.026810233,"about_ca_system_score_codex":0.004967225,"about_ca_system_score_gemma":0.0056165494,"threshold_uncertainty_score":0.14178771},"labels":[],"label_agreement":null},{"id":"W2616016052","doi":"10.2165/11590380-000000000-00000","title":"Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"AstraZeneca; Pfizer","keywords":"Medicine; Tiotropium bromide; Budesonide; Formoterol; Budesonide/formoterol; COPD; Exacerbation; Placebo; Obstructive lung disease; Internal medicine; Indirect costs; Intensive care medicine; Corticosteroid; Lung","score_opus":0.029686809704364013,"score_gpt":0.307279062413236,"score_spread":0.277592252708872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616016052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929188,0.004568336,0.00011417072,0.00061763293,0.00038316016,0.00016235195,0.0003030835,0.000015510339,0.000916944],"genre_scores_gemma":[0.9986179,0.0005535285,0.00013485228,0.00013648483,0.00011518138,0.00005855334,0.00012518975,0.0000021216456,0.00025624264],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985746,0.0008257314,0.00013440901,0.00015311685,0.000099618126,0.00021251237],"domain_scores_gemma":[0.9978405,0.0012376718,0.00030277864,0.000061013976,0.00008226662,0.00047566634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012464919,0.0010499521,0.0033531296,0.00059682346,0.00043202567,0.0012298515,0.0007217612,0.0020761765,0.0048120627],"category_scores_gemma":[0.004873625,0.0006419809,0.004791559,0.00044579682,0.0006739968,0.0012414993,0.0006878416,0.0022560842,0.00028777833],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97119427,0.0025328784,0.005020188,0.00050245173,0.0016587742,0.00014966824,0.000054900574,0.001768024,0.0012394243,0.00014236229,0.0002839091,0.015453178],"study_design_scores_gemma":[0.5166149,0.3407599,0.09755817,0.00039571096,0.022873085,0.0004803901,0.0006135664,0.015374423,0.0030803944,0.0007833187,0.0012956712,0.00017045582],"about_ca_topic_score_codex":0.004387901,"about_ca_topic_score_gemma":0.0045072264,"teacher_disagreement_score":0.0048120627,"about_ca_system_score_codex":0.002027641,"about_ca_system_score_gemma":0.0011686422,"threshold_uncertainty_score":0.016097963},"labels":[],"label_agreement":null},{"id":"W270132110","doi":"10.1007/s40273-015-0285-8","title":"Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment","year":2015,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Quetiapine; Olanzapine; Risperidone; Lurasidone; Medicine; Asenapine; Pharmacoeconomics; Population; Psychiatry; Systematic review; Antipsychotic; Randomized controlled trial; Schizophrenia (object-oriented programming); MEDLINE; Intensive care medicine; Internal medicine; Environmental health","score_opus":0.17674128122958377,"score_gpt":0.5194061597357834,"score_spread":0.34266487850619964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W270132110","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043956423,0.99812704,0.000274367,0.00015240532,0.0000995523,0.00036932618,0.00037273933,0.00000618827,0.00015876994],"genre_scores_gemma":[0.008204141,0.98878956,0.0014742272,0.00045495416,0.000073100215,0.0006768319,0.0002324758,0.0000065887393,0.00008802765],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9752573,0.009860965,0.009494505,0.0014302953,0.0035718952,0.00038522205],"domain_scores_gemma":[0.93869746,0.04862032,0.0086302925,0.0008574894,0.0028185102,0.00037598648],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02373368,0.0026703568,0.014915539,0.0153768025,0.0007729012,0.0043544243,0.002870697,0.002332103,0.0058087963],"category_scores_gemma":[0.08014798,0.0012675963,0.01724534,0.0139765,0.0014711322,0.0030350462,0.0026814982,0.0024377052,0.00039013237],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040558833,0.000020800559,0.0004758724,0.92746,0.03433449,0.00005518645,0.00009164037,0.00014615308,0.00010955006,0.00032125463,0.0006176388,0.03596184],"study_design_scores_gemma":[0.0007543022,0.00030827848,0.0033289252,0.7111955,0.2678222,0.00024244569,0.0001570136,0.00013890973,0.00025203056,0.0006584831,0.015075608,0.000066339904],"about_ca_topic_score_codex":0.011699249,"about_ca_topic_score_gemma":0.03083282,"teacher_disagreement_score":0.9762663,"about_ca_system_score_codex":0.006482475,"about_ca_system_score_gemma":0.01564138,"threshold_uncertainty_score":0.12551719},"labels":[],"label_agreement":null},{"id":"W2731101119","doi":"10.1007/s40273-017-0534-0","title":"Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Quality and Safety in Healthcare","field":"Health Professions","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Dice; Discrete event simulation; Code (set theory); Computer science; Event (particle physics); Quality of Life Research; Public health; Statistics; Medicine; Programming language; Simulation; Mathematics","score_opus":0.20129401367591784,"score_gpt":0.5753081631253333,"score_spread":0.37401414944941547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2731101119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76348054,0.00019567067,0.20269924,0.0010559311,0.0007959716,0.00059316395,0.0025940503,0.00668727,0.021898136],"genre_scores_gemma":[0.95358974,0.000043681288,0.043493863,0.00013956381,0.000015628862,0.00014954618,0.0009413444,0.00021297242,0.0014137166],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984591,0.00055512035,0.00010756554,0.00022311533,0.0004722748,0.0001827671],"domain_scores_gemma":[0.9876923,0.0076145753,0.00041743278,0.0014707863,0.0023508358,0.0004540767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028697117,0.00082265126,0.00083674386,0.00076357456,0.0007422415,0.0010743185,0.001642259,0.0016226356,0.0053023174],"category_scores_gemma":[0.014670883,0.0004254216,0.0007114096,0.0003874266,0.0010026757,0.0007074953,0.0009943689,0.0016808602,0.0006015667],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028953174,0.00016643654,0.00294943,0.00009759436,0.000041703366,0.000089399924,0.00006185729,0.98617935,0.0013861911,0.0025958484,0.00085496303,0.0052877082],"study_design_scores_gemma":[0.000088153676,0.00008351397,0.00044966798,0.0000137402085,0.0000076211486,0.000015364269,0.000016987748,0.99673873,0.0016239871,0.00039490443,0.0005587018,0.00000862451],"about_ca_topic_score_codex":0.02650066,"about_ca_topic_score_gemma":0.008826594,"teacher_disagreement_score":0.02650066,"about_ca_system_score_codex":0.0010736601,"about_ca_system_score_gemma":0.0030847096,"threshold_uncertainty_score":0.05269283},"labels":[],"label_agreement":null},{"id":"W2751752943","doi":"10.1007/s40273-017-0558-5","title":"Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Bristol-Myers Squibb (Canada); Augmentium Pharma Consulting (Canada)","funders":"Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Oncology; Survival analysis; Contouring; Clinical trial; Medical physics; Internal medicine; Statistics; Cancer; Mathematics; Computer science; Immunotherapy","score_opus":0.11388261087873913,"score_gpt":0.4255673181020439,"score_spread":0.31168470722330477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751752943","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028202197,0.009728756,0.9532637,0.0019998935,0.00011211791,0.003618708,0.0009948792,0.00021606512,0.0018636496],"genre_scores_gemma":[0.4311733,0.008827316,0.549317,0.0007348521,0.00011341185,0.008162715,0.0010809298,0.00010299044,0.00048750095],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.7284298,0.25575614,0.0066048033,0.0026270926,0.0060562016,0.00052598154],"domain_scores_gemma":[0.44693482,0.51355535,0.017776377,0.012025392,0.009126497,0.0005816023],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.19976416,0.0026410448,0.0049205464,0.0054821204,0.0005931567,0.0038460298,0.0026652021,0.0024194366,0.0011176197],"category_scores_gemma":[0.32760367,0.0016658312,0.008448627,0.004319226,0.0027175623,0.0027476351,0.0035635212,0.0041867504,0.00023698049],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006487102,0.0002768316,0.015491574,0.0073610395,0.0065185064,0.0004160562,0.0012325993,0.79119736,0.000532462,0.056074962,0.0017796423,0.1184703],"study_design_scores_gemma":[0.00048585096,0.001327467,0.0044106157,0.0075327107,0.0025040894,0.00017668359,0.0005037975,0.8159906,0.0010616403,0.16055028,0.0052692574,0.00018706034],"about_ca_topic_score_codex":0.0078360895,"about_ca_topic_score_gemma":0.0084257005,"teacher_disagreement_score":0.19976416,"about_ca_system_score_codex":0.004883162,"about_ca_system_score_gemma":0.010259879,"threshold_uncertainty_score":0.9868333},"labels":[],"label_agreement":null},{"id":"W2752145111","doi":"10.1007/s40273-017-0563-8","title":"Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature","year":2017,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Precision medicine; Erlotinib; Cancer; Population; Epidermal growth factor receptor; Intensive care medicine; Oncology; Internal medicine; Pathology; Environmental health","score_opus":0.23812144414758424,"score_gpt":0.5266995212851098,"score_spread":0.28857807713752553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752145111","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000093054376,0.9983298,0.000059053084,0.0010743224,0.000084266765,0.000004071757,0.000031316053,0.0000010110236,0.0003230343],"genre_scores_gemma":[0.0011335355,0.99804807,0.00012960662,0.0004360163,0.0001787081,0.000007136118,0.000016911314,7.0941394e-7,0.000049324986],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861765,0.000413726,0.0003241135,0.00012972487,0.00044087294,0.0000738899],"domain_scores_gemma":[0.9908963,0.0073858234,0.0010878948,0.00004628328,0.00048484572,0.000098746226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036196504,0.0007473329,0.0024414535,0.0030892747,0.00029073932,0.002211319,0.0011650049,0.0019249502,0.0060830894],"category_scores_gemma":[0.009901326,0.00036173037,0.0015584744,0.0048089973,0.0007101393,0.0017398562,0.00095063937,0.0019386156,0.00037102518],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033990553,0.00008228256,0.0007569746,0.1045996,0.001118833,0.00029560103,0.000062974075,0.0012899298,0.00025653208,0.009937049,0.022164894,0.8590955],"study_design_scores_gemma":[0.00027341026,0.0002670049,0.005776468,0.1799804,0.004819043,0.0023582557,0.00038451346,0.00093424617,0.0004069495,0.015634388,0.7890582,0.00010702755],"about_ca_topic_score_codex":0.0029160494,"about_ca_topic_score_gemma":0.0064456654,"teacher_disagreement_score":0.0060830894,"about_ca_system_score_codex":0.0018587479,"about_ca_system_score_gemma":0.0044799317,"threshold_uncertainty_score":0.02034998},"labels":[],"label_agreement":null},{"id":"W2761114208","doi":"10.1007/s40273-017-0577-2","title":"Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies","year":2017,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Biogen","keywords":"Medicine; Health economics; Economic evaluation; Systematic review; Disease; Cost effectiveness; Population; Quality-adjusted life year; Pharmacoeconomics; MEDLINE; Population health; Health technology; Family medicine; Public health; Intensive care medicine; Environmental health; Health care; Internal medicine; Pathology; Risk analysis (engineering)","score_opus":0.5082972032652955,"score_gpt":0.5324333321966794,"score_spread":0.02413612893138395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761114208","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00072787993,0.99856323,0.000089833266,0.00012554564,0.000049273556,0.000115025345,0.00021749223,0.0000032902258,0.000108579006],"genre_scores_gemma":[0.012423295,0.9862075,0.0006520698,0.0002944942,0.00005369776,0.00017412483,0.00015075285,0.0000026355979,0.000041470597],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9909247,0.0030401251,0.0034167112,0.0005867767,0.0017411738,0.0002904506],"domain_scores_gemma":[0.97555375,0.018988688,0.0038093321,0.00026086584,0.0011655015,0.00022184245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010965694,0.0019953041,0.011185529,0.009553234,0.00054495607,0.0029973513,0.0021788753,0.0019002027,0.0046571256],"category_scores_gemma":[0.036816657,0.0009877105,0.012246713,0.011059736,0.0008235164,0.0024144195,0.0018583268,0.0017420356,0.00020126115],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006540524,0.000045207926,0.0010950362,0.90674883,0.042048614,0.000097903874,0.000085504515,0.00022782096,0.00013850007,0.0002659238,0.0008871455,0.04770545],"study_design_scores_gemma":[0.0012110627,0.00035437135,0.0074106175,0.5628784,0.4121092,0.00044961474,0.00027343014,0.00022621108,0.00023764891,0.0006735123,0.014112898,0.0000630615],"about_ca_topic_score_codex":0.006620496,"about_ca_topic_score_gemma":0.020816538,"teacher_disagreement_score":0.011185529,"about_ca_system_score_codex":0.0039104973,"about_ca_system_score_gemma":0.00762812,"threshold_uncertainty_score":0.057992816},"labels":[],"label_agreement":null},{"id":"W2767875195","doi":"10.1007/s40273-017-0583-4","title":"Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; University of Toronto; Ottawa Public Health; Institute of Health Economics; University of Ottawa; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Quality of Life Research; Health economics; Key (lock); Markov model; Profit (economics); Management science; Computer science; Health administration; Health technology; Risk analysis (engineering); Markov chain; Actuarial science; Public health; Medicine; Health care; Business; Economics; Nursing; Computer security","score_opus":0.5489813413919996,"score_gpt":0.5914322835205265,"score_spread":0.04245094212852685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767875195","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002238321,0.012641587,0.120472796,0.8474957,0.0039176843,0.00006575278,0.00044691452,0.00086898566,0.0118523035],"genre_scores_gemma":[0.32101,0.058537874,0.40421665,0.14729714,0.023358125,0.0010535342,0.0015915054,0.0022594843,0.040675614],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9910584,0.006502625,0.00027372348,0.0004400001,0.001401144,0.00032403052],"domain_scores_gemma":[0.9394124,0.039425183,0.001991014,0.004859542,0.008929626,0.005382268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026223391,0.0015503147,0.001623617,0.0015103942,0.001930114,0.011738895,0.0031711208,0.0054918732,0.015671518],"category_scores_gemma":[0.09575493,0.0011454724,0.0009689997,0.0017460088,0.003386346,0.024965115,0.005355828,0.014080153,0.006815897],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011803687,0.00026264283,0.0023769839,0.00025591947,0.00019158215,0.00012543397,0.0006171916,0.01985913,0.00025430167,0.33434018,0.4888783,0.15272042],"study_design_scores_gemma":[0.000028200393,0.000022748342,0.0002911457,0.00037858498,0.000033394495,0.000038931434,0.00044526716,0.023385257,0.00012146544,0.87133664,0.103861354,0.000057022895],"about_ca_topic_score_codex":0.011570042,"about_ca_topic_score_gemma":0.011431469,"teacher_disagreement_score":0.026223391,"about_ca_system_score_codex":0.003329707,"about_ca_system_score_gemma":0.011845662,"threshold_uncertainty_score":0.13868421},"labels":[],"label_agreement":null},{"id":"W2772072809","doi":"10.1007/s40273-017-0582-5","title":"Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control","funders":"National Health and Medical Research Council; Cancer Australia; Medical Research Council; Australian Government","keywords":"Quality of life (healthcare); Quality-adjusted life year; Life expectancy; Medicine; Health economics; Population; Psychology; Gerontology; Public health; Cost effectiveness; Environmental health; Nursing","score_opus":0.5925945040015864,"score_gpt":0.5019002339167253,"score_spread":0.09069427008486108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772072809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53517306,0.0036458282,0.2197255,0.006575468,0.0009780736,0.014626127,0.044518046,0.0009773831,0.17378046],"genre_scores_gemma":[0.73797387,0.0015489615,0.2010301,0.0011666968,0.00008380828,0.015489356,0.015539358,0.00023824697,0.026929624],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9894246,0.0067211143,0.0007508055,0.00046989453,0.0023369787,0.00029651765],"domain_scores_gemma":[0.9903898,0.0037657854,0.0012194351,0.0011470388,0.0030901192,0.00038773066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014024493,0.0005142201,0.0006331236,0.002140506,0.0006029204,0.0012231027,0.0010646421,0.0006101339,0.0162743],"category_scores_gemma":[0.040811677,0.00030545404,0.0012815906,0.0028710617,0.000609318,0.0010270977,0.001993222,0.0016881895,0.0018874012],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022955982,0.0010521577,0.14572933,0.002215071,0.00056167814,0.00026801674,0.006816321,0.015728163,0.0041652992,0.04979625,0.12475162,0.6466206],"study_design_scores_gemma":[0.00068753905,0.0028164233,0.57375914,0.001383977,0.00043999078,0.0010191667,0.0029324652,0.038202524,0.0031897947,0.042833436,0.33238488,0.00035058553],"about_ca_topic_score_codex":0.015703531,"about_ca_topic_score_gemma":0.016155578,"teacher_disagreement_score":0.0162743,"about_ca_system_score_codex":0.0029507577,"about_ca_system_score_gemma":0.002156995,"threshold_uncertainty_score":0.07416952},"labels":[],"label_agreement":null},{"id":"W2779437291","doi":"10.1007/s40273-017-0603-4","title":"Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines","year":2017,"lang":"en","type":"editorial","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Technology Assessment international; Strong; Belgian Health Care Knowledge Centre; McGill University","keywords":"Health economics; Quality of Life Research; Public health; Health administration; Health informatics; Risk analysis (engineering); Business; Management science; Medicine; Economics; Nursing","score_opus":0.5059815237094502,"score_gpt":0.6015221664251202,"score_spread":0.09554064271567009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2779437291","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000050777217,0.024028309,0.007293102,0.3838137,0.58244646,0.00004336935,0.0001122167,0.000092518894,0.0021196364],"genre_scores_gemma":[0.0018873906,0.011531673,0.005888797,0.07756853,0.89969164,0.000120245146,0.000047800026,0.00013124009,0.0031326686],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9409118,0.028072203,0.008583626,0.0026502502,0.018747015,0.0010351377],"domain_scores_gemma":[0.6553088,0.28198838,0.008214327,0.0049842037,0.045374565,0.00412969],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.06903811,0.003217082,0.0053211777,0.0061511695,0.003935579,0.01899289,0.0076107914,0.039952073,0.0061333496],"category_scores_gemma":[0.2595504,0.00196358,0.00368885,0.0037757612,0.014426582,0.016123936,0.0050742105,0.06634111,0.0029903513],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024933986,0.00001543694,0.000032985037,0.00071735407,0.00014091498,0.00009108287,0.00017965006,0.0004024153,0.00003382853,0.030558255,0.9485566,0.019246424],"study_design_scores_gemma":[0.00013894988,0.000022334687,0.00014721086,0.0033868186,0.00027116275,0.00012989217,0.00016157252,0.0018082059,0.00012651435,0.13202195,0.8616808,0.00010465636],"about_ca_topic_score_codex":0.005346372,"about_ca_topic_score_gemma":0.010141426,"teacher_disagreement_score":0.9309619,"about_ca_system_score_codex":0.008566317,"about_ca_system_score_gemma":0.013511325,"threshold_uncertainty_score":0.36511278},"labels":[],"label_agreement":null},{"id":"W2781023254","doi":"10.1007/s40273-017-0601-6","title":"A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis","year":2017,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacoeconomics; Checklist; MEDLINE; Cost effectiveness; Health economics; Outcomes research; Generalizability theory; Health care; Intensive care medicine; Ulcerative colitis; Quality-adjusted life year; Family medicine; Public health; Alternative medicine; Internal medicine; Disease; Risk analysis (engineering); Pathology","score_opus":0.06905995891591639,"score_gpt":0.4084833777747435,"score_spread":0.3394234188588271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781023254","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018100793,0.9945351,0.00028598207,0.0004320903,0.00018209759,0.0008329684,0.0012719355,0.000012170563,0.0006375895],"genre_scores_gemma":[0.033386488,0.96213174,0.0014446459,0.0005518845,0.00013371216,0.001616084,0.00056377053,0.000010805879,0.00016088257],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9757724,0.010613004,0.007991804,0.0009991878,0.0041864123,0.00043712728],"domain_scores_gemma":[0.93334585,0.049835663,0.0107689565,0.0006718054,0.0049500316,0.00042772514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016409257,0.0019155756,0.011996935,0.015104786,0.00077368633,0.003633355,0.0025318242,0.0021507363,0.0062420755],"category_scores_gemma":[0.08686041,0.0011684891,0.01357835,0.01616931,0.00095445383,0.0028745553,0.0015108099,0.0017114704,0.0003506],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003620017,0.000013099964,0.00054964074,0.9602993,0.018737596,0.00009718023,0.000056763274,0.0001992298,0.00005628277,0.00026169865,0.00082773523,0.018539622],"study_design_scores_gemma":[0.0006902104,0.00028208978,0.00389704,0.83247143,0.15025425,0.0003348417,0.00016003572,0.00026003903,0.00013841118,0.0005104499,0.010964199,0.0000370823],"about_ca_topic_score_codex":0.009844007,"about_ca_topic_score_gemma":0.022172298,"teacher_disagreement_score":0.016409257,"about_ca_system_score_codex":0.008943506,"about_ca_system_score_gemma":0.014670712,"threshold_uncertainty_score":0.0867815},"labels":[],"label_agreement":null},{"id":"W2784872984","doi":"10.1007/s40273-018-0610-0","title":"The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011–2017","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"Canadian Institutes of Health Research","keywords":"Reimbursement; Medicine; Actuarial science; Consistency (knowledge bases); Transparency (behavior); Health economics; Logistic regression; Public health; Family medicine; Health care; Computer science; Business; Economics; Nursing","score_opus":0.4025310874392468,"score_gpt":0.5420175238655627,"score_spread":0.13948643642631586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784872984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92309344,0.016564496,0.007368907,0.02049584,0.00024578147,0.0029056394,0.013072927,0.00011376385,0.016139185],"genre_scores_gemma":[0.9850013,0.0019162544,0.009985647,0.00078850717,0.00005665228,0.000426841,0.0014082382,0.00001909967,0.00039761965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.83028543,0.08210136,0.023860427,0.007165737,0.050411824,0.006175213],"domain_scores_gemma":[0.33264697,0.52189106,0.06567045,0.007140517,0.06632652,0.0063244062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.121777855,0.0005222726,0.0014374726,0.0071979268,0.0030919474,0.007817668,0.0020053182,0.0014945876,0.0013217762],"category_scores_gemma":[0.48769674,0.0005204148,0.0025991437,0.013096516,0.002703055,0.0018828085,0.0024719234,0.0026324126,0.00015198505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005233841,0.0002536045,0.5809538,0.017213762,0.005709887,0.0009192864,0.03151276,0.01249823,0.0016623868,0.011944994,0.027793953,0.30430356],"study_design_scores_gemma":[0.0006636528,0.00064755144,0.87398374,0.00826482,0.003674147,0.00062454294,0.019614587,0.02862074,0.0021656,0.009783616,0.05130145,0.0006556005],"about_ca_topic_score_codex":0.56866544,"about_ca_topic_score_gemma":0.65363234,"teacher_disagreement_score":0.94945586,"about_ca_system_score_codex":0.05054415,"about_ca_system_score_gemma":0.08724876,"threshold_uncertainty_score":0.8677496},"labels":[],"label_agreement":null},{"id":"W2785073729","doi":"10.1007/s40273-018-0609-6","title":"Cost Effectiveness of Treatments for Chronic Constipation: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Bone and Joint Health Institute; University of Calgary","funders":"","keywords":"Quality of Life Research; Health economics; Chronic constipation; Health administration; Medicine; Cost effectiveness; Public health; Constipation; Systematic review; Intensive care medicine; Pharmacoeconomics; MEDLINE; Risk analysis (engineering); Internal medicine; Nursing; Political science","score_opus":0.14093524339637134,"score_gpt":0.4596411349477078,"score_spread":0.31870589155133644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785073729","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013465022,0.9980044,0.000058523896,0.00011714958,0.00006569879,0.000065344,0.000215121,0.0000035839155,0.0001236544],"genre_scores_gemma":[0.026772883,0.9719874,0.00044549585,0.00037005357,0.00008495701,0.00010457548,0.00016923765,0.0000035577862,0.00006187023],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9960032,0.0014777759,0.0012174345,0.00031714098,0.0007968514,0.00018758092],"domain_scores_gemma":[0.9883073,0.009024207,0.0019028737,0.00011257688,0.00050972635,0.00014337702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041046436,0.0014032339,0.008941592,0.0048848307,0.00038504382,0.0020714172,0.0015573632,0.0017847619,0.0053380174],"category_scores_gemma":[0.018644987,0.0009814173,0.011422119,0.0063166986,0.0006089081,0.0017581676,0.0013651712,0.0019052259,0.00017522887],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013130712,0.00006350736,0.0017885624,0.87662995,0.069690816,0.00011274208,0.00008435533,0.0002813051,0.00012398956,0.00024811813,0.0015537634,0.048109792],"study_design_scores_gemma":[0.002831316,0.00067542255,0.014794856,0.40108055,0.5646277,0.000609596,0.00039381193,0.00039832984,0.00018529448,0.00070979126,0.013600338,0.000093076706],"about_ca_topic_score_codex":0.009325322,"about_ca_topic_score_gemma":0.028286701,"teacher_disagreement_score":0.009325322,"about_ca_system_score_codex":0.0028826953,"about_ca_system_score_gemma":0.0041756122,"threshold_uncertainty_score":0.021707714},"labels":[],"label_agreement":null},{"id":"W2786627764","doi":"10.1007/s40273-017-0605-2","title":"A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Parathyroid Disorders and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Amgen","keywords":"Cinacalcet; Calcimimetic; Medicine; Cost effectiveness; Quality-adjusted life year; Internal medicine; Parathyroid hormone; Secondary hyperparathyroidism; Risk analysis (engineering)","score_opus":0.11123208547633699,"score_gpt":0.4375608287289462,"score_spread":0.3263287432526092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786627764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7328569,0.015369559,0.20410283,0.014542262,0.0010187045,0.0045517916,0.009056143,0.0005872669,0.017914457],"genre_scores_gemma":[0.97361505,0.0013917895,0.01955477,0.00069196214,0.0001195792,0.0011593442,0.0011707977,0.000027004098,0.0022697102],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9934709,0.005188608,0.00021120091,0.00043894642,0.00025107438,0.0004392946],"domain_scores_gemma":[0.96538246,0.031842735,0.0010033655,0.00020503282,0.00063447224,0.00093184476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010228959,0.002166335,0.004792765,0.0023512812,0.00066053215,0.0027671813,0.0025592733,0.003433532,0.010751384],"category_scores_gemma":[0.022582343,0.001299287,0.0035886732,0.0015274797,0.0009484158,0.001494448,0.0013582174,0.004213575,0.00049268414],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017029464,0.00086901296,0.0030370478,0.00057236286,0.001382179,0.00016187727,0.000051180265,0.952889,0.00025407437,0.0052936026,0.0015889367,0.01687125],"study_design_scores_gemma":[0.0031467495,0.0014341774,0.0009494869,0.00012825873,0.0009061311,0.00008131252,0.000045702847,0.988992,0.00012285766,0.00364841,0.00051509007,0.000029823083],"about_ca_topic_score_codex":0.022217767,"about_ca_topic_score_gemma":0.008397374,"teacher_disagreement_score":0.022217767,"about_ca_system_score_codex":0.0064329435,"about_ca_system_score_gemma":0.005889402,"threshold_uncertainty_score":0.05409658},"labels":[],"label_agreement":null},{"id":"W2788315630","doi":"10.1007/s40273-018-0623-8","title":"Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":399,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"EuroQol Research Foundation","keywords":"Statistic; EQ-5D; Descriptive statistics; Valuation (finance); Statistics; Psychology; Medicine; Econometrics; Economics; Mathematics; Health related quality of life","score_opus":0.4166524124455467,"score_gpt":0.44531346182943976,"score_spread":0.028661049383893078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788315630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773322,0.003786585,0.005710636,0.0010265973,0.000110718975,0.00008975861,0.0072882543,0.0000437797,0.0046114763],"genre_scores_gemma":[0.9945133,0.00027615778,0.0010295418,0.0002463449,0.000025966394,0.00003691385,0.0037324147,0.000018353569,0.000121088626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9810548,0.012769466,0.0012857266,0.0020905575,0.0021774876,0.0006219057],"domain_scores_gemma":[0.9559116,0.026179539,0.009486087,0.0047309543,0.002962634,0.00072918716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.031948995,0.0004896613,0.0012780147,0.0031279754,0.00034842303,0.0025453072,0.0009437352,0.00087456394,0.0016110421],"category_scores_gemma":[0.056254517,0.00032617044,0.0017217295,0.0044765687,0.0013622125,0.0021004544,0.0021161465,0.0007783574,0.0005690541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014424479,0.000059219594,0.9603073,0.00034033717,0.0030347798,0.00006495669,0.0005719886,0.0021830648,0.0002679166,0.0016922259,0.0019618506,0.028073944],"study_design_scores_gemma":[0.00014393576,0.00058172696,0.98900807,0.00027742912,0.00057452754,0.00015921057,0.00113503,0.0030520163,0.00035792566,0.0012162778,0.003439844,0.000054029933],"about_ca_topic_score_codex":0.004583098,"about_ca_topic_score_gemma":0.0034785168,"teacher_disagreement_score":0.031948995,"about_ca_system_score_codex":0.00097595656,"about_ca_system_score_gemma":0.0005579003,"threshold_uncertainty_score":0.16896445},"labels":[],"label_agreement":null},{"id":"W2799437595","doi":"10.1007/s40273-018-0664-z","title":"Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation","year":2018,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Health economics; Wake; Quality of Life Research; Public health; Health administration; Economics; Business; Actuarial science; Public economics; Medicine; Pathology; Engineering","score_opus":0.07024198141245815,"score_gpt":0.310089570329557,"score_spread":0.23984758891709884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799437595","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030604773,0.001379525,0.0002453007,0.988902,0.0061223735,0.000007422169,0.000033841472,0.000024858273,0.0029786674],"genre_scores_gemma":[0.0036179936,0.0006126749,0.00034438987,0.97554296,0.01682272,0.00002016674,0.000018759074,0.000029674842,0.0029906903],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98184985,0.004439569,0.0013937008,0.0023497273,0.007367132,0.0026000764],"domain_scores_gemma":[0.9376842,0.044268228,0.0031786307,0.0020982544,0.0051782695,0.0075925104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016540049,0.0009264551,0.0023921998,0.0010662494,0.0044423696,0.011388237,0.0041030827,0.14296901,0.013626346],"category_scores_gemma":[0.076048605,0.00086423557,0.0026227767,0.0009779525,0.012208558,0.011689957,0.005031149,0.09669547,0.005869096],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009953102,0.00007550209,0.00040630947,0.00007832481,0.00002554455,0.00103678,0.000195219,0.00012219592,0.00048348831,0.05144851,0.92963994,0.016388668],"study_design_scores_gemma":[0.00030044292,0.0000854457,0.0011103002,0.0004301937,0.00003383705,0.0007976384,0.0003276715,0.0005825946,0.00048606374,0.0959997,0.8997281,0.00011803028],"about_ca_topic_score_codex":0.004196603,"about_ca_topic_score_gemma":0.008823173,"teacher_disagreement_score":0.14296901,"about_ca_system_score_codex":0.008591811,"about_ca_system_score_gemma":0.011297673,"threshold_uncertainty_score":0.08747321},"labels":[],"label_agreement":null},{"id":"W2800669514","doi":"10.1007/s40273-018-0669-7","title":"Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canadian Agency for Drugs and Technologies in Health; Hospital for Sick Children; University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Dravet syndrome; Medicine; Clobazam; Cost–utility analysis; Cost effectiveness; Health economics; Pharmacoeconomics; Adjunctive treatment; Intensive care medicine; Pediatrics; Public health; Epilepsy; Psychiatry; Internal medicine; Risk analysis (engineering)","score_opus":0.09429722996436016,"score_gpt":0.4574857804400075,"score_spread":0.36318855047564735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800669514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85916024,0.08055754,0.02312171,0.0058870823,0.0005739249,0.0047593433,0.009946909,0.00022834328,0.015764907],"genre_scores_gemma":[0.9897782,0.004736474,0.0030371088,0.0002781445,0.000057996967,0.0004527329,0.0009183282,0.000019731326,0.0007212228],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9923799,0.0062692733,0.00025193542,0.00023082983,0.00050751935,0.00036050862],"domain_scores_gemma":[0.9873942,0.010603896,0.00080382434,0.00021408184,0.00043268283,0.00055135007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006629336,0.0020969792,0.0036020163,0.0026322799,0.00036254653,0.002809823,0.0013138609,0.0016086395,0.0070866854],"category_scores_gemma":[0.02428179,0.0007972973,0.0068222103,0.0022371802,0.00079111534,0.0016955812,0.0011759732,0.0027568738,0.00030145384],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32427806,0.0044420944,0.025957868,0.013047873,0.041903373,0.0015455458,0.00028881987,0.35328472,0.002391221,0.013902425,0.007503443,0.21145456],"study_design_scores_gemma":[0.08838347,0.04698524,0.04550167,0.0057284436,0.10439011,0.0026993114,0.001668335,0.67077833,0.002458464,0.016408004,0.014474266,0.00052442896],"about_ca_topic_score_codex":0.013003062,"about_ca_topic_score_gemma":0.006974993,"teacher_disagreement_score":0.013003062,"about_ca_system_score_codex":0.008013741,"about_ca_system_score_gemma":0.0038191334,"threshold_uncertainty_score":0.058144033},"labels":[],"label_agreement":null},{"id":"W2883422525","doi":"10.1007/s40273-018-0697-3","title":"Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Sensitivity (control systems); Probabilistic logic; Convergence (economics); Variance (accounting); Computer science; Mathematical optimization; Function (biology); Statistics; Econometrics; Mathematics","score_opus":0.4523610308962625,"score_gpt":0.47954391107213534,"score_spread":0.027182880175872837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883422525","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.110953026,0.0028238746,0.87926674,0.0018621255,0.00012519122,0.0007614823,0.0007268648,0.00033334785,0.0031472915],"genre_scores_gemma":[0.91389495,0.0016080454,0.0798159,0.0008280666,0.00013619485,0.0011351152,0.00078954524,0.00024456394,0.0015476195],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9270415,0.0665483,0.0014911122,0.0023773497,0.0015652745,0.00097646745],"domain_scores_gemma":[0.40820417,0.57474333,0.0064408993,0.0064132744,0.0032383678,0.000959867],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.14646676,0.0023937444,0.0052606678,0.004538888,0.0013333807,0.0040455773,0.004431032,0.0039299047,0.005471472],"category_scores_gemma":[0.39611936,0.002996109,0.008743053,0.0019859313,0.0029010826,0.00530591,0.005491485,0.007949576,0.0002966348],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005945702,0.00016002073,0.008399113,0.00041707436,0.002508482,0.00028646545,0.00030777545,0.94254285,0.00022711822,0.03422703,0.00095134985,0.009378175],"study_design_scores_gemma":[0.00010061461,0.00018464819,0.0014758464,0.00017371803,0.0008857836,0.00015041513,0.00008778943,0.9373844,0.00022394696,0.058780957,0.00050314603,0.000048801125],"about_ca_topic_score_codex":0.011097773,"about_ca_topic_score_gemma":0.0046141623,"teacher_disagreement_score":0.85353327,"about_ca_system_score_codex":0.0031901272,"about_ca_system_score_gemma":0.0034595698,"threshold_uncertainty_score":0.77459955},"labels":[],"label_agreement":null},{"id":"W2890132602","doi":"10.1007/s40273-018-0711-9","title":"Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution?","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Timeline; Transparency (behavior); Computer science; Risk analysis (engineering); Management science; Field (mathematics); Data aggregator; Health administration; Data science; Component (thermodynamics); Psychological intervention; Process management; Public health; Business; Medicine; Economics; Computer security","score_opus":0.44028548828523556,"score_gpt":0.5135493975386651,"score_spread":0.07326390925342957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890132602","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02613334,0.005823162,0.6469391,0.29719236,0.0049109277,0.00081824284,0.0009219131,0.0008953606,0.016365627],"genre_scores_gemma":[0.6925043,0.0027902783,0.25034076,0.0475177,0.002712951,0.0012528597,0.0007769626,0.0006651242,0.0014390398],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.5748834,0.3493188,0.023454487,0.013045444,0.0354594,0.0038383915],"domain_scores_gemma":[0.1071075,0.7475404,0.031333916,0.07692341,0.034242913,0.0028518387],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.5030977,0.0028835107,0.007865581,0.0033160343,0.0025260865,0.016935963,0.008862676,0.013288242,0.005933001],"category_scores_gemma":[0.81049174,0.0021011613,0.0049941624,0.0030709943,0.01435705,0.029352296,0.009491736,0.023443468,0.0017223622],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044106194,0.0012856944,0.039381817,0.0055596484,0.0125086075,0.0012759708,0.0047584674,0.04889031,0.001498134,0.59310925,0.048363328,0.23895821],"study_design_scores_gemma":[0.0009119387,0.0004443688,0.003698276,0.0038086113,0.0008444163,0.00024803428,0.00073105324,0.07866001,0.0014041504,0.8944407,0.014574346,0.00023406233],"about_ca_topic_score_codex":0.00540488,"about_ca_topic_score_gemma":0.003274677,"teacher_disagreement_score":0.4969023,"about_ca_system_score_codex":0.0062083662,"about_ca_system_score_gemma":0.020896886,"threshold_uncertainty_score":0.612769},"labels":[],"label_agreement":null},{"id":"W2896731765","doi":"10.1007/s40273-018-0729-z","title":"Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution","year":2018,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Health economics; Quality of Life Research; Scope (computer science); Health administration; Public health; Public economics; Pharmacoeconomics; Cost–benefit analysis; Economics; Actuarial science; Medicine; Political science; Computer science; Nursing; Microeconomics","score_opus":0.3488546231059756,"score_gpt":0.49418185887871285,"score_spread":0.14532723577273726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896731765","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009526791,0.0022136949,0.0004575802,0.98898345,0.0068001067,0.000011543705,0.00003349599,0.000016003218,0.001388765],"genre_scores_gemma":[0.0017316341,0.00084966765,0.0011717571,0.96546113,0.029742446,0.000051184175,0.000014301508,0.000030072384,0.0009479053],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9038741,0.044142704,0.016966777,0.007784728,0.024367003,0.002864732],"domain_scores_gemma":[0.5430195,0.3861359,0.009047661,0.009962319,0.042663377,0.009171247],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.10190837,0.002284871,0.007063896,0.0032893927,0.0063041584,0.015102622,0.010399944,0.12116202,0.009086398],"category_scores_gemma":[0.33472037,0.0024710982,0.0054687373,0.0033054797,0.031822715,0.027315795,0.009669499,0.18509136,0.0052755806],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020695152,0.00008479119,0.00057085947,0.0004730234,0.000128307,0.00072786555,0.0007652039,0.00028489914,0.00023913248,0.062269907,0.91171175,0.022537256],"study_design_scores_gemma":[0.0005225654,0.0001048426,0.0011384785,0.0057985904,0.00016839821,0.0013030644,0.001386242,0.0013993446,0.00026707622,0.24383804,0.74364054,0.00043280647],"about_ca_topic_score_codex":0.013443336,"about_ca_topic_score_gemma":0.024879025,"teacher_disagreement_score":0.8980916,"about_ca_system_score_codex":0.011119669,"about_ca_system_score_gemma":0.015187965,"threshold_uncertainty_score":0.53894943},"labels":[],"label_agreement":null},{"id":"W2899466366","doi":"10.1007/s40273-018-0732-4","title":"Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Midostaurin; Medicine; Cytarabine; Daunorubicin; Quality-adjusted life year; Internal medicine; Myeloid leukemia; Placebo; Oncology; Cost effectiveness; Leukemia; Surgery; Pathology","score_opus":0.04306016700287379,"score_gpt":0.37204935814548384,"score_spread":0.32898919114261005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899466366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657511,0.019874794,0.000265513,0.0068989755,0.00013376986,0.00005805106,0.0021863794,0.000023421979,0.0048079984],"genre_scores_gemma":[0.9966144,0.0020563903,0.000092715076,0.0005194404,0.000050445968,0.000011551464,0.00042496176,0.0000018577557,0.00022818102],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989736,0.0005989789,0.000082024075,0.00006111537,0.00014948533,0.0001348351],"domain_scores_gemma":[0.99887127,0.0004525258,0.00033681048,0.00001590453,0.000065399945,0.00025802664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000723917,0.00019698188,0.00046518713,0.0004993934,0.0001546309,0.00068429264,0.0002668791,0.0005822401,0.00155585],"category_scores_gemma":[0.0034559977,0.000104783714,0.0012930041,0.0007065099,0.00023859904,0.0004343553,0.00040309018,0.0006338016,0.000059673974],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05987322,0.0028308465,0.4664372,0.0016193177,0.005678637,0.0013093079,0.00017102367,0.061919887,0.002479479,0.005805751,0.020396024,0.3714793],"study_design_scores_gemma":[0.006381137,0.009389083,0.9186727,0.0006643694,0.005932397,0.0012792505,0.0008140924,0.044082135,0.0011772304,0.0023034965,0.009220096,0.0000839436],"about_ca_topic_score_codex":0.030003335,"about_ca_topic_score_gemma":0.047266886,"teacher_disagreement_score":0.030003335,"about_ca_system_score_codex":0.003958683,"about_ca_system_score_gemma":0.0020552052,"threshold_uncertainty_score":0.059657395},"labels":[],"label_agreement":null},{"id":"W2902546796","doi":"10.1007/s40273-018-0751-1","title":"Measuring Public Preferences for Health Outcomes and Expenditures in a Context of Healthcare Resource Re-Allocation","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"Institut National de la Santé et de la Recherche Médicale","keywords":"Health economics; Health administration; Public health; Health care; Context (archaeology); Resource allocation; Quality of Life Research; Health services research; Business; Public economics; Medicine; Economics; Nursing; Economic growth; Geography; Management","score_opus":0.5460828892878852,"score_gpt":0.48836308252882693,"score_spread":0.057719806759058245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902546796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917474,0.0001754754,0.002318502,0.0015320921,0.000010849182,0.000045661087,0.00037069456,0.000007592384,0.0037917818],"genre_scores_gemma":[0.99911004,0.000041243955,0.00057498144,0.000047847152,0.000009914817,0.000018737303,0.00009626817,0.0000015586679,0.000099500685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9863194,0.010691105,0.0004055104,0.00061384955,0.00099275,0.0009773775],"domain_scores_gemma":[0.94591147,0.037849337,0.010555795,0.0020989734,0.0019597057,0.0016246669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014878828,0.00052299246,0.0006785273,0.0015580442,0.00052465784,0.0034766858,0.00062943395,0.0015266081,0.0028709946],"category_scores_gemma":[0.048552383,0.00029466004,0.00084853463,0.0024784117,0.0012797322,0.002848819,0.0013776912,0.0020223688,0.00025383843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002045472,0.0021847787,0.88690704,0.00022844883,0.0012122679,0.00041208437,0.002037263,0.041651268,0.0009931186,0.022176512,0.0019779897,0.03817376],"study_design_scores_gemma":[0.00024290479,0.0020347345,0.83075905,0.00016358028,0.0005991978,0.00034302927,0.014891649,0.09377186,0.0021337413,0.05169772,0.0032299845,0.00013246806],"about_ca_topic_score_codex":0.006989454,"about_ca_topic_score_gemma":0.008368016,"teacher_disagreement_score":0.014878828,"about_ca_system_score_codex":0.0032690598,"about_ca_system_score_gemma":0.00190671,"threshold_uncertainty_score":0.07868767},"labels":[],"label_agreement":null},{"id":"W2922512552","doi":"10.1007/s40273-019-00777-6","title":"Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and Challenges","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Machine Learning in Healthcare","field":"Computer Science","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Computer science; Health care; Data science; Identification (biology); Pipeline (software); Artificial intelligence; Big data; Health administration; Machine learning; Data mining","score_opus":0.16780540659326584,"score_gpt":0.3561746233826987,"score_spread":0.18836921678943283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922512552","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030391961,0.13192064,0.2467562,0.5575377,0.0033955744,0.00025589985,0.002250416,0.00091434456,0.02657728],"genre_scores_gemma":[0.44094494,0.14727509,0.3416014,0.03750962,0.02343551,0.0007211561,0.0023858894,0.00056976883,0.005556683],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97167563,0.01745624,0.0011313488,0.0021611382,0.006980738,0.0005948669],"domain_scores_gemma":[0.7458032,0.22982822,0.0031895125,0.009695169,0.008843337,0.002640513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.046424877,0.0014784631,0.0027721939,0.006156702,0.0013485278,0.01245513,0.0041963793,0.004731723,0.0036827966],"category_scores_gemma":[0.09341591,0.001323202,0.0016054895,0.005468712,0.0087134065,0.02616586,0.009901958,0.010901675,0.001949598],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043292722,0.00035544712,0.031571053,0.0063685146,0.0016425947,0.0014211595,0.0038757473,0.023834223,0.003222914,0.25939748,0.06712244,0.60075545],"study_design_scores_gemma":[0.000042592386,0.00016692412,0.007116966,0.0020290392,0.00013398386,0.0010840574,0.0037510446,0.04618865,0.0008833806,0.8250903,0.1132587,0.0002544585],"about_ca_topic_score_codex":0.0024748023,"about_ca_topic_score_gemma":0.0027448758,"teacher_disagreement_score":0.046424877,"about_ca_system_score_codex":0.0016002221,"about_ca_system_score_gemma":0.0034022569,"threshold_uncertainty_score":0.24552119},"labels":[],"label_agreement":null},{"id":"W2949819367","doi":"10.1007/s40273-019-00814-4","title":"Cost Effectiveness of Advanced Pharmacy Services Provided in the Community and Primary Care Settings: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"National Institute for Health and Care Excellence","keywords":"Medicine; Nice; Pharmacy; Checklist; Economic evaluation; MEDLINE; Guideline; Family medicine; Health economics; Systematic review; Health care; Public health; Nursing; Psychology; Political science","score_opus":0.17700224680052437,"score_gpt":0.483331069486977,"score_spread":0.3063288226864527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949819367","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057709236,0.9932214,0.000079291836,0.00012894293,0.00007729256,0.00008675729,0.0005124135,0.0000045344514,0.00011846074],"genre_scores_gemma":[0.10014891,0.8980757,0.0005754325,0.00045821228,0.00010981121,0.00018724178,0.00035816053,0.00000615559,0.000080466896],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9917031,0.0028972202,0.0027225176,0.00076404196,0.0015424867,0.00037067532],"domain_scores_gemma":[0.9786105,0.015221278,0.0044023674,0.00024986902,0.0011821998,0.00033381177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005933063,0.0013705642,0.009911985,0.007445412,0.00047402238,0.0027839246,0.0015685868,0.0019547588,0.0031668819],"category_scores_gemma":[0.030268712,0.0010192222,0.014855957,0.011267371,0.0008143907,0.0020385755,0.0018478191,0.001787586,0.00014928692],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013808401,0.000077806,0.009817551,0.7859339,0.1639762,0.00013174521,0.00014761041,0.00037031743,0.000103461265,0.00025104158,0.0012034733,0.036606014],"study_design_scores_gemma":[0.0016460338,0.0006457563,0.040473543,0.325085,0.62145835,0.0005273018,0.00059290824,0.00035944761,0.00018193021,0.00044260113,0.008488283,0.00009884793],"about_ca_topic_score_codex":0.01652014,"about_ca_topic_score_gemma":0.049458075,"teacher_disagreement_score":0.01652014,"about_ca_system_score_codex":0.0048885313,"about_ca_system_score_gemma":0.006191238,"threshold_uncertainty_score":0.035468996},"labels":[],"label_agreement":null},{"id":"W2950152695","doi":"10.1007/s40273-019-00816-2","title":"Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; University of Ottawa","funders":"","keywords":"Epilepsy; Medicine; Cannabis; Pharmacoeconomics; Cochrane Library; MEDLINE; Drug Resistant Epilepsy; Economic evaluation; Vagus nerve stimulation; Population; Health economics; Cost effectiveness; Epilepsy surgery; Dravet syndrome; Health care; Intensive care medicine; Psychiatry; Meta-analysis; Public health; Environmental health; Internal medicine","score_opus":0.1453148856653226,"score_gpt":0.5142805400626335,"score_spread":0.3689656543973109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950152695","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004950946,0.98679566,0.005175599,0.0006929,0.00018681174,0.00055816857,0.0010154444,0.00004751165,0.0005769372],"genre_scores_gemma":[0.21547543,0.763141,0.0165337,0.0008167559,0.00031265683,0.0019945765,0.0013534854,0.00005121067,0.00032119625],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9695995,0.023898238,0.003426341,0.0008537838,0.0019054834,0.000316724],"domain_scores_gemma":[0.8806311,0.11242008,0.004562658,0.0006483369,0.0014311941,0.0003067537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.035400715,0.0038798202,0.013755,0.010467807,0.00040594436,0.0043159663,0.002737153,0.0025936535,0.0062198304],"category_scores_gemma":[0.10173216,0.0018568301,0.021729011,0.0070919245,0.00096273527,0.0033145896,0.0017820649,0.0042384765,0.00026053374],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060430192,0.0002901825,0.004693975,0.48450735,0.2979679,0.00016170138,0.00017630968,0.04123182,0.00014457901,0.007788991,0.0028141565,0.15418],"study_design_scores_gemma":[0.008874772,0.00145008,0.0060258904,0.22045428,0.6788421,0.00049496786,0.00034863208,0.044332873,0.00033581667,0.02516967,0.01344422,0.00022666382],"about_ca_topic_score_codex":0.009403612,"about_ca_topic_score_gemma":0.0131302215,"teacher_disagreement_score":0.035400715,"about_ca_system_score_codex":0.0064247567,"about_ca_system_score_gemma":0.0054989513,"threshold_uncertainty_score":0.18721914},"labels":[],"label_agreement":null},{"id":"W2951182219","doi":"10.1007/s40273-019-00817-1","title":"Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University; St. Paul's Hospital","funders":"National Institute on Drug Abuse; Ministry of Health, British Columbia","keywords":"Context (archaeology); Computer science; Population health; Health economics; Population; Psychological intervention; Data quality; Risk analysis (engineering); Public health; Medicine; Environmental health; Business; Service (business); Marketing; Nursing; Geography","score_opus":0.4289183444733304,"score_gpt":0.5406009061041488,"score_spread":0.11168256163081841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951182219","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006248531,0.9921582,0.0049926676,0.0008174059,0.00015214836,0.00016767888,0.00014643327,0.000019204552,0.00092149194],"genre_scores_gemma":[0.010501905,0.98029137,0.008050074,0.00039121628,0.00009929699,0.0003346317,0.00014418433,0.00001259453,0.0001746107],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99429965,0.0032627936,0.0010721202,0.00033651476,0.00089545856,0.00013342733],"domain_scores_gemma":[0.9439902,0.052486863,0.0015699398,0.0005329486,0.0013003,0.000119835466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013131556,0.0014846163,0.00434478,0.002670471,0.00049418403,0.0037035246,0.002643342,0.002417242,0.005833002],"category_scores_gemma":[0.052284256,0.001167802,0.0043106438,0.0026415247,0.0013138127,0.0025260455,0.0016711656,0.0028720377,0.0006810374],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032725974,0.000102910184,0.0007167334,0.45771205,0.0028249475,0.00023847433,0.00047205557,0.025718607,0.00041898293,0.05237195,0.007314788,0.4517812],"study_design_scores_gemma":[0.0006041483,0.0007054761,0.0018800716,0.50074995,0.020475646,0.0010829754,0.00088923814,0.018071616,0.0014290191,0.075027734,0.37883848,0.000245619],"about_ca_topic_score_codex":0.0065982617,"about_ca_topic_score_gemma":0.009437716,"teacher_disagreement_score":0.013131556,"about_ca_system_score_codex":0.0026492027,"about_ca_system_score_gemma":0.009640957,"threshold_uncertainty_score":0.06944716},"labels":[],"label_agreement":null},{"id":"W2955784899","doi":"10.1007/s40273-019-00819-z","title":"Transparency in Decision Modelling: What, Why, Who and How?","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"National Institute of General Medical Sciences; National Institutes of Health","keywords":"Transparency (behavior); Incentive; Stakeholder; Knowledge management; Business; Public relations; Computer science; Political science; Computer security; Economics","score_opus":0.6503032919285434,"score_gpt":0.5211485563238956,"score_spread":0.12915473560464785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955784899","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"reproducibility","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"reproducibility","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000108820575,0.9892819,0.001669054,0.007987325,0.00025309215,0.000008200114,0.00003385028,0.000007790205,0.0006497939],"genre_scores_gemma":[0.006029327,0.98938835,0.0017305145,0.0018918043,0.0007505275,0.000023107712,0.000038210794,0.000007890102,0.00014029758],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9783965,0.01488985,0.0019000262,0.0007886348,0.0035540827,0.00047083967],"domain_scores_gemma":[0.89037704,0.09906171,0.004377079,0.0014799181,0.004127473,0.00057673483],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.028502675,0.0013768426,0.0042356015,0.0036638859,0.00057509524,0.0060712323,0.0021000048,0.004249015,0.004364097],"category_scores_gemma":[0.067557596,0.0007649408,0.002196494,0.0061368416,0.0038283316,0.006211362,0.0019397618,0.007210228,0.0007303892],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013752336,0.000093067145,0.0006945759,0.043108787,0.0010744012,0.00007541481,0.0002621728,0.0045226216,0.00010288968,0.10521619,0.033167437,0.811545],"study_design_scores_gemma":[0.00021477809,0.00015155676,0.002216909,0.14733584,0.0020437036,0.0005344066,0.0004594206,0.004948072,0.00044826974,0.32142884,0.5200368,0.0001814094],"about_ca_topic_score_codex":0.008995731,"about_ca_topic_score_gemma":0.00847601,"teacher_disagreement_score":0.9714973,"about_ca_system_score_codex":0.004485886,"about_ca_system_score_gemma":0.011884287,"threshold_uncertainty_score":0.15073836},"labels":[],"label_agreement":null},{"id":"W2972254478","doi":"10.1007/s40273-019-00834-0","title":"Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; University of British Columbia","funders":"National Institutes of Health","keywords":"Context (archaeology); Health care; Health economics; Price elasticity of demand; Test (biology); Health administration; Econometrics; Confidence interval; Medicine; Actuarial science; Economics; Statistics; Microeconomics; Mathematics","score_opus":0.039894023046103746,"score_gpt":0.3386219699148572,"score_spread":0.2987279468687535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972254478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206334,0.000050193583,0.004685232,0.00031513273,0.00008540879,0.0007444672,0.00062027544,0.000038392744,0.0013975357],"genre_scores_gemma":[0.99092454,0.00003577429,0.0036311795,0.00029868726,0.00008268215,0.0014376194,0.0011311532,0.00003312458,0.0024252774],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9811813,0.015159189,0.00066414004,0.0012645229,0.0010890493,0.00064179196],"domain_scores_gemma":[0.6256732,0.32665497,0.013627121,0.02760863,0.004101719,0.002334458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.036727976,0.0015121973,0.00194482,0.0005182689,0.0016283931,0.0025497687,0.0025561128,0.0049972627,0.009939102],"category_scores_gemma":[0.1367242,0.0010302175,0.0016949421,0.00055368163,0.00370429,0.0022034927,0.001833531,0.0037175738,0.0021136235],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47830126,0.17430566,0.15771322,0.0012421028,0.0025723802,0.0010822114,0.0076016835,0.08077458,0.018357124,0.028755987,0.008195318,0.041098464],"study_design_scores_gemma":[0.12353647,0.19270393,0.27709594,0.00036819017,0.002602672,0.00107216,0.0033448718,0.30344573,0.02273592,0.051696926,0.020123566,0.0012736082],"about_ca_topic_score_codex":0.0021562397,"about_ca_topic_score_gemma":0.00091385195,"teacher_disagreement_score":0.036727976,"about_ca_system_score_codex":0.0015488554,"about_ca_system_score_gemma":0.0016159951,"threshold_uncertainty_score":0.19423842},"labels":[],"label_agreement":null},{"id":"W2975057760","doi":"10.1007/s40273-019-00841-1","title":"Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TransCanada (Canada)","funders":"Takeda Pharmaceutical Company; Takeda Pharmaceuticals U.S.A.","keywords":"Vedolizumab; Medicine; Health economics; Adalimumab; Ulcerative colitis; Discontinuation; Golimumab; Infliximab; Tofacitinib; Quality-adjusted life year; Cost effectiveness; Internal medicine; Public health; Disease; Rheumatoid arthritis","score_opus":0.014921809709046201,"score_gpt":0.2817782373427612,"score_spread":0.266856427633715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975057760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92005473,0.07226841,0.0024355361,0.0013480518,0.00016932821,0.00071930594,0.0016334071,0.000029594532,0.0013415861],"genre_scores_gemma":[0.99278414,0.0048046308,0.0010650911,0.00020771625,0.000032341482,0.00028137956,0.0006887469,0.000004097197,0.00013194726],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9973475,0.0017913166,0.00026662258,0.00023132628,0.00018613719,0.00017700461],"domain_scores_gemma":[0.99715143,0.0016959268,0.00062623183,0.00007233089,0.00018001503,0.00027421856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004246962,0.000849219,0.0038419217,0.001232891,0.00028174085,0.0011234569,0.00069440407,0.00083636405,0.001756157],"category_scores_gemma":[0.008647636,0.0005843586,0.009389968,0.0011442646,0.0003021582,0.0008147753,0.0006278064,0.0009973324,0.000060670784],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2256943,0.005188833,0.21158837,0.032398213,0.14045785,0.0014197708,0.00040165044,0.22635372,0.0025889345,0.0027005118,0.0038590084,0.14734885],"study_design_scores_gemma":[0.059464473,0.04512048,0.2632023,0.0052672247,0.23307627,0.0013161402,0.00093556347,0.3795847,0.0014715722,0.005423218,0.004800665,0.00033742658],"about_ca_topic_score_codex":0.011696085,"about_ca_topic_score_gemma":0.009957988,"teacher_disagreement_score":0.011696085,"about_ca_system_score_codex":0.003459765,"about_ca_system_score_gemma":0.002267907,"threshold_uncertainty_score":0.025102496},"labels":[],"label_agreement":null},{"id":"W2976981214","doi":"10.1007/s40273-019-00837-x","title":"A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health","keywords":"Computer science; Decision model; Transparency (behavior); Coding (social sciences); Decision analysis; Testbed; Data science; Decision support system; Management science; Data mining; Machine learning; Engineering","score_opus":0.4936290154930236,"score_gpt":0.49801941596912336,"score_spread":0.004390400476099732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976981214","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004395429,0.0007332988,0.8953679,0.081534296,0.0014184485,0.00063047296,0.0007775645,0.00092970603,0.014212827],"genre_scores_gemma":[0.15467432,0.0006810437,0.8280544,0.009378415,0.00076192943,0.002308471,0.0009101763,0.0004959714,0.0027351212],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.82300174,0.126182,0.017537693,0.007910753,0.021563085,0.0038048513],"domain_scores_gemma":[0.5640767,0.24569264,0.019586826,0.09229917,0.072879635,0.005464989],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.14929329,0.0016400034,0.00215565,0.007780765,0.007808836,0.018465688,0.0054657306,0.008094197,0.007385543],"category_scores_gemma":[0.39169005,0.0014344027,0.003335087,0.00790975,0.021160126,0.033409316,0.011802004,0.022181664,0.0017371104],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042531483,0.00003487079,0.00096258445,0.00016180037,0.00003438128,0.00005408306,0.0039367923,0.0017349031,0.00021019172,0.9476335,0.013758155,0.031436205],"study_design_scores_gemma":[0.000035437646,0.00003434116,0.00051914534,0.0008517577,0.000047809517,0.0001135849,0.0017877008,0.013066351,0.0005885109,0.9309443,0.0519008,0.00011024986],"about_ca_topic_score_codex":0.02420507,"about_ca_topic_score_gemma":0.01357881,"teacher_disagreement_score":0.8507067,"about_ca_system_score_codex":0.013423728,"about_ca_system_score_gemma":0.033368677,"threshold_uncertainty_score":0.7895478},"labels":[],"label_agreement":null},{"id":"W2977511836","doi":"10.1007/s40273-019-00830-4","title":"A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Toronto General Hospital","funders":"","keywords":"Weibull distribution; Statistics; Goodness of fit; Parametric statistics; Mathematics; Survival analysis; Computer science","score_opus":0.6160843926293349,"score_gpt":0.6119821199724155,"score_spread":0.004102272656919426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977511836","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044465188,0.00458148,0.944652,0.0014600215,0.00025486172,0.00082583784,0.0017704793,0.00058749964,0.0014025547],"genre_scores_gemma":[0.3650933,0.0027482894,0.62439364,0.0006244689,0.00027074997,0.0018587009,0.003062677,0.0008620539,0.0010862012],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.91774535,0.07299228,0.00278307,0.0021661997,0.003914981,0.00039806377],"domain_scores_gemma":[0.43351772,0.5401958,0.005740392,0.011934263,0.008079948,0.0005318283],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.107988976,0.0013860402,0.0023030152,0.0061177425,0.00053175667,0.0041577914,0.0025702273,0.001997016,0.005669037],"category_scores_gemma":[0.3224459,0.0008575509,0.005026181,0.0037665532,0.000883774,0.0035708093,0.0020598215,0.0032616851,0.0005059217],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012582648,0.0007997517,0.039608132,0.0031766014,0.013806433,0.00020567235,0.00097584014,0.16773306,0.0021004565,0.06500994,0.008954586,0.68504685],"study_design_scores_gemma":[0.0029722257,0.0018108963,0.018168753,0.0016502999,0.0037903073,0.0005315897,0.00038675292,0.8919243,0.0029485319,0.06665072,0.008843546,0.00032199838],"about_ca_topic_score_codex":0.0034524703,"about_ca_topic_score_gemma":0.002968542,"teacher_disagreement_score":0.89201105,"about_ca_system_score_codex":0.001831002,"about_ca_system_score_gemma":0.0022848882,"threshold_uncertainty_score":0.57110715},"labels":[],"label_agreement":null},{"id":"W2978265398","doi":"10.1007/s40273-019-00843-z","title":"Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application in Multimorbidity","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Bayesian probability; Outcome (game theory); Random effects model; Bayesian hierarchical modeling; Quality of life (healthcare); Quality of Life Research; Meta-analysis; Econometrics; Hierarchical database model; Quality-adjusted life year; Quality (philosophy); Bayesian inference; Computer science; Statistics; Medicine; Data mining; Public health; Risk analysis (engineering); Mathematics; Cost effectiveness","score_opus":0.6129231057444139,"score_gpt":0.5373582919347197,"score_spread":0.07556481380969415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978265398","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044514104,0.015464905,0.9752009,0.0013025855,0.0003293387,0.0005593909,0.0011160241,0.0011459817,0.00042947786],"genre_scores_gemma":[0.15358484,0.01083666,0.8222211,0.0015397079,0.0008310181,0.004962338,0.0024460927,0.0007726103,0.0028056845],"study_design_codex":"simulation_or_modeling","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.8194967,0.16470157,0.0044758464,0.0062838434,0.0042720824,0.0007700455],"domain_scores_gemma":[0.59874034,0.37756625,0.0063214847,0.012366679,0.003955439,0.0010498808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.15138872,0.0051788553,0.012580198,0.008948724,0.0026705714,0.0054117283,0.007891357,0.005595751,0.008082368],"category_scores_gemma":[0.2596927,0.004114401,0.01906018,0.011707373,0.0023456404,0.005454306,0.005017704,0.008525447,0.0013364409],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049493746,0.0005125818,0.01337531,0.0076289587,0.11454166,0.00086182205,0.0011403863,0.49378482,0.0008287397,0.13537268,0.017257882,0.2097459],"study_design_scores_gemma":[0.001920051,0.0004938766,0.0034732723,0.0010448802,0.019589396,0.00044004366,0.000109014145,0.67594963,0.00034684394,0.2883907,0.008000087,0.00024222663],"about_ca_topic_score_codex":0.021410065,"about_ca_topic_score_gemma":0.028872296,"teacher_disagreement_score":0.15138872,"about_ca_system_score_codex":0.0035230014,"about_ca_system_score_gemma":0.0057496196,"threshold_uncertainty_score":0.8006296},"labels":[],"label_agreement":null},{"id":"W2981358885","doi":"10.1007/s40273-019-00850-0","title":"Improving Transparency in Decision Models: Current Issues and Potential Solutions","year":2019,"lang":"en","type":"editorial","venue":"PharmacoEconomics","topic":"Data Quality and Management","field":"Decision Sciences","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Quality of Life Research; Transparency (behavior); Health economics; Health administration; Public health; Current (fluid); Management science; Business; Risk analysis (engineering); Computer science; Economics; Medicine; Engineering; Nursing","score_opus":0.1391068268644732,"score_gpt":0.440017613013958,"score_spread":0.30091078614948474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981358885","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":"reproducibility","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":"reproducibility","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029072415,0.011026655,0.00067679345,0.13730134,0.85012925,0.000021663916,0.00006988584,0.000050425002,0.00069483084],"genre_scores_gemma":[0.0006552751,0.008271719,0.0006543715,0.02483472,0.9636622,0.000027579666,0.000029148749,0.000043353375,0.0018215694],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9560555,0.015509375,0.0068693575,0.0024946926,0.017846365,0.0012246912],"domain_scores_gemma":[0.55282205,0.32996568,0.011043008,0.0064682616,0.08862397,0.011077121],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.058979847,0.0035650355,0.006015071,0.006161982,0.0043804627,0.019648518,0.0071199522,0.032470275,0.009579321],"category_scores_gemma":[0.24630126,0.0018338556,0.0043447926,0.0045486437,0.0075045093,0.010042072,0.0028640754,0.042908646,0.004771992],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003393291,0.000015906326,0.000027813363,0.00055612513,0.000056146935,0.00005388533,0.000034110937,0.000081022095,0.000021915232,0.0015615377,0.98957306,0.007984535],"study_design_scores_gemma":[0.00021844987,0.000043936074,0.00035370374,0.0043663653,0.00028020242,0.00027303555,0.00019831484,0.0015398317,0.00018888501,0.025812345,0.96662205,0.00010285104],"about_ca_topic_score_codex":0.004675587,"about_ca_topic_score_gemma":0.009886164,"teacher_disagreement_score":0.94102013,"about_ca_system_score_codex":0.0068949843,"about_ca_system_score_gemma":0.01341244,"threshold_uncertainty_score":0.31191903},"labels":[],"label_agreement":null},{"id":"W2986774082","doi":"10.1007/s40273-019-00852-y","title":"Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"Canadian Institutes of Health Research; Ontario Ministry of Research, Innovation and Science","keywords":"Medicine; Entecavir; Tenofovir alafenamide; Cost effectiveness; HBeAg; Chronic hepatitis; Hepatitis B virus; Internal medicine; Hepatitis B; Immunology; Lamivudine; Viral load; Virus; HBsAg","score_opus":0.03763253924656765,"score_gpt":0.33376211479872325,"score_spread":0.2961295755521556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986774082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96260095,0.021312544,0.00012970713,0.003754584,0.00012869491,0.00027724207,0.0047447816,0.00001454283,0.007036875],"genre_scores_gemma":[0.9938846,0.004356834,0.00013767027,0.00029469596,0.000022500755,0.000032000884,0.000655996,0.000002477233,0.000613091],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9983967,0.00061167305,0.0001328696,0.000073429925,0.00042022398,0.00036516043],"domain_scores_gemma":[0.9969216,0.0008633208,0.0004950602,0.000048422684,0.0008917629,0.00077974267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001339359,0.00033523666,0.00078767794,0.0009704017,0.0007507184,0.0010938408,0.0008841707,0.000577136,0.002356401],"category_scores_gemma":[0.007351065,0.00022352333,0.0013275014,0.0024839218,0.0005277769,0.00037964614,0.00045594087,0.00084281416,0.0000541929],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.073721394,0.0025278742,0.6403698,0.0054770224,0.008621591,0.0010984846,0.0005946683,0.034835476,0.0015124194,0.0051793796,0.01434108,0.21172082],"study_design_scores_gemma":[0.010279724,0.003896186,0.9473289,0.0015979833,0.007126457,0.00041532217,0.0015973082,0.017112201,0.0006835249,0.00065774925,0.009187655,0.00011691568],"about_ca_topic_score_codex":0.97926944,"about_ca_topic_score_gemma":0.98482174,"teacher_disagreement_score":0.05512997,"about_ca_system_score_codex":0.05512997,"about_ca_system_score_gemma":0.055631187,"threshold_uncertainty_score":0.39999783},"labels":[],"label_agreement":null},{"id":"W2989903818","doi":"10.1007/s40273-019-00845-x","title":"Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"Bristol-Myers Squibb","keywords":"Markov model; Survival analysis; Everolimus; Medicine; Quality of Life Research; Markov chain; Quality-adjusted life year; Statistics; Time horizon; Cost effectiveness; Mathematics; Oncology; Public health; Mathematical optimization","score_opus":0.6806953585897056,"score_gpt":0.5257657187454701,"score_spread":0.15492963984423558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989903818","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3084962,0.00544928,0.67507213,0.0018563074,0.00017012322,0.0029296102,0.0015972921,0.0003864555,0.0040426003],"genre_scores_gemma":[0.82285744,0.0016579104,0.17077759,0.0004391999,0.00007197563,0.0028900176,0.00074814336,0.000058666297,0.0004990204],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9634022,0.03354184,0.00073002436,0.00074333494,0.001244939,0.0003375605],"domain_scores_gemma":[0.80704904,0.1818089,0.00582777,0.0018071728,0.0028243593,0.0006827582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.047661286,0.0020390248,0.0019687337,0.0024343033,0.00036464812,0.0018278299,0.0016186676,0.001503396,0.003507008],"category_scores_gemma":[0.13250214,0.0011676496,0.004588799,0.0010576793,0.00073386123,0.001978289,0.002112636,0.00196771,0.00022678374],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022485084,0.00031217508,0.0068449373,0.00059515686,0.0022047316,0.000053782274,0.00014161879,0.9445749,0.00017594431,0.009757951,0.00034966768,0.032740586],"study_design_scores_gemma":[0.00036231705,0.0009051692,0.00095695135,0.00014855132,0.00042228668,0.000028590397,0.000040218536,0.9877626,0.00013804682,0.008884404,0.0003255343,0.000025382305],"about_ca_topic_score_codex":0.0083165495,"about_ca_topic_score_gemma":0.0053297933,"teacher_disagreement_score":0.047661286,"about_ca_system_score_codex":0.0038343498,"about_ca_system_score_gemma":0.003964727,"threshold_uncertainty_score":0.25206},"labels":[],"label_agreement":null},{"id":"W2996129671","doi":"","title":"HEALTH STATE UTILITY VALUES FOR JUVENILE IDIOPATHIC ARTHRITIS: A SYSTEMATIC REVIEW","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Arthritis; Juvenile; Health administration; Medicine; Environmental health; Nursing; Internal medicine; Biology","score_opus":0.07915591383738528,"score_gpt":0.4169901257717033,"score_spread":0.337834211934318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996129671","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007635545,0.9984968,0.00014944747,0.00010002388,0.000044069664,0.000052908817,0.00026132446,0.000007094876,0.00012488577],"genre_scores_gemma":[0.049408216,0.94857174,0.0009885988,0.000450715,0.0000885435,0.00014097408,0.0002627055,0.000009461101,0.000078958576],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99233633,0.0034313016,0.0020961456,0.00060739456,0.0013261264,0.00020273641],"domain_scores_gemma":[0.96155083,0.03300576,0.0038946648,0.0003583141,0.00097189785,0.00021854017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009185788,0.0014796971,0.009808748,0.008753139,0.000339004,0.0027674893,0.0017096153,0.0015582333,0.0057861195],"category_scores_gemma":[0.041753795,0.0011756809,0.012828168,0.009811953,0.0009920715,0.0022751724,0.0018670408,0.0024998602,0.00021362159],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009005189,0.000038230042,0.0032473726,0.82148516,0.085238874,0.000088619956,0.00013660474,0.0005544662,0.00009458336,0.00072680804,0.0026182362,0.08487055],"study_design_scores_gemma":[0.002561174,0.00039033173,0.016857298,0.44224265,0.5167923,0.000524685,0.00034267752,0.0009323687,0.0001970269,0.0026214893,0.016392248,0.00014575882],"about_ca_topic_score_codex":0.008338995,"about_ca_topic_score_gemma":0.02480686,"teacher_disagreement_score":0.009808748,"about_ca_system_score_codex":0.003167969,"about_ca_system_score_gemma":0.004154379,"threshold_uncertainty_score":0.048579693},"labels":[],"label_agreement":null},{"id":"W2996593023","doi":"10.1007/s40273-019-00869-3","title":"One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Environmental Impact and Sustainability","field":"Environmental Science","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"Canadian Institutes of Health Research; University of Alberta; Genome Canada","keywords":"Probabilistic logic; Sensitivity (control systems); Decision analysis; Probabilistic analysis of algorithms; Value of information; Computer science; Value (mathematics); Cost–benefit analysis; Net present value; Conditional probability; Quality of Life Research; Econometrics; Statistics; Mathematics; Machine learning; Artificial intelligence; Production (economics); Economics; Medicine; Public health","score_opus":0.022066577806376657,"score_gpt":0.299888191216219,"score_spread":0.27782161340984235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996593023","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042309705,0.0013798196,0.9903633,0.00026656952,0.00011481129,0.0006664623,0.00037741117,0.00018795511,0.0024127008],"genre_scores_gemma":[0.407293,0.0031108856,0.5788533,0.0006664991,0.00019598006,0.0065054167,0.00074959727,0.0003567468,0.0022685626],"study_design_codex":"simulation_or_modeling","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.91565347,0.07511472,0.0019653575,0.0020651584,0.004593364,0.000607975],"domain_scores_gemma":[0.8350067,0.15438236,0.0034055433,0.0039094714,0.0030611332,0.00023464949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.063395925,0.003553598,0.0039990223,0.0051587517,0.0006556004,0.0036826618,0.002763987,0.0026895097,0.008231274],"category_scores_gemma":[0.14131261,0.0012715576,0.008643806,0.003800699,0.0017476535,0.003488594,0.0030028436,0.006352909,0.00063038163],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005168236,0.0001450484,0.0019756,0.0027702143,0.0024342434,0.00032989998,0.00029109433,0.83143115,0.0012798444,0.10069042,0.0019667062,0.056169048],"study_design_scores_gemma":[0.00010975343,0.0005516021,0.0012076868,0.0007057336,0.0011044017,0.00044397483,0.00012684379,0.83254784,0.0021695306,0.15369645,0.0071058837,0.00023029772],"about_ca_topic_score_codex":0.002538905,"about_ca_topic_score_gemma":0.0017296721,"teacher_disagreement_score":0.063395925,"about_ca_system_score_codex":0.00290512,"about_ca_system_score_gemma":0.003511992,"threshold_uncertainty_score":0.33527374},"labels":[],"label_agreement":null},{"id":"W3004292749","doi":"10.2165/11594470-000000000-00000","title":"Measuring Quality of Life in Patients with Schizophrenia","year":2012,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oakville-Trafalgar Memorial Hospital; Humber River Regional Hospital; University of Toronto","funders":"National Institutes of Health","keywords":"Schizophrenia (object-oriented programming); Quality of life (healthcare); Quality of Life Research; Construct (python library); Pharmacoeconomics; Scale (ratio); Health economics; Psychometrics; Quality (philosophy); Psychology; Health care; Foundation (evidence); Field (mathematics); Mental health; Quality-adjusted life year; Psychiatry; Public health; Medicine; Clinical psychology; Cost effectiveness; Psychotherapist; Computer science; Risk analysis (engineering); Intensive care medicine; Epistemology; Political science","score_opus":0.1591562692255742,"score_gpt":0.3903914705090308,"score_spread":0.2312352012834566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004292749","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004150996,0.9991665,0.000044103344,0.00012911392,0.000040191648,0.0000061605388,0.000033070268,0.000001444275,0.00016434175],"genre_scores_gemma":[0.005614152,0.9938018,0.00024369315,0.0001799403,0.00004540246,0.000011769299,0.000047756024,6.6559505e-7,0.000054943786],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99922013,0.0002615866,0.00020123062,0.000075668446,0.00020517605,0.00003633896],"domain_scores_gemma":[0.99818206,0.0012244154,0.00037242446,0.000019800873,0.00016358717,0.000037699938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016476661,0.00086281623,0.002907042,0.002380829,0.00014738187,0.00081677816,0.0006655837,0.0006385734,0.0015593636],"category_scores_gemma":[0.0038356527,0.00028105485,0.00218653,0.0032535922,0.00037118315,0.0006566832,0.00064518943,0.001024667,0.00016886387],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003486457,0.0000764181,0.0027760537,0.09029256,0.0035811786,0.00006218949,0.00007153831,0.00034400958,0.00021897444,0.0006377192,0.004956259,0.8966346],"study_design_scores_gemma":[0.0020166049,0.0016517309,0.13615674,0.35454553,0.056010168,0.0033708052,0.0012461132,0.0015278658,0.0015062835,0.0072889323,0.43430832,0.00037086493],"about_ca_topic_score_codex":0.0051035914,"about_ca_topic_score_gemma":0.011357329,"teacher_disagreement_score":0.0051035914,"about_ca_system_score_codex":0.001092915,"about_ca_system_score_gemma":0.0014829511,"threshold_uncertainty_score":0.01014775},"labels":[],"label_agreement":null},{"id":"W3011675906","doi":"10.1007/s40273-020-00896-5","title":"A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Advanced Accelerator Applications; EMD Serono; Ipsen; Pfizer","keywords":"Carcinoid syndrome; Medicine; Discontinuation; Internal medicine","score_opus":0.01470325428347007,"score_gpt":0.31232168015496925,"score_spread":0.29761842587149917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011675906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7208216,0.004587303,0.1604827,0.014529326,0.0006275235,0.0020980802,0.026622597,0.00056883716,0.06966201],"genre_scores_gemma":[0.9626552,0.0009974625,0.010527034,0.000660027,0.00006731794,0.0013933,0.0029473864,0.00004714336,0.020705104],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99782795,0.001179849,0.000060274786,0.00029428594,0.000103389044,0.00053423725],"domain_scores_gemma":[0.99105173,0.0070100906,0.0007456778,0.00011960316,0.0004541945,0.0006187103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041960306,0.0019511442,0.0026851834,0.0016310068,0.000727131,0.0028387967,0.0026881427,0.0046502715,0.014938325],"category_scores_gemma":[0.012173506,0.0015227564,0.0024570476,0.0013034653,0.0016745197,0.0017457353,0.0017614681,0.0032055932,0.00084444886],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062995794,0.00007350096,0.0016502246,0.0000823317,0.000085478685,0.00018117216,0.00003313122,0.98828495,0.0000986282,0.0063190022,0.00093077373,0.0016308356],"study_design_scores_gemma":[0.0006591866,0.00036269202,0.001113827,0.00007085734,0.00022334784,0.00007823099,0.00008760042,0.9899412,0.00008195605,0.005910929,0.0014319305,0.000038172067],"about_ca_topic_score_codex":0.06346637,"about_ca_topic_score_gemma":0.022524381,"teacher_disagreement_score":0.06346637,"about_ca_system_score_codex":0.0058111376,"about_ca_system_score_gemma":0.0066062803,"threshold_uncertainty_score":0.12619388},"labels":[],"label_agreement":null},{"id":"W3022091895","doi":"10.1007/s40273-020-00912-8","title":"Economic Costs of Myasthenia Gravis: A Systematic Review","year":2020,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario; Ottawa Hospital; University of Ottawa","funders":"Karolinska Institutet","keywords":"Quality of Life Research; Myasthenia gravis; Health economics; Health administration; Public health; Medicine; Immunology; Pathology","score_opus":0.03662681501559282,"score_gpt":0.379098939055621,"score_spread":0.34247212404002814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022091895","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013369218,0.99687356,0.00012305881,0.0005181454,0.00011124086,0.00020379978,0.0004891565,0.000005370089,0.00033877775],"genre_scores_gemma":[0.021263134,0.9766203,0.000687415,0.00051451137,0.000119455726,0.00044365495,0.00025503605,0.0000056385657,0.0000907718],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9877236,0.0051935227,0.0037775573,0.00058994425,0.0023396127,0.00037586087],"domain_scores_gemma":[0.95140606,0.037200607,0.0077616693,0.00037493088,0.0029376985,0.00031899926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010184923,0.0018421884,0.008173777,0.014592647,0.0006551217,0.0039856057,0.0016719971,0.0021870087,0.0043864935],"category_scores_gemma":[0.060832918,0.0012224568,0.007616429,0.013761644,0.0008842292,0.002743585,0.0014563306,0.0017498079,0.00020942533],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019239268,0.00001881329,0.0013301936,0.94358295,0.012371077,0.00012384569,0.00012328158,0.00027942267,0.000055075394,0.00063870096,0.0022006684,0.039083697],"study_design_scores_gemma":[0.000275389,0.00016283646,0.0064089,0.9253013,0.052751083,0.0005524807,0.0003220846,0.00020350481,0.000088206,0.0007992151,0.013093827,0.000041154624],"about_ca_topic_score_codex":0.010552655,"about_ca_topic_score_gemma":0.026514748,"teacher_disagreement_score":0.014592647,"about_ca_system_score_codex":0.007311871,"about_ca_system_score_gemma":0.0126716895,"threshold_uncertainty_score":0.053863704},"labels":[],"label_agreement":null},{"id":"W3022637090","doi":"10.1007/s40273-020-00915-5","title":"Why it’s Time to Abandon the ICER","year":2020,"lang":"th","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Medicine; Health care management; Nursing","score_opus":0.38459270800461726,"score_gpt":0.4602094669120927,"score_spread":0.07561675890747543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022637090","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00065351854,0.01959977,0.0021136454,0.93873316,0.031801183,0.000022714175,0.00014008385,0.000079190184,0.0068567363],"genre_scores_gemma":[0.022675348,0.015539171,0.006498706,0.890525,0.0584638,0.0001395473,0.00018738945,0.00035105748,0.005620036],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97469,0.013732431,0.0019203309,0.0019221246,0.0062500313,0.0014852284],"domain_scores_gemma":[0.74788547,0.1833592,0.010679413,0.00606624,0.040893074,0.011116652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07630894,0.0010632601,0.0027344846,0.0016384592,0.0015254718,0.011222862,0.0030174272,0.013845244,0.021201424],"category_scores_gemma":[0.25167298,0.00062390754,0.0026687041,0.001776767,0.009156349,0.020657485,0.0028745118,0.036926452,0.007965031],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003744944,0.00011302988,0.0010267769,0.0005866142,0.00023698735,0.00009871267,0.0001504032,0.0007327379,0.00007082423,0.063902326,0.8471477,0.0855595],"study_design_scores_gemma":[0.00075257686,0.00024044284,0.002272694,0.0054084915,0.00024458754,0.0003096779,0.00075932447,0.0015747212,0.00023422988,0.22440542,0.763612,0.00018580568],"about_ca_topic_score_codex":0.00785094,"about_ca_topic_score_gemma":0.007450654,"teacher_disagreement_score":0.07630894,"about_ca_system_score_codex":0.004930861,"about_ca_system_score_gemma":0.009683066,"threshold_uncertainty_score":0.4035651},"labels":[],"label_agreement":null},{"id":"W3023257101","doi":"10.1007/s40273-020-00921-7","title":"Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence?","year":2020,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Alberta Children's Hospital; Alberta Bone and Joint Health Institute; University of Calgary","funders":"Canadian Institutes of Health Research; Arthritis Society; ZonMw; Genome Canada","keywords":"Medicine; Arthritis; Population; PsycINFO; CINAHL; EconLit; MEDLINE; Psychological intervention; Juvenile; Family medicine; Physical therapy; Psychiatry; Internal medicine; Environmental health","score_opus":0.10712298763180524,"score_gpt":0.4258787776795187,"score_spread":0.3187557900477135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023257101","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000079329206,0.99901915,0.00009106917,0.000484343,0.000062273815,0.0000035255423,0.000042431668,0.0000018133076,0.00021605683],"genre_scores_gemma":[0.004094181,0.9948265,0.00028878558,0.00048017438,0.00018157669,0.000014245805,0.0000432606,0.000002346393,0.00006890067],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9956065,0.0023070115,0.00069597346,0.00033062726,0.0009399949,0.00011988649],"domain_scores_gemma":[0.9695696,0.02695467,0.0019799909,0.00023194391,0.0010632416,0.00020049368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0086195925,0.0012409986,0.0075630476,0.0046824003,0.00029318157,0.003814902,0.002066833,0.002346739,0.007188633],"category_scores_gemma":[0.027955547,0.00080117,0.003610549,0.0066608815,0.0013846187,0.00267933,0.0014125798,0.0035186552,0.00057757844],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062110496,0.000070861584,0.0016308691,0.1381465,0.005748538,0.00011847102,0.00010608781,0.0013343309,0.00008354506,0.0103073465,0.013527215,0.8283052],"study_design_scores_gemma":[0.0014258397,0.00048186365,0.015293097,0.50627875,0.033503268,0.0018212496,0.00059118215,0.0033814867,0.00046038345,0.04857173,0.3879075,0.00028359468],"about_ca_topic_score_codex":0.008361371,"about_ca_topic_score_gemma":0.011514395,"teacher_disagreement_score":0.0086195925,"about_ca_system_score_codex":0.0028939808,"about_ca_system_score_gemma":0.0043541095,"threshold_uncertainty_score":0.045585275},"labels":[],"label_agreement":null},{"id":"W3023668533","doi":"10.1007/s40273-020-00914-6","title":"Calculating and Interpreting ICERs and Net Benefit","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cost effectiveness; Ranking (information retrieval); Computer science; Measure (data warehouse); Cost–benefit analysis; Incremental cost-effectiveness ratio; Scale (ratio); Cost-effectiveness analysis; Health economics; Health technology; Risk analysis (engineering); Health administration; Operations research; Data mining; Economics; Health care; Medicine; Machine learning; Mathematics","score_opus":0.30847562941787654,"score_gpt":0.4477828229898945,"score_spread":0.13930719357201798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023668533","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18041456,0.033440515,0.6158465,0.02688153,0.0028272432,0.0015078608,0.034073718,0.0023446113,0.10266345],"genre_scores_gemma":[0.77948797,0.005388722,0.1973588,0.0019637807,0.0014512029,0.00085365283,0.007275964,0.00073256873,0.0054873433],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.97826433,0.017318217,0.0013880659,0.0010030947,0.0016777812,0.0003483971],"domain_scores_gemma":[0.7795901,0.20587023,0.0062927115,0.0046202303,0.0031995133,0.0004272393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03630083,0.0010133451,0.0014383798,0.003087403,0.00017952712,0.003572099,0.0011559696,0.00093951094,0.007398657],"category_scores_gemma":[0.19021711,0.00041746077,0.002362109,0.0028133097,0.00069134746,0.0028559677,0.0007134539,0.0021649369,0.0009618803],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002484153,0.0002173622,0.060353372,0.004606677,0.0067365333,0.00041511867,0.00035886044,0.34033883,0.0005712083,0.17061622,0.063434735,0.34986702],"study_design_scores_gemma":[0.000858392,0.00079120183,0.03511818,0.002423583,0.0043633357,0.0011829784,0.0004846731,0.34636933,0.0030961905,0.5294067,0.07574402,0.0001614158],"about_ca_topic_score_codex":0.0044012475,"about_ca_topic_score_gemma":0.004226238,"teacher_disagreement_score":0.03630083,"about_ca_system_score_codex":0.0015101914,"about_ca_system_score_gemma":0.0022988336,"threshold_uncertainty_score":0.19197941},"labels":[],"label_agreement":null},{"id":"W3025743578","doi":"10.1007/s40273-020-00923-5","title":"Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; University of Ottawa","funders":"","keywords":"Dravet syndrome; Clobazam; Medicine; Cannabinoid; Adjunctive treatment; Psychiatry; Epilepsy; Internal medicine","score_opus":0.08761818601841995,"score_gpt":0.41109201558652475,"score_spread":0.3234738295681048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025743578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8393046,0.08317739,0.03325527,0.0067084795,0.0006769234,0.0060215257,0.009904082,0.00028404067,0.020667668],"genre_scores_gemma":[0.98835456,0.005325356,0.003585447,0.000351588,0.00006257225,0.00051391806,0.00078912335,0.000020729563,0.0009966663],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9916823,0.0069877035,0.0002248193,0.00024481505,0.0005054109,0.00035498635],"domain_scores_gemma":[0.9821554,0.01572482,0.00085447857,0.00026148127,0.00049753435,0.0005063275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074971467,0.0021776606,0.0038135974,0.0025461947,0.00038307006,0.0027889144,0.0014017933,0.0017762157,0.0073466436],"category_scores_gemma":[0.029563637,0.00095162535,0.00656138,0.002183347,0.00083421025,0.0017173585,0.0011896658,0.0027719792,0.0002801463],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24847293,0.00402294,0.020576302,0.013225855,0.038308114,0.0016509364,0.00025161853,0.4519858,0.0023452211,0.016571436,0.00765359,0.19493526],"study_design_scores_gemma":[0.06744031,0.028745305,0.031290337,0.0049128025,0.08471805,0.0021161563,0.001287614,0.74584746,0.0021214117,0.018847853,0.012222094,0.00045062142],"about_ca_topic_score_codex":0.01617384,"about_ca_topic_score_gemma":0.008203906,"teacher_disagreement_score":0.01617384,"about_ca_system_score_codex":0.00864218,"about_ca_system_score_gemma":0.0043101283,"threshold_uncertainty_score":0.06270373},"labels":[],"label_agreement":null},{"id":"W3036705592","doi":"10.1007/s40273-020-00935-1","title":"Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines","year":2020,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Horizon 2020 Framework Programme; European Commission; US-UK Fulbright Commission; Yale University","keywords":"Health technology; Surrogate endpoint; Medicine; Health care; Pharmacoeconomics; Health economics; Excellence; Documentation; Agency (philosophy); Economic evaluation; Public health; Intensive care medicine; Political science; Nursing","score_opus":0.8580959001230754,"score_gpt":0.6873668140175412,"score_spread":0.17072908610553417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036705592","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002431873,0.9684743,0.019301737,0.009179981,0.0008803273,0.00031493412,0.00016947769,0.000039119815,0.0013968662],"genre_scores_gemma":[0.011155845,0.9120223,0.066512085,0.00651433,0.0012401625,0.001775284,0.00039876005,0.00013894693,0.00024223325],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.5896223,0.27517858,0.08259277,0.009034168,0.042244483,0.0013277391],"domain_scores_gemma":[0.27942365,0.633631,0.02625472,0.019364297,0.040317327,0.0010089588],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.3951682,0.0028611762,0.008181519,0.023116827,0.0017738196,0.011655571,0.0077039283,0.008849325,0.002961347],"category_scores_gemma":[0.55835557,0.0029601466,0.009690695,0.030615782,0.00899588,0.008826306,0.009015366,0.013853762,0.0011262327],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035961118,0.00012042089,0.0019565832,0.16830973,0.0037262852,0.00014201652,0.002120553,0.004387605,0.0003219865,0.0859515,0.025007714,0.70759606],"study_design_scores_gemma":[0.0003123264,0.00024936633,0.002750519,0.52637535,0.004972526,0.0005481361,0.0007584095,0.0030078592,0.0010329252,0.09024714,0.36947685,0.00026854826],"about_ca_topic_score_codex":0.007482419,"about_ca_topic_score_gemma":0.0068665347,"teacher_disagreement_score":0.6048318,"about_ca_system_score_codex":0.013037875,"about_ca_system_score_gemma":0.03125608,"threshold_uncertainty_score":0.74586535},"labels":[],"label_agreement":null},{"id":"W3044208311","doi":"10.1007/s40273-020-00945-z","title":"Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"Genentech","keywords":"Medicine; Health economics; Lennox–Gastaut syndrome; Quality-adjusted life year; Cost effectiveness; Health care; Epilepsy; Pediatrics; Public health; Psychiatry; Economics","score_opus":0.13521192117446132,"score_gpt":0.4168105716841582,"score_spread":0.2815986505096969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044208311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850641,0.010883151,0.0002206631,0.001096569,0.00013886979,0.00016906197,0.0003630875,0.000022856191,0.0020416693],"genre_scores_gemma":[0.99768364,0.0016247284,0.00023831328,0.00009855637,0.000038720947,0.000032632997,0.00012819945,0.0000018162883,0.00015332202],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99937135,0.00030774518,0.00007188102,0.00006042204,0.00009616258,0.00009248447],"domain_scores_gemma":[0.999153,0.00040016722,0.00014193256,0.000025884423,0.000035530073,0.00024343975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006543289,0.0004574685,0.0013589659,0.00082551467,0.0002732685,0.0007853583,0.00059086137,0.00086910033,0.004256365],"category_scores_gemma":[0.0032584001,0.00020063882,0.0020817332,0.0005978041,0.00039516756,0.0006651807,0.00059767475,0.0009978788,0.00012667735],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5093164,0.0102690775,0.041538358,0.0029114303,0.007957217,0.0012693262,0.0001535105,0.018055342,0.0024514527,0.002188483,0.002345,0.4015444],"study_design_scores_gemma":[0.22044986,0.160665,0.46778277,0.0029073195,0.03805551,0.004044474,0.001727302,0.08724078,0.0035891088,0.0072984444,0.0058945864,0.00034479948],"about_ca_topic_score_codex":0.009700324,"about_ca_topic_score_gemma":0.0114666615,"teacher_disagreement_score":0.009700324,"about_ca_system_score_codex":0.0031597293,"about_ca_system_score_gemma":0.0015204585,"threshold_uncertainty_score":0.022925556},"labels":[],"label_agreement":null},{"id":"W3047292418","doi":"10.1007/s40273-020-00947-x","title":"Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer","year":2020,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; Erasmus Medisch Centrum","keywords":"Meta-analysis; Medicine; Lung cancer; Subgroup analysis; Study heterogeneity; Confidence interval; Psychological intervention; MEDLINE; Systematic review; Oncology; Internal medicine","score_opus":0.6761268977008804,"score_gpt":0.5850854871264585,"score_spread":0.09104141057442194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047292418","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023846375,0.9945391,0.00095275586,0.00028097036,0.0001725263,0.0006249934,0.0007423152,0.000027532642,0.0002751108],"genre_scores_gemma":[0.13984534,0.84755385,0.005191275,0.0012891775,0.00034744496,0.0040564705,0.0013409965,0.00004812875,0.00032734306],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9672204,0.020062955,0.007506358,0.0018023592,0.002874871,0.0005331133],"domain_scores_gemma":[0.93912464,0.05004386,0.0063085924,0.001527916,0.0026656683,0.00032922934],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.03393041,0.003211309,0.02079772,0.010328873,0.0006973871,0.0039562886,0.002348928,0.0024537423,0.003974827],"category_scores_gemma":[0.10306167,0.0014784955,0.04255751,0.009658255,0.0010458102,0.002459083,0.0021238634,0.002684568,0.0003161013],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001007876,0.000018175459,0.001901864,0.48915675,0.49520183,0.00007012575,0.00006800594,0.0005368737,0.000077006465,0.00023832534,0.0006695688,0.01105364],"study_design_scores_gemma":[0.0006346755,0.00016811318,0.0026255504,0.076082006,0.9173428,0.000088462184,0.00004739707,0.0002992149,0.00009458485,0.00057001243,0.0020167916,0.000030381167],"about_ca_topic_score_codex":0.00844639,"about_ca_topic_score_gemma":0.014529386,"teacher_disagreement_score":0.9792023,"about_ca_system_score_codex":0.004636489,"about_ca_system_score_gemma":0.0060342457,"threshold_uncertainty_score":0.1794433},"labels":[],"label_agreement":null},{"id":"W3079151182","doi":"10.1007/s40273-020-00950-2","title":"Correction to: Calculating and Interpreting ICERs and Net Benefit","year":2020,"lang":"en","type":"erratum","venue":"PharmacoEconomics","topic":"demographic modeling and climate adaptation","field":"Decision Sciences","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Computer science; Information retrieval; Medicine; Pathology","score_opus":0.0703299118165864,"score_gpt":0.3858785051849443,"score_spread":0.31554859336835794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3079151182","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002499566,0.0010070585,0.0030853644,0.053714067,0.893977,0.00011480739,0.029010978,0.0016948538,0.01714599],"genre_scores_gemma":[0.015761549,0.005002768,0.0318805,0.091741204,0.20558129,0.0015516841,0.04233525,0.009322614,0.5968232],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922265,0.0014499498,0.0013301364,0.0006952263,0.003692437,0.00060586544],"domain_scores_gemma":[0.9296374,0.01771964,0.0026212758,0.0038344536,0.043957137,0.0022302228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069328877,0.0028852606,0.0024554983,0.0061538434,0.002495289,0.0071490854,0.00440888,0.0067484374,0.1930399],"category_scores_gemma":[0.11401154,0.001680285,0.002103496,0.0053223106,0.0017374627,0.003545784,0.0024611743,0.010352453,0.109774165],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001833474,0.000003340119,0.000037830127,0.000069928225,0.000005504846,0.000018720162,0.0000057564766,0.000085534404,0.000007119399,0.000485927,0.9964574,0.002804663],"study_design_scores_gemma":[0.00007516719,0.000009846692,0.00065482414,0.00040526214,0.00003199728,0.000081026075,0.00005919063,0.0007712253,0.00018289151,0.0039397585,0.993747,0.000041721058],"about_ca_topic_score_codex":0.06521241,"about_ca_topic_score_gemma":0.07167456,"teacher_disagreement_score":0.1930399,"about_ca_system_score_codex":0.0062800623,"about_ca_system_score_gemma":0.011886106,"threshold_uncertainty_score":0.64578277},"labels":[],"label_agreement":null},{"id":"W3084165494","doi":"10.1007/s40273-020-00957-9","title":"The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D?","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Vancouver Coastal Health","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Statistics; Medicine; Mathematics; Nursing","score_opus":0.30514779123155,"score_gpt":0.42792486373214983,"score_spread":0.12277707250059983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084165494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7323497,0.030802436,0.05277221,0.14498812,0.008389667,0.0005283654,0.010406107,0.0003743989,0.019388972],"genre_scores_gemma":[0.96845686,0.0027269125,0.015812563,0.0058386787,0.0018347153,0.00032739667,0.0033652955,0.0003984947,0.0012391707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.8889259,0.08604888,0.0054927403,0.007160015,0.010649372,0.0017230673],"domain_scores_gemma":[0.76329327,0.2018807,0.01062235,0.007933905,0.014432558,0.001837208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.13464732,0.0010008309,0.0024618534,0.0027307863,0.00096490514,0.0063042566,0.00213041,0.0025182096,0.007452043],"category_scores_gemma":[0.33898032,0.00048389033,0.0035679636,0.0051600146,0.0021252555,0.0063623856,0.0026835736,0.004367805,0.0020449676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011193171,0.00045719903,0.5738892,0.0010234904,0.0053292564,0.000119532124,0.0019052923,0.0049531297,0.00054495054,0.009636412,0.030803842,0.3601446],"study_design_scores_gemma":[0.0030351083,0.0026607122,0.85963094,0.003195511,0.0041684113,0.0007801388,0.0040291985,0.056522753,0.0013466933,0.0317755,0.032360118,0.0004950316],"about_ca_topic_score_codex":0.021011403,"about_ca_topic_score_gemma":0.01657624,"teacher_disagreement_score":0.13464732,"about_ca_system_score_codex":0.0037370762,"about_ca_system_score_gemma":0.0028198962,"threshold_uncertainty_score":0.7120916},"labels":[],"label_agreement":null},{"id":"W3086476996","doi":"10.1007/s40273-020-00959-7","title":"On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19?","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"COVID-19 epidemiological studies","field":"Mathematics","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Social distance; Public health; Pandemic; Preparedness; Socioeconomic status; Context (archaeology); Economic impact analysis; Social inequality; Social determinants of health; Psychological intervention; Epidemiology; Economic growth; Environmental health; Health economics; Development economics; Medicine; Inequality; Political science; Population; Geography; Coronavirus disease 2019 (COVID-19); Economics; Infectious disease (medical specialty); Nursing; Disease","score_opus":0.5614062400663362,"score_gpt":0.49535503699358047,"score_spread":0.06605120307275575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086476996","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07928746,0.0056848265,0.18424165,0.68545234,0.0019529184,0.00014009359,0.00078602514,0.00040410625,0.042050622],"genre_scores_gemma":[0.91435295,0.0060955137,0.058207918,0.013667979,0.0029384186,0.0002233953,0.00044811534,0.00029227106,0.003773458],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.983752,0.013928399,0.00025633164,0.0006339503,0.00082031364,0.00060896913],"domain_scores_gemma":[0.84444505,0.1297365,0.005992401,0.0057248236,0.008985989,0.0051151984],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.029359225,0.0012504815,0.0017463063,0.0015072002,0.0015887823,0.00608891,0.0036226597,0.0031724821,0.011060747],"category_scores_gemma":[0.20250826,0.0004840843,0.0009878413,0.0014712891,0.0037258798,0.015639832,0.0035935633,0.0060648844,0.0009737408],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005253733,0.00052151404,0.02112885,0.00053770014,0.00058775,0.0001999097,0.0016038163,0.103664696,0.0002466941,0.7010984,0.056342915,0.11354233],"study_design_scores_gemma":[0.00008588748,0.0001099163,0.0023246314,0.00042443105,0.00007633193,0.000041178067,0.0019365391,0.11294093,0.00026935368,0.87120634,0.010527525,0.00005702807],"about_ca_topic_score_codex":0.02047685,"about_ca_topic_score_gemma":0.011020616,"teacher_disagreement_score":0.9706408,"about_ca_system_score_codex":0.003476788,"about_ca_system_score_gemma":0.008419806,"threshold_uncertainty_score":0.15526825},"labels":[],"label_agreement":null},{"id":"W3087414342","doi":"10.1007/s40273-020-00962-y","title":"Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Human leukocyte antigen; Reimbursement; Medicine; Allele; Cost effectiveness; Health economics; Immunology; Public health; Health care; Genetics; Biology; Antigen; Economics; Risk analysis (engineering)","score_opus":0.015570843668834246,"score_gpt":0.27407521792443945,"score_spread":0.2585043742556052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087414342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98918545,0.005807004,0.00035501702,0.0015338168,0.00006943823,0.000052347783,0.0007377066,0.000012965156,0.0022462816],"genre_scores_gemma":[0.998679,0.0006392632,0.00015480116,0.0001348802,0.000027831133,0.000013719561,0.00020599402,0.0000017589799,0.00014261904],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986987,0.0007589381,0.00008239078,0.0001236674,0.00014776412,0.00018847373],"domain_scores_gemma":[0.9979323,0.0013463612,0.0003155029,0.00007029255,0.00009917027,0.00023632824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016478577,0.00036095033,0.00083177665,0.0005249025,0.00020449246,0.0008358622,0.0003670797,0.00086160767,0.0025524865],"category_scores_gemma":[0.006223521,0.00019498578,0.002790709,0.0005226222,0.00020027968,0.00074355374,0.00048476402,0.00086029345,0.00010236133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13685188,0.0037128013,0.5386872,0.001138789,0.011256137,0.00073001056,0.00030454912,0.04234899,0.0015043494,0.0027713983,0.0039528334,0.25674102],"study_design_scores_gemma":[0.010779169,0.022216778,0.89230895,0.00045507075,0.011244987,0.0009721108,0.00086822786,0.05538796,0.0011271635,0.0026403375,0.0019021847,0.00009714487],"about_ca_topic_score_codex":0.010514363,"about_ca_topic_score_gemma":0.007624601,"teacher_disagreement_score":0.010514363,"about_ca_system_score_codex":0.0018871839,"about_ca_system_score_gemma":0.0008816116,"threshold_uncertainty_score":0.02090627},"labels":[],"label_agreement":null},{"id":"W3095966269","doi":"10.1007/s40273-020-00974-8","title":"Evaluating New Zealanders’ Values for Drug Coverage Decision Making: Trade-Offs between Treatments for Rare and Common Conditions","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Payment; Cash; Equity (law); Public health; Health economics; Actuarial science; Ranking (information retrieval); Quality of life (healthcare); Medicine; Business; Quality (philosophy); Public economics; Finance; Economics; Nursing","score_opus":0.4880991223190696,"score_gpt":0.5308752155511116,"score_spread":0.04277609323204201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095966269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8350199,0.014553279,0.009566964,0.039867327,0.00029014403,0.00075435266,0.0028286579,0.000040780888,0.09707864],"genre_scores_gemma":[0.9920184,0.0014853582,0.0039457725,0.0005981768,0.00006358769,0.00008300828,0.00031846162,0.0000148126865,0.0014723128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98114544,0.012911316,0.0011431616,0.00073353766,0.0032835337,0.0007829481],"domain_scores_gemma":[0.89873534,0.079467036,0.009619409,0.0025526432,0.0066778297,0.0029477824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.032787625,0.0007280202,0.0012454416,0.0015969435,0.00061524345,0.005035566,0.0009791361,0.0017736566,0.006039745],"category_scores_gemma":[0.17601559,0.00046933492,0.0014899289,0.0018820202,0.0029151386,0.0032347115,0.0019994085,0.00303708,0.00030930614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014583257,0.000734647,0.4852705,0.002894467,0.0073517654,0.0020191746,0.0067033996,0.06698752,0.0018977382,0.074998155,0.01564441,0.320915],"study_design_scores_gemma":[0.0034302704,0.003992004,0.66643745,0.003958589,0.0048727524,0.0023278135,0.012280989,0.120870925,0.0026114045,0.12943897,0.04922113,0.0005576532],"about_ca_topic_score_codex":0.11752534,"about_ca_topic_score_gemma":0.13795564,"teacher_disagreement_score":0.11752534,"about_ca_system_score_codex":0.011533802,"about_ca_system_score_gemma":0.006247496,"threshold_uncertainty_score":0.23368251},"labels":[],"label_agreement":null},{"id":"W3108709596","doi":"10.1007/s40273-020-00983-7","title":"Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"Medical Research Council","keywords":"Probabilistic logic; Sensitivity (control systems); Econometrics; Conditional probability; Economic model; Probabilistic analysis of algorithms; Efficient frontier; Computer science; Economics; Mathematics; Statistics; Artificial intelligence; Microeconomics","score_opus":0.2836535530466422,"score_gpt":0.4000692221858455,"score_spread":0.11641566913920331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108709596","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011862357,0.004101877,0.9752366,0.0014056716,0.00016997349,0.0014416269,0.0006313017,0.00019780139,0.004952768],"genre_scores_gemma":[0.63244945,0.004787257,0.35215724,0.0015013381,0.00020669984,0.006242914,0.000639307,0.0001848858,0.0018309422],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.84830564,0.13956624,0.0023473718,0.0031193432,0.0056351107,0.0010262182],"domain_scores_gemma":[0.73876625,0.24773657,0.005060968,0.0051735817,0.0028226466,0.0004399442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.13132977,0.003597164,0.005640595,0.0052047907,0.00072949496,0.0041638627,0.0033132005,0.0034154248,0.0072160778],"category_scores_gemma":[0.19375157,0.0013352883,0.008987901,0.0031118325,0.0028189083,0.005976153,0.0052702855,0.0063036745,0.00036152164],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010493121,0.00014512212,0.0018837464,0.0027888145,0.004196153,0.00025106344,0.00025267107,0.78715605,0.0004967407,0.1430384,0.0015991647,0.057142727],"study_design_scores_gemma":[0.00034608183,0.000726772,0.0011679827,0.0011069771,0.0020832925,0.00022322581,0.00012706287,0.6016491,0.0010465516,0.38711748,0.0042098756,0.00019567316],"about_ca_topic_score_codex":0.002788974,"about_ca_topic_score_gemma":0.00130489,"teacher_disagreement_score":0.13132977,"about_ca_system_score_codex":0.0034918531,"about_ca_system_score_gemma":0.0038499981,"threshold_uncertainty_score":0.6945465},"labels":[],"label_agreement":null},{"id":"W3123759598","doi":"10.1007/s40273-020-00990-8","title":"NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Nice; Quality of Life Research; Discounting; Health economics; Obstacle; Health administration; Economics; Positive economics; Public health; Public economics; Political science; Medicine; Law; Computer science; Nursing; Finance","score_opus":0.6158531719708071,"score_gpt":0.5486504033419459,"score_spread":0.06720276862886121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123759598","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010437963,0.9478106,0.0024386095,0.042102505,0.003970856,0.00007062477,0.00010325638,0.00004108709,0.0033581636],"genre_scores_gemma":[0.0104855215,0.900854,0.010502981,0.0653209,0.01042733,0.00037588575,0.00018895612,0.000086876345,0.0017576077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9614567,0.024673449,0.0041967155,0.0013088983,0.0075958166,0.00076832063],"domain_scores_gemma":[0.88984275,0.09459193,0.0049920096,0.00236665,0.007090747,0.0011159024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.041610193,0.0013157311,0.005884585,0.0026702897,0.00060327194,0.005141057,0.00283901,0.008398756,0.004545274],"category_scores_gemma":[0.14287339,0.0009322863,0.0032399045,0.003177666,0.003607598,0.0057483194,0.0018782994,0.015117547,0.0014281383],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005487109,0.0000430902,0.00016141028,0.038426492,0.0018068588,0.00013788718,0.00013515574,0.00075663667,0.00014156474,0.09236303,0.27645132,0.58902776],"study_design_scores_gemma":[0.0009615636,0.00017020684,0.0006167679,0.058387123,0.0019745724,0.00049333385,0.00006472138,0.00049126806,0.0001710437,0.090920955,0.845649,0.00009951832],"about_ca_topic_score_codex":0.0044615166,"about_ca_topic_score_gemma":0.0045940774,"teacher_disagreement_score":0.041610193,"about_ca_system_score_codex":0.0054001734,"about_ca_system_score_gemma":0.010650857,"threshold_uncertainty_score":0.22005838},"labels":[],"label_agreement":null},{"id":"W3124464435","doi":"10.1007/s40273-020-00995-3","title":"Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review","year":2021,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia; Canadian Centre for Applied Research in Cancer Control; Simon Fraser University","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Reimbursement; Quality of Life Research; Health economics; Medicine; Clinical trial; Public health; Health administration; Drug approval; Family medicine; Clinical Oncology; Oncology; Alternative medicine; Drug; Drug development; Internal medicine; Pharmacology; Health care; Nursing; Political science; Cancer; Pathology","score_opus":0.7247299571339836,"score_gpt":0.6212900794390437,"score_spread":0.1034398776949399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124464435","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007540028,0.0063692657,0.00052064634,0.88040507,0.04977947,0.0006902569,0.002322842,0.00020254246,0.05895584],"genre_scores_gemma":[0.005159168,0.003624739,0.0012205449,0.8497088,0.03362189,0.00036254423,0.00092020317,0.0001475948,0.10523457],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9654133,0.006409449,0.003088332,0.0014859514,0.01872359,0.0048794006],"domain_scores_gemma":[0.8584655,0.05482241,0.0064515667,0.0033868246,0.053715296,0.023158481],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.03684918,0.0014112957,0.0030740325,0.0033045385,0.0076936884,0.011670729,0.0045206808,0.065523855,0.020145338],"category_scores_gemma":[0.09471267,0.0015881737,0.0030414648,0.0032460454,0.0039757616,0.0029221948,0.0027567216,0.02518398,0.012225607],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039228988,0.000009981678,0.00011262991,0.000039561295,0.000008611073,0.00006937505,0.000014717437,0.000019408297,0.000033658587,0.0009187367,0.99636626,0.002367893],"study_design_scores_gemma":[0.00022742328,0.00002773578,0.0014388359,0.0002650253,0.000043614662,0.00007693788,0.0000545241,0.00024601675,0.00010401141,0.0013740851,0.9960939,0.00004797233],"about_ca_topic_score_codex":0.31517428,"about_ca_topic_score_gemma":0.7064546,"teacher_disagreement_score":0.96361476,"about_ca_system_score_codex":0.036385234,"about_ca_system_score_gemma":0.0908161,"threshold_uncertainty_score":0.62667954},"labels":[],"label_agreement":null},{"id":"W3128103964","doi":"10.1007/s40273-020-00988-2","title":"Modifying NICE’s Approach to Equity Weighting","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Nice; Equity (law); Excellence; Population; Health economics; Health technology; Population health; Actuarial science; Health care; Weighting; Economics; Medicine; Public economics; Risk analysis (engineering); Computer science; Political science; Economic growth; Law","score_opus":0.5740007790783229,"score_gpt":0.5192792688717156,"score_spread":0.054721510206607316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128103964","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009741376,0.005278052,0.84686154,0.055109214,0.003278808,0.00052095385,0.00088458153,0.00034421947,0.077981286],"genre_scores_gemma":[0.47008887,0.00231902,0.47414026,0.023343356,0.0037335525,0.0013113786,0.000447758,0.0006166663,0.023999177],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9303076,0.04881386,0.003302337,0.0035572264,0.012429707,0.0015892873],"domain_scores_gemma":[0.91026735,0.069909245,0.0018535707,0.007204279,0.009875195,0.0008903905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.061297078,0.0012841388,0.0027268287,0.0056141503,0.0012699406,0.0063342885,0.003601522,0.0052183457,0.008201001],"category_scores_gemma":[0.23426835,0.0011216069,0.0028809973,0.0044538733,0.003115654,0.006774983,0.0043885596,0.0075282743,0.00075689325],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012287659,0.000073286814,0.0017077007,0.0002878567,0.0006185536,0.000118983924,0.0004109646,0.006105331,0.00014296125,0.82467306,0.036468804,0.1292698],"study_design_scores_gemma":[0.00012480388,0.000046949193,0.00097498373,0.00041869632,0.0002927058,0.00024731844,0.00011217195,0.024412429,0.00031147242,0.9177589,0.055238318,0.000061200895],"about_ca_topic_score_codex":0.009372207,"about_ca_topic_score_gemma":0.00985468,"teacher_disagreement_score":0.061297078,"about_ca_system_score_codex":0.004728142,"about_ca_system_score_gemma":0.0034808961,"threshold_uncertainty_score":0.3241738},"labels":[],"label_agreement":null},{"id":"W3135068797","doi":"10.1007/s40273-021-01007-8","title":"The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases","year":2021,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Pharmacoeconomics; Medicine; Intensive care medicine; Nursing","score_opus":0.16470911239705432,"score_gpt":0.3657572656773199,"score_spread":0.2010481532802656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135068797","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028869245,0.0009776967,0.00025575023,0.99135417,0.0042760847,0.000012823966,0.00008981103,0.000016439764,0.0027284904],"genre_scores_gemma":[0.0033414662,0.0005485651,0.00091290247,0.9825117,0.010858048,0.000038700924,0.000043093456,0.000022541755,0.0017230734],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9252914,0.03395925,0.008484381,0.00529827,0.02203151,0.004935042],"domain_scores_gemma":[0.45278165,0.4824859,0.013404046,0.008805091,0.027034177,0.015489199],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.08813626,0.0009593433,0.004086412,0.002491745,0.0053026397,0.016400725,0.0075257914,0.15008393,0.010511485],"category_scores_gemma":[0.32840583,0.0018007656,0.0036992375,0.0023333346,0.018289577,0.018529054,0.0075670574,0.09351962,0.005153442],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035053742,0.00009403901,0.00092928804,0.00035778846,0.00012417247,0.0009285643,0.0004054367,0.00038226735,0.00042143997,0.07654032,0.8991513,0.020314666],"study_design_scores_gemma":[0.0008477502,0.00013434954,0.0029717186,0.0022428436,0.00014829218,0.00085791544,0.0009810001,0.0019701517,0.0005385438,0.2530323,0.7359699,0.00030523606],"about_ca_topic_score_codex":0.015549077,"about_ca_topic_score_gemma":0.024437131,"teacher_disagreement_score":0.91186374,"about_ca_system_score_codex":0.010314407,"about_ca_system_score_gemma":0.032355923,"threshold_uncertainty_score":0.4661147},"labels":[],"label_agreement":null},{"id":"W3143019137","doi":"10.1007/s40273-021-01022-9","title":"Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"","keywords":"Afatinib; Erlotinib; Gefitinib; Medicine; Lung cancer; Cost effectiveness; Internal medicine; Oncology; Epidermal growth factor receptor; Cancer registry; Cancer; Risk analysis (engineering)","score_opus":0.025514685803821453,"score_gpt":0.36743199878691274,"score_spread":0.3419173129830913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143019137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9463145,0.017347092,0.0003556205,0.0059180674,0.00014766463,0.0010190087,0.018806897,0.000043528526,0.010047631],"genre_scores_gemma":[0.9902676,0.003649237,0.00041303012,0.0006203052,0.000041122214,0.00014158367,0.0032612854,0.000009134327,0.0015969033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971118,0.0005937066,0.00024546788,0.0001990798,0.0009436228,0.00090624986],"domain_scores_gemma":[0.9951643,0.0008089643,0.0009805138,0.00007013308,0.0013567125,0.0016193804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015304849,0.0006677764,0.0016095978,0.0013158683,0.0012220232,0.0020724956,0.0017447436,0.0009356599,0.0031221462],"category_scores_gemma":[0.0074201603,0.0006373562,0.0034054306,0.003921093,0.0007394958,0.0005396242,0.00085887406,0.0013827065,0.0001071855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041144833,0.0021251265,0.7286238,0.0063926373,0.0143552255,0.0014808282,0.0010161464,0.064085215,0.0016197807,0.0054101963,0.03952103,0.09422507],"study_design_scores_gemma":[0.0075072595,0.002011049,0.9409828,0.0009954011,0.0072229947,0.0004506919,0.0015313941,0.029109973,0.00034309726,0.00048097078,0.009199553,0.00016471755],"about_ca_topic_score_codex":0.9931995,"about_ca_topic_score_gemma":0.9958341,"teacher_disagreement_score":0.16447747,"about_ca_system_score_codex":0.16447747,"about_ca_system_score_gemma":0.12656406,"threshold_uncertainty_score":0.9690877},"labels":[],"label_agreement":null},{"id":"W3147761275","doi":"","title":"A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.","year":2003,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Folinic acid; Fluorouracil; Quality of Life Research; Medicine; Tegafur; Colorectal cancer; Uracil; Internal medicine; Cancer; Health administration; Gastroenterology; Public health; Chemistry; Nursing; Biochemistry","score_opus":0.06443878898341866,"score_gpt":0.3865505635148839,"score_spread":0.3221117745314653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147761275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9343883,0.039853483,0.00043232006,0.0057675615,0.00036018822,0.0010364921,0.008351716,0.000041687636,0.009768253],"genre_scores_gemma":[0.9900718,0.0062170085,0.00055671163,0.0006234919,0.00006120771,0.00011854149,0.0013256667,0.000007640025,0.0010178819],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99795616,0.0007540079,0.00014181758,0.000106992884,0.000594302,0.0004466109],"domain_scores_gemma":[0.9973304,0.0006427328,0.00037270403,0.000048457372,0.0007926792,0.00081304874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012758437,0.0005931417,0.0009883543,0.0010358557,0.0009146198,0.0010911236,0.00087786216,0.000921298,0.0049308115],"category_scores_gemma":[0.007071083,0.00031713577,0.0018063921,0.0028222653,0.0006072992,0.0005426249,0.0007093131,0.0012600926,0.00012948258],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42344317,0.0044805724,0.18658316,0.010155426,0.011277091,0.0010404567,0.00074228004,0.02732593,0.002699375,0.0067721247,0.02892797,0.29655248],"study_design_scores_gemma":[0.0733882,0.02815911,0.80054796,0.0030797801,0.029358845,0.0011321572,0.003282759,0.024180297,0.0018429129,0.0017218859,0.032917503,0.000388624],"about_ca_topic_score_codex":0.9560697,"about_ca_topic_score_gemma":0.96806866,"teacher_disagreement_score":0.059411827,"about_ca_system_score_codex":0.059411827,"about_ca_system_score_gemma":0.05170387,"threshold_uncertainty_score":0.43106496},"labels":[],"label_agreement":null},{"id":"W3157441924","doi":"10.1007/s40273-021-01018-5","title":"Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Health economics; Health administration; Process (computing); Qualitative research; Actuarial science; Management science; Public health; Psychology; Medicine; Computer science; Economics; Nursing; Sociology; Social science","score_opus":0.389916815006682,"score_gpt":0.4312852943937915,"score_spread":0.04136847938710947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157441924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47970927,0.006235361,0.0480215,0.4078694,0.0007063582,0.0007526526,0.00022589906,0.00006539219,0.056414206],"genre_scores_gemma":[0.9781188,0.0018909028,0.0072401804,0.011622283,0.00014028737,0.00042003873,0.000033822285,0.000018886687,0.00051484886],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.6601984,0.3140496,0.0050470857,0.0021906896,0.014715005,0.0037992403],"domain_scores_gemma":[0.33840775,0.61544186,0.023715414,0.0077026724,0.011223526,0.0035087336],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.19950297,0.0005436813,0.0007838054,0.0015418614,0.0057608746,0.008506677,0.002055206,0.0051568802,0.0039150747],"category_scores_gemma":[0.37082133,0.0005339157,0.0010395522,0.0022075325,0.0226935,0.010544189,0.00946971,0.0069385595,0.00027987536],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074830395,0.00059559627,0.07199269,0.0036827049,0.00047442413,0.0016621446,0.4257327,0.0046195835,0.0009945579,0.35107818,0.013180407,0.12523873],"study_design_scores_gemma":[0.0002500621,0.00067772734,0.027910445,0.008209152,0.00038012653,0.0014876958,0.48380134,0.007078662,0.0018439759,0.39067107,0.07740172,0.00028801284],"about_ca_topic_score_codex":0.001528291,"about_ca_topic_score_gemma":0.0015524013,"teacher_disagreement_score":0.19950297,"about_ca_system_score_codex":0.0073233712,"about_ca_system_score_gemma":0.011126745,"threshold_uncertainty_score":0.9871553},"labels":[],"label_agreement":null},{"id":"W3160261501","doi":"10.1007/s40273-021-01028-3","title":"Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Breast cancer; Quality-adjusted life year; Tamoxifen; Discontinuation; Aromatase inhibitor; Cost effectiveness; Internal medicine; Oncology; Cost-effectiveness analysis; Health economics; Gynecology; Hazard ratio; Cancer; Public health; Confidence interval","score_opus":0.02113951258208011,"score_gpt":0.3660010550140271,"score_spread":0.34486154243194694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160261501","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22937812,0.39962095,0.0014257989,0.2143834,0.0018291441,0.00042871755,0.023636743,0.000111937145,0.12918532],"genre_scores_gemma":[0.8585118,0.115121335,0.0018549309,0.013392337,0.0011728148,0.00007104291,0.0042248336,0.000029667952,0.0056211255],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980692,0.00050319696,0.000093964714,0.00012462129,0.00067020766,0.0005388142],"domain_scores_gemma":[0.9968509,0.00082646555,0.00042311705,0.000029717708,0.00095265283,0.00091706193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016801505,0.0007052607,0.0011047149,0.0015472266,0.0010808345,0.0030557313,0.0013167133,0.0017088173,0.007384536],"category_scores_gemma":[0.0070123067,0.0003515663,0.0023064537,0.0031631645,0.00083521404,0.00070241233,0.0007162819,0.0025498862,0.00022297818],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016337434,0.0011675816,0.10500712,0.009176415,0.010146606,0.0017134196,0.0008167336,0.07246687,0.0022807457,0.06337087,0.1862877,0.5312285],"study_design_scores_gemma":[0.009299464,0.0047677592,0.5902537,0.016093843,0.026257321,0.0024505998,0.005545438,0.050011694,0.0011533401,0.025621966,0.2677436,0.0008013034],"about_ca_topic_score_codex":0.9559093,"about_ca_topic_score_gemma":0.9755499,"teacher_disagreement_score":0.92683625,"about_ca_system_score_codex":0.07316373,"about_ca_system_score_gemma":0.07799778,"threshold_uncertainty_score":0.53084254},"labels":[],"label_agreement":null},{"id":"W3160294153","doi":"10.1007/s40273-021-01031-8","title":"What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Substance Abuse Treatment and Outcomes","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Institute for Work & Health; Centre for Addiction and Mental Health","funders":"Technische Universität Dresden","keywords":"Health economics; Quality of Life Research; Health administration; Public health; Environmental health; Public economics; Systematic review; Pharmacoeconomics; Economics; MEDLINE; Medicine; Business; Political science; Intensive care medicine; Nursing","score_opus":0.16284389797184504,"score_gpt":0.41539621465990023,"score_spread":0.2525523166880552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160294153","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008299806,0.977719,0.004485207,0.0019801743,0.00027633732,0.0010310787,0.004710657,0.00004834394,0.001449486],"genre_scores_gemma":[0.1931044,0.7916293,0.008306416,0.0012079908,0.0002562365,0.0026918727,0.0022286272,0.000055594526,0.00051947485],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.97857386,0.013647633,0.004082258,0.00103456,0.0019930801,0.00066866964],"domain_scores_gemma":[0.9634872,0.029271636,0.004275138,0.000588974,0.0020991063,0.0002779224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020580921,0.0028058419,0.012597689,0.0124673415,0.00055918435,0.004221567,0.0028941568,0.0026483159,0.006770729],"category_scores_gemma":[0.061624225,0.0019346561,0.03624973,0.014556337,0.00070934655,0.0031063596,0.0019004026,0.0024418822,0.00054796634],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011393686,0.00008807347,0.009614264,0.65910304,0.26232255,0.00065326964,0.00026150644,0.015988283,0.0001568224,0.0042950287,0.0042318213,0.042145994],"study_design_scores_gemma":[0.0014574358,0.0007026646,0.017706735,0.29355082,0.63553673,0.0014633808,0.00046403846,0.013724856,0.0002854415,0.009240418,0.02566477,0.00020274699],"about_ca_topic_score_codex":0.028531024,"about_ca_topic_score_gemma":0.037089154,"teacher_disagreement_score":0.028531024,"about_ca_system_score_codex":0.008191512,"about_ca_system_score_gemma":0.010132038,"threshold_uncertainty_score":0.108843625},"labels":[],"label_agreement":null},{"id":"W3164984637","doi":"10.1007/s40273-021-01042-5","title":"Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Suicidal ideation; Major depressive disorder; Psychiatry; Cluster (spacecraft); Medicine; Clinical psychology; Psychology; Poison control; Suicide prevention; Emergency medicine; Mood","score_opus":0.015612625681551164,"score_gpt":0.30762794213114486,"score_spread":0.2920153164495937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164984637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99409324,0.00018000406,0.00058285956,0.00015509258,0.0000074988247,0.000118710675,0.0046226955,0.000016241158,0.00022375926],"genre_scores_gemma":[0.9906996,0.00012851709,0.0013385391,0.0000350452,0.0000038635194,0.00013841556,0.007507117,0.0000059283166,0.00014298542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808204,0.0007152209,0.00035021923,0.0004039303,0.00021406164,0.00023465832],"domain_scores_gemma":[0.9960234,0.0008183475,0.0015342515,0.00035844478,0.0008644902,0.00040097552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021030887,0.00025444056,0.00049751025,0.002787097,0.0006088037,0.0008485823,0.00072317885,0.0003234926,0.0013772714],"category_scores_gemma":[0.008586906,0.00023992649,0.0011907943,0.004566658,0.00022908347,0.00043828908,0.0016496456,0.00045539447,0.00016199808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023571486,0.00004783511,0.99320966,0.00005286544,0.00027455683,0.000051841496,0.0004545521,0.00072677335,0.00006964018,0.00011873892,0.0011666423,0.0035912981],"study_design_scores_gemma":[0.00003872023,0.00008425517,0.99019873,0.00004654943,0.00011462736,0.00013380288,0.0021677194,0.006043846,0.00007936938,0.00028193285,0.0007957964,0.000014721244],"about_ca_topic_score_codex":0.09750342,"about_ca_topic_score_gemma":0.08877004,"teacher_disagreement_score":0.09750342,"about_ca_system_score_codex":0.0015307721,"about_ca_system_score_gemma":0.0030036645,"threshold_uncertainty_score":0.1938718},"labels":[],"label_agreement":null},{"id":"W3170157997","doi":"10.1007/s40273-021-01027-4","title":"Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Hazard ratio; Oncology; Metastatic breast cancer; Discontinuation; Internal medicine; Breast cancer; Cancer; Progression-free survival; Quality-adjusted life year; Letrozole; Cost effectiveness; Gynecology; Estrogen receptor; Tamoxifen; Confidence interval; Overall survival","score_opus":0.033363795315044825,"score_gpt":0.35892055458306005,"score_spread":0.3255567592680152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170157997","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16451879,0.39250553,0.002231918,0.28505957,0.0022599972,0.00037701603,0.021420069,0.00015934142,0.13146776],"genre_scores_gemma":[0.82416266,0.14153615,0.002856578,0.018433057,0.0019663703,0.0000874845,0.0049830154,0.00004490857,0.0059298063],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9978829,0.0006780805,0.000093483584,0.00013096446,0.00081398996,0.0004005617],"domain_scores_gemma":[0.9961434,0.0010716965,0.00052729755,0.000039391594,0.0013846504,0.00083363184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019127859,0.0008693811,0.0011729274,0.0017617834,0.0007824353,0.003134198,0.0012587875,0.0018587443,0.006756132],"category_scores_gemma":[0.0074139084,0.0003438652,0.0024931475,0.002770507,0.0007752606,0.00074169354,0.0006494431,0.0026038254,0.00032695217],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017092146,0.00082933856,0.058479443,0.006676107,0.011012762,0.0017462558,0.0004444477,0.08741268,0.0033082394,0.049027953,0.20818454,0.5557861],"study_design_scores_gemma":[0.013819647,0.0073475298,0.4142192,0.017038692,0.03300772,0.0035815793,0.0038393238,0.0759594,0.002035234,0.027486976,0.4008446,0.00082014804],"about_ca_topic_score_codex":0.84789133,"about_ca_topic_score_gemma":0.9010628,"teacher_disagreement_score":0.15210867,"about_ca_system_score_codex":0.05447413,"about_ca_system_score_gemma":0.050794423,"threshold_uncertainty_score":0.39523935},"labels":[],"label_agreement":null},{"id":"W3171952049","doi":"10.1007/s40273-021-01037-2","title":"A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Institute of Health Economics","funders":"Government of Alberta","keywords":"Context (archaeology); Population; Public health; Medicine; Population health; Psychological intervention; Environmental health; Geography","score_opus":0.0491800786459314,"score_gpt":0.3596159511467342,"score_spread":0.31043587250080285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171952049","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15443149,0.0010277272,0.78757906,0.0032496108,0.00019328015,0.0014638228,0.0017914566,0.0003200991,0.049943443],"genre_scores_gemma":[0.8064864,0.00052008807,0.1767807,0.00045910786,0.000062198174,0.0011830231,0.0004847793,0.000068651134,0.013955047],"study_design_codex":"simulation_or_modeling","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9987098,0.000862602,0.000020298803,0.00011788298,0.00015424727,0.0001351361],"domain_scores_gemma":[0.9981565,0.0014033294,0.00013165892,0.000027692276,0.00020035324,0.00008045216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030204095,0.0012878199,0.0014047488,0.0014926725,0.0006154367,0.0015372342,0.0017439381,0.0015764522,0.009502816],"category_scores_gemma":[0.0061948504,0.0007969027,0.0010181962,0.00082168693,0.0009806335,0.00095679105,0.00095366663,0.0014068466,0.00037296023],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005701224,0.000023995737,0.0003374901,0.000025502242,0.000023881043,0.000017276494,0.000015292322,0.99194735,0.000071267,0.0051178606,0.0002743858,0.0020886406],"study_design_scores_gemma":[0.000056158802,0.000059478032,0.00020221614,0.00001674241,0.000028543696,0.000008015097,0.000024310537,0.9916889,0.00005305627,0.007074699,0.00078164507,0.0000063060547],"about_ca_topic_score_codex":0.078953,"about_ca_topic_score_gemma":0.06788624,"teacher_disagreement_score":0.078953,"about_ca_system_score_codex":0.0078560375,"about_ca_system_score_gemma":0.008348697,"threshold_uncertainty_score":0.15698689},"labels":[],"label_agreement":null},{"id":"W3173737570","doi":"10.1007/s40273-021-01059-w","title":"Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Alexion Pharmaceuticals","keywords":"Medicine; Life expectancy; Kidney disease; Population; Dialysis; Public health; Demography; Internal medicine; Environmental health; Pathology","score_opus":0.021425084205299646,"score_gpt":0.2988199142499436,"score_spread":0.27739483004464394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173737570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964246,0.00003504149,0.0018909426,0.000043116735,0.000014364358,0.0007979614,0.0001771531,0.000006087724,0.00061064714],"genre_scores_gemma":[0.9887714,0.00005869997,0.006614472,0.000066245906,0.000009803848,0.0037504674,0.0002676032,0.000002780309,0.0004585221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98035353,0.017227748,0.0006864498,0.0006642421,0.00046609965,0.00060192996],"domain_scores_gemma":[0.937722,0.05133163,0.005712187,0.0027484207,0.0010992326,0.0013865181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024583934,0.0011902868,0.001275707,0.00067407265,0.00073542283,0.0025638016,0.0009271367,0.0019587136,0.0036623895],"category_scores_gemma":[0.0358774,0.00072569627,0.002290269,0.0008690022,0.0021515642,0.0015201623,0.001647307,0.002075096,0.00028685108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24220845,0.09563262,0.29053122,0.0023290243,0.0054055657,0.0013010842,0.0097333435,0.242836,0.016578045,0.025891071,0.0018688892,0.065684825],"study_design_scores_gemma":[0.03911482,0.23464973,0.2014769,0.0004592582,0.0023886245,0.00037450864,0.00650322,0.4699908,0.012219312,0.026954971,0.0051110657,0.0007568538],"about_ca_topic_score_codex":0.0017265248,"about_ca_topic_score_gemma":0.0012373126,"teacher_disagreement_score":0.024583934,"about_ca_system_score_codex":0.0016696126,"about_ca_system_score_gemma":0.0011916482,"threshold_uncertainty_score":0.13001382},"labels":[],"label_agreement":null},{"id":"W3174028996","doi":"10.1007/s40273-021-01051-4","title":"Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care; Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Medicine; Cost effectiveness; MEDLINE; EconLit; CINAHL; Health economics; Systematic review; Economic evaluation; Quality-adjusted life year; Cost–benefit analysis; Intensive care medicine; Public health; Actuarial science; Psychological intervention; Psychiatry; Pathology; Risk analysis (engineering)","score_opus":0.12902176028496853,"score_gpt":0.45309648081650333,"score_spread":0.3240747205315348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174028996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042429453,0.9984012,0.00008017627,0.00032073632,0.00008098162,0.000069856134,0.00037832904,0.0000027619153,0.00024165788],"genre_scores_gemma":[0.0073250025,0.99154705,0.00024803038,0.0005252859,0.000064304455,0.00009887602,0.00012583144,0.0000024467708,0.00006308272],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962202,0.0014740613,0.001119756,0.0002733763,0.00073571946,0.00017697069],"domain_scores_gemma":[0.97861093,0.01716559,0.0030958338,0.00016893742,0.0007776018,0.00018110982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064386483,0.0011332219,0.0065104966,0.006502516,0.0003094312,0.002521507,0.0013162555,0.0018460382,0.010726563],"category_scores_gemma":[0.024808453,0.0007469887,0.006231631,0.0074804393,0.0007553246,0.001650498,0.0012161273,0.0016373675,0.00042306952],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000694707,0.00003405082,0.00059979217,0.9135306,0.017352166,0.00009360383,0.000048587663,0.00024953877,0.00012855217,0.0006094912,0.0033075754,0.06335136],"study_design_scores_gemma":[0.0013921519,0.00025344704,0.0046346243,0.7996284,0.15624051,0.0003296144,0.00020019179,0.00017285663,0.00016455869,0.0013791752,0.035554364,0.000050158036],"about_ca_topic_score_codex":0.0059846034,"about_ca_topic_score_gemma":0.017417707,"teacher_disagreement_score":0.010726563,"about_ca_system_score_codex":0.0029447037,"about_ca_system_score_gemma":0.0066573583,"threshold_uncertainty_score":0.035883963},"labels":[],"label_agreement":null},{"id":"W3177437141","doi":"10.1007/s40273-021-01039-0","title":"Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT)","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; St. Joseph’s Healthcare Hamilton; Toronto Public Health; Hamilton Health Sciences; Toronto General Hospital; University Health Network; University of Ottawa; Canadian Centre for Applied Research in Cancer Control; Sunnybrook Health Science Centre; McMaster University; Impact","funders":"","keywords":"Health economics; Transparency (behavior); Population health; Health services research; Population; Public health; Health administration; Medicine; Context (archaeology); Reimbursement; Actuarial science; Health care; Computer science; Economics; Environmental health; Nursing","score_opus":0.40149455450833305,"score_gpt":0.5137128038663795,"score_spread":0.11221824935804647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177437141","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01927505,0.0027990045,0.92544967,0.027277997,0.00087287405,0.0010287382,0.0033271066,0.0029439824,0.017025571],"genre_scores_gemma":[0.39943522,0.0020075063,0.57789534,0.00795057,0.0014884782,0.0025216765,0.004147831,0.002396712,0.0021566388],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.46152377,0.4438208,0.041162748,0.007085263,0.043845303,0.0025620542],"domain_scores_gemma":[0.08348601,0.8234205,0.022527432,0.04733781,0.021862825,0.0013653557],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.40534356,0.0017092883,0.0029818392,0.010285335,0.0016534786,0.026368633,0.004394616,0.0057007615,0.0064248904],"category_scores_gemma":[0.7548132,0.002087536,0.0035582408,0.012540821,0.0049783634,0.015074539,0.013083118,0.013067537,0.0020144389],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002229686,0.0005893167,0.02641166,0.0041363095,0.002365429,0.00060866994,0.0069256183,0.015381297,0.0015508063,0.3445469,0.058060076,0.53719425],"study_design_scores_gemma":[0.0013178895,0.000565348,0.014503549,0.0077744587,0.0013633817,0.0011415111,0.0015480146,0.12174539,0.008096078,0.74385685,0.0975142,0.0005732955],"about_ca_topic_score_codex":0.0024137099,"about_ca_topic_score_gemma":0.0013058871,"teacher_disagreement_score":0.59465647,"about_ca_system_score_codex":0.002772691,"about_ca_system_score_gemma":0.014391423,"threshold_uncertainty_score":0.73331726},"labels":[],"label_agreement":null},{"id":"W3180826043","doi":"10.1007/s40273-021-01050-5","title":"Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Horizon 2020; Università Bocconi; Australian Government","keywords":"Population; Population health; Reimbursement; Medicine; Health economics; European union; Health care; Business; Public health; Economic growth; Environmental health; Nursing; Economics","score_opus":0.03657067670491413,"score_gpt":0.37479128884331225,"score_spread":0.3382206121383981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180826043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41651317,0.08516854,0.05253351,0.29662728,0.0031998183,0.004835315,0.0036408936,0.0004074295,0.137074],"genre_scores_gemma":[0.9229969,0.013012815,0.035679545,0.022076653,0.00043912054,0.0012937759,0.0010117708,0.00007588151,0.003413561],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.89501625,0.07083218,0.013208471,0.003008517,0.0141133685,0.003821249],"domain_scores_gemma":[0.71912366,0.1944058,0.047146447,0.010705553,0.01986858,0.008749984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.104957685,0.00024102519,0.0005336135,0.0017405022,0.0015952368,0.005036481,0.0016910599,0.0017235613,0.0036749179],"category_scores_gemma":[0.1971087,0.0003595102,0.0011865902,0.0027961046,0.0031452838,0.005243861,0.0058335164,0.0027073477,0.0002274403],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010902982,0.00048216467,0.1416645,0.016913984,0.00061094435,0.0018081891,0.02515228,0.0057352087,0.0011450367,0.15841971,0.03879202,0.6081857],"study_design_scores_gemma":[0.0006848721,0.0016734006,0.17086317,0.055908017,0.0007285588,0.0024301857,0.032059047,0.0061708307,0.0033706308,0.049751207,0.67593944,0.00042061886],"about_ca_topic_score_codex":0.016774854,"about_ca_topic_score_gemma":0.02698958,"teacher_disagreement_score":0.104957685,"about_ca_system_score_codex":0.011151321,"about_ca_system_score_gemma":0.038283024,"threshold_uncertainty_score":0.5550759},"labels":[],"label_agreement":null},{"id":"W3182482494","doi":"10.1007/s40273-021-01044-3","title":"Lack of Cost-Effectiveness of Preoperative Erythropoiesis-Stimulating Agents and/or Iron Therapy in Anaemic, Elective Surgery Patients: A Systematic Review and Updated Analysis","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Health economics; Quality of Life Research; Intravenous iron; Erythropoiesis; Health administration; Abdominal surgery; Intensive care medicine; Iron therapy; Hematinic; General surgery; Anemia; Surgery; Public health; Internal medicine; Iron deficiency; Nursing","score_opus":0.09232097224802718,"score_gpt":0.41998019079104987,"score_spread":0.3276592185430227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182482494","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028592213,0.9941591,0.00025124493,0.00052799407,0.00012912942,0.00036972694,0.0012880977,0.000010138118,0.00040534593],"genre_scores_gemma":[0.056357257,0.9390965,0.0012085739,0.0011633143,0.00015548394,0.001042932,0.0008168937,0.00001868456,0.00014047434],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9832197,0.005301328,0.007271126,0.0010500134,0.0027178894,0.00044002436],"domain_scores_gemma":[0.92887306,0.052795034,0.01199508,0.00089941616,0.0050261253,0.00041122545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017156862,0.001591795,0.0117713455,0.011966723,0.0004659502,0.0038888608,0.0019333942,0.0019303518,0.0043548583],"category_scores_gemma":[0.07401092,0.001422907,0.017748581,0.0104489755,0.0007869412,0.0026043172,0.0015248117,0.0018061807,0.00027003235],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058137707,0.000023097404,0.0014138456,0.91648716,0.055183835,0.000078286845,0.00007906544,0.00021720582,0.00009310057,0.0002846661,0.0012375329,0.024320725],"study_design_scores_gemma":[0.0008264929,0.00031831337,0.008795006,0.58696437,0.39182168,0.00037983936,0.00016820375,0.00031120432,0.00020431576,0.00063503627,0.009515493,0.000060082926],"about_ca_topic_score_codex":0.0091786515,"about_ca_topic_score_gemma":0.022199247,"teacher_disagreement_score":0.017156862,"about_ca_system_score_codex":0.0059214057,"about_ca_system_score_gemma":0.010721216,"threshold_uncertainty_score":0.0907352},"labels":[],"label_agreement":null},{"id":"W3188660209","doi":"10.1007/s40273-021-01068-9","title":"Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"Karyopharm Therapeutics","keywords":"Medicine; Bortezomib; Multiple myeloma; Dexamethasone; Internal medicine; Oncology; Pomalidomide; Progression-free survival; Chemotherapy","score_opus":0.08245124933852116,"score_gpt":0.3953296840196429,"score_spread":0.31287843468112175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188660209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96385485,0.012136444,0.0069027375,0.0030485424,0.00019035462,0.0007968149,0.0034518542,0.000086651875,0.009531634],"genre_scores_gemma":[0.9958092,0.0011073075,0.0013739727,0.0002415335,0.00002047507,0.00015772982,0.00086885336,0.000008622385,0.00041245052],"study_design_codex":"simulation_or_modeling","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9963786,0.002786397,0.00014880807,0.00017475915,0.00034844346,0.00016297674],"domain_scores_gemma":[0.99501735,0.0041205124,0.0003776942,0.00010817963,0.00016756289,0.00020874433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006937157,0.0007023089,0.0010022603,0.00071946747,0.00015532441,0.0014738882,0.000610971,0.00072816253,0.003189924],"category_scores_gemma":[0.016335852,0.0002841983,0.0031065352,0.00068146654,0.0003477318,0.0011365121,0.0007078548,0.0015308894,0.00014290978],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.097905815,0.0015241045,0.019374525,0.0015807154,0.0049936213,0.0005301716,0.00014607194,0.73087925,0.0022131857,0.016433744,0.0049937307,0.11942507],"study_design_scores_gemma":[0.04055365,0.03456741,0.04582887,0.0015577544,0.013343463,0.0010816449,0.00043132334,0.8058348,0.0042586206,0.037998833,0.014289211,0.00025443174],"about_ca_topic_score_codex":0.004331403,"about_ca_topic_score_gemma":0.0039339084,"teacher_disagreement_score":0.006937157,"about_ca_system_score_codex":0.0031269318,"about_ca_system_score_gemma":0.0015351336,"threshold_uncertainty_score":0.036687672},"labels":[],"label_agreement":null},{"id":"W3195253306","doi":"10.1007/s40273-021-01074-x","title":"Conceptualising ‘Benefits Beyond Health’ in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health; Simon Fraser University","funders":"","keywords":"Context (archaeology); Health care; Conceptual framework; Health economics; Sociology; Quality of life (healthcare); Psychology; Public relations; Medicine; Economics; Nursing; Political science; Social science; Economic growth","score_opus":0.4710139165391754,"score_gpt":0.5318463444281387,"score_spread":0.060832427888963314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195253306","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010426004,0.99225736,0.00080629636,0.005714736,0.0007101585,0.000024426357,0.000057877736,0.000003441528,0.00032137576],"genre_scores_gemma":[0.007818979,0.9817758,0.0017446548,0.006623599,0.0016456543,0.00019701904,0.00007652401,0.000012671861,0.00010517838],"study_design_codex":"systematic_review","study_design_gemma":"qualitative","domain_scores_codex":[0.97639525,0.015426304,0.003416608,0.001484,0.002782933,0.0004950534],"domain_scores_gemma":[0.82251513,0.16706257,0.0038408448,0.0015848534,0.0045622056,0.00043438486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.065474704,0.002722378,0.011342091,0.013735988,0.0009985232,0.010007631,0.0054572066,0.006571013,0.004815839],"category_scores_gemma":[0.114794046,0.0012532538,0.004095335,0.011090423,0.006659702,0.01136502,0.0042347168,0.012897809,0.00085518934],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048773142,0.000092442635,0.0008637309,0.42730317,0.0059281527,0.00028813333,0.0027941642,0.002281766,0.00043798852,0.22293508,0.030159095,0.30642852],"study_design_scores_gemma":[0.00014360587,0.00013732546,0.0024960956,0.63111705,0.006827058,0.00032813576,0.0021923995,0.00072072755,0.00025946912,0.12490912,0.23073883,0.00013015124],"about_ca_topic_score_codex":0.009065377,"about_ca_topic_score_gemma":0.015833365,"teacher_disagreement_score":0.065474704,"about_ca_system_score_codex":0.01250172,"about_ca_system_score_gemma":0.016989872,"threshold_uncertainty_score":0.34626746},"labels":[],"label_agreement":null},{"id":"W3203366108","doi":"10.1007/s40273-021-01089-4","title":"Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Lung cancer; Quality of Life Research; Health economics; Oncology; Intensive care medicine; Pharmacoeconomics; Clinical Oncology; Internal medicine; Cancer; Public health; Medical physics; Pathology","score_opus":0.08006326009607585,"score_gpt":0.42086895525250584,"score_spread":0.34080569515643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203366108","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016433378,0.9881364,0.005043091,0.0021902185,0.0002699816,0.0012072781,0.00084703224,0.000039290164,0.0006233318],"genre_scores_gemma":[0.07618221,0.8939767,0.02037503,0.0022966038,0.00042906575,0.0055200974,0.000943991,0.00005092515,0.00022537453],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.89828974,0.074521236,0.017892636,0.002280478,0.006295839,0.00072003383],"domain_scores_gemma":[0.6332645,0.33588815,0.016673129,0.0037673942,0.009947244,0.0004596228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.09766272,0.002723643,0.012958372,0.013128671,0.0006408121,0.005400875,0.0036893706,0.0037061032,0.0034614084],"category_scores_gemma":[0.30793643,0.0024085932,0.021360926,0.012905321,0.0011537953,0.004235598,0.0019872019,0.002619493,0.00040339807],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000342999,0.000048543094,0.0013503252,0.8476449,0.07233456,0.00020915721,0.0002208936,0.0070996187,0.00007640129,0.0032733814,0.0029466248,0.064452596],"study_design_scores_gemma":[0.0007952953,0.0005551087,0.0027288762,0.7419635,0.21141557,0.00039655794,0.00039013335,0.0075589055,0.00026722054,0.012473805,0.021298934,0.00015597975],"about_ca_topic_score_codex":0.011683954,"about_ca_topic_score_gemma":0.019109793,"teacher_disagreement_score":0.09766272,"about_ca_system_score_codex":0.008411148,"about_ca_system_score_gemma":0.022150947,"threshold_uncertainty_score":0.51649594},"labels":[],"label_agreement":null},{"id":"W3203852858","doi":"10.1007/s40273-021-01087-6","title":"Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Global Health Care Issues","field":"Health Professions","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Health economics; Health administration; Quality of Life Research; Health care; Public health; Health services research; Public economics; Economics; Actuarial science; Environmental health; Econometrics; Medicine; Economic growth; Nursing","score_opus":0.5755898216990788,"score_gpt":0.6149285070464087,"score_spread":0.03933868534732987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203852858","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006220811,0.91498727,0.053967003,0.006580733,0.00062570133,0.00023058317,0.0055,0.00006748288,0.011820425],"genre_scores_gemma":[0.11970513,0.82569784,0.045758802,0.0020163453,0.0006166857,0.0009902983,0.0033158108,0.00011678166,0.0017823117],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98655176,0.009367647,0.0012507084,0.0008313244,0.0017785546,0.00022002793],"domain_scores_gemma":[0.896765,0.095538676,0.0027101228,0.0021838227,0.0026126544,0.00018973325],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.031099925,0.0014739141,0.0046978886,0.005866387,0.00026538965,0.0042482666,0.0040092953,0.0015831838,0.0058675744],"category_scores_gemma":[0.08753021,0.0008662026,0.0038739184,0.011757026,0.0026231643,0.004117292,0.0018621013,0.0034459434,0.0007542695],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052454177,0.00013749937,0.012941236,0.1223429,0.026922746,0.00037796592,0.00045266977,0.058265336,0.00030921047,0.25326097,0.021125074,0.5033398],"study_design_scores_gemma":[0.00034554218,0.00041831288,0.056684367,0.15782899,0.02702732,0.0024332053,0.0019656,0.025265543,0.0016964348,0.3546313,0.3714435,0.00025993522],"about_ca_topic_score_codex":0.007630766,"about_ca_topic_score_gemma":0.008353322,"teacher_disagreement_score":0.9689001,"about_ca_system_score_codex":0.0040337844,"about_ca_system_score_gemma":0.0028563726,"threshold_uncertainty_score":0.16447413},"labels":[],"label_agreement":null},{"id":"W3206304124","doi":"10.1007/s40273-021-01095-6","title":"Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"F. Hoffmann-La Roche; Roche","keywords":"Medicine; SMA*; Neuromuscular disease; Systematic review; Economic evaluation; MEDLINE; Physical medicine and rehabilitation; Cochrane Library; Reimbursement; Cost effectiveness; EconLit; Quality of life (healthcare); Spinal muscular atrophy; Physical therapy; Health care; Intensive care medicine; Disease; Randomized controlled trial; Surgery; Pathology; Risk analysis (engineering); Nursing","score_opus":0.10929610605984029,"score_gpt":0.49663223390911965,"score_spread":0.38733612784927934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206304124","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034523837,0.9616479,0.003793684,0.001870366,0.00073178293,0.0166843,0.007681749,0.000097845754,0.0040398655],"genre_scores_gemma":[0.096950255,0.8267995,0.017134747,0.0029848078,0.0005328119,0.05056922,0.004126025,0.00008459584,0.0008179742],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.88146824,0.073077686,0.028847154,0.0028769195,0.01233428,0.0013957015],"domain_scores_gemma":[0.7913611,0.16890557,0.023528203,0.002786381,0.012344773,0.0010740807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06898295,0.0041532884,0.018030992,0.023045251,0.0011637604,0.0065748584,0.0032172028,0.003583766,0.014515075],"category_scores_gemma":[0.25967795,0.0019519951,0.021681277,0.017131142,0.0015694054,0.0056926073,0.0042763646,0.003599809,0.0008592956],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005615141,0.00002800906,0.00049563934,0.9448761,0.029481819,0.000079996404,0.000108935994,0.00048246075,0.00004903373,0.0009294387,0.0012896922,0.021617526],"study_design_scores_gemma":[0.001427252,0.0004357591,0.0022312386,0.86149794,0.11499404,0.0001882077,0.00023526727,0.0005669592,0.00015437433,0.002438137,0.015770128,0.00006073522],"about_ca_topic_score_codex":0.0072228545,"about_ca_topic_score_gemma":0.0121666,"teacher_disagreement_score":0.06898295,"about_ca_system_score_codex":0.014884463,"about_ca_system_score_gemma":0.023923144,"threshold_uncertainty_score":0.36482108},"labels":[],"label_agreement":null},{"id":"W3206420890","doi":"10.1007/s40273-021-01093-8","title":"The Utility of a Rapid Review Evaluation Process to a National HTA Agency","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Medicine; Pharmacoeconomics; Reimbursement; Health technology; Orphan drug; Economic evaluation; Health economics; Intensive care medicine; Public health; Health care; Nursing; Bioinformatics; Pathology","score_opus":0.7108393322923651,"score_gpt":0.6075579680623567,"score_spread":0.10328136423000833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206420890","genre_codex":"methods","genre_gemma":"review","domain_codex":"methods","domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12813258,0.032346666,0.35476935,0.14986308,0.012838291,0.119238466,0.016171185,0.011454518,0.17518584],"genre_scores_gemma":[0.50046873,0.006597721,0.40943465,0.01735822,0.0050068586,0.04390711,0.004681205,0.0009473052,0.011598167],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.25175545,0.56470346,0.08807001,0.020169731,0.06927684,0.006024522],"domain_scores_gemma":[0.053259075,0.54182065,0.13578244,0.062836505,0.19295177,0.013349578],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.6195961,0.0024590539,0.0039918516,0.0129828695,0.004684085,0.023539104,0.008343957,0.0061185984,0.020571746],"category_scores_gemma":[0.8174985,0.0033854125,0.005320057,0.009136151,0.003840783,0.019434217,0.014738256,0.0068118405,0.0074142455],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008836194,0.0013323626,0.065001585,0.033486824,0.0041713775,0.0024300946,0.010412152,0.011772296,0.0021624968,0.033897575,0.19830452,0.62819254],"study_design_scores_gemma":[0.0066687856,0.009856925,0.15464969,0.049026668,0.0054361243,0.0036995986,0.007800267,0.06277686,0.0063302726,0.032147754,0.65974885,0.0018581263],"about_ca_topic_score_codex":0.010254108,"about_ca_topic_score_gemma":0.011088876,"teacher_disagreement_score":0.38040388,"about_ca_system_score_codex":0.021091672,"about_ca_system_score_gemma":0.11931209,"threshold_uncertainty_score":0.46910578},"labels":[],"label_agreement":null},{"id":"W334668128","doi":"10.1007/s40273-015-0278-7","title":"Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?","year":2015,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Canadian Agency for Drugs and Technologies in Health; Cancer Care Ontario; Saskatchewan Cancer Agency; Canadian Centre for Applied Research in Cancer Control; St. Michael's Hospital","funders":"","keywords":"Health economics; Pharmacoeconomics; Health technology; Health care; Economic evaluation; Population health; Medicine; Gerontology; Library science; Political science; Law; Computer science; Intensive care medicine","score_opus":0.32836396874757645,"score_gpt":0.5090665514113875,"score_spread":0.180702582663811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W334668128","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047512204,0.003211207,0.00009423489,0.9883752,0.006113719,0.000014282112,0.000119056036,0.0000069025064,0.0015902489],"genre_scores_gemma":[0.0237088,0.007364613,0.0006584899,0.9497551,0.015531747,0.000059639,0.00012117235,0.000030838495,0.0027696926],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9525282,0.012411708,0.003900336,0.0025960712,0.024523068,0.004040661],"domain_scores_gemma":[0.70418763,0.17857714,0.01471242,0.003549157,0.08685654,0.012117113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04105437,0.00036886963,0.001163484,0.001569898,0.0046922197,0.008942953,0.0033088715,0.020436676,0.008707786],"category_scores_gemma":[0.22326359,0.00062240014,0.0014625111,0.0031778023,0.0070978506,0.0045743417,0.0020547397,0.022651916,0.002124024],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022591693,0.000022437001,0.0023163806,0.00050041836,0.00008475044,0.00026340902,0.00030144487,0.00014784026,0.00010098746,0.011358582,0.95708543,0.027592452],"study_design_scores_gemma":[0.00029595793,0.00011802204,0.008076557,0.0034114027,0.00022634518,0.00047592554,0.0011767391,0.00082628767,0.000624707,0.010999799,0.9735581,0.00021019828],"about_ca_topic_score_codex":0.35335696,"about_ca_topic_score_gemma":0.38372165,"teacher_disagreement_score":0.95287067,"about_ca_system_score_codex":0.047129307,"about_ca_system_score_gemma":0.08947396,"threshold_uncertainty_score":0.70260036},"labels":[],"label_agreement":null},{"id":"W4200248641","doi":"10.1007/s40273-021-01115-5","title":"Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"F. Hoffmann-La Roche","keywords":"Spinal muscular atrophy; SMA*; Health economics; Quality of Life Research; Medicine; Public health; Physical medicine and rehabilitation; Physical therapy; Gerontology; Pathology; Disease; Computer science","score_opus":0.030892511151640295,"score_gpt":0.3814285843364808,"score_spread":0.3505360731848405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200248641","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025300665,0.98894626,0.00073011464,0.0005708875,0.00018504476,0.0023911223,0.0034293574,0.000025304887,0.001191942],"genre_scores_gemma":[0.04592934,0.94276446,0.0029972834,0.0011554285,0.00013814075,0.005126549,0.0016247283,0.000018399927,0.00024565967],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9782282,0.008569532,0.008794448,0.0011014421,0.0028495695,0.000456841],"domain_scores_gemma":[0.93665045,0.049289517,0.008906723,0.00077814533,0.00395421,0.00042091982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016015496,0.0018460373,0.010583812,0.021332148,0.00080883433,0.003312928,0.002226302,0.0019422595,0.0073547647],"category_scores_gemma":[0.0981217,0.0010739225,0.009079338,0.018793393,0.0010889517,0.0031639722,0.0025430538,0.001460623,0.0004619657],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012819248,0.0000089706,0.0007895763,0.97372425,0.008452071,0.000096648095,0.00015279916,0.00009373612,0.000044650627,0.00024886505,0.0010011162,0.015259049],"study_design_scores_gemma":[0.00024203108,0.000111845584,0.002786535,0.9397323,0.046979297,0.00025707722,0.00025006858,0.0000894879,0.00007563529,0.0004958848,0.008952512,0.000027202852],"about_ca_topic_score_codex":0.008826697,"about_ca_topic_score_gemma":0.02137715,"teacher_disagreement_score":0.021332148,"about_ca_system_score_codex":0.0063838037,"about_ca_system_score_gemma":0.017644463,"threshold_uncertainty_score":0.084699094},"labels":[],"label_agreement":null},{"id":"W4200579141","doi":"10.1007/s40273-021-01106-6","title":"Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Hôpital Notre-Dame; Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"Sanofi Genzyme; EMD Serono; Monash University; Novartis Pharma; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Mylan; Biogen; MedDay Pharmaceuticals; Celgene; Sanofi","keywords":"Fingolimod; Natalizumab; Medicine; Multiple sclerosis; Health economics; Relapsing remitting; Cost effectiveness; Quality of Life Research; Public health; Pharmacoeconomics; Disease; Intensive care medicine; Physical therapy; Immunology; Internal medicine; Pathology","score_opus":0.11934353170114638,"score_gpt":0.3735801482993999,"score_spread":0.25423661659825353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200579141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730473,0.021719674,0.0005679851,0.0007040208,0.00008191612,0.00020306946,0.0016471818,0.000011431271,0.0020174016],"genre_scores_gemma":[0.9979601,0.0011098536,0.0002106551,0.000085962594,0.00001050175,0.00006479819,0.00045603502,0.0000021009373,0.00010006588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9892429,0.008503722,0.0008436974,0.00044322797,0.00060317724,0.0003632568],"domain_scores_gemma":[0.9872996,0.008364711,0.0028495546,0.00041230602,0.00059279107,0.0004810417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00685652,0.0005204292,0.001633659,0.001028204,0.00015399144,0.001388048,0.00074771227,0.0010426517,0.0021265754],"category_scores_gemma":[0.034946118,0.00037184724,0.0027087217,0.0010904378,0.00057152344,0.00085407495,0.001313311,0.00075038365,0.00012334164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24214259,0.0013619389,0.4003584,0.011344235,0.036114223,0.001533141,0.0013119398,0.15924346,0.0016270503,0.005737434,0.0046836687,0.13454191],"study_design_scores_gemma":[0.061315034,0.031154025,0.7408304,0.0060953074,0.034179423,0.002874658,0.0016775633,0.106874,0.0020620693,0.0040477132,0.008512162,0.00037773317],"about_ca_topic_score_codex":0.018589556,"about_ca_topic_score_gemma":0.012001423,"teacher_disagreement_score":0.018589556,"about_ca_system_score_codex":0.0051469062,"about_ca_system_score_gemma":0.0011643288,"threshold_uncertainty_score":0.03734356},"labels":[],"label_agreement":null},{"id":"W4205508841","doi":"10.1007/s40273-021-01124-4","title":"Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut Universitaire en Santé Mentale de Québec; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Université de Sherbrooke","funders":"Fonds de Recherche du Québec - Santé","keywords":"Coronavirus disease 2019 (COVID-19); Health economics; Quality of Life Research; Public health; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Health administration; Vaccination; Medicine; Public economics; Virology; Economics; Nursing; Outbreak; Infectious disease (medical specialty)","score_opus":0.10267109511763596,"score_gpt":0.41702008499681426,"score_spread":0.3143489898791783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205508841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960658,0.000027084172,0.0002799971,0.0001737933,0.000009606318,0.00049811543,0.00035837764,0.0000087373965,0.0025785712],"genre_scores_gemma":[0.99079585,0.000053032963,0.0013008415,0.00028834195,0.000009797097,0.00080026843,0.0002995644,0.0000034163268,0.0064488044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987471,0.0005903055,0.000038120488,0.00015692427,0.0001831489,0.0002844712],"domain_scores_gemma":[0.99671066,0.0014735856,0.00045472578,0.00016676214,0.00052603136,0.0006683223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003063379,0.00044342023,0.00036674843,0.00027836915,0.0014673972,0.0011531261,0.0005918939,0.001016367,0.008261614],"category_scores_gemma":[0.0031729273,0.00017527048,0.00035946854,0.00030553705,0.00072526076,0.0004557256,0.00035577663,0.0006893858,0.00055782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039748356,0.11194717,0.6283226,0.0008129829,0.0006652386,0.0014186896,0.0151533205,0.01837123,0.05202411,0.006880146,0.02207345,0.1025827],"study_design_scores_gemma":[0.0058698007,0.035157353,0.8526993,0.0002167666,0.00028714145,0.000107759515,0.007918237,0.06709512,0.00573747,0.0011865717,0.023432288,0.00029223986],"about_ca_topic_score_codex":0.7031881,"about_ca_topic_score_gemma":0.80011016,"teacher_disagreement_score":0.29681188,"about_ca_system_score_codex":0.011825858,"about_ca_system_score_gemma":0.0064092968,"threshold_uncertainty_score":0.5971197},"labels":[],"label_agreement":null},{"id":"W4206321249","doi":"10.1007/s40273-021-01112-8","title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute of Health Economics; University of Ottawa","funders":"National Institute for Health and Care Research; National Institute for Health Research Health Protection Research Unit","keywords":"Economic evaluation; Checklist; Public health; Context (archaeology); Health care; Health economics; Rebuttal; Public relations; Health policy; Stakeholder; Health administration; Population health; Medicine; Political science; Psychology; Nursing; Law","score_opus":0.3605172056295309,"score_gpt":0.5650338421019704,"score_spread":0.2045166364724395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206321249","genre_codex":"dataset","genre_gemma":"methods","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002606585,0.06837926,0.23016654,0.110115886,0.039684452,0.13075702,0.32671028,0.011274304,0.08030573],"genre_scores_gemma":[0.018765979,0.07098099,0.30470163,0.028575692,0.0073726443,0.3229407,0.22337079,0.004753539,0.018538104],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.48824167,0.3122154,0.11189403,0.008242457,0.073954225,0.005452227],"domain_scores_gemma":[0.268004,0.37504724,0.09307132,0.040398546,0.21924034,0.0042386153],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.35440123,0.0049252603,0.01160523,0.021374054,0.0026435645,0.018879514,0.010311152,0.01272517,0.050780013],"category_scores_gemma":[0.72130024,0.0046469006,0.014687298,0.039896853,0.0050926837,0.010606826,0.00821801,0.022818219,0.029094819],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013046435,0.00015692919,0.0011833698,0.046679284,0.00147502,0.00014068975,0.000692445,0.0023731242,0.00020960753,0.022615958,0.8017424,0.12142645],"study_design_scores_gemma":[0.0021092193,0.00024930408,0.003489544,0.08924785,0.0017011383,0.0002752671,0.00046590102,0.0036713574,0.0010482748,0.037609417,0.8596637,0.00046901024],"about_ca_topic_score_codex":0.010859604,"about_ca_topic_score_gemma":0.005691207,"teacher_disagreement_score":0.64559877,"about_ca_system_score_codex":0.013912,"about_ca_system_score_gemma":0.052796327,"threshold_uncertainty_score":0.7961382},"labels":[],"label_agreement":null},{"id":"W4211031897","doi":"10.1007/s40273-022-01134-w","title":"Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment","year":2022,"lang":"en","type":"erratum","venue":"PharmacoEconomics","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire en santé mentale de Montréal; Institut Universitaire en Santé Mentale de Québec; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Université de Sherbrooke","funders":"","keywords":"Health economics; Coronavirus disease 2019 (COVID-19); Quality of Life Research; Public health; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Health administration; Medicine; Virology; Outbreak; Nursing; Infectious disease (medical specialty)","score_opus":0.059554445466792325,"score_gpt":0.41142534208965603,"score_spread":0.3518708966228637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211031897","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011426572,0.0008715548,0.0014439899,0.1790027,0.76477534,0.00019899245,0.0346919,0.00056176254,0.017311115],"genre_scores_gemma":[0.04606663,0.002338799,0.009026487,0.11933507,0.06086474,0.0012051666,0.012371479,0.0019636606,0.7468279],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942206,0.0014240077,0.0006463333,0.0006119618,0.0024854587,0.000611642],"domain_scores_gemma":[0.9110353,0.029307295,0.002001527,0.004875425,0.04977272,0.0030077351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009463008,0.0014285927,0.0020885426,0.0026905676,0.0048584016,0.0044791047,0.0038141008,0.0063060788,0.12297666],"category_scores_gemma":[0.12159351,0.00083999446,0.0015365903,0.003523345,0.0024733243,0.0019267859,0.001262992,0.0073523554,0.025330368],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023613593,0.0000037482582,0.0000857299,0.000022284485,0.0000037292643,0.000029105333,0.00002303267,0.000034223565,0.000004747112,0.00052007736,0.99835396,0.0008957489],"study_design_scores_gemma":[0.00035918024,0.000028923503,0.0045360774,0.0005341312,0.0000720093,0.00012484097,0.00062170724,0.0012987208,0.0002876282,0.002906828,0.98910517,0.00012472578],"about_ca_topic_score_codex":0.72108376,"about_ca_topic_score_gemma":0.71315205,"teacher_disagreement_score":0.27891624,"about_ca_system_score_codex":0.024280502,"about_ca_system_score_gemma":0.031200685,"threshold_uncertainty_score":0.56111765},"labels":[],"label_agreement":null},{"id":"W4233811006","doi":"10.2165/11633650-000000000-00000","title":"The Authors’ Reply","year":2012,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oakville-Trafalgar Memorial Hospital; Humber River Regional Hospital; University of Toronto","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Medicine; Nursing","score_opus":0.043183239044388894,"score_gpt":0.37449832528882926,"score_spread":0.3313150862444404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233811006","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029086336,0.0009002963,0.00006716034,0.95433354,0.043468975,0.000009108409,0.00004021004,0.000019259787,0.0008705881],"genre_scores_gemma":[0.0019957195,0.00037503394,0.000089008005,0.9759169,0.018525068,0.000023963903,0.000012468607,0.000017793114,0.0030439738],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99201787,0.0019487934,0.0010066418,0.0015542856,0.002301416,0.0011710499],"domain_scores_gemma":[0.9663531,0.016497599,0.0028174608,0.0014542905,0.00957685,0.0033006729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007439984,0.0007775564,0.0021510618,0.0013302687,0.004878604,0.006489373,0.0033604933,0.06697026,0.012022168],"category_scores_gemma":[0.07480526,0.0012446708,0.0018799341,0.0008930784,0.0050543025,0.0047374726,0.004128501,0.07199539,0.007780827],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004255587,0.000013545195,0.0004294479,0.00006348557,0.000039002218,0.00055217586,0.0003478757,0.000031243668,0.00012680201,0.0026108127,0.9933482,0.0023947516],"study_design_scores_gemma":[0.000111999754,0.000039845723,0.0012409273,0.00037916302,0.00008074013,0.0010651381,0.0013452884,0.0001703927,0.0004460614,0.0059039514,0.9890716,0.00014476702],"about_ca_topic_score_codex":0.0060466533,"about_ca_topic_score_gemma":0.006347262,"teacher_disagreement_score":0.06697026,"about_ca_system_score_codex":0.0042863353,"about_ca_system_score_gemma":0.007977331,"threshold_uncertainty_score":0.040218174},"labels":[],"label_agreement":null},{"id":"W4247657589","doi":"10.2165/00019053-200523080-00010","title":"The authors’ reply","year":2005,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Case Reports on Hematomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Medicine; Nursing","score_opus":0.023422205533933683,"score_gpt":0.35319992582309323,"score_spread":0.3297777202891595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247657589","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009877505,0.0017322316,0.00014949875,0.9119437,0.08316988,0.000021532265,0.000056611545,0.00004658422,0.0018921687],"genre_scores_gemma":[0.006431246,0.00079656986,0.0002494419,0.946309,0.0402467,0.000043241544,0.000022188558,0.00003558771,0.0058660875],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99498475,0.0012334372,0.00079170824,0.0008400853,0.0014304875,0.00071950146],"domain_scores_gemma":[0.969613,0.014600999,0.0033002603,0.0016937939,0.008486094,0.0023058981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042915056,0.0006828165,0.0020748896,0.0012825747,0.0035532385,0.0041843737,0.0034526144,0.05594851,0.0131284855],"category_scores_gemma":[0.06099334,0.0012099808,0.0015114349,0.00086361566,0.0034565525,0.0033205685,0.003284628,0.048465624,0.007730467],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000683355,0.000020755877,0.0009826141,0.000111945265,0.00006898406,0.00379839,0.0004909097,0.00005690873,0.00031284912,0.0024771306,0.98765755,0.0039535942],"study_design_scores_gemma":[0.000119946846,0.000060950024,0.0018338867,0.0003358,0.00011336147,0.005054475,0.0011560775,0.00027156738,0.0006604505,0.0037577737,0.9864885,0.0001471813],"about_ca_topic_score_codex":0.0032117055,"about_ca_topic_score_gemma":0.0036152508,"teacher_disagreement_score":0.05594851,"about_ca_system_score_codex":0.0032223954,"about_ca_system_score_gemma":0.0037668,"threshold_uncertainty_score":0.043919146},"labels":[],"label_agreement":null},{"id":"W4280518447","doi":"10.1007/s40273-022-01142-w","title":"Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Respiratory viral infections research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health; University of Calgary; University of British Columbia; Public Health Ontario; BC Children's Hospital; University of Toronto; Institute of Health Economics; University of Alberta","funders":"Canadian Immunization Research Network","keywords":"Medicine; Incidence (geometry); Disease burden; Comorbidity; Vaccination; Health care; Public health; Pediatrics; Health economics; Disease; Demography; Internal medicine; Immunology","score_opus":0.16119341745767313,"score_gpt":0.4793994207351008,"score_spread":0.31820600327742765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280518447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908489,0.0013616532,0.00055631687,0.00031467882,0.000010214835,0.00007890488,0.0050278795,0.000011025473,0.0017905073],"genre_scores_gemma":[0.99557483,0.0006363749,0.00082319113,0.000036234436,0.000011888243,0.000030642685,0.0025457365,0.000003025242,0.0003381748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989378,0.00026342957,0.00011726687,0.000114964074,0.00036488497,0.00020163396],"domain_scores_gemma":[0.9975828,0.00041559045,0.0009901021,0.000056746623,0.00063796504,0.00031667028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013858739,0.00049977936,0.00033918908,0.0021723693,0.00046004096,0.0009438508,0.0007604253,0.00036704817,0.00166994],"category_scores_gemma":[0.004927656,0.0001891508,0.0011013262,0.0023541208,0.00030245478,0.00040495468,0.0005754777,0.00036218655,0.00012559665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015379407,0.000033735425,0.9903053,0.000060506925,0.0003069767,0.00004450198,0.00004678749,0.0028221593,0.00006563451,0.00014669618,0.00038697504,0.00562693],"study_design_scores_gemma":[0.000010057088,0.00011241485,0.99418217,0.00004342344,0.00017801911,0.00010024354,0.00018622965,0.004447988,0.0000964681,0.00012080614,0.0005148683,0.000007398699],"about_ca_topic_score_codex":0.5855262,"about_ca_topic_score_gemma":0.6313123,"teacher_disagreement_score":0.5855262,"about_ca_system_score_codex":0.009016598,"about_ca_system_score_gemma":0.005021731,"threshold_uncertainty_score":0.8338294},"labels":[],"label_agreement":null},{"id":"W4285726954","doi":"10.1007/s40273-022-01169-z","title":"The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Gilead Sciences (Canada); McMaster University","funders":"Gilead Sciences","keywords":"Medicine; Aggressive lymphoma; Cost effectiveness; Quality of life (healthcare); Quality-adjusted life year; Health care; Health economics; Public health; Lymphoma; Health administration; Quality of Life Research; Rituximab; Cost-effectiveness analysis; Intensive care medicine; Oncology; Internal medicine; Risk analysis (engineering); Nursing","score_opus":0.021292195897557455,"score_gpt":0.32236795008721936,"score_spread":0.3010757541896619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285726954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97620493,0.013677868,0.00010854433,0.0040209563,0.00008954827,0.00009996483,0.0011135926,0.000016045813,0.004668661],"genre_scores_gemma":[0.99670666,0.001972671,0.00012501047,0.00034837343,0.000032334443,0.00001368132,0.00033230707,0.0000027964759,0.00046628434],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99938726,0.00023647698,0.000044075663,0.00004950274,0.00011749453,0.00016522771],"domain_scores_gemma":[0.99888974,0.00026993896,0.00021739991,0.000018298555,0.0001203717,0.0004841692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005356215,0.00017275513,0.00045238138,0.00037849514,0.0003363225,0.00090103416,0.00050296914,0.00044953113,0.0022360606],"category_scores_gemma":[0.00282848,0.00010035143,0.00076651806,0.00069475494,0.00043476664,0.00033373758,0.0003730409,0.00082398497,0.00007977458],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20415367,0.0034184682,0.2469201,0.002036227,0.0034305833,0.0009608159,0.00041868456,0.022471638,0.0024243554,0.0027326706,0.015951797,0.495081],"study_design_scores_gemma":[0.020466784,0.02344937,0.9082101,0.00086401263,0.0050748866,0.00090420636,0.0016069799,0.024323557,0.0011782474,0.00080366887,0.012998128,0.000120141915],"about_ca_topic_score_codex":0.56439126,"about_ca_topic_score_gemma":0.7747763,"teacher_disagreement_score":0.43560874,"about_ca_system_score_codex":0.019802904,"about_ca_system_score_gemma":0.01097129,"threshold_uncertainty_score":0.87634826},"labels":[],"label_agreement":null},{"id":"W4285727040","doi":"10.1007/s40273-022-01151-9","title":"China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population","year":2022,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre; Impact","funders":"National Natural Science Foundation of China","keywords":"Health economics; China; Quality of Life Research; Health administration; Measure (data warehouse); Preference; Population health; Public health; Population; Environmental health; Medicine; Geography; Statistics; Computer science; Data mining; Nursing; Mathematics","score_opus":0.5756447524729171,"score_gpt":0.49666025212832327,"score_spread":0.07898450034459387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285727040","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07539267,0.8366362,0.03030161,0.005924858,0.0013709168,0.0051457165,0.029416021,0.0002079921,0.015604026],"genre_scores_gemma":[0.29763624,0.5696419,0.09029052,0.004473744,0.000813922,0.008293592,0.02499771,0.00007181408,0.0037806553],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961367,0.0013369034,0.0006440162,0.00022860013,0.0015274705,0.00012631917],"domain_scores_gemma":[0.9956909,0.0018171523,0.00077485887,0.00016450265,0.0013769772,0.00017560166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010987549,0.0012814618,0.002849274,0.0069121467,0.00039233788,0.0011001282,0.0011393663,0.0006383236,0.0019654469],"category_scores_gemma":[0.011081186,0.00028949935,0.0030561571,0.009412496,0.0003812972,0.0012036121,0.0012725834,0.0013870299,0.00022637889],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004942662,0.00024127986,0.03413348,0.020485133,0.0038664336,0.000084401436,0.00022117913,0.0011910817,0.00043886367,0.007541826,0.015574992,0.91572714],"study_design_scores_gemma":[0.0017705644,0.0022502344,0.65696025,0.024406396,0.01759604,0.0010265908,0.0008244626,0.009169187,0.0024349405,0.0135515835,0.26946774,0.00054205494],"about_ca_topic_score_codex":0.030825717,"about_ca_topic_score_gemma":0.044414885,"teacher_disagreement_score":0.030825717,"about_ca_system_score_codex":0.0030115987,"about_ca_system_score_gemma":0.007210812,"threshold_uncertainty_score":0.06129253},"labels":[],"label_agreement":null},{"id":"W4287092191","doi":"10.1007/s40273-022-01175-1","title":"Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived Experience","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Mental Health and Patient Involvement","field":"Health Professions","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; Vancouver Coastal Health Research Institute; University of British Columbia; Arthritis Research Centre of Canada; Vancouver Coastal Health","funders":"Genome British Columbia; Michael Smith Health Research BC; Genome Canada","keywords":"General partnership; Health care; Best practice; Process (computing); Medicine; Psychology; Process management; Knowledge management; Nursing; Business; Computer science; Political science","score_opus":0.3285797779699407,"score_gpt":0.49089423232397783,"score_spread":0.16231445435403713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287092191","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26949316,0.0026265949,0.65296197,0.033384334,0.0002333857,0.0012748827,0.00032844086,0.00026406598,0.03943317],"genre_scores_gemma":[0.8273687,0.001150204,0.1689963,0.0006897786,0.000034043263,0.00063289615,0.00014913654,0.00005141203,0.0009274933],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.92477,0.06903763,0.0015043293,0.0017522599,0.0022439572,0.0006917617],"domain_scores_gemma":[0.89608955,0.08520295,0.0045331162,0.007919875,0.0038169534,0.0024374907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.057369895,0.00073599286,0.00053189637,0.0018348449,0.002686811,0.009451112,0.002895572,0.0022797545,0.0046624024],"category_scores_gemma":[0.12643458,0.00063930714,0.0012034877,0.0009619784,0.005502569,0.010485999,0.011731309,0.0027269959,0.0003802706],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004494683,0.0015396102,0.11369857,0.0027707636,0.00091569056,0.001968101,0.17655407,0.12977654,0.0016510993,0.30481964,0.0048040817,0.26105237],"study_design_scores_gemma":[0.00026141712,0.0012162505,0.012685073,0.006964415,0.0005308611,0.0011621846,0.13032933,0.22905993,0.0029823086,0.5202673,0.09417816,0.0003627893],"about_ca_topic_score_codex":0.005449363,"about_ca_topic_score_gemma":0.009972575,"teacher_disagreement_score":0.057369895,"about_ca_system_score_codex":0.0046113227,"about_ca_system_score_gemma":0.010757391,"threshold_uncertainty_score":0.3034047},"labels":[],"label_agreement":null},{"id":"W4288176181","doi":"10.1007/s40273-022-01176-0","title":"Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions","year":2022,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Vancouver Coastal Health; Canadian Centre for Applied Research in Cancer Control; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"EconLit; Precision medicine; Psychological intervention; Health care; Health economics; Cost–benefit analysis; MEDLINE; Computer science; Management science; Actuarial science; Risk analysis (engineering); Medicine; Business; Economics","score_opus":0.7536605107723361,"score_gpt":0.6234118746189133,"score_spread":0.13024863615342275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288176181","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010348963,0.99516195,0.002284969,0.0014992126,0.0001425555,0.00012648472,0.00013031796,0.000011456399,0.0005396059],"genre_scores_gemma":[0.0045674653,0.98611975,0.007437366,0.00090475107,0.00021631237,0.0004963841,0.00014122385,0.000015942367,0.000100767524],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9438167,0.03298552,0.0113351345,0.0018298429,0.009369005,0.0006638847],"domain_scores_gemma":[0.7188256,0.25437894,0.01310037,0.0037720646,0.009290651,0.0006324096],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.095403776,0.0037926629,0.013183081,0.022468576,0.0010463224,0.0110979825,0.0045772484,0.006131237,0.005953749],"category_scores_gemma":[0.2237862,0.0018026285,0.009394632,0.02207802,0.004124213,0.009367375,0.006107404,0.0067947763,0.00075549737],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003125222,0.0000994955,0.0006748269,0.3100456,0.0064537004,0.000072246854,0.00031731557,0.0025717958,0.00012798485,0.044152923,0.008864771,0.62630683],"study_design_scores_gemma":[0.00027109345,0.00016856076,0.0015360041,0.7954453,0.014521646,0.00027896493,0.00033438607,0.0020076686,0.0002839725,0.06966847,0.11534358,0.00014038908],"about_ca_topic_score_codex":0.008879023,"about_ca_topic_score_gemma":0.012154874,"teacher_disagreement_score":0.9045962,"about_ca_system_score_codex":0.011421181,"about_ca_system_score_gemma":0.020168759,"threshold_uncertainty_score":0.5045494},"labels":[],"label_agreement":null},{"id":"W4288748903","doi":"10.1007/s40273-022-01179-x","title":"Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network","year":2022,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Healthcare Systems and Technology","field":"Business, Management and Accounting","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Centre for Advancing Health Outcomes; University of British Columbia; St. Paul's Hospital; University of British Columbia Hospital","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Health informatics; Peer review; Computer science; Business; Process management; Medicine; Nursing; Political science","score_opus":0.07771509447881658,"score_gpt":0.35066329016791425,"score_spread":0.2729481956890977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288748903","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":"reproducibility","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":"reproducibility","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0139692975,0.00040607734,0.15302737,0.7215743,0.006104955,0.0008764597,0.0004039628,0.0036930225,0.09994456],"genre_scores_gemma":[0.35755032,0.0013712898,0.2693027,0.22056931,0.007217591,0.0019474147,0.0010530375,0.0025279408,0.13846041],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9803759,0.009876038,0.0007432924,0.00097097567,0.006869963,0.0011637725],"domain_scores_gemma":[0.8679517,0.08539632,0.0038364485,0.014507686,0.019207405,0.0091004325],"candidate_categories":["metaresearch","open_science"],"consensus_categories":[],"category_scores_codex":[0.028460769,0.0005251324,0.0004182561,0.0012334536,0.00430781,0.006404932,0.0032944884,0.014809725,0.022414563],"category_scores_gemma":[0.09631662,0.0007454594,0.0008781562,0.0005962614,0.0030226086,0.018814117,0.0074657616,0.009601967,0.0060708667],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001978276,0.0006453546,0.0037968068,0.000119162214,0.000048467908,0.0014867992,0.0013290837,0.0039064405,0.0018113811,0.08343008,0.7637533,0.13947535],"study_design_scores_gemma":[0.00024636305,0.0003111137,0.0018858819,0.00028266598,0.000036938756,0.0009911412,0.0024084558,0.05205745,0.002748681,0.10106659,0.8378006,0.00016409438],"about_ca_topic_score_codex":0.009615267,"about_ca_topic_score_gemma":0.015342539,"teacher_disagreement_score":0.99670553,"about_ca_system_score_codex":0.0027554152,"about_ca_system_score_gemma":0.013995617,"threshold_uncertainty_score":0.15051675},"labels":[],"label_agreement":null},{"id":"W4294992035","doi":"10.1007/s40273-022-01180-4","title":"Engaging Patients and Caregivers in an Early Health Economic Evaluation: Discerning Treatment Value Based on Lived Experience","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Ottawa Public Health; University of Toronto; Sunnybrook Health Science Centre; University of Ottawa; Ottawa Hospital","funders":"Ontario Institute for Cancer Research","keywords":"Economic evaluation; Medicine; Quality of life (healthcare); Health economics; Qualitative research; Health care; Public health; Nursing; Political science","score_opus":0.37430102742359167,"score_gpt":0.4838093124781059,"score_spread":0.10950828505451421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294992035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9070298,0.007865454,0.013436797,0.048317906,0.00047407756,0.001201021,0.0006745829,0.000064048036,0.020936422],"genre_scores_gemma":[0.98641473,0.0017475564,0.009117129,0.0014828646,0.00012556586,0.0005087947,0.00015188311,0.0000108936565,0.00044065446],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.97199607,0.02291008,0.001987346,0.00036823715,0.0015951452,0.0011430944],"domain_scores_gemma":[0.9106315,0.066249266,0.009708548,0.0018897397,0.0053399457,0.0061809677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04284991,0.0005614897,0.0014269773,0.0021350333,0.001347719,0.005901119,0.00073526346,0.0017530951,0.0033058506],"category_scores_gemma":[0.21045347,0.00049680745,0.0009074623,0.0009837253,0.001060266,0.006617117,0.004220457,0.003919577,0.00039079794],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056156623,0.004144927,0.4823513,0.0015549455,0.0011265227,0.0020891835,0.04488622,0.0028035876,0.00062553416,0.009675559,0.017487014,0.4276395],"study_design_scores_gemma":[0.0018707851,0.007483576,0.54163593,0.010084404,0.0020782666,0.004604183,0.17486551,0.030836975,0.004416344,0.15459827,0.06651273,0.0010129802],"about_ca_topic_score_codex":0.0016641176,"about_ca_topic_score_gemma":0.003637305,"teacher_disagreement_score":0.04284991,"about_ca_system_score_codex":0.0022266686,"about_ca_system_score_gemma":0.004462061,"threshold_uncertainty_score":0.22661471},"labels":[],"label_agreement":null},{"id":"W4308954619","doi":"10.1007/s40273-022-01198-8","title":"Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments","year":2022,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Economic and Environmental Valuation","field":"Economics, Econometrics and Finance","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Macquarie University","keywords":"Quality of Life Research; Health economics; Pharmacotherapy; Pharmacoeconomics; Health administration; Medicine; Public health; Intensive care medicine; Oncology; Internal medicine; Nursing","score_opus":0.21727704471184267,"score_gpt":0.37035633105890164,"score_spread":0.15307928634705897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308954619","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033557077,0.99217016,0.0012830631,0.00043733945,0.00011834111,0.0014658938,0.000656135,0.000013511145,0.0004998166],"genre_scores_gemma":[0.08809266,0.896073,0.007129836,0.0013661779,0.0001485104,0.006298455,0.00064627227,0.000018060757,0.00022702674],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9512741,0.031922024,0.010628458,0.0017860668,0.004083401,0.00030585972],"domain_scores_gemma":[0.722215,0.26034945,0.012304987,0.0018677625,0.0028695578,0.0003932263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.045640837,0.0016051303,0.009993515,0.0044045122,0.00054347224,0.0028837384,0.0020716488,0.0019875793,0.0061090686],"category_scores_gemma":[0.13311906,0.0007964609,0.015096906,0.0058928393,0.0012470144,0.0025148608,0.0013389119,0.0017033314,0.0002185394],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001346601,0.000095261785,0.0007903665,0.90861136,0.030609164,0.00007183265,0.00022347027,0.0004236686,0.00010147906,0.0009393262,0.0006706608,0.056116834],"study_design_scores_gemma":[0.0032742221,0.001886129,0.0062912926,0.77957845,0.17914052,0.00026652752,0.0005579783,0.00093604496,0.00053795107,0.0037299104,0.023653945,0.00014698043],"about_ca_topic_score_codex":0.0030378785,"about_ca_topic_score_gemma":0.0063950038,"teacher_disagreement_score":0.045640837,"about_ca_system_score_codex":0.00490518,"about_ca_system_score_gemma":0.0069207447,"threshold_uncertainty_score":0.24137473},"labels":[],"label_agreement":null},{"id":"W4310595031","doi":"10.1007/s40273-022-01225-8","title":"Best Practices: A Collection of Systematic Critical Reviews of Modeling Approaches in Specific Disease Areas","year":2022,"lang":"en","type":"editorial","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Systematic review; Disease; MEDLINE; Management science; Medicine; Political science; Economics; Pathology","score_opus":0.6882038685906825,"score_gpt":0.5168785522757147,"score_spread":0.17132531631496783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310595031","genre_codex":"review","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022590713,0.70612293,0.00337694,0.06232315,0.21948782,0.0023545893,0.0030641996,0.00038993667,0.0026545217],"genre_scores_gemma":[0.003666578,0.6977517,0.019305326,0.06931493,0.19785935,0.0050082384,0.0025384605,0.0004929546,0.0040624877],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.8989535,0.036501706,0.033353567,0.003167131,0.02673446,0.0012896791],"domain_scores_gemma":[0.53473234,0.28215557,0.06730681,0.008772983,0.10021658,0.0068156742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.09924788,0.0051299483,0.01307676,0.04226506,0.0024627047,0.011906901,0.007001995,0.009778343,0.0072744284],"category_scores_gemma":[0.29656333,0.0035718682,0.007902796,0.022410363,0.0034925982,0.007705288,0.004907536,0.010760893,0.0038608082],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032187082,0.00004780279,0.00014814666,0.08730871,0.0026819448,0.000083242114,0.0003407549,0.00015594267,0.00024590522,0.00066614745,0.8288542,0.07914529],"study_design_scores_gemma":[0.0009069587,0.0001538714,0.0016479309,0.3220283,0.0074623954,0.00025874499,0.0003016724,0.00032527573,0.0004248834,0.0035196214,0.662768,0.00020238865],"about_ca_topic_score_codex":0.0070307185,"about_ca_topic_score_gemma":0.026926626,"teacher_disagreement_score":0.09924788,"about_ca_system_score_codex":0.010738201,"about_ca_system_score_gemma":0.030133676,"threshold_uncertainty_score":0.5248792},"labels":[],"label_agreement":null},{"id":"W4311329766","doi":"10.1007/s40273-022-01197-9","title":"Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review","year":2022,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Children's Hospital of Eastern Ontario; McGill University","funders":"","keywords":"Caregiver burden; SMA*; Medicine; Spinal muscular atrophy; Quality of life (healthcare); Anxiety; Caregiver stress; Disease burden; Gerontology; Disease; Psychiatry; Physical therapy; Nursing; Pathology","score_opus":0.07882230820770512,"score_gpt":0.41957258342108233,"score_spread":0.3407502752133772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311329766","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011655211,0.99791485,0.00007646915,0.00014893492,0.00008993836,0.0000925854,0.00038343295,0.0000048851625,0.000123375],"genre_scores_gemma":[0.01846947,0.98034143,0.00029654347,0.000424372,0.00006187323,0.00015732898,0.00017636166,0.0000029655166,0.0000696654],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99641836,0.0011131283,0.0012993196,0.00039544597,0.0005931175,0.00018067632],"domain_scores_gemma":[0.9876409,0.009029136,0.0022695402,0.00014610212,0.00072247314,0.00019189072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042765713,0.0016198733,0.008894794,0.0055986177,0.0005243746,0.0020750258,0.0014835042,0.002085346,0.00551022],"category_scores_gemma":[0.021787904,0.0011992925,0.009503916,0.007632217,0.00063415506,0.0019465273,0.0020175,0.0016431804,0.00026683608],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033251895,0.000021690827,0.0022163345,0.93453574,0.03537583,0.00013692351,0.00014687031,0.00013002017,0.00008157618,0.00014726837,0.0017651478,0.025109995],"study_design_scores_gemma":[0.00072266365,0.00020755637,0.013220383,0.6807288,0.2923576,0.0005017957,0.0004686821,0.00014668179,0.00009894574,0.00037011705,0.011092743,0.000084064384],"about_ca_topic_score_codex":0.01581679,"about_ca_topic_score_gemma":0.050582528,"teacher_disagreement_score":0.01581679,"about_ca_system_score_codex":0.002741243,"about_ca_system_score_gemma":0.0063885534,"threshold_uncertainty_score":0.031449437},"labels":[],"label_agreement":null},{"id":"W4317474345","doi":"10.1007/s40273-022-01232-9","title":"Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Government of Jiangsu Province","keywords":"Quality of Life Research; Health economics; Medicine; Adverse effect; Public health; Cancer therapy; Drug; Cancer; Health administration; Cancer drugs; Intensive care medicine; Pharmacotherapy; Pharmacoeconomics; Pharmacology; Internal medicine; Nursing","score_opus":0.6428468017640477,"score_gpt":0.5620661032464104,"score_spread":0.08078069851763736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317474345","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.062369183,0.8704793,0.03228917,0.010331533,0.0010618638,0.004784411,0.00918542,0.00009405026,0.009405107],"genre_scores_gemma":[0.7563715,0.19961265,0.029747134,0.0033280007,0.00043412676,0.0070699607,0.0029979257,0.000090072564,0.000348624],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.6704898,0.25408477,0.048774336,0.00588508,0.019179258,0.001586692],"domain_scores_gemma":[0.50312555,0.45193714,0.028744647,0.0042184996,0.011219483,0.0007547324],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.21032536,0.0019664508,0.006588171,0.01589757,0.0006493426,0.007605657,0.0022636845,0.0024194517,0.002587006],"category_scores_gemma":[0.48648676,0.0013622774,0.022496326,0.0148880305,0.0019190913,0.0063678892,0.0032853507,0.0044220104,0.00022555888],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071957796,0.00028468028,0.09254088,0.3734179,0.18911476,0.00033377952,0.0026177212,0.027229939,0.0003483478,0.02226351,0.0066410787,0.27801162],"study_design_scores_gemma":[0.0035737474,0.0036074314,0.09343615,0.515309,0.20767877,0.0016324441,0.0029588328,0.043952946,0.0024630525,0.07416181,0.05026908,0.00095677667],"about_ca_topic_score_codex":0.006421147,"about_ca_topic_score_gemma":0.006455609,"teacher_disagreement_score":0.78967464,"about_ca_system_score_codex":0.009688106,"about_ca_system_score_gemma":0.0072194673,"threshold_uncertainty_score":0.9738094},"labels":[],"label_agreement":null},{"id":"W4317613981","doi":"10.1007/s40273-022-01238-3","title":"Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Twente; ZonMw","keywords":"Medicine; Lung cancer screening; Context (archaeology); Cost effectiveness; Population; Quality-adjusted life year; Lung cancer; Cost-effectiveness analysis; Health care; Intensive care medicine; Internal medicine; Environmental health","score_opus":0.14688918361923978,"score_gpt":0.4771261555207007,"score_spread":0.33023697190146095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317613981","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017238922,0.9955497,0.00040196895,0.00043166245,0.00009845893,0.0005475575,0.0008384143,0.000013168822,0.00039522973],"genre_scores_gemma":[0.03613408,0.9596121,0.0014980608,0.00051707105,0.00009221706,0.0015034932,0.00052534,0.000012177753,0.00010547217],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.97638196,0.01241689,0.006733729,0.0009340534,0.0030394658,0.0004938697],"domain_scores_gemma":[0.9005904,0.08356004,0.009897938,0.0009783771,0.0044945576,0.00047863025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02247813,0.0021667485,0.011622313,0.014199647,0.0005898536,0.0036361285,0.0022563138,0.0020978586,0.0058988286],"category_scores_gemma":[0.11484903,0.001353419,0.012789599,0.013507925,0.0009096061,0.0023914194,0.0017767882,0.0018902556,0.00027981293],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047678532,0.000026424339,0.0008271151,0.9417754,0.024267772,0.000088303685,0.00008551865,0.00039598407,0.00005161206,0.00039913456,0.0010447057,0.030561265],"study_design_scores_gemma":[0.00074222445,0.00029901962,0.004256122,0.8441633,0.13955966,0.0002979945,0.00021032762,0.00045892436,0.00015787462,0.0008348747,0.0089713335,0.000048273036],"about_ca_topic_score_codex":0.008498958,"about_ca_topic_score_gemma":0.016807398,"teacher_disagreement_score":0.02247813,"about_ca_system_score_codex":0.008498532,"about_ca_system_score_gemma":0.01256046,"threshold_uncertainty_score":0.11887717},"labels":[],"label_agreement":null},{"id":"W4318345202","doi":"10.1007/s40273-022-01236-5","title":"Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"Ontario Ministry of Research and Innovation; Canadian Institutes of Health Research","keywords":"Medicine; Vaccination; Hepatitis B; Public health; Health economics; Cost effectiveness; Cost-effectiveness analysis; Environmental health; Hepatitis B vaccine; Demography; Pediatrics; Immunology; Hepatitis B virus; Risk analysis (engineering)","score_opus":0.05315135069654738,"score_gpt":0.37040243647340376,"score_spread":0.3172510857768564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318345202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829229,0.0006732494,0.0014135654,0.001453427,0.000020907564,0.0004144634,0.0021096074,0.000050114,0.010941791],"genre_scores_gemma":[0.99735403,0.0002692247,0.0007367532,0.000068370784,0.000003425624,0.00005461359,0.0004920826,0.000004023113,0.0010173726],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99861634,0.0004020407,0.000051489624,0.000104099025,0.0003225359,0.00050345605],"domain_scores_gemma":[0.9972887,0.0009746167,0.00043784842,0.00008282673,0.0006924865,0.0005235575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017371832,0.00041941553,0.00042758702,0.000367833,0.0009269009,0.0010313881,0.0012714651,0.00057792175,0.003741766],"category_scores_gemma":[0.00849499,0.00032267606,0.0010620514,0.00056038675,0.0005235932,0.00056628516,0.0008486503,0.0005022199,0.00011402329],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006801234,0.0010665953,0.3368759,0.000977099,0.0011295226,0.0008315981,0.00097213377,0.52652895,0.0019966722,0.008928163,0.0074728862,0.106419176],"study_design_scores_gemma":[0.0019059661,0.0039291517,0.42000028,0.00037313465,0.0014374021,0.00026798932,0.0021341697,0.55558217,0.0015291189,0.004196094,0.008523009,0.00012154949],"about_ca_topic_score_codex":0.95945346,"about_ca_topic_score_gemma":0.9560987,"teacher_disagreement_score":0.9306144,"about_ca_system_score_codex":0.069385566,"about_ca_system_score_gemma":0.05191903,"threshold_uncertainty_score":0.5034299},"labels":[],"label_agreement":null},{"id":"W4318832711","doi":"10.1007/s40273-023-01244-z","title":"Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Health Technology Assessment Programme; National Institute for Health and Care Research","keywords":"Nice; Medicine; Excellence; Health technology; Critical appraisal; Population; Systematic review; Health care; Family medicine; Health economics; Population health; MEDLINE; Public health; Alternative medicine; Nursing; Pathology; Political science; Environmental health","score_opus":0.5971191702844785,"score_gpt":0.5753690734773254,"score_spread":0.02175009680715312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318832711","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014813342,0.44209737,0.017880205,0.4896861,0.017738447,0.00603841,0.0014917158,0.0004011559,0.023185335],"genre_scores_gemma":[0.06941348,0.3581428,0.27733183,0.2344687,0.029530974,0.019316137,0.0023206852,0.00061495055,0.008860407],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.66245645,0.2335385,0.05458694,0.007378446,0.037172336,0.004867353],"domain_scores_gemma":[0.5422225,0.24351145,0.04895665,0.020294674,0.13101833,0.013996464],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.3222859,0.002485605,0.010210033,0.0124347005,0.0020916178,0.027425198,0.006811724,0.022747383,0.007574628],"category_scores_gemma":[0.3857894,0.0029742366,0.014928625,0.010595993,0.005583098,0.012015238,0.0076361946,0.016133463,0.004389629],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019298597,0.00018224132,0.0014070355,0.22824383,0.009981399,0.0014493384,0.0032713418,0.003715295,0.001895863,0.08761599,0.3826416,0.27766624],"study_design_scores_gemma":[0.0033573278,0.0018319614,0.0037094865,0.33176976,0.010077551,0.0013826608,0.0011238134,0.0024674467,0.0011174099,0.051155925,0.5915836,0.00042306253],"about_ca_topic_score_codex":0.006651596,"about_ca_topic_score_gemma":0.00710376,"teacher_disagreement_score":0.3222859,"about_ca_system_score_codex":0.013843415,"about_ca_system_score_gemma":0.07359796,"threshold_uncertainty_score":0.8357422},"labels":[],"label_agreement":null},{"id":"W4318922016","doi":"10.1007/s40273-022-01235-6","title":"Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre; Impact","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; China; Value (mathematics); Qualitative research; Medicine; Statistics; Geography; Mathematics; Sociology; Nursing; Social science","score_opus":0.5276679003206807,"score_gpt":0.60088825065496,"score_spread":0.07322035033427932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318922016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99089056,0.00021776618,0.0020123194,0.0025237023,0.000017316464,0.00017213717,0.00004461729,0.000004767272,0.004116789],"genre_scores_gemma":[0.9984127,0.000078801866,0.0009173498,0.0001340975,0.0000022761728,0.000056043213,0.000017007613,0.0000022786487,0.00037944666],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9859903,0.009960502,0.0006016635,0.00046138556,0.0014200817,0.001566071],"domain_scores_gemma":[0.97625136,0.016122999,0.0017885296,0.0005468802,0.003226167,0.002064167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025133364,0.00043146327,0.00070651266,0.0024701615,0.01032404,0.004854286,0.0015643738,0.0011951751,0.0019824312],"category_scores_gemma":[0.022678372,0.0003456252,0.0003764907,0.004775653,0.0063575916,0.0039057676,0.0035141823,0.002372359,0.00009708245],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059869024,0.0001900059,0.043296624,0.00022318348,0.000021582015,0.00070466334,0.9143175,0.00035528035,0.0010811506,0.019583827,0.0009783459,0.019187976],"study_design_scores_gemma":[0.0000089842415,0.000051983392,0.013372893,0.00016382271,0.000012889513,0.00010158827,0.9759157,0.0013143535,0.00034282974,0.0030934818,0.0055864393,0.00003507213],"about_ca_topic_score_codex":0.047596615,"about_ca_topic_score_gemma":0.046992946,"teacher_disagreement_score":0.047596615,"about_ca_system_score_codex":0.022897562,"about_ca_system_score_gemma":0.02540457,"threshold_uncertainty_score":0.16613424},"labels":[],"label_agreement":null},{"id":"W4323920777","doi":"10.1007/s40273-022-01234-7","title":"Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Innovate UK; National Institute for Health and Care Research","keywords":"Medicine; Health care; MEDLINE; Health economics; Systematic review; Payment; Economic evaluation; Cost effectiveness; Actuarial science; Public health; Risk analysis (engineering); Business; Nursing; Economics; Pathology; Finance; Biology","score_opus":0.531812539584388,"score_gpt":0.5290833640695236,"score_spread":0.0027291755148644015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323920777","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027865686,0.99208295,0.0013433597,0.0010663576,0.00020320372,0.00089169637,0.0006284646,0.000010625295,0.0009868447],"genre_scores_gemma":[0.10527051,0.8839857,0.006246096,0.0012255362,0.0001891706,0.002412965,0.00047214824,0.000018742363,0.0001790659],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9296928,0.04337783,0.014296123,0.00232756,0.00940217,0.0009034842],"domain_scores_gemma":[0.7118999,0.25964573,0.017730087,0.001978415,0.008201511,0.00054440857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.050698686,0.0022508372,0.0091072535,0.011101677,0.0007757613,0.0067455294,0.002901539,0.003280475,0.0040892074],"category_scores_gemma":[0.21892577,0.0016954174,0.013954813,0.011145023,0.001581829,0.005521326,0.0020344937,0.0030919192,0.00024659466],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004840045,0.000032885197,0.0013408404,0.90562004,0.031353686,0.00012146533,0.00030216563,0.0017050719,0.00011951777,0.0025947893,0.001260303,0.055065192],"study_design_scores_gemma":[0.00041256347,0.00031632578,0.0029224681,0.87974656,0.09633666,0.00026989463,0.00055674615,0.0011405837,0.00032147838,0.0033375649,0.014550911,0.000088233675],"about_ca_topic_score_codex":0.010904812,"about_ca_topic_score_gemma":0.022839455,"teacher_disagreement_score":0.050698686,"about_ca_system_score_codex":0.011231093,"about_ca_system_score_gemma":0.02149698,"threshold_uncertainty_score":0.26812345},"labels":[],"label_agreement":null},{"id":"W4362704228","doi":"10.1007/s40273-023-01262-x","title":"Developing a Framework of Cost Elements of Socioeconomic Burden of Rare Disease: A Scoping Review","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Alberta Health Services; SickKids Foundation; University of Toronto; Ontario Genomics; Children's Hospital of Eastern Ontario; Genome Canada; Alberta Bone and Joint Health Institute; McGill University; University of Ottawa; Institute for Clinical Evaluative Sciences; University of Calgary; Alberta Children's Hospital","funders":"Canadian Institutes of Health Research","keywords":"EconLit; PsycINFO; Health economics; Socioeconomic status; Medicine; Health care; Systematic review; MEDLINE; Health administration; Rare disease; Comparability; Public health; Family medicine; Disease; Nursing; Environmental health; Population; Political science; Economic growth; Economics; Pathology","score_opus":0.06618045749901443,"score_gpt":0.42112342945115405,"score_spread":0.35494297195213964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362704228","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014473872,0.99580187,0.00080440927,0.0021911473,0.00026081558,0.00003108659,0.00009598209,0.0000058420387,0.00066411565],"genre_scores_gemma":[0.0028848036,0.9941849,0.0015221003,0.0008827679,0.00024397574,0.00008331461,0.00007274984,0.0000041657586,0.00012124124],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.995544,0.001891414,0.00094665587,0.0004014204,0.0010195038,0.00019699046],"domain_scores_gemma":[0.972568,0.02334246,0.001609113,0.00025637948,0.0020301268,0.00019399491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012957652,0.0019465643,0.0044620503,0.010165953,0.00068032084,0.005454725,0.0025540579,0.0031782736,0.0045998855],"category_scores_gemma":[0.035251763,0.00087866007,0.0032744918,0.009952056,0.0017925927,0.0056892587,0.002998802,0.003650927,0.0005170385],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014729427,0.00007488731,0.0016544883,0.15587083,0.0029851464,0.00028115677,0.0005203661,0.0028432356,0.00019184082,0.076841846,0.02083205,0.73775685],"study_design_scores_gemma":[0.00009327549,0.000112972106,0.0036155265,0.5959689,0.007354272,0.0008716943,0.0010355171,0.0013906871,0.0002056464,0.058017183,0.33121595,0.00011832671],"about_ca_topic_score_codex":0.0116134975,"about_ca_topic_score_gemma":0.017705515,"teacher_disagreement_score":0.012957652,"about_ca_system_score_codex":0.0062232153,"about_ca_system_score_gemma":0.013734606,"threshold_uncertainty_score":0.0685274},"labels":[],"label_agreement":null},{"id":"W4367187286","doi":"10.1007/s40273-023-01274-7","title":"Patient and Public Involvement in Health Economics Modelling Raises the Need for Normative Guidance","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Mental Health and Patient Involvement","field":"Health Professions","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"Michael Smith Health Research BC","keywords":"Normative; Health economics; Public health; Health administration; Perspective (graphical); Interpretation (philosophy); Quality of Life Research; Public relations; Value (mathematics); Health policy; Public finance; Medicine; Positive economics; Public economics; Engineering ethics; Sociology; Political science; Economics; Nursing; Computer science; Law","score_opus":0.31200491538175945,"score_gpt":0.4432809946576637,"score_spread":0.13127607927590423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367187286","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019944383,0.0014527673,0.46276903,0.3337413,0.0015705854,0.0005319435,0.0004948624,0.00026035856,0.17923476],"genre_scores_gemma":[0.7909142,0.0015903971,0.15831362,0.03581228,0.002077589,0.0021584374,0.00037731478,0.00036562496,0.008390545],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.91155416,0.0650943,0.004329809,0.0044359234,0.01217623,0.0024096072],"domain_scores_gemma":[0.5797128,0.3689906,0.008198584,0.015064083,0.023290347,0.0047436175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10489999,0.0017679941,0.0049925935,0.0025831552,0.0046139504,0.018983243,0.00959732,0.017337052,0.010254727],"category_scores_gemma":[0.346755,0.0022971893,0.002264948,0.0023910915,0.016793793,0.032876063,0.009488689,0.032269966,0.0014953463],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021057404,0.00008674736,0.00059787417,0.00007692854,0.000035426146,0.00006123577,0.00091957295,0.008807785,0.000027392283,0.98248166,0.0028751143,0.0040091057],"study_design_scores_gemma":[0.000018046767,0.00000875377,0.0000840719,0.00019109774,0.0000073395663,0.000023723092,0.0004341091,0.011185352,0.000026173937,0.9844407,0.003563869,0.00001673441],"about_ca_topic_score_codex":0.016705949,"about_ca_topic_score_gemma":0.025854064,"teacher_disagreement_score":0.10489999,"about_ca_system_score_codex":0.007954067,"about_ca_system_score_gemma":0.017093278,"threshold_uncertainty_score":0.5547708},"labels":[],"label_agreement":null},{"id":"W4372295364","doi":"10.1007/s40273-023-01271-w","title":"Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; University of Alberta; Alberta Environment and Protected Areas","funders":"","keywords":"Health economics; Quality of Life Research; Thrombopoietin; Medicine; Pharmacoeconomics; Public health; Intensive care medicine; Quality-adjusted life year; Romiplostim; Cost effectiveness; Pathology","score_opus":0.08885232747354482,"score_gpt":0.4068468718428829,"score_spread":0.31799454436933805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4372295364","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020164065,0.9971476,0.000077742836,0.00013185739,0.00009017166,0.000074410746,0.00029087596,0.000005902899,0.00016504055],"genre_scores_gemma":[0.036338743,0.9621008,0.00041727468,0.0005674938,0.00010455701,0.00012212756,0.00023503062,0.000004795534,0.00010908684],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99796945,0.00072955183,0.00065715984,0.00019038287,0.00034709013,0.00010624634],"domain_scores_gemma":[0.9935774,0.004751717,0.0012108936,0.00007247957,0.00028846232,0.00009911884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029567652,0.0010773727,0.0084988335,0.0026639819,0.00025088975,0.0017557633,0.0013278574,0.0015715559,0.005183916],"category_scores_gemma":[0.011972561,0.00076680776,0.010057984,0.003961094,0.00046100692,0.0011570057,0.0008818742,0.0015832854,0.00023486023],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025402808,0.000065603,0.0017354055,0.8495421,0.09395825,0.00013148504,0.00006457774,0.0003358102,0.00020824846,0.00023468083,0.0020592734,0.049124304],"study_design_scores_gemma":[0.0050337967,0.00079231407,0.0129110785,0.2735286,0.6923,0.00043309532,0.00020817529,0.00043448847,0.00023206629,0.0006107638,0.013429271,0.000086177664],"about_ca_topic_score_codex":0.0059950054,"about_ca_topic_score_gemma":0.01832455,"teacher_disagreement_score":0.0084988335,"about_ca_system_score_codex":0.0016897524,"about_ca_system_score_gemma":0.002702641,"threshold_uncertainty_score":0.017341912},"labels":[],"label_agreement":null},{"id":"W4379197252","doi":"10.1007/s40273-023-01279-2","title":"A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Waterloo; Women's College Hospital; University of Toronto","funders":"","keywords":"Ceritinib; Crizotinib; Medicine; Anaplastic lymphoma kinase; Alectinib; ALK inhibitor; Lung cancer; Internal medicine; Systematic review; Oncology; Cochrane Library; Population; non-small cell lung cancer (NSCLC); Intensive care medicine; MEDLINE; Meta-analysis; Environmental health","score_opus":0.045303811579656184,"score_gpt":0.41740954539548386,"score_spread":0.3721057338158277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379197252","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019219576,0.99641377,0.00016362786,0.000216338,0.000111040776,0.00016750004,0.0006891396,0.000008516492,0.00030810648],"genre_scores_gemma":[0.041005604,0.9567221,0.000719949,0.00063876814,0.00008255374,0.00026040347,0.0003819965,0.0000067378946,0.00018193436],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9957634,0.0018092496,0.0013146815,0.00031347113,0.0006396366,0.00015957537],"domain_scores_gemma":[0.99193865,0.0059086303,0.0014499447,0.00010226113,0.00048541938,0.00011505458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005386049,0.0013281311,0.008396021,0.0035210303,0.00028391584,0.0018946634,0.0012149307,0.0011973566,0.0051828194],"category_scores_gemma":[0.017996345,0.0007549166,0.012221049,0.004932784,0.00043960568,0.001169957,0.0010161331,0.00159751,0.0002548776],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018568254,0.00003386205,0.0009739174,0.8478995,0.10398746,0.000100793906,0.00006187553,0.00047691542,0.000239625,0.0002822988,0.0017347755,0.042352226],"study_design_scores_gemma":[0.0029301296,0.0005795707,0.0081618,0.2813036,0.68841493,0.00034302182,0.00012957654,0.00034312505,0.00023881646,0.000631671,0.01686373,0.00005999143],"about_ca_topic_score_codex":0.0091095,"about_ca_topic_score_gemma":0.028910814,"teacher_disagreement_score":0.0091095,"about_ca_system_score_codex":0.0028171341,"about_ca_system_score_gemma":0.004224868,"threshold_uncertainty_score":0.028484523},"labels":[],"label_agreement":null},{"id":"W4382631068","doi":"10.1007/s40273-023-01295-2","title":"Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC)","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Health care; Checklist; Indirect costs; Health economics; Disease; Family medicine; Public health; Oncology; Internal medicine; Pathology; Business; Psychology; Political science","score_opus":0.059147768534668646,"score_gpt":0.3996942043017581,"score_spread":0.3405464357670895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382631068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00466307,0.9669566,0.0013767366,0.0010910406,0.00032819988,0.007264991,0.015962582,0.00006938896,0.0022873378],"genre_scores_gemma":[0.045179494,0.92511237,0.0051471395,0.0018411383,0.00017686991,0.016084183,0.005698318,0.000049708553,0.00071070605],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9744309,0.0077802497,0.012489317,0.0012034168,0.0035440149,0.0005520891],"domain_scores_gemma":[0.92658585,0.05312221,0.01290829,0.0012394766,0.005607678,0.0005364002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017516285,0.0022301555,0.011665374,0.025543757,0.0011224835,0.0041692783,0.0028881223,0.002536812,0.009685205],"category_scores_gemma":[0.090362996,0.0014375555,0.009868909,0.024551107,0.0011863003,0.0039833994,0.002910682,0.0015627734,0.000813746],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009161322,0.000006741263,0.0005226502,0.98360264,0.0064249528,0.000082575716,0.00012633728,0.0000700674,0.0000667876,0.00016748565,0.0010591088,0.0077790734],"study_design_scores_gemma":[0.00018203502,0.000091291295,0.0021089665,0.94845515,0.037281793,0.0001965293,0.0002126069,0.00006836092,0.00009975229,0.0002959839,0.010982794,0.000024815845],"about_ca_topic_score_codex":0.010090201,"about_ca_topic_score_gemma":0.02793706,"teacher_disagreement_score":0.025543757,"about_ca_system_score_codex":0.007204462,"about_ca_system_score_gemma":0.023516925,"threshold_uncertainty_score":0.09263605},"labels":[],"label_agreement":null},{"id":"W4382795765","doi":"10.1007/s40273-023-01293-4","title":"Cost-Effectiveness of Emerging Treatments for Atopic Dermatitis: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; EconLit; Health economics; Dupilumab; Cost effectiveness; Atopic dermatitis; Systematic review; MEDLINE; Health care; Economic evaluation; Health technology; Health administration; Cochrane Library; Family medicine; Public health; Randomized controlled trial; Nursing; Surgery; Dermatology; Political science","score_opus":0.1403825494111308,"score_gpt":0.466394680152419,"score_spread":0.3260121307412882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382795765","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018260995,0.9965423,0.0001750037,0.00031233268,0.0000879963,0.00027223077,0.00046255995,0.0000058992027,0.0003154883],"genre_scores_gemma":[0.04606719,0.9510806,0.0010308891,0.00049380003,0.00013128064,0.0006998537,0.00038771398,0.000007308202,0.00010128292],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98235023,0.008229267,0.005016272,0.0008779814,0.0031417026,0.00038450785],"domain_scores_gemma":[0.9411197,0.046373207,0.00848993,0.00050858076,0.0031584115,0.000350248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015282362,0.0016985438,0.00899279,0.012099046,0.0005579154,0.0033052235,0.0017241226,0.0019248364,0.0049156575],"category_scores_gemma":[0.06295757,0.000985405,0.013119536,0.0102899615,0.0007933877,0.0025717865,0.0013885583,0.0016840341,0.00021595375],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007232088,0.00003724674,0.0013016915,0.9305167,0.02953773,0.000112576825,0.0000814904,0.00029426225,0.00008114918,0.0003676388,0.0009970564,0.035949185],"study_design_scores_gemma":[0.0010780145,0.0004884569,0.0075945584,0.7732102,0.20530462,0.00053226785,0.00024524945,0.0003928591,0.00020106061,0.00080372527,0.010097235,0.000051700496],"about_ca_topic_score_codex":0.006022228,"about_ca_topic_score_gemma":0.015442536,"teacher_disagreement_score":0.015282362,"about_ca_system_score_codex":0.0058415616,"about_ca_system_score_gemma":0.008478622,"threshold_uncertainty_score":0.08082181},"labels":[],"label_agreement":null},{"id":"W4384626521","doi":"10.1007/s40273-023-01296-1","title":"Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact; McMaster University Medical Centre","funders":"","keywords":"Medicine; WOMAC; Health economics; Indirect costs; MEDLINE; Systematic review; Osteoarthritis; Sample size determination; Sample (material); Quality of life (healthcare); Quality of Life Research; Public health; Alternative medicine; Accounting; Statistics; Pathology","score_opus":0.0733953867695345,"score_gpt":0.4112069541592986,"score_spread":0.3378115673897641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384626521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017229281,0.99659544,0.0001501249,0.00020595513,0.00011299809,0.000106075975,0.0009623711,0.000007969041,0.00013612336],"genre_scores_gemma":[0.029582376,0.96796733,0.00076294894,0.0006747972,0.000114378774,0.00021282253,0.0005855202,0.000009627007,0.00009035999],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98915625,0.0032421413,0.004771428,0.0008377204,0.0017263835,0.00026604588],"domain_scores_gemma":[0.9671691,0.022440864,0.0070656687,0.0007057321,0.0023156859,0.0003029382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013599678,0.0016895939,0.011066831,0.010140315,0.00047121977,0.0028803756,0.0014098703,0.0016318408,0.0036470816],"category_scores_gemma":[0.046077445,0.0012798004,0.0137310745,0.011440008,0.0008738484,0.0021840816,0.0023767054,0.0014262776,0.00026041674],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008439378,0.000020604837,0.0050564255,0.81584245,0.13752773,0.00012971714,0.00014014055,0.00018852668,0.00018209155,0.0002145518,0.002086423,0.03776741],"study_design_scores_gemma":[0.0012483165,0.00020729123,0.027000934,0.29382944,0.6609877,0.0005815304,0.00027417886,0.00015017395,0.00015084642,0.0006037846,0.014863302,0.0001025268],"about_ca_topic_score_codex":0.012610275,"about_ca_topic_score_gemma":0.042542376,"teacher_disagreement_score":0.013599678,"about_ca_system_score_codex":0.0028942146,"about_ca_system_score_gemma":0.0076781916,"threshold_uncertainty_score":0.07192284},"labels":[],"label_agreement":null},{"id":"W4384627184","doi":"10.1007/s40273-023-01294-3","title":"Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Haukeland Universitetssjukehus; Norges Forskningsråd; Universitetet i Bergen","keywords":"Medicine; Cost effectiveness; Dosing; Regimen; Economic evaluation; Disease burden; Quality-adjusted life year; Health economics; Pediatrics; Sickle cell anemia; Anemia; Public health; Disease; Internal medicine","score_opus":0.0418944135521632,"score_gpt":0.3783064997852639,"score_spread":0.3364120862331007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384627184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97774065,0.0018351203,0.010719542,0.0010865787,0.00008870072,0.0007582038,0.0015810918,0.00008575731,0.006104328],"genre_scores_gemma":[0.99377716,0.00042762607,0.0041655893,0.00011475506,0.000013861844,0.0003558664,0.00030209176,0.000013378413,0.00082970446],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99804544,0.0013624369,0.000060405095,0.00015978739,0.00009653811,0.0002753461],"domain_scores_gemma":[0.9797838,0.017629942,0.0010935724,0.00023960022,0.0006792878,0.00057379995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005327357,0.001983083,0.002606787,0.0017430998,0.0007884203,0.0022083665,0.0026452849,0.002839901,0.0064395852],"category_scores_gemma":[0.017462429,0.001039723,0.0039374116,0.001378912,0.0010803203,0.0016780237,0.0012583499,0.002551677,0.00021235013],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018432073,0.0004459692,0.0028179751,0.00017912702,0.00030282466,0.000107658656,0.000030010191,0.99036634,0.00013904842,0.0012075922,0.00023990335,0.0023203087],"study_design_scores_gemma":[0.0014032074,0.0017181664,0.0023994308,0.000102508675,0.0006567788,0.000075366115,0.0000989988,0.991413,0.00022996584,0.0015155334,0.00034509783,0.00004196669],"about_ca_topic_score_codex":0.034460973,"about_ca_topic_score_gemma":0.013912167,"teacher_disagreement_score":0.034460973,"about_ca_system_score_codex":0.006497811,"about_ca_system_score_gemma":0.004661338,"threshold_uncertainty_score":0.068520725},"labels":[],"label_agreement":null},{"id":"W4385968941","doi":"10.1007/s40273-023-01308-0","title":"Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; Alberta Bone and Joint Health Institute; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Socioeconomic status; Health economics; Psychological intervention; Indirect costs; Economic cost; Medicine; Government (linguistics); Health care; Disease burden; Economic evaluation; Health administration; Public health; Economic impact analysis; Cost–benefit analysis; Environmental health; Business; Economic growth; Economics; Psychiatry; Population; Nursing; Political science; Pathology","score_opus":0.10651673489686381,"score_gpt":0.44336325701213886,"score_spread":0.33684652211527505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385968941","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022259062,0.9978909,0.0001339021,0.0011337299,0.00011720488,0.000021488646,0.00020790748,0.0000020718303,0.0002701522],"genre_scores_gemma":[0.0056496942,0.9930305,0.00045157567,0.0004971823,0.00013163922,0.000060299066,0.00012936842,0.0000032560922,0.000046642323],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9870248,0.006789588,0.002824551,0.00068008027,0.0022402743,0.00044070985],"domain_scores_gemma":[0.9329852,0.05813164,0.0050689587,0.0005744422,0.0029247545,0.00031491337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024764659,0.0020244757,0.007933838,0.008894991,0.00046132298,0.0050209067,0.0025632982,0.0028811428,0.005809485],"category_scores_gemma":[0.08872957,0.00091163383,0.005751441,0.01215571,0.0011697704,0.004232421,0.0022689688,0.0025803677,0.000357839],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008830715,0.00008748513,0.0032079644,0.41035444,0.022963794,0.00015600999,0.00016686841,0.0016149676,0.00011818432,0.009748097,0.011585003,0.53911406],"study_design_scores_gemma":[0.00042372354,0.00020506079,0.0076356996,0.83939254,0.04105665,0.00053693523,0.0004529102,0.00087335706,0.00020467589,0.011637606,0.09748472,0.00009601468],"about_ca_topic_score_codex":0.01105997,"about_ca_topic_score_gemma":0.015113697,"teacher_disagreement_score":0.024764659,"about_ca_system_score_codex":0.0052431994,"about_ca_system_score_gemma":0.00926674,"threshold_uncertainty_score":0.13096958},"labels":[],"label_agreement":null},{"id":"W4385997350","doi":"10.1007/s40273-023-01309-z","title":"Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Western University","funders":"Canadian Institutes of Health Research","keywords":"Warfarin; Apixaban; Rivaroxaban; Medicine; Pharmacogenomics; Atrial fibrillation; Quality-adjusted life year; Cost-effectiveness analysis; Cost effectiveness; Internal medicine; Pharmacology; Risk analysis (engineering)","score_opus":0.17157161540634408,"score_gpt":0.43830788094396717,"score_spread":0.2667362655376231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385997350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766285,0.008474613,0.00042373186,0.0025089881,0.00009165793,0.0008130711,0.0058177463,0.000032847434,0.005208836],"genre_scores_gemma":[0.9951486,0.0018714162,0.00046871597,0.0003315564,0.000028349557,0.000098921744,0.0011492384,0.0000048365914,0.0008982515],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9975618,0.00084328634,0.00018439884,0.00018447766,0.00061066105,0.00061529095],"domain_scores_gemma":[0.99558985,0.0012618614,0.0009118961,0.00007891965,0.0009769149,0.0011806306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016558542,0.0006504652,0.0012165693,0.0009333743,0.00084207166,0.0014857817,0.0015086677,0.00084279047,0.0032005585],"category_scores_gemma":[0.008176092,0.0005793196,0.0026341898,0.0023564748,0.00075580995,0.0004649211,0.0008276417,0.0010936445,0.00009028797],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10525284,0.0042562513,0.6014078,0.0060028434,0.016016848,0.0011928827,0.0008327782,0.1253584,0.0019839946,0.0059551606,0.02659756,0.10514255],"study_design_scores_gemma":[0.021821752,0.0069437665,0.8697716,0.0010007634,0.01054728,0.00047995037,0.0013754482,0.08010866,0.0005277743,0.0008217489,0.006384769,0.00021640176],"about_ca_topic_score_codex":0.9809729,"about_ca_topic_score_gemma":0.9848769,"teacher_disagreement_score":0.103855684,"about_ca_system_score_codex":0.103855684,"about_ca_system_score_gemma":0.06776657,"threshold_uncertainty_score":0.75352925},"labels":[],"label_agreement":null},{"id":"W4387033463","doi":"10.1007/s40273-023-01318-y","title":"Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; University of Toronto; McMaster University","funders":"","keywords":"Deep brain stimulation; Medicine; Meta-analysis; Movement disorders; Economic evaluation; Quality-adjusted life year; Population; Systematic review; MEDLINE; Physical medicine and rehabilitation; Cost effectiveness; Physical therapy; Disease; Parkinson's disease; Internal medicine; Pathology","score_opus":0.3161301884010959,"score_gpt":0.514219521678214,"score_spread":0.19808933327711814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387033463","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018122105,0.9783301,0.0012854134,0.00039000076,0.00033817158,0.00033533102,0.00064038154,0.00003179166,0.00052676897],"genre_scores_gemma":[0.4207789,0.5720102,0.0032790862,0.0011199884,0.00035514767,0.000820583,0.0008974278,0.000048656082,0.0006899591],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99314874,0.004491646,0.0011312282,0.00042785867,0.0005425798,0.0002579719],"domain_scores_gemma":[0.9886091,0.009368266,0.0012595883,0.00026797678,0.00035204866,0.00014309879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010990067,0.0025543214,0.012309769,0.002442146,0.0002874876,0.0021458655,0.0013506383,0.0015842331,0.0047957157],"category_scores_gemma":[0.021587145,0.0010885384,0.025787607,0.0028216345,0.0005567712,0.0011286745,0.0011614563,0.0027207045,0.00024118656],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023573307,0.00011281719,0.0015822386,0.12995575,0.8174779,0.00009188152,0.00003975665,0.00142844,0.00021261894,0.0003381164,0.00072055764,0.024466645],"study_design_scores_gemma":[0.009778806,0.0007489931,0.002683451,0.010655993,0.973118,0.00007779732,0.000044553515,0.00062015495,0.00013132674,0.00063417223,0.001474975,0.000031731255],"about_ca_topic_score_codex":0.005792676,"about_ca_topic_score_gemma":0.009937314,"teacher_disagreement_score":0.012309769,"about_ca_system_score_codex":0.0026680504,"about_ca_system_score_gemma":0.0017405056,"threshold_uncertainty_score":0.05812174},"labels":[],"label_agreement":null},{"id":"W4388541047","doi":"10.1007/s40273-023-01331-1","title":"A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mental Health Research Canada; Institute for Clinical Evaluative Sciences; University of Toronto; SickKids Foundation; Public Health Ontario; Hospital for Sick Children","funders":"Hospital for Sick Children; Canada Excellence Research Chairs, Government of Canada","keywords":"Spillover effect; CINAHL; Medicine; Meta-analysis; MEDLINE; Systematic review; Actuarial science; Psychological intervention; Business; Economics; Psychiatry; Political science","score_opus":0.6886712454235581,"score_gpt":0.6439042946604315,"score_spread":0.044766950763126534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388541047","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000548989,0.9894657,0.0028239582,0.0007040589,0.00022820265,0.0036322868,0.0013832449,0.00003781226,0.0011756768],"genre_scores_gemma":[0.015631977,0.9557911,0.01385203,0.00096996425,0.0001474315,0.0124362325,0.0008159381,0.000045151035,0.00031012873],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.8924328,0.06296899,0.028689126,0.0030805226,0.011932393,0.00089615834],"domain_scores_gemma":[0.7161776,0.24678735,0.019478902,0.0037747747,0.013189305,0.0005919917],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.07142977,0.003603351,0.011738054,0.027185695,0.0012874716,0.0064875716,0.004350721,0.003113522,0.011073706],"category_scores_gemma":[0.28752986,0.0020072334,0.022219999,0.025633005,0.0015852246,0.004867163,0.003392634,0.0036343026,0.0008347696],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002584209,0.000022945478,0.0005986043,0.8862971,0.014519918,0.00008727334,0.00027892337,0.00058535027,0.00005137963,0.001554311,0.0020658753,0.09367998],"study_design_scores_gemma":[0.00026203613,0.00012946999,0.0014842668,0.9318992,0.04193189,0.00017082851,0.00019671977,0.00038324308,0.00012409622,0.0013270837,0.022038858,0.00005234104],"about_ca_topic_score_codex":0.014430331,"about_ca_topic_score_gemma":0.030955384,"teacher_disagreement_score":0.9285702,"about_ca_system_score_codex":0.01451839,"about_ca_system_score_gemma":0.030939111,"threshold_uncertainty_score":0.37776124},"labels":[],"label_agreement":null},{"id":"W4388902252","doi":"10.1007/s40273-023-01334-y","title":"Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Geomechanica (Canada)","funders":"Bristol-Myers Squibb","keywords":"Health technology; Relevance (law); Risk analysis (engineering); Health economics; Surrogate endpoint; Psychological intervention; Valuation (finance); Medicine; Actuarial science; Health care; Business; Economics; Public health; Political science; Nursing","score_opus":0.6501982156129451,"score_gpt":0.543712539937482,"score_spread":0.10648567567546308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388902252","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019772416,0.049510594,0.37607613,0.5253332,0.0026453983,0.00050810707,0.0005565936,0.00013885715,0.025458744],"genre_scores_gemma":[0.6835392,0.024118379,0.24028783,0.039562915,0.008892994,0.0011511963,0.00030155247,0.00021986938,0.001926011],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.60703945,0.3440412,0.014769765,0.0061252317,0.026168738,0.0018554945],"domain_scores_gemma":[0.14216834,0.8035292,0.015266932,0.023142785,0.011918845,0.0039739124],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.38034263,0.0021036381,0.006210279,0.007330571,0.002420445,0.024639672,0.007270669,0.019511087,0.00814836],"category_scores_gemma":[0.7248473,0.001675089,0.0027477643,0.0065939715,0.034508016,0.04036708,0.014748134,0.025759991,0.00090750644],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007015453,0.00022483246,0.0125678945,0.0015149288,0.0008921508,0.0006063429,0.0017475612,0.008240139,0.00016398205,0.7667581,0.009147467,0.19743504],"study_design_scores_gemma":[0.000117527554,0.000090513466,0.00065561803,0.0017578652,0.00012926318,0.00028168887,0.00022935586,0.0069988826,0.0001149081,0.9844157,0.005151413,0.000057236197],"about_ca_topic_score_codex":0.002029707,"about_ca_topic_score_gemma":0.0018696826,"teacher_disagreement_score":0.6196574,"about_ca_system_score_codex":0.0062788157,"about_ca_system_score_gemma":0.013895792,"threshold_uncertainty_score":0.7641479},"labels":[],"label_agreement":null},{"id":"W4389272687","doi":"10.1007/s40273-023-01321-3","title":"Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Irish Research Council; University of Galway; National Institute for Health and Care Research; Health Service Executive; Harvard T.H. Chan School of Public Health; Tufts Medical Center","keywords":"Health economics; Quality of Life Research; Psychological intervention; Task force; Task (project management); Public health; Health administration; Public economics; Relation (database); Health care; Psychology; Medicine; Business; Economics; Political science; Economic growth; Nursing; Management; Computer science; Psychiatry; Public administration","score_opus":0.41454006501719176,"score_gpt":0.5650736797024618,"score_spread":0.15053361468527005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389272687","genre_codex":"commentary","genre_gemma":"methods","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030342962,0.15465778,0.078038484,0.6774451,0.030646691,0.040532578,0.002842566,0.0014567989,0.011345664],"genre_scores_gemma":[0.025557477,0.09359561,0.64541847,0.12582539,0.0041717268,0.09690881,0.0028670272,0.0010937948,0.004561779],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.21035247,0.5187431,0.1677256,0.014095439,0.07888359,0.010199758],"domain_scores_gemma":[0.06490184,0.6747263,0.05372168,0.037203826,0.15807287,0.011373508],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.78613997,0.0062723327,0.016273452,0.028014518,0.010076361,0.035015173,0.024670085,0.053255472,0.0078083114],"category_scores_gemma":[0.84208876,0.008085381,0.030863335,0.027424613,0.023038508,0.034199014,0.029431466,0.05013089,0.0055941595],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008750544,0.00083711237,0.0032656277,0.15924677,0.0022274342,0.00079898315,0.026847364,0.0036480217,0.0012763508,0.052231483,0.26278818,0.48595762],"study_design_scores_gemma":[0.0010540838,0.00054343685,0.0038249143,0.60479915,0.00259977,0.00040699582,0.012221172,0.00282194,0.0015133523,0.061293527,0.30819443,0.00072712294],"about_ca_topic_score_codex":0.022107186,"about_ca_topic_score_gemma":0.024520274,"teacher_disagreement_score":0.21386003,"about_ca_system_score_codex":0.04536425,"about_ca_system_score_gemma":0.21294688,"threshold_uncertainty_score":0.32914215},"labels":[],"label_agreement":null},{"id":"W4389477446","doi":"10.1007/s40273-023-01325-z","title":"A Framework for the Fair Pricing of Medicines","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Economic surplus; Health economics; Incentive; Public economics; Health care; Willingness to pay; Marginal cost; Economics; Public health; Population; Fair value; Health administration; Population health; Actuarial science; Business; Welfare; Microeconomics; Medicine; Finance; Economic growth","score_opus":0.4724225739610756,"score_gpt":0.5252047214042598,"score_spread":0.05278214744318416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389477446","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027426605,0.0032520532,0.81102365,0.031516038,0.0010531839,0.00043411806,0.00025544007,0.00016933885,0.14955355],"genre_scores_gemma":[0.324059,0.004953862,0.63305247,0.0073145265,0.0028430906,0.0019028138,0.00024068562,0.00024950167,0.025384083],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9768869,0.013068793,0.00079113,0.0016094914,0.0064541954,0.0011895243],"domain_scores_gemma":[0.9875415,0.00716887,0.0007536905,0.0016195737,0.0022997258,0.00061659794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.032225106,0.0020563966,0.0021262264,0.0030219117,0.0038236354,0.011722543,0.0065728375,0.011456921,0.0101177385],"category_scores_gemma":[0.033802524,0.0012583175,0.002507737,0.0024636632,0.015132654,0.012893767,0.0059029073,0.010500074,0.0018287871],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003487147,0.000007037248,0.000011187512,0.000014220729,0.0000033596193,0.0000136297585,0.00003628856,0.0028099131,0.00002053053,0.99449414,0.0009806363,0.0016055808],"study_design_scores_gemma":[0.000017985018,0.00001192592,0.000029184212,0.000056425222,0.0000058055152,0.000020432492,0.000029651459,0.006384871,0.000036686914,0.97933257,0.0140622975,0.000012219241],"about_ca_topic_score_codex":0.00867971,"about_ca_topic_score_gemma":0.007057417,"teacher_disagreement_score":0.032225106,"about_ca_system_score_codex":0.010873298,"about_ca_system_score_gemma":0.015534202,"threshold_uncertainty_score":0.17042464},"labels":[],"label_agreement":null},{"id":"W4390267034","doi":"10.1007/s40273-023-01345-9","title":"An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Cost effectiveness; Cost-effectiveness analysis; Health care; Health administration; Quality-adjusted life year; Cancer screening; Breast cancer screening; Breast cancer; Public health; Cancer; Internal medicine; Mammography","score_opus":0.07472670987217402,"score_gpt":0.3515686772154051,"score_spread":0.2768419673432311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390267034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893421,0.0027714872,0.00020145958,0.0008319975,0.000041525826,0.0004889498,0.0034519308,0.00001523775,0.002855278],"genre_scores_gemma":[0.99702007,0.00075755076,0.00035453276,0.00022437761,0.000016364178,0.000080286336,0.00084127893,0.0000060459593,0.0006994373],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9954521,0.0015538422,0.0002790906,0.0003346881,0.00096306327,0.0014172079],"domain_scores_gemma":[0.99175996,0.0031741548,0.001475884,0.00022027547,0.0017214285,0.0016484464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023828435,0.0007841711,0.0013276032,0.0010234817,0.0018588868,0.0018165818,0.0019644697,0.0010442521,0.0034706858],"category_scores_gemma":[0.013476895,0.00062323385,0.0033105544,0.0033038745,0.0012727955,0.0005027808,0.0009689332,0.0012780349,0.000114892166],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08420901,0.0041048722,0.80325913,0.0027458936,0.0075972597,0.00078322616,0.0010599737,0.03260153,0.0013389513,0.002629008,0.007660432,0.05201062],"study_design_scores_gemma":[0.0061939745,0.00819941,0.9525989,0.0003927138,0.004728845,0.00022478822,0.0019218632,0.022519516,0.00040800622,0.00034712275,0.002320449,0.00014436843],"about_ca_topic_score_codex":0.9890592,"about_ca_topic_score_gemma":0.99109966,"teacher_disagreement_score":0.10375965,"about_ca_system_score_codex":0.10375965,"about_ca_system_score_gemma":0.08334812,"threshold_uncertainty_score":0.7528324},"labels":[],"label_agreement":null},{"id":"W4390973218","doi":"10.1007/s40273-023-01348-6","title":"Making Decision Models Fit for Purpose: The Importance of Ensuring Stakeholder Involvement","year":2024,"lang":"en","type":"editorial","venue":"PharmacoEconomics","topic":"Complex Systems and Decision Making","field":"Decision Sciences","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stornoway Diamond (Canada); University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Stakeholder; Public health; Business; Stakeholder engagement; Health services research; Process management; Management science; Environmental resource management; Medicine; Economics; Public relations; Political science; Nursing","score_opus":0.4173727128217211,"score_gpt":0.4740352929066522,"score_spread":0.05666258008493108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390973218","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047056757,0.0090632085,0.0016660119,0.11560594,0.87211,0.000034434812,0.00006964274,0.00006848559,0.0013352674],"genre_scores_gemma":[0.0017791947,0.00966572,0.0023744188,0.038738545,0.94319206,0.00009284893,0.000037774353,0.00011179146,0.0040076138],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.96402353,0.016465347,0.003909427,0.0020616082,0.012766328,0.0007737252],"domain_scores_gemma":[0.6173349,0.30513585,0.0076545966,0.006045986,0.05586407,0.007964559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04871539,0.00395284,0.004850404,0.0041634636,0.004860913,0.01849223,0.0064623784,0.03284066,0.008993194],"category_scores_gemma":[0.20674743,0.0017689066,0.0030315926,0.0027893547,0.009364007,0.009069908,0.0030047258,0.04382718,0.0059885983],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023414546,0.00001674221,0.000025541898,0.00064138515,0.00006612579,0.00008714747,0.00008234779,0.00018743047,0.000045576933,0.0031582776,0.9855253,0.010140782],"study_design_scores_gemma":[0.0001040882,0.00003248097,0.0001799435,0.0023147902,0.00013757816,0.00023502631,0.00023879188,0.0016443031,0.00019645724,0.034851313,0.9599771,0.00008826381],"about_ca_topic_score_codex":0.0033515142,"about_ca_topic_score_gemma":0.008911624,"teacher_disagreement_score":0.04871539,"about_ca_system_score_codex":0.0054135816,"about_ca_system_score_gemma":0.011390449,"threshold_uncertainty_score":0.2576347},"labels":[],"label_agreement":null},{"id":"W4391786302","doi":"10.1007/s40273-024-01357-z","title":"Exploring the Use of Pictorial Approaches in the Development of Paediatric Patient-Reported Outcome Instruments: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Pediatric Pain Management Techniques","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"EuroQol Research Foundation; Flinders University; University of Technology Sydney; Australian Government","keywords":"Patient-reported outcome; Context (archaeology); Inclusion (mineral); Likert scale; Quality of life (healthcare); Systematic review; Medicine; Quality of Life Research; MEDLINE; Psychology; Medical education; Family medicine; Nursing; Public health; Developmental psychology; Social psychology","score_opus":0.4874934670233488,"score_gpt":0.3950674980723151,"score_spread":0.09242596895103367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391786302","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009913011,0.9961611,0.0005118048,0.00030201694,0.000104095234,0.001110193,0.00045070745,0.000015241843,0.00035341972],"genre_scores_gemma":[0.015803747,0.9779326,0.0026036212,0.00056280306,0.00007578903,0.0026232572,0.00028896943,0.000009828152,0.00009933373],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9735478,0.012190626,0.0084960265,0.0012761145,0.0041256724,0.00036372695],"domain_scores_gemma":[0.90658396,0.07276161,0.013867419,0.0013642304,0.0050797546,0.00034301443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02305739,0.0016822274,0.007324224,0.0150389625,0.00075324194,0.0040357136,0.002233882,0.0020344171,0.005398849],"category_scores_gemma":[0.1082123,0.0011230438,0.010461032,0.014800717,0.001369945,0.0045472514,0.0022164972,0.001567723,0.0004740926],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014412374,0.000017246777,0.0005002462,0.9484817,0.0043685273,0.0000443429,0.0002004566,0.00008161697,0.00007652631,0.0002802932,0.00076976063,0.04503516],"study_design_scores_gemma":[0.0001931576,0.00016332915,0.001992948,0.95607567,0.030206377,0.00017012093,0.00025143105,0.0001090006,0.00013764662,0.0003118891,0.010353486,0.00003500333],"about_ca_topic_score_codex":0.0056322915,"about_ca_topic_score_gemma":0.015827613,"teacher_disagreement_score":0.02305739,"about_ca_system_score_codex":0.0043005436,"about_ca_system_score_gemma":0.014092901,"threshold_uncertainty_score":0.12194055},"labels":[],"label_agreement":null},{"id":"W4392739550","doi":"10.1007/s40273-024-01369-9","title":"Reply to Comment on “A Framework for Fair Pricing of Medicines”","year":2024,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Business; Actuarial science; Economics; Medicine; Nursing","score_opus":0.08685281343077769,"score_gpt":0.36353599715388063,"score_spread":0.27668318372310297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392739550","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032263112,0.00042696824,0.00016129794,0.9860606,0.009095509,0.00002512856,0.0001572737,0.0000274535,0.003723096],"genre_scores_gemma":[0.0010863229,0.00008410098,0.000094607516,0.9895968,0.004667312,0.00003999941,0.000018524412,0.00001555215,0.0043967287],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9809833,0.004163516,0.0022562998,0.0023833744,0.005619088,0.004594398],"domain_scores_gemma":[0.96705306,0.021365533,0.0018665906,0.0008585514,0.005471979,0.00338421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018659646,0.0016160666,0.003396803,0.0016418885,0.010392585,0.012338442,0.007011427,0.2072659,0.012204648],"category_scores_gemma":[0.071641065,0.002421379,0.0038723052,0.0020956963,0.00797105,0.0077862814,0.0051283226,0.09884879,0.008457123],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000080731064,0.000023856252,0.00029664268,0.000049445727,0.00003078617,0.0004419883,0.00026387093,0.00009346133,0.00010465075,0.009603019,0.98729634,0.001715234],"study_design_scores_gemma":[0.00031848118,0.0000696318,0.002760186,0.0006790611,0.00014027135,0.00039851738,0.0011313498,0.0010120779,0.00043102825,0.03459818,0.9581985,0.00026281725],"about_ca_topic_score_codex":0.05512546,"about_ca_topic_score_gemma":0.08288415,"teacher_disagreement_score":0.2072659,"about_ca_system_score_codex":0.015032438,"about_ca_system_score_gemma":0.020509342,"threshold_uncertainty_score":0.109609246},"labels":[],"label_agreement":null},{"id":"W4394063337","doi":"10.1007/s40273-024-01372-0","title":"Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Public Health Ontario; Hospital for Sick Children","funders":"Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs","keywords":"Value of information; Context (archaeology); Computer science; Risk analysis (engineering); Management science; Research design; Decision analysis; Health economics; Data science; Medicine; Public health; Artificial intelligence; Engineering; Mathematics; Statistics","score_opus":0.6583874461216297,"score_gpt":0.5621874695543043,"score_spread":0.09619997656732537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394063337","genre_codex":"methods","genre_gemma":"methods","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011428883,0.03034386,0.8840431,0.04341264,0.0022830882,0.0064924387,0.0014955697,0.00037145132,0.020129],"genre_scores_gemma":[0.37587717,0.008475082,0.5846087,0.0115436865,0.002421794,0.014657931,0.0008273117,0.00027498638,0.0013133901],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.29469052,0.6375514,0.026395079,0.00890338,0.030726984,0.0017325789],"domain_scores_gemma":[0.10891267,0.8418359,0.018420696,0.020767206,0.0088955695,0.0011679415],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.5020451,0.0035308697,0.012017322,0.010683632,0.0023470928,0.016862635,0.005896243,0.013005125,0.0067540426],"category_scores_gemma":[0.7950651,0.0028479917,0.007414193,0.010469501,0.009971112,0.022869369,0.008153799,0.013743109,0.0010242772],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006760789,0.00042220773,0.008848983,0.013473963,0.0071087796,0.00044290855,0.0025020863,0.042567343,0.0005058138,0.4436559,0.011109804,0.46260142],"study_design_scores_gemma":[0.0017150178,0.0013760377,0.0025765104,0.00907392,0.002549319,0.00036467976,0.0003130178,0.051098224,0.0008507765,0.9093612,0.02039693,0.0003242397],"about_ca_topic_score_codex":0.0024089175,"about_ca_topic_score_gemma":0.0016524611,"teacher_disagreement_score":0.4979549,"about_ca_system_score_codex":0.009835041,"about_ca_system_score_gemma":0.016064836,"threshold_uncertainty_score":0.6140671},"labels":[],"label_agreement":null},{"id":"W4394751671","doi":"10.1007/s40273-024-01374-y","title":"Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Focus group; Facilitator; Health technology; Knowledge management; Incentive; Standardization; Process management; Public relations; Business; Medicine; Health care; Computer science; Psychology; Political science; Marketing","score_opus":0.33840827808757995,"score_gpt":0.5143683553736645,"score_spread":0.1759600772860846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394751671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.745542,0.0043406193,0.18143512,0.020676082,0.00037599966,0.0067120944,0.0014313911,0.0013124028,0.03817439],"genre_scores_gemma":[0.8867396,0.0011367776,0.09791642,0.002758818,0.00015473228,0.006727295,0.00046079466,0.0011606038,0.0029449542],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.50638103,0.42348495,0.024602465,0.009912496,0.029839575,0.0057795346],"domain_scores_gemma":[0.040133834,0.9233103,0.008198944,0.012006754,0.015536308,0.00081380294],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.43341175,0.0012945548,0.001542625,0.0023472602,0.002611819,0.004295517,0.0033322936,0.0023643384,0.0057257195],"category_scores_gemma":[0.77377725,0.0013091168,0.0033140604,0.0029325765,0.0027697617,0.007717708,0.007969874,0.0055952948,0.0016719525],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00749669,0.0024759565,0.17676225,0.009774396,0.0018580345,0.0015335131,0.2299262,0.0090005975,0.008171136,0.026283551,0.014979409,0.5117382],"study_design_scores_gemma":[0.002139055,0.009081087,0.43866122,0.02110366,0.0061883293,0.0037355404,0.14880659,0.108837105,0.03783012,0.08169528,0.14058918,0.0013328337],"about_ca_topic_score_codex":0.010366463,"about_ca_topic_score_gemma":0.012075018,"teacher_disagreement_score":0.5665883,"about_ca_system_score_codex":0.0031463816,"about_ca_system_score_gemma":0.0089176735,"threshold_uncertainty_score":0.69870424},"labels":[],"label_agreement":null},{"id":"W4396769645","doi":"10.1007/s40273-024-01383-x","title":"Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"EuroQol Research Foundation; Flinders University; University of Technology Sydney; Australian Government","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Quality of life (healthcare); Preference; Quality-adjusted life year; Health related quality of life; Medicine; Environmental health; Statistics; Nursing; Cost effectiveness; Mathematics; Risk analysis (engineering); Internal medicine","score_opus":0.574580267070628,"score_gpt":0.46145077725317746,"score_spread":0.11312948981745058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396769645","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5422817,0.035725776,0.3058819,0.08996194,0.001429322,0.0004499848,0.008495021,0.0001364383,0.015638033],"genre_scores_gemma":[0.93968475,0.004024019,0.051439304,0.0025284372,0.00043526865,0.00043544284,0.00093193667,0.000058620866,0.0004622205],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9085107,0.074697524,0.0058461493,0.0031285498,0.006807597,0.0010094864],"domain_scores_gemma":[0.72945863,0.22028396,0.023059128,0.010685179,0.014461756,0.0020513018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1277838,0.00068682997,0.0021639955,0.002274589,0.00069039874,0.004337052,0.0025051225,0.0016310968,0.0010837194],"category_scores_gemma":[0.27863297,0.0006600863,0.0009734812,0.0065569244,0.0017410832,0.0039930255,0.0032243028,0.004830377,0.00017280324],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074878824,0.00030642966,0.48443925,0.0019527201,0.004814529,0.00022053524,0.0025681525,0.021689825,0.0005715447,0.08702744,0.017545283,0.3781155],"study_design_scores_gemma":[0.00026935153,0.0011677624,0.46737775,0.003996599,0.0013218337,0.0014240451,0.006329478,0.098833814,0.0028931603,0.3697638,0.046266336,0.00035610158],"about_ca_topic_score_codex":0.017177224,"about_ca_topic_score_gemma":0.021588016,"teacher_disagreement_score":0.1277838,"about_ca_system_score_codex":0.0029074717,"about_ca_system_score_gemma":0.003598925,"threshold_uncertainty_score":0.6757934},"labels":[],"label_agreement":null},{"id":"W4399232927","doi":"10.1007/s40273-024-01397-5","title":"A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses","year":2024,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mental Health Research Canada; Institute for Clinical Evaluative Sciences; University of Toronto; SickKids Foundation; Public Health Ontario; Hospital for Sick Children","funders":"Sickkids Research Institute; Canada Excellence Research Chairs, Government of Canada","keywords":"Health economics; Quality of Life Research; Spillover effect; Public health; Health administration; Medicine; Systematic review; Environmental health; Public economics; Actuarial science; MEDLINE; Economics; Nursing; Political science","score_opus":0.513144724203133,"score_gpt":0.6380443423790316,"score_spread":0.12489961817589867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399232927","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004881178,0.98394173,0.0050582066,0.0018935237,0.0005252397,0.00533767,0.0014116986,0.000060724356,0.0012831689],"genre_scores_gemma":[0.010073538,0.94448036,0.027908947,0.0014613678,0.00019308357,0.014861948,0.00067208684,0.000038913873,0.0003097522],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.8667735,0.06989964,0.0434965,0.003814818,0.015087974,0.000927502],"domain_scores_gemma":[0.6960537,0.24873719,0.02680707,0.0056052343,0.02185107,0.0009457859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10136336,0.00336493,0.011811339,0.03479691,0.0017632374,0.007389207,0.005804854,0.004482006,0.0076899906],"category_scores_gemma":[0.35558432,0.0023459073,0.015977487,0.031207712,0.0024390346,0.0076327403,0.00421565,0.00376364,0.00086899137],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001304643,0.000019593761,0.00045697956,0.88916606,0.008159682,0.00008839677,0.0004558835,0.000520205,0.00006550173,0.0028636446,0.00435407,0.0937194],"study_design_scores_gemma":[0.0001231442,0.000047070433,0.0005521195,0.96420026,0.01608743,0.00008822138,0.00014266543,0.0002530338,0.00006459057,0.001351827,0.017052945,0.000036738427],"about_ca_topic_score_codex":0.020238047,"about_ca_topic_score_gemma":0.053005934,"teacher_disagreement_score":0.10136336,"about_ca_system_score_codex":0.019478912,"about_ca_system_score_gemma":0.05760712,"threshold_uncertainty_score":0.5360671},"labels":[],"label_agreement":null},{"id":"W4401010505","doi":"10.1007/s40273-024-01413-8","title":"Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer","year":2024,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Enterprise Ireland","keywords":"Quality of Life Research; Health economics; Medicine; Cancer; Pharmacoeconomics; Intensive care medicine; Health administration; Public health; Internal medicine; Pathology","score_opus":0.07880618533681719,"score_gpt":0.46942738858019645,"score_spread":0.39062120324337923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401010505","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018729762,0.99218595,0.00063129084,0.0005965868,0.00024491394,0.0015760087,0.0018395043,0.000022281078,0.001030461],"genre_scores_gemma":[0.04595874,0.944627,0.0025443085,0.00088416407,0.00017509378,0.0044497033,0.0010190695,0.00002422964,0.00031765632],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.95635027,0.02531685,0.011134195,0.0013812934,0.0051074405,0.0007099583],"domain_scores_gemma":[0.9061009,0.07406827,0.012672549,0.0011874217,0.005422774,0.00054810476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027216477,0.002808856,0.014687229,0.016547518,0.0008780947,0.0043773777,0.0025520434,0.0026083111,0.0073372433],"category_scores_gemma":[0.13583426,0.0013615243,0.0142546715,0.013991109,0.0013409985,0.0027294506,0.0022569622,0.0024728654,0.00040624844],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045727816,0.000014946247,0.00031536687,0.9580011,0.01944051,0.0000750233,0.00006597783,0.00034283943,0.000052997133,0.0004531417,0.0011317857,0.019648999],"study_design_scores_gemma":[0.0008994347,0.0003188934,0.002406451,0.86450756,0.116244085,0.00023732647,0.0001677492,0.00038778837,0.0001850565,0.0010509236,0.013548103,0.000046564146],"about_ca_topic_score_codex":0.009883588,"about_ca_topic_score_gemma":0.020633308,"teacher_disagreement_score":0.027216477,"about_ca_system_score_codex":0.009967596,"about_ca_system_score_gemma":0.016550096,"threshold_uncertainty_score":0.14393622},"labels":[],"label_agreement":null},{"id":"W4401391220","doi":"10.1007/s40273-024-01401-y","title":"Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD)","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Advanced Causal Inference Techniques","field":"Mathematics","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Institute of Health Economics; University of Alberta","funders":"Medical Research Council","keywords":"Transparency (behavior); Computer science; Decision model; Decision analysis; Management science; Scrutiny; Data science; Economics; Machine learning; Computer security; Mathematical economics; Political science","score_opus":0.09701390709738864,"score_gpt":0.40910001256669143,"score_spread":0.3120861054693028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401391220","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033900545,0.00015510406,0.99428153,0.0009013076,0.000044467775,0.000041799074,0.000053954303,0.00020128026,0.00093046774],"genre_scores_gemma":[0.24144527,0.00041763944,0.7557316,0.00040557946,0.00011417866,0.00017148192,0.00012730762,0.00014022201,0.001446707],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9554515,0.035702985,0.0014279259,0.0020110682,0.004870734,0.0005358091],"domain_scores_gemma":[0.83462846,0.1422621,0.0054053343,0.012859816,0.003993913,0.0008503317],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.035512853,0.0010004572,0.0016697358,0.0016836389,0.00079642556,0.004123338,0.001856398,0.0014494667,0.004330223],"category_scores_gemma":[0.16197418,0.0009888159,0.0019851595,0.0014432556,0.002068785,0.0049785078,0.0052372785,0.0057925885,0.00050186506],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040953915,0.00027852526,0.0019246314,0.0003254002,0.00034170016,0.00014242239,0.000596568,0.123156175,0.0015523519,0.6893893,0.0035611168,0.17832236],"study_design_scores_gemma":[0.00006913956,0.000063408705,0.00025895197,0.000061826824,0.00007519615,0.000038394275,0.000028583187,0.42530888,0.0014452799,0.5701266,0.0024864478,0.000037285048],"about_ca_topic_score_codex":0.002930844,"about_ca_topic_score_gemma":0.00216454,"teacher_disagreement_score":0.96448714,"about_ca_system_score_codex":0.0021741614,"about_ca_system_score_gemma":0.0046267943,"threshold_uncertainty_score":0.18781215},"labels":[],"label_agreement":null},{"id":"W4403011711","doi":"10.1007/s40273-024-01434-3","title":"Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"University of Sydney","keywords":"Quality of Life Research; Health economics; Health administration; Public health; Mental health; System dynamics; Dynamics (music); Health policy; Public economics; Management science; Economics; Psychology; Computer science; Medicine; Psychiatry; Nursing","score_opus":0.3731745996694658,"score_gpt":0.49937677884003134,"score_spread":0.12620217917056553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403011711","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043879148,0.002319733,0.89587384,0.014822451,0.00030582916,0.00046292672,0.00047335023,0.0001099466,0.041752767],"genre_scores_gemma":[0.8291912,0.0042746835,0.15664545,0.0008092953,0.00029377575,0.0012896748,0.00029951212,0.00010592839,0.0070904694],"study_design_codex":"simulation_or_modeling","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.996406,0.0027251875,0.000103068465,0.00018003614,0.00034475184,0.00024092714],"domain_scores_gemma":[0.9858823,0.012293835,0.00070233044,0.00028888168,0.00047890958,0.00035379085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005969871,0.0010389383,0.0013103212,0.0016865637,0.0014121252,0.0036469449,0.0015665098,0.0024188636,0.0035508315],"category_scores_gemma":[0.019635525,0.0008793536,0.0016576026,0.00181046,0.0029862004,0.004335102,0.003724664,0.0035521144,0.00024526796],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015285,0.00002792983,0.0015155042,0.000083974395,0.00006961981,0.00010394384,0.000267587,0.7422755,0.000055987683,0.25000244,0.0006485262,0.004933786],"study_design_scores_gemma":[0.00002130066,0.00003206812,0.0005216938,0.00010052009,0.000035504705,0.00004078857,0.00034787727,0.621482,0.000042143503,0.37134156,0.0059956266,0.000038876104],"about_ca_topic_score_codex":0.024160802,"about_ca_topic_score_gemma":0.026170643,"teacher_disagreement_score":0.024160802,"about_ca_system_score_codex":0.006402984,"about_ca_system_score_gemma":0.0059345867,"threshold_uncertainty_score":0.04804033},"labels":[],"label_agreement":null},{"id":"W4404997121","doi":"10.1007/s40273-024-01456-x","title":"Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Fulvestrant; Medicine; Cost effectiveness; Anastrozole; Breast cancer; Quality of Life Research; Oncology; Health economics; Internal medicine; Cancer; Gynecology; Tamoxifen; Public health; Nursing; Risk analysis (engineering)","score_opus":0.04592795873233327,"score_gpt":0.4144842457790218,"score_spread":0.3685562870466885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404997121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8622439,0.099005386,0.001792342,0.010667021,0.0008604316,0.0006121064,0.005815535,0.00013703592,0.018866217],"genre_scores_gemma":[0.9912607,0.005490382,0.00049164146,0.0008093083,0.00017517265,0.00009563645,0.0009766908,0.000010358488,0.00069014],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.997988,0.0012267976,0.000114764975,0.00014302006,0.00032787732,0.00019956053],"domain_scores_gemma":[0.9969399,0.0018708342,0.00051385857,0.000075416756,0.0001617372,0.000438288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021121015,0.0006211495,0.0016631467,0.00085873035,0.00018900099,0.0015517533,0.0005227176,0.0011946452,0.00515395],"category_scores_gemma":[0.008199236,0.00025508692,0.0039700256,0.00096120825,0.00030887945,0.0010612498,0.00048523952,0.00209293,0.00024863632],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30808103,0.004828711,0.04414426,0.004995398,0.018635161,0.00075788534,0.00011384429,0.0857374,0.0031986237,0.0053997887,0.014592996,0.50951487],"study_design_scores_gemma":[0.103676185,0.11437374,0.45730832,0.0042654807,0.07308258,0.004783121,0.0010360365,0.18514037,0.0057326164,0.009068859,0.041150667,0.0003820146],"about_ca_topic_score_codex":0.008975397,"about_ca_topic_score_gemma":0.009388283,"teacher_disagreement_score":0.008975397,"about_ca_system_score_codex":0.004494512,"about_ca_system_score_gemma":0.0025295527,"threshold_uncertainty_score":0.032610178},"labels":[],"label_agreement":null},{"id":"W4406274851","doi":"10.1007/s40273-024-01465-w","title":"Projections of Public Spending on Pharmaceuticals: A Review of Methods","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Institut National d'assurance Maladie-Invalidité; Uppsala Universitet; Universidad Carlos III de Madrid","keywords":"Quality of Life Research; Health economics; Public health; Health administration; Public finance; Business; Medicine; Public economics; Economics; Nursing","score_opus":0.4462416303200376,"score_gpt":0.5513911100974495,"score_spread":0.10514947977741185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406274851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015782348,0.96175414,0.023409273,0.0021686673,0.00033696793,0.00039197985,0.005339194,0.00022572237,0.004795921],"genre_scores_gemma":[0.010517811,0.9681764,0.01834861,0.00023853082,0.00019361115,0.00049112,0.0017415767,0.000050892373,0.00024134322],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9907206,0.0045166034,0.0017858624,0.00092130364,0.0019133441,0.00014218617],"domain_scores_gemma":[0.948466,0.044480663,0.0023366495,0.0011248223,0.0034184046,0.00017343633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015305025,0.003443251,0.0035949878,0.016668634,0.00043918472,0.0041501005,0.0033291834,0.0012159616,0.007131652],"category_scores_gemma":[0.048819803,0.0013425517,0.005483738,0.026606578,0.00097408553,0.0044046626,0.0017942146,0.0016585443,0.0017410269],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016581951,0.00005773367,0.0030284354,0.094709836,0.0015677063,0.00012699259,0.00022772932,0.009746084,0.00008420539,0.008228413,0.011802236,0.8702549],"study_design_scores_gemma":[0.00018281903,0.0003020655,0.021582417,0.39918664,0.008566403,0.0015430198,0.0013491941,0.019127235,0.0015391927,0.04619248,0.49995995,0.00046853203],"about_ca_topic_score_codex":0.008458091,"about_ca_topic_score_gemma":0.0061700265,"teacher_disagreement_score":0.016668634,"about_ca_system_score_codex":0.0033622237,"about_ca_system_score_gemma":0.0068843057,"threshold_uncertainty_score":0.08094168},"labels":[],"label_agreement":null},{"id":"W4408622151","doi":"10.1007/s40273-025-01479-y","title":"What are the Revealed and Stated Population Preferences for Environmental Sustainability in Healthcare? A Scoping Review","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Climate Change and Health Impacts","field":"Environmental Science","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Université Catholique de Louvain","keywords":"Health economics; Sustainability; Health care; Quality of Life Research; Health administration; Population health; Public health; Population; Health services research; Public economics; Business; Environmental health; Environmental planning; Medicine; Economics; Nursing; Geography; Economic growth","score_opus":0.11562820263609733,"score_gpt":0.45322801381734346,"score_spread":0.33759981118124616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408622151","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044562508,0.99795026,0.00012957747,0.00081879826,0.00011196716,0.00003412351,0.00010665463,0.0000017240776,0.00040131816],"genre_scores_gemma":[0.0047967145,0.9940982,0.00030713668,0.0005910602,0.000061906816,0.000050904022,0.00003990963,0.0000012285742,0.000052950443],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99370605,0.0027127548,0.0017667692,0.00052605954,0.0010523763,0.00023597328],"domain_scores_gemma":[0.9639942,0.031101324,0.002985819,0.00028294072,0.0014612491,0.00017448586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013492784,0.0008353163,0.0031912802,0.004708493,0.00045110247,0.0043806457,0.0011367081,0.0022447566,0.0036303352],"category_scores_gemma":[0.05024105,0.0007282794,0.0035959133,0.00708098,0.0012557218,0.0030344548,0.0016950665,0.0021998212,0.00028888418],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017975776,0.00005398655,0.0022923367,0.5677851,0.0061710263,0.00013588395,0.0008664774,0.0003683151,0.00017680219,0.0041132523,0.0052739177,0.41258323],"study_design_scores_gemma":[0.00005933676,0.00011661053,0.0048144455,0.89405423,0.013465349,0.00035905538,0.001276329,0.00014946252,0.00018161983,0.0024948628,0.08297527,0.000053531192],"about_ca_topic_score_codex":0.0096222535,"about_ca_topic_score_gemma":0.024878563,"teacher_disagreement_score":0.013492784,"about_ca_system_score_codex":0.0028361995,"about_ca_system_score_gemma":0.008923845,"threshold_uncertainty_score":0.07135749},"labels":[],"label_agreement":null},{"id":"W4409000501","doi":"10.1007/s40273-025-01485-0","title":"Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic Areas","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Observational study; Operationalization; Set (abstract data type); A priori and a posteriori; Medicine; Computer science","score_opus":0.6791320076222206,"score_gpt":0.657551346819709,"score_spread":0.021580660802511642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409000501","genre_codex":"methods","genre_gemma":"review","domain_codex":"methods","domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003334184,0.007788583,0.9129316,0.015190028,0.0013286577,0.039100707,0.002406865,0.00044331775,0.017476035],"genre_scores_gemma":[0.060446266,0.0019765622,0.8605929,0.0050647105,0.00047863787,0.06952045,0.0013338269,0.00008877941,0.0004978872],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.18513782,0.71125567,0.058270723,0.010723223,0.03254179,0.0020706751],"domain_scores_gemma":[0.16171783,0.67051846,0.039291363,0.052340508,0.072961055,0.0031707105],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.7517088,0.004215466,0.006478419,0.016596291,0.003646453,0.015989764,0.013394066,0.010865983,0.00521669],"category_scores_gemma":[0.7871175,0.003535782,0.01510351,0.009881311,0.014803547,0.01281337,0.016237859,0.019158117,0.0015651494],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015127542,0.00024948426,0.0045183715,0.021907188,0.0040171193,0.00036541652,0.007925706,0.04594255,0.0006453827,0.7255175,0.017239902,0.17015862],"study_design_scores_gemma":[0.0018498491,0.002118258,0.003784979,0.047411628,0.0040923115,0.00050919753,0.0017015002,0.05559805,0.003365377,0.75887054,0.12013989,0.0005583784],"about_ca_topic_score_codex":0.0061405734,"about_ca_topic_score_gemma":0.0034972678,"teacher_disagreement_score":0.7517088,"about_ca_system_score_codex":0.020883085,"about_ca_system_score_gemma":0.088656455,"threshold_uncertainty_score":0.30618733},"labels":[],"label_agreement":null},{"id":"W4409086257","doi":"10.1007/s40273-025-01484-1","title":"A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University; University of Waterloo","funders":"","keywords":"Medicine; Psychological intervention; Face validity; Health economics; Time horizon; Economic evaluation; Physical therapy; Public health; Economics; Psychometrics; Clinical psychology; Finance; Psychiatry","score_opus":0.18348839057683064,"score_gpt":0.4544855835411183,"score_spread":0.27099719296428765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409086257","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21931963,0.008745924,0.7148492,0.012034169,0.00075620244,0.002833295,0.008506734,0.000923883,0.032030974],"genre_scores_gemma":[0.9040665,0.002382579,0.07517806,0.00074502727,0.00021626185,0.0020518892,0.0027142859,0.00009448619,0.012550857],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99179053,0.006370217,0.00024649184,0.0005886467,0.00047864282,0.0005254707],"domain_scores_gemma":[0.9863148,0.011571815,0.0005409975,0.00027274265,0.00084899756,0.0004506576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013656399,0.0023005272,0.0044269487,0.002855271,0.0007683571,0.0046485728,0.004133613,0.0038726695,0.01259387],"category_scores_gemma":[0.027185343,0.0011990755,0.002676816,0.0026627672,0.0013315273,0.0027678616,0.0019681305,0.0033681057,0.0010715098],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012599003,0.0006001919,0.006242445,0.00033170183,0.00095527445,0.00018789814,0.00010513417,0.9175583,0.00016172719,0.044117827,0.00334095,0.025138661],"study_design_scores_gemma":[0.0004338216,0.00027814327,0.0020632965,0.00011125841,0.00039080434,0.00009617032,0.00006168562,0.97644377,0.000038541035,0.018740263,0.0013043762,0.000037893642],"about_ca_topic_score_codex":0.02915232,"about_ca_topic_score_gemma":0.01586245,"teacher_disagreement_score":0.02915232,"about_ca_system_score_codex":0.004652711,"about_ca_system_score_gemma":0.005148858,"threshold_uncertainty_score":0.07222277},"labels":[],"label_agreement":null},{"id":"W4409503028","doi":"10.1007/s40273-025-01489-w","title":"Correction: What are the Revealed and Stated Population Preferences for Environmental Sustainability in Healthcare? A Scoping Review","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Healthcare and Environmental Waste Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Health economics; Sustainability; Population health; Quality of Life Research; Health care; Health administration; Public health; Public economics; Population; Health services research; Business; Medicine; Environmental health; Economics; Nursing; Economic growth","score_opus":0.060093842245396815,"score_gpt":0.4226044510783155,"score_spread":0.3625106088329187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409503028","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001300222,0.019499686,0.00058060925,0.22895753,0.7454439,0.00014436271,0.0034305474,0.00020362211,0.0016097778],"genre_scores_gemma":[0.015907254,0.1086761,0.007161962,0.479877,0.3300941,0.0031664644,0.0043181404,0.0016302314,0.049168766],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.95503837,0.011868913,0.01495544,0.0030863958,0.012756129,0.0022947525],"domain_scores_gemma":[0.7443589,0.08392625,0.024753312,0.011064808,0.13169111,0.004205603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04389199,0.0026732413,0.004916416,0.008871556,0.0029673553,0.007928488,0.0057699927,0.014742646,0.03755522],"category_scores_gemma":[0.374334,0.002608043,0.0047629736,0.010410269,0.004834457,0.0056094513,0.0068196617,0.0149197,0.01843519],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004773497,0.0000033417418,0.00012225223,0.006023902,0.0001241947,0.00014249196,0.0001907115,0.000023197725,0.000030706942,0.00053950737,0.985496,0.007255902],"study_design_scores_gemma":[0.00026122743,0.000030526673,0.0014654851,0.038452823,0.00088816084,0.00061561365,0.0005556853,0.00015319466,0.0002590628,0.0022476912,0.9549332,0.00013723313],"about_ca_topic_score_codex":0.036998827,"about_ca_topic_score_gemma":0.03512891,"teacher_disagreement_score":0.04389199,"about_ca_system_score_codex":0.009017339,"about_ca_system_score_gemma":0.031012364,"threshold_uncertainty_score":0.23212576},"labels":[],"label_agreement":null},{"id":"W4409722550","doi":"10.1007/s40273-025-01488-x","title":"Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Alectinib; Medicine; Lung cancer; Quality of Life Research; Oncology; Chemotherapy; Health economics; Adjuvant chemotherapy; Internal medicine; Pharmacoeconomics; Cisplatin; Intensive care medicine; Public health; Cancer; Crizotinib; Pathology","score_opus":0.013683453788698027,"score_gpt":0.3488611628773168,"score_spread":0.33517770908861877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409722550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750538,0.0038395664,0.0025425402,0.0035076295,0.000044672463,0.00045811507,0.0060042534,0.000051937728,0.008497455],"genre_scores_gemma":[0.9968843,0.0006098627,0.00085405435,0.00012423708,0.0000040145283,0.000039314942,0.0009158821,0.000005220724,0.00056305615],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9992042,0.00027220044,0.000033777997,0.00009531835,0.00014923194,0.00024525708],"domain_scores_gemma":[0.99843687,0.0006161702,0.00020468819,0.000031062144,0.00038669168,0.00032447325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014363498,0.00065100106,0.0006919186,0.0006845291,0.0008469885,0.0015002713,0.0011787686,0.0006148955,0.002187982],"category_scores_gemma":[0.0059656138,0.00033803438,0.001315463,0.0011295715,0.0006325898,0.0005262859,0.0007847606,0.00078422716,0.00010360179],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053328397,0.0003990895,0.11794058,0.00054628274,0.0011223879,0.0005476202,0.00018830001,0.8315413,0.00054662174,0.0054242355,0.005155766,0.03125501],"study_design_scores_gemma":[0.002141703,0.0012205531,0.07986541,0.00043517398,0.0014808902,0.00034155746,0.000835109,0.90451103,0.0008690798,0.003471694,0.0047052274,0.00012259887],"about_ca_topic_score_codex":0.9573946,"about_ca_topic_score_gemma":0.9578058,"teacher_disagreement_score":0.073104054,"about_ca_system_score_codex":0.073104054,"about_ca_system_score_gemma":0.050299577,"threshold_uncertainty_score":0.5304095},"labels":[],"label_agreement":null},{"id":"W4410254351","doi":"10.1007/s40273-025-01483-2","title":"The Use of EQ-5D in the Middle East and North Africa Region: A Systematic Literature Review","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Health Technology Assessment international; King Hussein Cancer Center","keywords":"Quality of Life Research; Middle East; Health economics; Public health; Health administration; Systematic review; Geography; Environmental health; Medicine; MEDLINE; Political science; Nursing; Archaeology","score_opus":0.7772787200599502,"score_gpt":0.45473236566846653,"score_spread":0.3225463543914837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410254351","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011879042,0.99732435,0.00013256625,0.00032778745,0.00010371361,0.00046171952,0.00025163128,0.0000059774707,0.00020435406],"genre_scores_gemma":[0.019013004,0.9777859,0.00090937136,0.00068428565,0.000095342526,0.0011915765,0.00022228643,0.000005179307,0.00009299076],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.983107,0.0063913683,0.005807149,0.0010822016,0.0030867727,0.0005254411],"domain_scores_gemma":[0.95625085,0.029623909,0.009033677,0.00062252406,0.0040438725,0.00042527396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01759008,0.0017104384,0.007699533,0.017297646,0.0011050354,0.003289826,0.0020854839,0.0022670957,0.0032597417],"category_scores_gemma":[0.06357254,0.0013429098,0.0066635823,0.0154345045,0.0012404415,0.0038768416,0.0022522083,0.0013593762,0.00029110681],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009511497,0.000013309516,0.0013086376,0.96528107,0.0040937047,0.00013430987,0.0003314055,0.00006545821,0.00009693232,0.00021920455,0.0011672432,0.027193595],"study_design_scores_gemma":[0.000108594555,0.000109063054,0.005215244,0.9586263,0.023659179,0.00043003634,0.00057769235,0.00006064492,0.00010040491,0.00021827646,0.010864428,0.000030015002],"about_ca_topic_score_codex":0.0102778915,"about_ca_topic_score_gemma":0.027653683,"teacher_disagreement_score":0.01759008,"about_ca_system_score_codex":0.006056445,"about_ca_system_score_gemma":0.024029877,"threshold_uncertainty_score":0.09302634},"labels":[],"label_agreement":null},{"id":"W4411500165","doi":"10.1007/s40273-025-01512-0","title":"Innovation Headroom for a Highly Accurate PD-L1 Companion Diagnostic in Non-small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care; University of British Columbia Hospital; Polytechnique Montréal; University of British Columbia","funders":"NanoMedicines Innovation Network","keywords":"Medicine; Lung cancer; Oncology","score_opus":0.02262593603436821,"score_gpt":0.3470991397382342,"score_spread":0.324473203703866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411500165","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017802278,0.0208302,0.14017916,0.67350185,0.062764876,0.0010542857,0.002504849,0.0052138297,0.076148614],"genre_scores_gemma":[0.2755006,0.019051112,0.21043913,0.2939447,0.06751299,0.0016988913,0.003983123,0.0015463714,0.12632303],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99404013,0.0014566674,0.0002612802,0.0007912822,0.0026862777,0.0007643529],"domain_scores_gemma":[0.98721015,0.0039449404,0.0006603559,0.00092135975,0.004271229,0.0029920174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0134448735,0.00067609537,0.00073433213,0.0008779638,0.0011346255,0.004309678,0.0019070166,0.0065492443,0.0337882],"category_scores_gemma":[0.01627233,0.00044904373,0.0012073652,0.00033314567,0.0016502158,0.0040272013,0.0029186308,0.00858637,0.014761095],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012704358,0.0005316208,0.0037013472,0.00047693643,0.000117902826,0.0012921552,0.00013075408,0.0010758805,0.0228759,0.028092207,0.52278775,0.41764712],"study_design_scores_gemma":[0.0004887231,0.0017474379,0.0029686743,0.0004562848,0.00010542595,0.0023592694,0.00023613988,0.0061235866,0.026450796,0.031076888,0.927868,0.00011870236],"about_ca_topic_score_codex":0.0009268907,"about_ca_topic_score_gemma":0.0012484412,"teacher_disagreement_score":0.0337882,"about_ca_system_score_codex":0.0018950757,"about_ca_system_score_gemma":0.0060898224,"threshold_uncertainty_score":0.11303282},"labels":[],"label_agreement":null},{"id":"W4413291804","doi":"10.1007/s40273-025-01532-w","title":"Developing a Comprehensive Framework for Cost-Effectiveness Evaluation in Metastatic Castration-Sensitive Prostate Cancer: Insights from a Systematic Review","year":2025,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pharmaceuticals Bayer","keywords":"Health economics; Economic evaluation; Systematic review; Health administration; Cost effectiveness; Prostate cancer; Health care; Health technology; Flexibility (engineering); Agency (philosophy); Cost–benefit analysis; Medicine; Management science; Risk analysis (engineering); MEDLINE; Public health; Cancer; Economics; Sociology","score_opus":0.21509109056000753,"score_gpt":0.5196098635613617,"score_spread":0.3045187730013542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413291804","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0053137657,0.5771054,0.35409796,0.032025684,0.0008939904,0.013993377,0.005115277,0.0004594216,0.010995147],"genre_scores_gemma":[0.12963897,0.20298222,0.63032126,0.006099438,0.00064810266,0.026653092,0.0028481495,0.00011352177,0.00069531164],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.70009005,0.25119475,0.027189177,0.0043248907,0.015381136,0.0018199078],"domain_scores_gemma":[0.57811815,0.3864936,0.011845244,0.005378672,0.017141525,0.0010227793],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.23577236,0.004620294,0.010462691,0.035230402,0.0017952586,0.012308574,0.0060025,0.0056099645,0.0036728368],"category_scores_gemma":[0.3517091,0.0023648108,0.017079353,0.021330446,0.0024994428,0.009328758,0.007114884,0.0055858763,0.00054598367],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029891895,0.00016332247,0.0031989494,0.34343624,0.024676215,0.0007698216,0.0025710976,0.10095329,0.00045416335,0.23931292,0.015857447,0.26830766],"study_design_scores_gemma":[0.00071560155,0.00064025586,0.0034821446,0.4457624,0.033827912,0.0006578325,0.0019591483,0.077662595,0.00077660556,0.34687024,0.08727699,0.0003683777],"about_ca_topic_score_codex":0.019820906,"about_ca_topic_score_gemma":0.032950114,"teacher_disagreement_score":0.23577236,"about_ca_system_score_codex":0.02418301,"about_ca_system_score_gemma":0.04711355,"threshold_uncertainty_score":0.94242877},"labels":[],"label_agreement":null},{"id":"W4413301583","doi":"10.1007/s40273-025-01530-y","title":"Eliciting and Anchoring Health State Preferences Using Discrete Choice Experiments Among Adults, Adolescents, and Children","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre; Impact","funders":"EuroQol Research Foundation","keywords":"Health economics; Quality of Life Research; Anchoring; Public health; Health administration; Psychology; Discrete choice; Medicine; Economics; Social psychology; Econometrics; Nursing","score_opus":0.19532427329104582,"score_gpt":0.4631339987364767,"score_spread":0.2678097254454309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413301583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954346,0.000028228244,0.0034073428,0.00011974502,0.000010798441,0.00023324421,0.00008777484,0.0000066853218,0.0006715374],"genre_scores_gemma":[0.98681563,0.0001163941,0.011288117,0.00010120425,0.00001552885,0.0010677277,0.00015192831,0.0000046976747,0.0004387823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946484,0.004300527,0.00024893574,0.0003277064,0.00023504095,0.000239472],"domain_scores_gemma":[0.9170405,0.07637738,0.00405123,0.0013697922,0.0004226953,0.00073831977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0113664605,0.0005801423,0.00066894805,0.00032721163,0.00043729937,0.0018535347,0.0006008183,0.0014434982,0.0026577143],"category_scores_gemma":[0.04152075,0.00049376284,0.00058834796,0.0005055286,0.0012528815,0.0012799973,0.0009146098,0.0020698376,0.00022519058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09959032,0.081079155,0.31065512,0.0021238057,0.0022010505,0.00083141396,0.032683212,0.1822336,0.050978653,0.07555279,0.00361291,0.15845801],"study_design_scores_gemma":[0.037029956,0.08597731,0.20900178,0.0006490223,0.0017976154,0.00041174854,0.014071532,0.45191061,0.04740157,0.13941096,0.011485151,0.00085282593],"about_ca_topic_score_codex":0.00292816,"about_ca_topic_score_gemma":0.003019538,"teacher_disagreement_score":0.0113664605,"about_ca_system_score_codex":0.0010946873,"about_ca_system_score_gemma":0.0010545683,"threshold_uncertainty_score":0.060112298},"labels":[],"label_agreement":null},{"id":"W4416459789","doi":"10.1007/s40273-025-01561-5","title":"The ‘Values in Modelling’ Framework for Patient and Public Involvement in Health Economics Modelling: Development and Application in the LEAP Model Project","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver Coastal Health Research Institute; Stornoway Diamond (Canada); Vancouver Coastal Health","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Health economics; Public health; Deliberation; Process (computing); Quality of Life Research; Health administration; Health informatics; Outcome (game theory); Cost–benefit analysis","score_opus":0.38643299910462664,"score_gpt":0.4564710037805315,"score_spread":0.07003800467590487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416459789","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0073751337,0.00027760843,0.9450829,0.0077109556,0.00020175554,0.00017420502,0.00054931483,0.00026429724,0.0383638],"genre_scores_gemma":[0.39030284,0.00077713444,0.5946641,0.0009187189,0.00022420628,0.001238953,0.0008844457,0.00056155934,0.010428176],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9923463,0.00634852,0.0001882887,0.00025582997,0.00065184094,0.00020915452],"domain_scores_gemma":[0.983643,0.012690297,0.00054205966,0.0010990091,0.0013696197,0.0006559373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011428183,0.0010356595,0.0007598426,0.0011330303,0.0011045187,0.0048965802,0.0028692274,0.0023774293,0.009138383],"category_scores_gemma":[0.02809403,0.0007304971,0.0012997492,0.0018862905,0.002342926,0.0062470348,0.004221573,0.0040819785,0.0013199257],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030101282,0.000073612915,0.0006905804,0.00007901385,0.000045815053,0.00005196895,0.0003710563,0.102969855,0.00009713552,0.873841,0.004883284,0.016866488],"study_design_scores_gemma":[0.00003278734,0.000022621722,0.00022224127,0.000094809104,0.000019411114,0.00004133805,0.00017862339,0.30082092,0.00022136977,0.6705339,0.02778453,0.000027403157],"about_ca_topic_score_codex":0.0076777814,"about_ca_topic_score_gemma":0.008068779,"teacher_disagreement_score":0.011428183,"about_ca_system_score_codex":0.002790112,"about_ca_system_score_gemma":0.0053097187,"threshold_uncertainty_score":0.060438693},"labels":[],"label_agreement":null},{"id":"W4417329433","doi":"10.1007/s40273-025-01579-9","title":"Economic Consequences of Increasing the NICE Cost-Effectiveness Threshold","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Quality of Life Research; Nice; Health economics; Public health; Health administration; Public finance","score_opus":0.31248029096377505,"score_gpt":0.4946353380343216,"score_spread":0.18215504707054653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417329433","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1554738,0.052775368,0.05694692,0.4660055,0.006304566,0.00051409815,0.0041567795,0.00096191256,0.25686106],"genre_scores_gemma":[0.93534166,0.0029612677,0.0095933,0.047545213,0.0020503008,0.00024701128,0.0004002789,0.00010480234,0.0017563119],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.92948484,0.043704472,0.006317681,0.002359067,0.014520789,0.0036131714],"domain_scores_gemma":[0.6832196,0.28181064,0.010071642,0.0070429402,0.012760375,0.0050947564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.044686023,0.0006708506,0.0029909555,0.0025851708,0.00078042515,0.007856814,0.002128108,0.010362483,0.0070653306],"category_scores_gemma":[0.29993978,0.0007161218,0.0029356189,0.0019059924,0.0025498995,0.0062844916,0.003090836,0.009423729,0.00079463876],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005310647,0.00090232963,0.028777618,0.0026623656,0.0031365678,0.0027277402,0.0008427522,0.062577926,0.0028699834,0.554664,0.13040861,0.20511945],"study_design_scores_gemma":[0.0024235675,0.0016583563,0.054824885,0.0033155254,0.0028697026,0.0062221116,0.00088215544,0.059133682,0.0019658513,0.8012902,0.065010235,0.00040366413],"about_ca_topic_score_codex":0.00504188,"about_ca_topic_score_gemma":0.0029918756,"teacher_disagreement_score":0.044686023,"about_ca_system_score_codex":0.0058432366,"about_ca_system_score_gemma":0.0049941763,"threshold_uncertainty_score":0.23632509},"labels":[],"label_agreement":null},{"id":"W576972216","doi":"10.1007/s40273-015-0297-4","title":"The Silence in Hoch et al.’s Commentary about the Rationale for and Objective(s) of Canada’s Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers’ Dollars","year":2015,"lang":"en","type":"letter","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Accountability; Transparency (behavior); Ambiguity; Medicine; Law and economics; Public relations; Positive economics; Sociology; Political science; Law; Economics; Computer science","score_opus":0.24557794106517278,"score_gpt":0.4589232006110723,"score_spread":0.2133452595458995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W576972216","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008800922,0.0009926225,0.0001380675,0.9850975,0.013133235,0.0000066702296,0.000024533574,0.000012971335,0.00050646655],"genre_scores_gemma":[0.0015612843,0.00033817493,0.00012190863,0.9903943,0.0066850428,0.000021857892,0.000006401649,0.00003419161,0.0008369028],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.93602914,0.026948087,0.0044042966,0.006524218,0.02005886,0.0060353624],"domain_scores_gemma":[0.8126163,0.13714859,0.00684545,0.0022057788,0.03334129,0.007842642],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.037714522,0.001605271,0.0025968468,0.0018200566,0.017832754,0.015685963,0.010003583,0.08319502,0.0051688296],"category_scores_gemma":[0.20524143,0.0020336572,0.0026469887,0.0026413063,0.025853347,0.014445213,0.007874106,0.11512016,0.0038245001],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026134332,0.000006525855,0.000085354564,0.00016981795,0.000012339947,0.00014042278,0.0034742563,0.000035513785,0.00009013546,0.00917527,0.9847244,0.0020598897],"study_design_scores_gemma":[0.000047631456,0.000027607777,0.00036475316,0.0013483292,0.000036653273,0.00035586627,0.006872998,0.00026432902,0.0006137757,0.011446736,0.97840387,0.00021754188],"about_ca_topic_score_codex":0.085846685,"about_ca_topic_score_gemma":0.08367647,"teacher_disagreement_score":0.96886444,"about_ca_system_score_codex":0.03113553,"about_ca_system_score_gemma":0.039696675,"threshold_uncertainty_score":0.22590512},"labels":[],"label_agreement":null},{"id":"W659344829","doi":"10.1007/s40273-015-0293-8","title":"Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review","year":2015,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Cancer Institute NSW; National Health and Medical Research Council; HCF Research Foundation","keywords":"Disinvestment; Reimbursement; Value-Based Purchasing; Public economics; Health economics; Purchasing; Business; Stakeholder; Formulary; Grey literature; Pharmaceutical policy; Health care; Health policy; Economics; Economic growth; Medicine; Marketing; Political science","score_opus":0.7054976458037195,"score_gpt":0.6065338041121112,"score_spread":0.09896384169160832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W659344829","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000103912826,0.999524,0.000047244608,0.00014314253,0.000020130055,0.0000029112014,0.0000083495215,7.453233e-7,0.00014962461],"genre_scores_gemma":[0.001502534,0.9981359,0.0001310614,0.00011532314,0.000053361124,0.0000042644606,0.000010757457,5.7729164e-7,0.00004612831],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9988926,0.00033964656,0.00019583885,0.00013125059,0.0003709966,0.00006960755],"domain_scores_gemma":[0.9930067,0.0054913005,0.00090966286,0.00007670857,0.00043537308,0.00008013852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039026798,0.0009389512,0.0024683434,0.0032641848,0.00021097236,0.0020573,0.0011219665,0.0017329,0.004216415],"category_scores_gemma":[0.008680034,0.00038765807,0.0016314099,0.0052687763,0.00089888746,0.0020959277,0.0009019446,0.0014074683,0.00036445347],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019458719,0.000114990304,0.0007978397,0.06877767,0.0009622008,0.00010909701,0.000059541657,0.00087963894,0.00019253323,0.006359004,0.009089368,0.9124635],"study_design_scores_gemma":[0.0005127459,0.00078768656,0.014311313,0.18551748,0.01081428,0.0022708513,0.000469817,0.0014617126,0.000857792,0.032104176,0.75071007,0.00018203782],"about_ca_topic_score_codex":0.0025694598,"about_ca_topic_score_gemma":0.005445007,"teacher_disagreement_score":0.004216415,"about_ca_system_score_codex":0.0012955335,"about_ca_system_score_gemma":0.0030363959,"threshold_uncertainty_score":0.020639539},"labels":[],"label_agreement":null},{"id":"W874651150","doi":"","title":"Up the garden PATH of 'cost savings' in Ontario Canada: When costing less means costing more.","year":2007,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Activity-based costing; Health economics; Quality of Life Research; Health administration; Public health; Pharmacoeconomics; Operations management; Business; Economics; Public economics; Actuarial science; Agricultural economics; Medicine; Accounting; Nursing; Microeconomics","score_opus":0.20817539888370737,"score_gpt":0.44016017304388405,"score_spread":0.23198477416017668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W874651150","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028472016,0.005305252,0.0005204587,0.9379563,0.00070601766,0.000050534218,0.00038881015,0.000035831803,0.026564976],"genre_scores_gemma":[0.70820254,0.0095555335,0.005462303,0.2523539,0.00048445936,0.00012116486,0.00042995566,0.00011016407,0.023280112],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9921651,0.0020977675,0.00028492563,0.00039291062,0.0028943091,0.0021649795],"domain_scores_gemma":[0.98186904,0.0030162996,0.001121115,0.00026935848,0.0061521037,0.0075720283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005388604,0.00028821983,0.0003524719,0.0008872164,0.009311728,0.0074813417,0.0014771213,0.006177124,0.012625852],"category_scores_gemma":[0.029347159,0.00037312164,0.0004309778,0.0020588387,0.0065089944,0.004519183,0.002961601,0.0076264553,0.0006803309],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032374152,0.00020342514,0.03988448,0.0006899264,0.000120415345,0.0007863113,0.016539646,0.0007540709,0.0009776818,0.08301135,0.7298764,0.12683259],"study_design_scores_gemma":[0.00029917562,0.0001585135,0.16212599,0.0021949948,0.00016685904,0.0002593783,0.042787857,0.0011787799,0.0007518352,0.03911848,0.7507062,0.00025192584],"about_ca_topic_score_codex":0.9778715,"about_ca_topic_score_gemma":0.99397635,"teacher_disagreement_score":0.098448776,"about_ca_system_score_codex":0.098448776,"about_ca_system_score_gemma":0.27616644,"threshold_uncertainty_score":0.7142992},"labels":[],"label_agreement":null}]}